Function_ID	ProtDescription	AAchange	Codon_Number	WT_AA	Mutant_AA	SwissProtLink	Structural_motif	Codon72AA	Conserved_WT_Function	Loss_of_Function	Dominant_Negative_Activity	Gain_of_Function	Temperature_Sensitivity	Temp_ref	Cell_assay	Cell_lines	Assay_design	Method	FRef_ID	Authors	Title	Year	Journal	Volume	Start_page	PubMed
2093	p.M1_A159del	M1_A159del	1	Met	NA		N-term/Transactivation	NA	NA	TR (HSP70)	NA	No [TA (HSP70)]	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2105	p.M1_A159del	M1_A159del	1	Met	NA		N-term/Transactivation	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
501	p.P4S	P4S	4	Pro	Ser		N-term/Transactivation	NA	NA	NA	NA	NA	Yes mut_H (GADD45); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
589	p.V10L	V10L	10	Val	Leu		N-term/Transactivation	NA	NA	NA	NA	NA	No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
502	p.V10L	V10L	10	Val	Leu		N-term/Transactivation	NA	NA	NA	NA	NA	Yes mut_H (AIP1); No (WAF1, MDM2, BAX, 14-3-3s, GADD45, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1823	[p.L14M;P80H]	L14M/P80H	14	Leu	NA		N-term/Transactivation/NES	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
2022	[p.L14Q;F19S]	L14Q/F19S	14	Leu	NA		N-term/Transactivation/NES	NA	GS	TA (p53CON, MDM2) partial; TR (CMV) partial	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	CAT or beta-GAL assay	143	Leiter LM;Chen J;Marathe T;Tanaka M;Dutta A;	Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	1996	Oncogene	12	2661	8700525
4242	p.S15A	S15A	15	Ser	Ala		N-term/Transactivation/NES	NA	NA	Upregulation (p21waf1) 5-aza-CdR induced; GA 5-aza-CdR induced	NA	NA	NA	37°C 	Human	H1299	WT control	5-aza-2'-deoxycitidine treatment and western blot, proliferation assay	311	Wang H;Zhao Y;Li L;McNutt MA;Wu L;Lu S;Yu Y;Zhou W;Feng J;Chai G;Yang Y;Zhu WG;	An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment	2008	J Biol Chem 	283	2564	17977830
4245	p.S15A	S15A	15	Ser	Ala		N-term/Transactivation/NES	NA	Super-upregulation (p21waf1, mdm2); mono-methylation at histone H3 K4; abrogation of di-methylation at histone H3 K9; superDNAb (WAF1)	NA	NA	Acetylation at histone H3 K9 and K14	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Western blot, CHIP assay	312	Warnock LJ;Adamson R;Lynch CJ;Milner J;	Crosstalk between site-specific modifications on p53 and histone H3	2008	Oncogene	27	1639	17891183
4213	p.S15A	S15A	15	Ser	Ala		N-term/Transactivation/NES	NA	No APO; upregulation (puma)	CDDP sensitivity (partial)	NA	NA	NA	37°C 	Human	OVCAR-3	WT control	Hoechst 33258 staining, cisplatin treatment, western blot	293	Fraser M;Bai T;Tsang BK;	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function	2008	Int J Cancer	122	534	17918180
4214	[p.S15A;S20A]	S15A/S20A	15	Ser	NA		N-term/Transactivation/NES	NA	No APO; upregulation (puma)	CDDP sensitivity	NA	NA	NA	37°C 	Human	OVCAR-3	WT control	Hoechst 33258 staining, cisplatin treatment, western blot	293	Fraser M;Bai T;Tsang BK;	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function	2008	Int J Cancer	122	534	17918180
4246	p.S15D	S15D	15	Ser	Asp		N-term/Transactivation/NES	NA	Super-upregulation (p21waf1, mdm2); mono-methylation at histone H3 K4; abrogation of di-methylation at histone H3 K9; superDNAb (WAF1)	NA	NA	Acetylation at histone H3 K9 and K14	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Western blot, CHIP assay	312	Warnock LJ;Adamson R;Lynch CJ;Milner J;	Crosstalk between site-specific modifications on p53 and histone H3	2008	Oncogene	27	1639	17891183
4210	[p.E17K;H193L]	E17K/H193L	17	Glu	NA		N-term/Transactivation/NES	NA	NA	TA (WAF1, MDM2, BAX, PUMA, AIP1); APO partial; DOX, CDDP and 5-FU sensitivity	NA	DOX, CDDP and 5-FU resistance	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, treatment with Doxorubicin, Cisplatin or 5-FU	298	Kawamata H;Omotehara F;Nakashiro K;Uchida D;Shinagawa Y;Tachibana M;Imai Y;Fujimori T;	Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage	2007	Int J Oncol 	30	1089	17390010
4160	p.S20A	S20A	20	Ser	Ala		N-term/Transactivation/NES	NA	No APO; upregulation (puma)	CDDP sensitivity (partial)	NA	NA	NA	37°C 	Human	OVCAR-3	WT control	Hoechst 33258 staining, cisplatin treatment, western blot	293	Fraser M;Bai T;Tsang BK;	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function	2008	Int J Cancer	122	534	17918180
1758	[p.L22E;W23S]	L22E/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	TR (RECQ4)	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	107	Sengupta S;Shimamoto A;Koshiji M;Pedeux R;Rusin M;Spillare EA;Shen JC;Huang LE;Lindor NM;Furuichi Y;Harris CC;	Tumor suppressor p53 represses transcription of RECQ4 helicase	2005	Oncogene	24	1738	15674334
424	[p.L22E;W23S]	L22E/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	TA (WAF1, p53CON, Cyclin G, GADD45)	TA (BAX, MDM2, IGF-BP3-boxA&B, RGC)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
1839	[p.L22Q;W23S]	L22Q/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	HR repression; RPA binding and interference	TA (WAF1) partial	NA	NA	NA	37°C 	Human	H1299	WT control	CAT assay, homologous recombination (HR) assay, IP	121	Romanova LY;Willers H;Blagosklonny MV;Powell SN;	The interaction of p53 with replication protein A mediates suppression of homologous recombination	2004	Oncogene	23	9025	15489903
2021	[p.L22Q;W23S]	L22Q/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	NA	TA (p53CON, MDM2); TR (CMV); GS partial	NA	TA (CMV)	NA	37°C 	Human	H1299	WT control	CAT or beta-GAL assay, CFA	143	Leiter LM;Chen J;Marathe T;Tanaka M;Dutta A;	Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	1996	Oncogene	12	2661	8700525
3329	[p.L22Q;W23S]	L22Q/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	Downregulation (Vrk1)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot	226	Valbuena A;Vega FM;Blanco S;Lazo PA;	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop	2006	Mol Cell Biol 	26	4782	16782868
4234	[p.L22Q;W23S]	L22Q/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	Upregulation (APAF1, KILLER/DR5, BTG2)	Upregulation (PIG3, WAF1); upregulation (CD95-Fas) partial; APO partial	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	RT-qPCR, FACS analysis	308	Smith JM;Stubbert LJ;Hamill JD;McKay BC;	The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific	2007	Neoplasia 	9	1057	18084613
1845	[p.L22Q;W23S]	L22Q/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	HR repression	NA	NA	NA	NA	37°C 	Human	K-562	WT control	Homologous recombination (HR) assay	123	Boehden GS;Akyuz N;Roemer K;Wiesmuller L;	p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair	2003	Oncogene	22	4111	12821945
2020	[p.L22Q;W23S]	L22Q/W23S	22	Leu	NA		N-term/Transactivation/NES	NA	NA	TA (p53CON) partial; TR (CMV); GS partial	NA	TA (CMV)	NA	37°C 	Human	Saos-2	WT control	CAT or beta-GAL assay, CFA	143	Leiter LM;Chen J;Marathe T;Tanaka M;Dutta A;	Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	1996	Oncogene	12	2661	8700525
1486	[p.L22Q;W23S;D281G]	L22Q/W23S/D281G	22	Leu	NA		N-term/Transactivation/NES	NA	NA	NA	NA	No (Mdm2 stabilization)	NA	37°C 	Human	H1299	WT control	Western blot, IF	80	Peng Y;Chen L;Li C;Lu W;Agrawal S;Chen J;	Stabilization of the MDM2 oncoprotein by mutant p53	2001	J Biol Chem	276	6874	11152666
1714	[p.L22Q;W23S;D281G]	L22Q/W23S/D281G	22	Leu	NA		N-term/Transactivation/NES	NA	NA	NA	NA	No [TA(NFkB2-P2)]	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
1768	[p.L22Q;W23S;D281G]	L22Q/W23S/D281G	22	Leu	NA		N-term/Transactivation/NES	NA	NA	TR (ASNS, ANGPT1, EBAG-9, ITGA6)	NA	TA (ASNS, ANGPT1, EBAG-9, ITGA6)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	111	Scian MJ;Stagliano KE;Ellis MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Modulation of gene expression by tumor-derived p53 mutants	2004	Cancer Res	64	7447	15492269
4236	[p.L22Q;W23S;W53Q;F54S]	L22Q/W23S/W53Q/F54S	22	Leu	NA		N-term/Transactivation/NES	NA	NA	Upregulation (PIG3, WAF1, APAF1, BTG2); upregulation (CD95-Fas, KILLER/DR5) partial; APO partial	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	RT-qPCR, FACS analysis	308	Smith JM;Stubbert LJ;Hamill JD;McKay BC;	The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific	2007	Neoplasia 	9	1057	18084613
4207	p.N30S	N30S	30	Asn	Ser		N-term/Transactivation	NA	TA (WAF1, MDM2, BAX, PUMA, AIP1); APO; DOX, CDDP and 5-FU sensitivity	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, treatment with Doxorubicin, Cisplatin or 5-FU	298	Kawamata H;Omotehara F;Nakashiro K;Uchida D;Shinagawa Y;Tachibana M;Imai Y;Fujimori T;	Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage	2007	Int J Oncol 	30	1089	17390010
4522	p.V31I	V31I	31	Val	Ile	044554	N-term/Transactivation	NA	TA (BAX)	TA (WAF1, MDM2) partial; GS (partial)	NA	NA	NA	37°C 	Human	H1299	WT control	luciferase assay, proliferation assay	332	Yamada H;Shinmura K;Okudela K;Goto M;Suzuki M;Kuriki K;Tsuneyoshi T;Sugimura H;	Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population	2007	Carcinogenesis	28	2013	17690113
1984	p.S33_T125del	S33_T125del	33	Ser	NA		N-term/Transactivation	NA	NA	TA (RGC, p53CON)	Yes [TA (RGC, p53CON)] partial	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
1764	p.S33A	S33A	33	Ser	Ala		N-term/Transactivation	NA	TA (PG13)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	109	Sanchez-Prieto R;Rojas JM;Taya Y;Gutkind JS;	A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents	2000	Cancer Res	60	2464	10811125
4247	p.S37A	S37A	37	Ser	Ala		N-term/Transactivation	NA	Super-upregulation (p21waf1, mdm2); mono-methylation at histone H3 K4; abrogation of di-methylation at histone H3 K9; superDNAb (WAF1)	NA	NA	Acetylation at histone H3 K9	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Western blot, CHIP assay	312	Warnock LJ;Adamson R;Lynch CJ;Milner J;	Crosstalk between site-specific modifications on p53 and histone H3	2008	Oncogene	27	1639	17891183
4161	p.S37A	S37A	37	Ser	Ala		N-term/Transactivation	NA	No APO; CDDP sensitivity; upregulation (puma)	NA	NA	NA	NA	37°C 	Human	OVCAR-3	WT control	Hoechst 33258 staining, cisplatin treatment, western blot	293	Fraser M;Bai T;Tsang BK;	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function	2008	Int J Cancer	122	534	17918180
4248	p.S37D	S37D	37	Ser	Asp		N-term/Transactivation	NA	Super-upregulation (p21waf1, mdm2); mono-methylation at histone H3 K4; abrogation of di-methylation at histone H3 K9; superDNAb (WAF1)	NA	NA	No (acetylation at histone H3 K9)	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Western blot, CHIP assay	312	Warnock LJ;Adamson R;Lynch CJ;Milner J;	Crosstalk between site-specific modifications on p53 and histone H3	2008	Oncogene	27	1639	17891183
1825	p.L43S	L43S	43	Leu	Ser	005853	N-term/Transactivation	P 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1892	p.S46A	S46A	46	Ser	Ala		N-term/Transactivation	NA	Super-upregulation (MDM2); upregulation (PTEN); super-uregulation (mdm2); upregulation (pten)	ETO sensitivity (partial)	NA	NA	NA	37°C 	Human	H1299	WT control	Northern blot, western blot, etoposide treatment	128	Mayo LD;Seo YR;Jackson MW;Smith ML;Rivera GJ;Korgaonkar CK;Donner DB;	Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified	2005	J Biol Chem	280	25953	15843377
1715	p.S46A	S46A	46	Ser	Ala		N-term/Transactivation	NA	NA	TA (PCNA) partial; TA (WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	100	Shan B;Morris GF;	Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53	2005	Exp Cell Res	305	10	15777783
4215	p.S46A	S46A	46	Ser	Ala		N-term/Transactivation	NA	DOX sensitivity; upregulation (WAF1, AIP1) DOX-induced	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Doxorubicin treatment and RT-qPCR, FACS analysis	299	Kurihara A;Nagoshi H;Yabuki M;Okuyama R;Obinata M;Ikawa S;	Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis	2007	Genes Cells	12	853	17584297
1827	p.S46A	S46A	46	Ser	Ala		N-term/Transactivation	NA	NA	GS	NA	NA	NA	37°C 	Human	HSC2	WT control	CFA	117	Ichwan SJ;Yamada S;Sumrejkanchanakij P;Ibrahim-Auerkari E;Eto K;Ikeda MA;	Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells	2005	Oncogene			16247456
1763	p.S46A	S46A	46	Ser	Ala		N-term/Transactivation	NA	TA (WAF1); DNAb (WAF1)	APO partial; TA (AIP1) partial; DNAb (AIP1)	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	TUNEL assay, luciferase assay, EMSA	108	Oda K;Arakawa H;Tanaka T;Matsuda K;Tanikawa C;Mori T;Nishimori H;Tamai K;Tokino T;Nakamura Y;Taya Y;	p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53	2000	Cell	102	849	11030628
1891	p.S46A	S46A	46	Ser	Ala		N-term/Transactivation	NA	TA (MDM2)	TA (PTEN)	NA	NA	NA	37°C 	Human	U2OS	WT control	Luciferase assay	128	Mayo LD;Seo YR;Jackson MW;Smith ML;Rivera GJ;Korgaonkar CK;Donner DB;	Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified	2005	J Biol Chem	280	25953	15843377
2182	p.S46D	S46D	46	Ser	Asp		N-term/Transactivation	NA	Upregulation (PTEN); super-upregulation (pten); ETO sensitivity	Upregulation (MDM2); upregulation (mdm2) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Northern blot, western blot, etoposide treatment	128	Mayo LD;Seo YR;Jackson MW;Smith ML;Rivera GJ;Korgaonkar CK;Donner DB;	Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified	2005	J Biol Chem	280	25953	15843377
2181	p.S46D	S46D	46	Ser	Asp		N-term/Transactivation	NA	TA (PTEN) supertrans	TA (MDM2)	NA	NA	NA	37°C 	Human	U2OS	WT control	Luciferase assay	128	Mayo LD;Seo YR;Jackson MW;Smith ML;Rivera GJ;Korgaonkar CK;Donner DB;	Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified	2005	J Biol Chem	280	25953	15843377
4216	p.S46E	S46E	46	Ser	Glu		N-term/Transactivation	NA	DOX sensitivity; upregulation (WAF1, AIP1) DOX-induced	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Doxorubicin treatment and RT-qPCR, FACS analysis	299	Kurihara A;Nagoshi H;Yabuki M;Okuyama R;Obinata M;Ikawa S;	Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis	2007	Genes Cells	12	853	17584297
3340	p.S46F	S46F	46	Ser	Phe	044567	N-term/Transactivation	NA	SuperAPO; upregulation (bax)	Upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	ACC-LC-176, LS174T	WT control	FACS analysis, western blot	229	Nakamura Y;Futamura M;Kamino H;Yoshida K;Nakamura Y;Arakawa H;	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis	2006	Cancer Sci 	97	633	16827804
3341	p.S46F	S46F	46	Ser	Phe	044567	N-term/Transactivation	NA	SuperAPO; super-upregulation (bax); super-upregulation (WAF1, p53RFP, BAX, PUMA, NOXA); TA (WAF1, P53RFP, AIP1, BAX, PUMA, NOXA, P53DINP1, P53R2, P53RDL1, SEMA3F) superTRANS; superTUMOR-	Upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis, western blot, northern blot, luciferase assay, tumorigenicity assay	229	Nakamura Y;Futamura M;Kamino H;Yoshida K;Nakamura Y;Arakawa H;	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis	2006	Cancer Sci 	97	633	16827804
3487	p.S46F	S46F	46	Ser	Phe	044567	N-term/Transactivation	NA	SuperAPO; upregulation (bax); super-upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	HCT-116	WT control	FACS analysis, western blot	229	Nakamura Y;Futamura M;Kamino H;Yoshida K;Nakamura Y;Arakawa H;	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis	2006	Cancer Sci 	97	633	16827804
3486	p.S46F	S46F	46	Ser	Phe	044567	N-term/Transactivation	NA	SuperAPO; super-upregulation (bax)	Upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	HepG2, A549	WT control	FACS analysis, western blot	229	Nakamura Y;Futamura M;Kamino H;Yoshida K;Nakamura Y;Arakawa H;	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis	2006	Cancer Sci 	97	633	16827804
1840	[p.D48H;D49H]	D48H/D49H	48	Asp	NA		N-term/Transactivation	NA	TA (WAF1)	HR repression; RPA interference	NA	NA	NA	37°C 	Human	H1299	WT control	CAT assay, homologous recombination (HR) assay, IP	121	Romanova LY;Willers H;Blagosklonny MV;Powell SN;	The interaction of p53 with replication protein A mediates suppression of homologous recombination	2004	Oncogene	23	9025	15489903
2023	[p.D48H;D49H]	D48H/D49H	48	Asp	NA		N-term/Transactivation	NA	GS	TA (p53CON, MDM2) partial; TR (CMV) partial	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	CAT or beta-GAL assay, CFA	143	Leiter LM;Chen J;Marathe T;Tanaka M;Dutta A;	Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	1996	Oncogene	12	2661	8700525
4103	p.D49H	D49H	49	Asp	His	044571	N-term/Transactivation	NA	NA	NA	NA	Upregulation (VEGF); VEGF production	NA	37°C 	Human	Saos-2	WT control	RT-PCR, study of supernatant	285	Narendran A;Ganjavi H;Morson N;Connor A;Barlow JW;Keystone E;Malkin D;Freedman MH;	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth	2003	Exp Hematol 	31	693	12901974
1272	p.W53C	W53C	53	Trp	Cys	005854	N-term	P 	TA (WAF1 5', p53CON, P53R2, GADD45, CD95-Fas, PCNA, MDM2, BAX, PUMA, AIP1, NOXA)	TA (RGC, WAF1 3') partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4235	[p.W53Q;F54S]	W53Q/F54S	53	Trp	NA		N-term	NA	Upregulation (KILLER/DR5, BTG2)	Upregulation (PIG3, WAF1); upregulation (CD95-Fas, APAF1) partial; APO partial	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	RT-qPCR, FACS analysis	308	Smith JM;Stubbert LJ;Hamill JD;McKay BC;	The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific	2007	Neoplasia 	9	1057	18084613
1841	[p.W53S;F54S]	W53S/F54S	53	Trp	NA		N-term	NA	TA (WAF1)	HR repression; RPA binding and interference	NA	NA	NA	37°C 	Human	H1299	WT control	CAT assay, homologous recombination (HR) assay, IP	121	Romanova LY;Willers H;Blagosklonny MV;Powell SN;	The interaction of p53 with replication protein A mediates suppression of homologous recombination	2004	Oncogene	23	9025	15489903
2025	[p.W53S;F54S]	W53S/F54S	53	Trp	NA		N-term	NA	GS	TA (p53CON, MDM2) partial; TR (CMV)	NA	NA	NA	37°C 	Human	H1299, Saos-2	WT control	CAT or beta-GAL assay, CFA	143	Leiter LM;Chen J;Marathe T;Tanaka M;Dutta A;	Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	1996	Oncogene	12	2661	8700525
2653	p.W53*	W53X	53	Trp	Stop		N-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	167	Tada M;Iggo RD;Ishii N;Shinohe Y;Sakuma S;Estreicher A;Sawamura Y;Abe H;	Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay	1996	Int J Cancer	67	447	8707423
1273	p.F54S	F54S	54	Phe	Ser		N-term	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1274	p.P58S	P58S	58	Pro	Ser		N-term	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2024	[p.D61H;E62K]	D61H/E62K	61	Asp	NA		SH3-like/Pro-rich	NA	GS	TA (p53CON, MDM2) partial; TR (CMV) partial	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	CAT or beta-GAL assay	143	Leiter LM;Chen J;Marathe T;Tanaka M;Dutta A;	Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	1996	Oncogene	12	2661	8700525
830	p.E62_W91del	E62_W91del	62	Glu	NA		SH3-like/Pro-rich	NA	TA (MDM2)	TA (PIG3); APO	Yes [TA (PIG3)]	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, TUNEL assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
35	p.A63_A78del	A63_A78del	63	Ala	NA		SH3-like/Pro-rich	NA	TA (PCNA) supertrans	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4129	p.A63_A78del	A63_A78del	63	Ala	NA		SH3-like/Pro-rich	NA	NA	Upregulation (p21waf1)	NA	No [downregulation (p21waf1)]; culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	Western blot, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
828	p.A63_A78del	A63_A78del	63	Ala	NA		SH3-like/Pro-rich	NA	NA	TA (RGC) partial	No [TA (RGC)]	NA	Yes mut_L (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1275	p.M66T	M66T	66	Met	Thr		SH3-like/Pro-rich	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
732	p.E68G	E68G	68	Glu	Gly	044597	SH3-like/Pro-rich	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2655	p.E68G	E68G	68	Glu	Gly	044597	SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
1775	p.E68Q	E68Q	68	Glu	Gln	044598	SH3-like/Pro-rich	NA	DNAb (p53CON)	TA (p53CON) partial	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay, EMSA	113	Lin SR;Yang YC;Jung JH;Tsai JH;	A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors	1996	DNA Cell Biol	15	793	8892752
1895	p.R72H	R72H	72	Pro/Arg	His	045786	SH3-like/Pro-rich	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1896	[p.R72H;R175H]	R72H/R175H	72	Pro/Arg	NA		SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4157	p.P75L	P75L	75	Pro	Leu	044609	SH3-like/Pro-rich	NA	TA (WAF1 5', PUMA); TA (WAF1 3') supertrans; super-upregulation (p21waf1); 5-FU sensitivity	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Beta-gal assay, western blot, FACS analysis	292	Fen CX;Coomber DW;Lane DP;Ghadessy FJ;	Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization	2007	J Mol Biol 	371	1238	17610896
1276	p.A76V	A76V	76	Ala	Val		SH3-like/Pro-rich	P 	TA (RGC, WAF1 5')	NA	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1277	p.A79S	A79S	79	Ala	Ser		SH3-like/Pro-rich	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1278	p.T81A	T81A	81	Thr	Ala		SH3-like/Pro-rich	P 	NA	TA (RGC, WAF1 5')	NA	NA	No (WAF1 5')	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4296	[p.T81S;A83V;S240R;R273H]	T81S/A83V/S240R/R273H	81	Thr	NA		SH3-like/Pro-rich	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4654	p.P82L	P82L	82	Pro	Leu	044621	SH3-like/Pro-rich	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
762	p.A83E	A83E	83	Ala	Glu	044623	SH3-like/Pro-rich	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
782	p.A84G	A84G	84	Ala	Gly	044625	SH3-like/Pro-rich	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
834	p.P85S	P85S	85	Pro	Ser	044628	SH3-like/Pro-rich	NA	TA (MDM2, PIG3)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
764	p.A86E	A86E	86	Ala	Glu		SH3-like/Pro-rich	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
763	p.A86T	A86T	86	Ala	Thr		SH3-like/Pro-rich	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
783	p.A86V	A86V	86	Ala	Val	044629	SH3-like/Pro-rich	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
4297	[p.P87R;Q100L;Q104P;Q144L;S240R;R273H]	P87R/Q100L/Q104P/Q144L/S240R/R273H	87	Pro	NA		SH3-like/Pro-rich	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1795	[p.S90P;I195N;E346G]	S90P/I195N/E346G	90	Ser	NA		SH3-like/Pro-rich	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
2694	p.W91*	W91X	91	Trp	Stop		SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	175	Takahashi M;	[Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining]	1998	Hokkaido Igaku Zasshi	73	275	9719952
733	p.W91*	W91X	91	Trp	Stop		SH3-like/Pro-rich	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
1279	p.L93P	L93P	93	Leu	Pro	044641	SH3-like/Pro-rich	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1280	p.L93Q	L93Q	93	Leu	Gln		SH3-like/Pro-rich	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1281	p.S94P	S94P	94	Ser	Pro		SH3-like/Pro-rich	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2872	p.S94*	S94X	94	Ser	Stop		SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3010	p.S94*	S94X	94	Ser	Stop		SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
1282	p.S95P	S95P	95	Ser	Pro		SH3-like/Pro-rich	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3008	p.S96F	S96F	96	Ser	Phe	044646	SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2765	p.S96P	S96P	96	Ser	Pro	044647	SH3-like/Pro-rich	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
835	p.S96P	S96P	96	Ser	Pro	044647	SH3-like/Pro-rich	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
503	p.S96T	S96T	96	Ser	Thr		SH3-like/Pro-rich	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4700	p.V97I	V97I	97	Val	Ile	044650	SH3-like/Pro-rich	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4168	p.P98A	P98A	98	Pro	Ala		SH3-like/Pro-rich	NA	NA	TA (WAF1, BAX, RGC) partial	NA	NA	Yes mut_H (WAF1); No (BAX); Yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
694	p.P98H	P98H	98	Pro	His		SH3-like/Pro-rich	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
711	p.P98L	P98L	98	Pro	Leu	044651	SH3-like/Pro-rich	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
693	p.P98S	P98S	98	Pro	Ser	044652	SH3-like/Pro-rich	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
697	p.S99F	S99F	99	Ser	Phe	044653	N-term	NA	NA	NA	No [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
334	p.S99F	S99F	99	Ser	Phe	044653	N-term	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_L (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3409	p.S99F	S99F	99	Ser	Phe	044653	N-term	P 	NA	TA (RGC)	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
504	p.S99P	S99P	99	Ser	Pro	044654	N-term	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
696	p.S99Y	S99Y	99	Ser	Tyr		N-term	NA	NA	NA	No [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
333	p.S99Y	S99Y	99	Ser	Tyr		N-term	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3410	p.S99Y	S99Y	99	Ser	Tyr		N-term	P 	NA	TA (RGC)	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
1776	p.Q100*	Q100X	100	Gln	Stop		N-term	NA	NA	TA (p53CON); DNAb (p53CON)	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay, EMSA	113	Lin SR;Yang YC;Jung JH;Tsai JH;	A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors	1996	DNA Cell Biol	15	793	8892752
3066	p.Q100*	Q100X	100	Gln	Stop		N-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
1803	[p.T102A;R280T;E287G]	T102A/R280T/E287G	102	Thr	NA		NDBL/beta-sheets	P 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1777	p.T102I	T102I	102	Thr	Ile	044658	NDBL/beta-sheets	NA	NA	TA (p53CON); DNAb (p53CON)	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay, EMSA	113	Lin SR;Yang YC;Jung JH;Tsai JH;	A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors	1996	DNA Cell Biol	15	793	8892752
1284	p.Y103F	Y103F	103	Tyr	Phe		NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1283	p.Y103N	Y103N	103	Tyr	Asn		NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_H (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4550	p.Y103*	Y103X	103	Tyr	Stop		NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
2692	p.Q104*	Q104X	104	Gln	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	174	Kashiwazaki H;Tonoki H;Tada M;Chiba I;Shindoh M;Totsuka Y;Iggo R;Moriuchi T;	High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay	1997	Oncogene	15	2667	9400993
1943	p.Q104*	Q104X	104	Gln	Stop		NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3082	p.G105C	G105C	105	Gly	Cys	044661	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
4620	p.G105C	G105C	105	Gly	Cys	044661	NDBL/beta-sheets	NA	TA (WAF1)	TA (MDM2, BAX, PUMA) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3261	p.G105D	G105D	105	Gly	Asp	044662	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
1285	p.G105D	G105D	105	Gly	Asp	044662	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4688	p.S106R	S106R	106	Ser	Arg	044667	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
939	p.G108_L111delinsIQ	G108_L111delinsIQ	108	Gly	NA		NDBL/beta-sheets	NA	Mdm2 binding	Upregulation (p21waf1); GS	NA	NA	NA	37°C 	Human	H1299	WT control	Co-IP, western blot, CFA	65	Gu J;Kawai H;Wiederschain D;Yuan ZM;	Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain	2001	Cancer Res	61	1741	11245491
1286	p.G108D	G108D	108	Gly	Asp	044671	NDBL/beta-sheets	P 	TA (WAF1 5', RGC)	NA	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1728	p.G108S	G108S	108	Gly	Ser	044672	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
1287	p.F109L	F109L	109	Phe	Leu	044674	NDBL/beta-sheets	P 	TA (WAF1 5', RGC)	NA	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3847	p.R110H	R110H	110	Arg	His	044677	NDBL/beta-sheets	R 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3848	p.R110H	R110H	110	Arg	His	044677	NDBL/beta-sheets	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3922	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	NA	NA	Upregulation (GEF-H1)	NA	37°C 	Human	SCaBER (endo)	Endogenous Mutant	siRNA, RT-qPCR	221	Mizuarai S;Yamanaka K;Kotani H;	Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells	2006	Cancer Res 	66	6319	16778209
4169	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (WAF1, RGC) partial; TA (BAX)	NA	NA	Yes mut_H (WAF1, RGC); Yes mut_H (BAX) low	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
784	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
1872	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
3259	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
3088	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3100	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
2791	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3007	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2970	p.R110L	R110L	110	Arg	Leu	005861	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3268	p.L111P	L111P	111	Leu	Pro	044680	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
2767	p.L111Q	L111Q	111	Leu	Gln	044681	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2691	p.L111Q	L111Q	111	Leu	Gln	044681	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	174	Kashiwazaki H;Tonoki H;Tada M;Chiba I;Shindoh M;Totsuka Y;Iggo R;Moriuchi T;	High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay	1997	Oncogene	15	2667	9400993
2662	p.L111R	L111R	111	Leu	Arg	044682	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
734	p.L111R	L111R	111	Leu	Arg	044682	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
3348	p.G112_V122del	G112_V122del	112	Gly	NA		NDBL/beta-sheets	NA	NA	TA (MDM2); upregulation (p21waf1, mdm2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, western blot	232	Feuerborn A;Moritz C;Von Bonin F;Dobbelstein M;Trumper L;Sturzenhofecker B;Kube D;	Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma	2006	Leuk Lymphoma	47	1932	17065008
505	p.G112R	G112R	112	Gly	Arg		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1897	p.F113C	F113C	113	Phe	Cys	005863	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4282	[p.F113L;G245S]	F113L/G245S	113	Phe	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
2686	p.F113V	F113V	113	Phe	Val	033033	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
2878	p.F113V	F113V	113	Phe	Val	033033	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2900	p.F113V	F113V	113	Phe	Val	033033	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
590	p.F113Y	F113Y	113	Phe	Tyr		NDBL/beta-sheets	NA	NA	NA	NA	NA	No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
489	p.F113Y	F113Y	113	Phe	Tyr		NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, 14-3-3s); No (MDM2, BAX, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4283	[p.L114V;T123P;V172I;A189V;G245S]	L114V/T123P/V172I/A189V/G245S	114	Leu	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
836	p.H115R	H115R	115	His	Arg		L1/S/H2	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
735	p.H115Y	H115Y	115	His	Tyr	044688	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
801	p.H115Y	H115Y	115	His	Tyr	044688	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
2650	p.H115Y	H115Y	115	His	Tyr	044688	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	167	Tada M;Iggo RD;Ishii N;Shinohe Y;Sakuma S;Estreicher A;Sawamura Y;Abe H;	Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay	1996	Int J Cancer	67	447	8707423
936	[p.S116A;S127A]	S116A/S127A	116	Ser	NA		L1/S/H2	NA	TA (RGC); DNAb (RGC)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	luciferase assay, EMSA	63	Wei G;Liu G;Liu X;	Identification of two serine residues important for p53 DNA binding and protein stability	2003	FEBS Lett	543	16	12753897
937	[p.S116D;S127D]	S116D/S127D	116	Ser	NA		L1/S/H2	NA	NA	TA (RGC); DNAb (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	luciferase assay	63	Wei G;Liu G;Liu X;	Identification of two serine residues important for p53 DNA binding and protein stability	2003	FEBS Lett	543	16	12753897
837	p.S116T	S116T	116	Ser	Thr		L1/S/H2	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1233	p.G117A	G117A	117	Gly	Ala		L1/S/H2	P 	TA (WAF1 5', BAX)	TA (P53R2, GADD45, CD95-Fas, PCNA, AIP1, PA26) partial; TA (14-3-3s, RGC, WAF1 3', MDM2-RE2)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
802	p.G117E	G117E	117	Gly	Glu	044692	L1/S/H2	P 	NA	TA (RGC)	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
712	p.G117E	G117E	117	Gly	Glu	044692	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
643	p.G117E	G117E	117	Gly	Glu	044692	L1/S/H2	P 	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
360	p.G117E	G117E	117	Gly	Glu	044692	L1/S/H2	NA	NA	TA (WAF1 5', BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
268	p.G117E	G117E	117	Gly	Glu	044692	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4158	p.T118A	T118A	118	Thr	Ala	044694	L1/S/H2	NA	TA (WAF1 5', WAF1 3') supertrans; super-upregulation (p21waf1); 5-FU sensitivity	TA (PUMA) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Beta-gal assay, western blot, FACS analysis	292	Fen CX;Coomber DW;Lane DP;Ghadessy FJ;	Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization	2007	J Mol Biol 	371	1238	17610896
4286	[p.T118M;H168R;R249S]	T118M/H168R/R249S	118	Thr	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1288	p.A119S	A119S	119	Ala	Ser		L1/S/H2	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1234	p.A119V	A119V	119	Ala	Val		L1/S/H2	P 	TA (WAF1 5', MDM2-RE2, PA26, BAX); TA (GADD45) supertrans	TA (P53R2, CD95-Fas, 14-3-3s, PCNA, AIP1, RGC) partial; TA (WAF1 3')	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
319	p.A119V	A119V	119	Ala	Val		L1/S/H2	NA	TA (WAF1)	TA (PIG3); TA (BAX) partial	NA	NA	Yes mut_L (BAX); No (WAF1, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
644	p.A119V	A119V	119	Ala	Val		L1/S/H2	NA	NA	NA	No [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3285	p.K120A	K120A	120	Lys	Ala		L1/S/H2	NA	APO	Sensitivity to 5-FU; DNAb (WAF1 5') partial; TA (WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis, ChIP, RT-PCR	217	Zupnick A;Prives C;	Mutational analysis of the p53 core domain L1 loop	2006	J Biol Chem 	281	20464	16687402
3297	p.K120E	K120E	120	Lys	Glu	044699	L1/S/H2	NA	NA	GA; DNAb (WAF1, PIG3); DNAb (PUMA) partial; TA (WAF1, PUMA, PIG3); CPT sensitivity	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis, ChIP + RT-qPCR, camptothecin treatment	220	Sykes SM;Mellert HS;Holbert MA;Li K;Marmorstein R;Lane WS;McMahon SB;	Acetylation of the p53 DNA-binding domain regulates apoptosis induction	2006	Mol Cell	24	841	17189187
3048	p.K120E	K120E	120	Lys	Glu	044699	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
1235	p.K120E	K120E	120	Lys	Glu	044699	L1/S/H2	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, NOXA, PUMA, C-FOS, RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3298	p.K120M	K120M	120	Lys	Met	044700	L1/S/H2	NA	NA	GA; DNAb (WAF1); DNAb (PUMA,PIG3) partial; TA (WAF1, PUMA, PIG3); CPT sensitivity	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis, ChIP + RT-qPCR, camptothecin treatment	220	Sykes SM;Mellert HS;Holbert MA;Li K;Marmorstein R;Lane WS;McMahon SB;	Acetylation of the p53 DNA-binding domain regulates apoptosis induction	2006	Mol Cell	24	841	17189187
3299	p.K120R	K120R	120	Lys	Arg	044702	L1/S/H2	NA	GA; DNAb (PUMA, MDM2, WAF1); TA (WAF1, MDM2)	DNAb (BAX) partial; TA (BAX, PUMA) partial; (CPT, DOX, gamma-irradiation, UV sensitivity) partial	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis, ChIP + RT-qPCR, camptothecin, doxorubicin, gamma-irradiation or UV treatment	220	Sykes SM;Mellert HS;Holbert MA;Li K;Marmorstein R;Lane WS;McMahon SB;	Acetylation of the p53 DNA-binding domain regulates apoptosis induction	2006	Mol Cell	24	841	17189187
3347	p.K120R	K120R	120	Lys	Arg	044702	L1/S/H2	NA	Upregulation (mdm2); DNAb (MDM2, WAF1, PUMA); GA	Upregulation (puma); upregulation (p21waf1) partial; APO partial	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot, ChIP, FACS analysis, BrdU incorporation assay	231	Tang Y;Luo J;Zhang W;Gu W;	Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis	2006	Mol Cell	24	827	17189186
3127	p.K120R	K120R	120	Lys	Arg	044702	L1/S/H2	NA	TA (WAF1 5')	TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
374	p.K120R	K120R	120	Lys	Arg	044702	L1/S/H2	NA	TA (WAF1 5')	TA (BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
3287	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	NA	APO partial	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	217	Zupnick A;Prives C;	Mutational analysis of the p53 core domain L1 loop	2006	J Biol Chem 	281	20464	16687402
1884	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperDNAb (BAX, AIP1); DNAb (PIG3); TA (BAX) supertrans	DNAb (WAF1, MDM2); DNAb (PUMA) partial; TA (WAF1, MDM2, PIG3)	NA	NA	NA	37°C 	Human	H1299	WT control	ChIP, RT-qPCR	102	Kaeser MD;Iggo RD;	Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo	2002	Proc Natl Acad Sci U S A	99	95	11756653
3343	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	TUMOR-	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Tumorigenicity assay	229	Nakamura Y;Futamura M;Kamino H;Yoshida K;Nakamura Y;Arakawa H;	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis	2006	Cancer Sci 	97	633	16827804
3477	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperAPO; super-upregulation (BAX; PIR121)	Upregulation (mdm2); upregulation (p21waf1, fas) partial; upregulation (MDM2, WAF1, CyclinG)	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis, western blot, northern blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
1683	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperAPO	NA	NA	NA	NA	37°C 	Human	HUG-15	WT control	FACS analysis	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
1658	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	GS	Upregulation (WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	RNase protection assay, CFA	87	Freeman J;Schmidt S;Scharer E;Iggo R;	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein	1994	EMBO J	13	5393	7957105
1681	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperAPO; upregulation (BAX, PIR121)	TA (MDM2); upregulation (mdm2); upregulation (p21waf1) partial; upregulation (MDM2, WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, western blot, northern blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
3278	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperGS; superAPO; superGA; UV supersensitivity; TA (MSH2, BAX) supertrans; superDNAb (MSH2); DNAb (BAX); super-upregulation (bax, Msh2)	TA (WAF1, MDM2); gamma-irradiation resistance; DNAb (WAF1, MDM2); upregulation (p21waf1, mdm2)  partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment, ChIP, western blot, luciferase assay	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
885	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	GS	TA (WAF1, BAX, MDM2); upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, western blot	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
951	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	superAPO	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	69	Kakudo Y;	Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s	2005	Cancer Res	65	2108	15781620
3481	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperAPO; super-upregulation (PIR121); upregulation (mdm2)	NA	NA	NA	NA	37°C 	Human	U2OS	WT control	FACS analysis, northern blot, western blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
3479	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	SuperAPO; upregulation (mdm2)	NA	NA	NA	NA	37°C 	Human	U-87MG	WT control	FACS analysis, western blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
840	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	TA (WAF1); TA (RGC, PIG3, BAX) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1236	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, C-FOS, RGC) supertrans	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3135	p.S121F	S121F	121	Ser	Phe	044703	L1/S/H2	NA	TA (BAX)	TA (WAF1 5')	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
1237	p.V122A	V122A	122	Val	Ala		L1/S/H2	P 	TA (IGF-BP3, MDM2-RE2, PA26) supertrans	TA (PCNA, AIP1) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1207	p.V122A	V122A	122	Val	Ala		L1/S/H2	NA	TA (P53R2); TA (WAF1 5', GADD45, CD95-Fas, IGF-BP3-boxA) supertrans	TA (MDM2, RGC, WAF1 3'); TA (14-3-3s)  partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection (low expression of mutant p53)	76	Inga A;Storici F;Darden TA;Resnick MA;	Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence	2002	Mol Cell Biol	22	8612	12446780
4287	[p.V122I;C124S;H168R;R249S]	V122I/C124S/H168R/R249S	122	Val	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4208	p.V122*	V122X	122	Val	Stop		L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, PUMA, AIP1); APO; DOX, CDDP and 5-FU sensitivity	NA	No (DOX, CDDP or 5-FU resistance)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, treatment with Doxorubicin, Cisplatin or 5-FU	298	Kawamata H;Omotehara F;Nakashiro K;Uchida D;Shinagawa Y;Tachibana M;Imai Y;Fujimori T;	Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage	2007	Int J Oncol 	30	1089	17390010
4159	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	TA (WAF1 5', WAF1 3'); super-upregulation (p21waf1); 5-FU supersensitivity	TA (PUMA) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Beta-gal assay, western blot, FACS analysis	292	Fen CX;Coomber DW;Lane DP;Ghadessy FJ;	Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization	2007	J Mol Biol 	371	1238	17610896
3286	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	SuperAPO	NA	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	217	Zupnick A;Prives C;	Mutational analysis of the p53 core domain L1 loop	2006	J Biol Chem 	281	20464	16687402
1659	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	Upregulation (WAF1); GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	RNase protection assay, CFA	87	Freeman J;Schmidt S;Scharer E;Iggo R;	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein	1994	EMBO J	13	5393	7957105
2065	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	NIM, DOX sensitivity	NA	NA	No (CDDP, BLEO resistance)	NA	37°C 	Human	Saos-2	WT control	Treatment with cisplatin, nimustine, doxorubicin or bleomycin	152	Wang LH;Okaichi K;Ihara M;Okumura Y;	Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point	1998	Anticancer Res	18	321	9568097
886	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	TA (WAF1, MDM2, BAX); GS; upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, western blot	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
4017	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	Ionizing radiation sensitivity	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	X-ray irradiation	266	Okaichi K;Wang LH;Ihara M;Okumura Y;	Sensitivity to ionizing radiation in Saos-2 cells transfected with mutant p53 genes depends on the mutation position	1998	J Radiat Res (Tokyo)	39	111	9735599
841	p.T123A	T123A	123	Thr	Ala		L1/S/H2	NA	TA (WAF1); TA (RGC, PIG3, BAX) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1238	p.T123A	T123A	123	Thr	Ala		L1/S/H2	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, C-FOS, RGC) supertrans	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1353	[p.T123A;C176R]	T123A/C176R	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1372	[p.T123A;C277Y]	T123A/C277Y	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1369	[p.T123A;D259Y]	T123A/D259Y	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1378	[p.T123A;D281G]	T123A/D281G	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1379	[p.T123A;D281Y]	T123A/D281Y	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1621	[p.T123A;G244D]	T123A/G244D	123	Thr	NA		L1/S/H2	NA	TA (PG13, WAF1)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1358	[p.T123A;G244D]	T123A/G244D	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1359	[p.T123A;G244S]	T123A/G244S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1360	[p.T123A;G245D]	T123A/G245D	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1362	[p.T123A;G245R]	T123A/G245R	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1361	[p.T123A;G245S]	T123A/G245S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1375	[p.T123A;G279E]	T123A/G279E	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1349	[p.T123A;H168R;R249S]	T123A/H168R/R249S	123	Thr	NA		L1/S/H2	NA	NA	TA (PG13, WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1344	[p.T123A;H168R;R249S]	T123A/H168R/R249S	123	Thr	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1354	[p.T123A;H179N]	T123A/H179N	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1367	[p.T123A;L252_I254del]	T123A/L252_I254del	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1366	[p.T123A;L252I]	T123A/L252I	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1368	[p.T123A;L257P]	T123A/L257P	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1370	[p.T123A;L265P]	T123A/L265P	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1626	[p.T123A;M246I]	T123A/M246I	123	Thr	NA		L1/S/H2	NA	TA (PG13, WAF1)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1363	[p.T123A;M246I]	T123A/M246I	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1364	[p.T123A;M246R]	T123A/M246R	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1373	[p.T123A;P278H]	T123A/P278H	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1374	[p.T123A;P278S]	T123A/P278S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1352	[p.T123A;R175_E180del]	T123A/R175_E180del	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1351	[p.T123A;R175H]	T123A/R175H	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1365	[p.T123A;R248W]	T123A/R248W	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1342	[p.T123A;R249S]	T123A/R249S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1371	[p.T123A;R273P]	T123A/R273P	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	No [TR (p53CON)]	NA	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1376	[p.T123A;R280S]	T123A/R280S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1377	[p.T123A;R280T]	T123A/R280T	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
4291	[p.R123A;S240R;R273C]	T123A/S240R/R273C	123	Thr	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1357	[p.T123A;S241F]	T123A/S241F	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1355	[p.T123A;V216del]	T123A/V216del	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1356	[p.T123A;Y236D]	T123A/Y236D	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
3277	p.T123P	T123P	123	Thr	Pro		L1/S/H2	NA	GS; APO; GA; UV sensitivity; gamma-irradiation resistance	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
1239	p.T123P	T123P	123	Thr	Pro		L1/S/H2	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, C-FOS, RGC) supertrans	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4284	[p.T123P;A189V;G245S]	T123P/A189V/G245S	123	Thr	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1563	[p.T123P;C176R]	T123P/C176R	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1583	[p.T123P;C277Y]	T123P/C277Y	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1580	[p.T123P;D259Y]	T123P/D259Y	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1589	[p.T123P;D281G]	T123P/D281G	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1590	[p.T123P;D281Y]	T123P/D281Y	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1622	[p.T123P;G244D]	T123P/G244D	123	Thr	NA		L1/S/H2	NA	TA (PG13) ; TA (WAF1) supertrans	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1568	[p.T123P;G244D]	T123P/G244D	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1624	[p.T123P;G244S]	T123P/G244S	123	Thr	NA		L1/S/H2	NA	TA (PG13); TA (WAF1) supertrans	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1569	[p.T123P;G244S]	T123P/G244S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1570	[p.T123P;G245D]	T123P/G245D	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1571	[p.T123P;G245R]	T123P/G245R	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1336	[p.T123P;G245S]	T123P/G245S	123	Thr	NA		L1/S/H2	NA	TA (PG13, WAF1)	NA	NA	NA	No (p53CON)	37°C 	Human	Saos-2	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1334	[p.T123P;G245S]	T123P/G245S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON) partial	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1586	[p.T123P;G279E]	T123P/G279E	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1576	[p.T123P;H168R;R249S]	T123P/H168R/R249S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1564	[p.T123P;H179N]	T123P/H179N	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1578	[p.T123P;L252_I254del]	T123P/L252_I254del	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1577	[p.T123P;L252I]	T123P/L252I	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1579	[p.T123P;L257P]	T123P/L257P	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1581	[p.T123P;L265P]	T123P/L265P	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1627	[p.T123P;M246I]	T123P/M246I	123	Thr	NA		L1/S/H2	NA	TA (WAF1) supertrans	TA (PG13) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1573	[p.T123P;M246I]	T123P/M246I	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1574	[p.T123P;M246P]	T123P/M246R	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1584	[p.T123P;P278H]	T123P/P278H	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1633	[p.T123P;P278S]	T123P/P278S	123	Thr	NA		L1/S/H2	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1585	[p.T123P;P278S]	T123P/P278S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1562	[p.T123P;R175_E180del]	T123P/R175_E180del	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1561	[p.T123P;R175H]	T123P/R175H	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1575	[p.T123P;R248W]	T123P/R248W	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1582	[p.T123P;R273P]	T123P/R273P	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1587	[p.T123P;R280S]	T123P/R280S	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1588	[p.T123P;R280T]	T123P/R280T	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1567	[p.T123P;S241F]	T123P/S241F	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1565	p.T123P;V216del	T123P/V216del	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1566	[p.T123P;Y236D]	T123P/Y236D	123	Thr	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
854	p.T123S	T123S	123	Thr	Ser		L1/S/H2	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
843	p.C124F	C124F	124	Cys	Phe		L1/S/H2	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1240	p.C124F	C124F	124	Cys	Phe		L1/S/H2	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, C-FOS, RGC) supertrans	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
803	p.C124R	C124R	124	Cys	Arg	044708	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
736	p.C124R	C124R	124	Cys	Arg	044708	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2658	p.C124R	C124R	124	Cys	Arg	044708	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
1241	p.C124S	C124S	124	Cys	Ser	044709	L1/S/H2	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, PA26, BAX, C-FOS, RGC) supertrans; TA (CD95-Fas, IGF-BP3)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3274	p.C124*	C124X	124	Cys	Stop		L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	215	Smardova J;Pavlova S;Svitakova M;Grochova D;Ravcukova B;	Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124	2005	Oncol Rep 	14	901	16142349
887	p.C124Y	C124Y	124	Cys	Tyr	044711	L1/S/H2	NA	TA (WAF1, MDM2, BAX); GS; upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, western blot	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
842	p.C124Y	C124Y	124	Cys	Tyr	044711	L1/S/H2	NA	TA (WAF1); TA (RGC, PIG3, BAX) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1242	p.C124Y	C124Y	124	Cys	Tyr	044711	L1/S/H2	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, RGC, IGF-BP3, PA26, BAX, C-FOS, RGC) supertrans; TA (MDM2-RE2)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
171	p.T125A	T125A	125	Thr	Ala	044712	L1/S/H2	NA	NA	IGF-II repression; TR (IGF-II)	NA	Upregulation (IGF-II); TA (IGF-II)	NA	37°C 	Human	Hep3B	WT control	Northern blot, CAT assay	31	Lee YI;Lee S;Das GC;Park US;Park SM;Lee YI;	Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma	2000	Oncogene	19	3717	10949925
1243	p.T125K	T125K	125	Thr	Lys	044713	L1/S/H2	P 	TA (GADD45, PA26); TA (14-3-3s, MDM2, MDM2-RE2, RGC, IGF-BP3, WAF1 3', BAX, C-FOS) supertrans	TA (WAF1 5', P53R2, CD95-Fas, PCNA, AIP1)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2780	p.T125M	T125M	125	Thr	Met	005864	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
3280	p.T125R	T125R	125	Thr	Arg	044715	L1/S/H2	NA	DNAb (MDM2, BAX, MSH2); TA (MDM2, BAX) superTRANS; super-upregulation (MDM2, BAX)	GS partial; APO partial; GA; UV sensitivity (partial); gamma-irradiation resistance; DNAb (WAF1) partial; upregulation (p21waf1) partial; upregulation (msh2); TA (WAF1, MSH2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment, ChIP, western blot, luciferase assay	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
2890	p.T125R	T125R	125	Thr	Arg	044715	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
1244	p.T125R	T125R	125	Thr	Arg	044715	L1/S/H2	P 	TA (WAF1 5', WAF1 3', GADD45, 14-3-3s, IGF-BP3, MDM2-RE2, BAX, C-FOS) supertrans; TA (MDM2, PA26)	TA (P53R2) partial; TA (CD95-Fas, PCNA, AIP1, RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4553	p.T125R	T125R	125	Thr	Arg	044715	L1/S/H2	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
2668	p.Y126_K132del	Y126_K132del	126	Tyr	NA		L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
4147	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4135	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4114	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1); upregulation (IL-6) moderate; culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
19	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	TA (PCNA)	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
401	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
2980	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
4170	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1) low; Yes mut_H (BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
4701	p.Y126C	Y126C	126	Tyr	Cys	044716	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2897	p.Y126D	Y126D	126	Tyr	Asp	005865	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
645	p.Y126D	Y126D	126	Tyr	Asp	005865	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
269	p.Y126D	Y126D	126	Tyr	Asp	005865	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1289	p.Y126H	Y126H	126	Tyr	His	044718	L1/S/H2	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
270	p.Y126S	Y126S	126	Tyr	Ser	044719	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
646	p.Y126S	Y126S	126	Tyr	Ser	044719	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
2092	p.Y126*	Y126X	126	Tyr	Stop		L1/S/H2	NA	NA	TR (HSP70) partial	NA	No (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2104	p.Y126*	Y126X	126	Tyr	Stop		L1/S/H2	NA	NA	NA	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2877	p.Y126*	Y126X	126	Tyr	Stop		L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
500	p.S127A	S127A	127	Ser	Ala		L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3267	p.S127F	S127F	127	Ser	Phe	005867	L1/S/H2	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
1898	p.S127F	S127F	127	Ser	Phe	005867	L1/S/H2	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3250	p.S127P	S127P	127	Ser	Pro	044721	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
335	p.S127P	S127P	127	Ser	Pro	044721	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1441	p.S127P	S127P	127	Ser	Pro	044721	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1592	[p.S127P;N239Y]	S127P/N239Y	127	Ser	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1603	[p.S127P;S240N]	S127P/S240N	127	Ser	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
804	p.S127Y	S127Y	127	Ser	Tyr	044723	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
765	p.S127Y	S127Y	127	Ser	Tyr	044723	L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1727	p.A129_R249del	A129_R249del	129	Ala	NA		L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
3262	p.L130F	L130F	130	Leu	Phe	044730	L1/S/H2	P 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
506	p.L130I	L130I	130	Leu	Ile	044732	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4554	p.L130V	L130V	130	Leu	Val	044734	L1/S/H2	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
507	p.N131H	N131H	131	Asn	His	044736	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
508	p.N131S	N131S	131	Asn	Ser	005871	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2889	p.K132E	K132E	132	Lys	Glu	044740	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2730	p.K132E	K132E	132	Lys	Glu	044740	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
4635	p.K132E	K132E	132	Lys	Glu	044740	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA]; No [TA (WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3840	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	Saos-2	no WT control	Proliferation assay	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
2729	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
3015	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2776	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
3217	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3093	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
336	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1414	p.K132N	K132N	132	Lys	Asn	044741	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1593	[p.K132N;N239Y]	K132N/N239Y	132	Lys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1604	[p.K132N;S240N]	K132N/S240N	132	Lys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
2992	p.K132Q	K132Q	132	Lys	Gln	005874	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
2762	p.K132R	K132R	132	Lys	Arg	044742	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
3212	p.K132R	K132R	132	Lys	Arg	044742	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1409	p.K132R	K132R	132	Lys	Arg	044742	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3849	p.M133L	M133L	133	Met	Leu	044746	L1/S/H2	R 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3850	p.M133L	M133L	133	Met	Leu	044746	L1/S/H2	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4641	p.M133R	M133R	133	Met	Arg	044747	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1725	p.M133R	M133R	133	Met	Arg	044747	L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
1290	p.M133T	M133T	133	Met	Thr	005875	L1/S/H2	P 	TA (WAF1 5', p53CON, P53R2, GADD45, CD95-Fas, PCNA, MDM2, BAX, PUMA, AIP1, NOXA)	TA (RGC, WAF1 3') partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4642	p.M133T	M133T	133	Met	Thr	005875	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
271	p.F134I	F134I	134	Phe	Ile	044750	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3740	p.F134L	F134L	134	Phe	Leu	036504	L1/S/H2	NA	NA	TUMOR-	NA	TUMOR+	NA	37°C 	Human	LNCaP	no WT control	Tumorigenicity assay	244	Perryman LA;Blair JM;Kingsley EA;Szymanska B;Ow KT;Wen VW;MacKenzie KL;Vermeulen PB;Jackson P;Russell PJ;	Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo	2006	Biochem Biophys Res Commun 	345	1207	16723121
1899	p.F134L	F134L	134	Phe	Leu	036504	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2887	p.F134L	F134L	134	Phe	Leu	036504	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
4466	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	NA	NA	No (CDDP, VM26, VINC and DOX resistance)	NA	37°C 	Human	IMR/KAT100 (endo)	Endogenous Mutant	siRNA and drugs treatment	325	Xue C;Haber M;Flemming C;Marshall GM;Lock RB;MacKenzie KL;Gurova KV;Norris MD;Gudkov AV;	p53 determines multidrug sensitivity of childhood neuroblastoma	2007	Cancer Res 	67	10351	17974978
4465	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	Upregulation (p21waf1) DOX-induced (partial); gamma-irradiation sensitivity	Yes (CDDP, VM26, VINC, DOX and KAT resistance); no (MET, TAX resistance)	NA	NA	37°C 	Human	SHEP	no WT control	Stable transfection + various treatments & western blot, FACS analysis, or CFA	325	Xue C;Haber M;Flemming C;Marshall GM;Lock RB;MacKenzie KL;Gurova KV;Norris MD;Gudkov AV;	p53 determines multidrug sensitivity of childhood neuroblastoma	2007	Cancer Res 	67	10351	17974978
4555	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
2913	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
2942	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3214	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1900	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
337	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1411	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GML, KILLER/DR5, MDM2, WAF1 3', type IV collagenase)]; No [TA (GADD45, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
766	p.C135F	C135F	135	Cys	Phe	005877	L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1594	[p.C135F;N239Y]	C135F/N239Y	135	Cys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_H	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1605	[p.C135F;S240N]	C135F/S240N	135	Cys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
2882	p.C135G	C135G	135	Cys	Gly	044753	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2843	p.C135G	C135G	135	Cys	Gly	044753	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
4171	p.C135G	C135G	135	Cys	Gly	044753	L1/S/H2	NA	TA (WAF1)	TA (BAX, RGC) partial	NA	NA	Yes mut_H (WAF1); Yes (BAX, RGC) low	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
2959	p.C135R	C135R	135	Cys	Arg	044754	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
272	p.C135R	C135R	135	Cys	Arg	044754	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4022	p.C135S	C135S	135	Cys	Ser	005876	L1/S/H2	NA	NA	CDDP and gamma-irradiation sensitivity (partial)	NA	NA	NA	37°C 	Human	GM607	no WT control	Cisplatin or gamma-irradiation treatment + FACS analysis	267	Piovesan B;Pennell N;Berinstein NL;	Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity	1998	Oncogene	17	2339	9811465
1967	p.C135S	C135S	135	Cys	Ser	005876	L1/S/H2	NA	NA	TR (HPV-18)	NA	TA (HPV-18)	NA	37°C 	Human	NHK, C33A	WT control	CAT assay	137	Alvarez-Salas LM;Velazquez A;Lopez-Bayghen E;Woodworth CD;Garrido E;Gariglio P;DiPaolo JA;	Transcriptional repression in normal human keratinocytes by wild-type and mutant p53	1995	Cancer Lett	91	85	7750099
4101	p.C135S	C135S	135	Cys	Ser	005876	L1/S/H2	NA	NA	NA	NA	VEGF production; leukemia cell growth increase	NA	37°C 	Human	Normal stroma cells	no WT control	Study of supernatant, coculture with leukemia cells	285	Narendran A;Ganjavi H;Morson N;Connor A;Barlow JW;Keystone E;Malkin D;Freedman MH;	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth	2003	Exp Hematol 	31	693	12901974
1832	p.C135S	C135S	135	Cys	Ser	005876	L1/S/H2	NA	NA	APO	NA	NA	NA	37°C 	Human	Saos-2, HOS, MNNG, KHOS	WT control	TUNEL assay	118	Ganjavi H;Gee M;Narendran A;Parkinson N;Krishnamoorthy M;Freedman MH;Malkin D;	Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin	2005	Cancer Gene Ther			16211088
2013	p.C135S	C135S	135	Cys	Ser	005876	L1/S/H2	R 	NA	NA	NA	TRANSF+ (moderate); no (hsc70 binding)	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
3485	p.C135S	C135S	135	Cys	Ser	005876	L1/S/H2	R 	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	162	Slingerland JM;Benchimol S;	Transforming activity of mutant human p53 alleles	1991	J Cell Physiol	148	391	1918170
3087	p.C135T	C135T	135	Cys	Thr	045792	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2725	p.C135W	C135W	135	Cys	Trp	044755	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2659	p.C135W	C135W	135	Cys	Trp	044755	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
509	p.C135W	C135W	135	Cys	Trp	044755	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
737	p.C135W	C135W	135	Cys	Trp	044755	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
3022	p.C135*	C135X	135	Cys	Stop		L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
1982	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	NA	NA	TA (RGC, p53CON)	Yes [TA (RGC, p53CON)]	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
1882	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	HSC2	WT control	CFA	117	Ichwan SJ;Yamada S;Sumrejkanchanakij P;Ibrahim-Auerkari E;Eto K;Ikeda MA;	Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells	2005	Oncogene			16247456
3005	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2815	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3206	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
785	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
1403	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4556	p.C135Y	C135Y	135	Cys	Tyr	044756	L1/S/H2	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4404	[p.C135Y;N235K]	C135Y/N235K	135	Cys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4406	[p.C135Y;N235K;N239Y]	C135Y/N235K/N239Y	135	Cys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4405	[p.C135Y;N239Y]	C135Y/N239Y	135	Cys	NA		L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
2960	p.Q136*	Q136X	136	Gln	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selectionn	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2709	p.L137Q	L137Q	137	Leu	Gln	005880	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
861	p.L137Q	L137Q	137	Leu	Gln	005880	NDBL/beta-sheets	NA	TA (MDM2)	NA	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
4603	p.A138P	A138P	138	Ala	Pro	005881	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA)]; No [TA (WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4604	p.A138S	A138S	138	Ala	Ser	044764	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
510	p.A138T	A138T	138	Ala	Thr	044765	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4461	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	GS; upregulation (WAF1, GADD45); upregulation (MDM2) partial	NA	NA	Yes mut_H (APO); Yes mut_H (WAF1, MDM2, GADD45)	37°C 	Human	Jurkat	no WT control	Stable transfection + proliferation assay, Northern blot, temperature sensitive assay at 32,5°C	323	Yamato K;Yamamoto M;Hirano Y;Tsuchida N;	A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes	1995	Oncogene	11	1	7624116
3935	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	GS; GA; upregulation (p21waf1); downregulation (bcl-2)	NA	No (growth advantage); upregulation (MRP1); upregulation (Mrp1); drug resistance	Mut_H (growth inhibition); Mut_H (GA); Mut_H (p21waf1, bcl-2); Mut_H (MRP1); no (Mrp1)	38°C 	Human	LNCaP	no WT control	Proliferation assay, CFA, northern & western blot, VIN treatment, temp. sensitive assay at 32°C	127	Sullivan GF;Yang JM;Vassil A;Yang J;Bash-Babula J;Hait WN;	Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells	2000	J Clin Invest	105	1261	10792001
4460	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	GS; upregulation (GADD45)	NA	No (growth advantage)	Yes mut_H (GA); Yes mut_H (GADD45)	37°C 	Human	Saos-2	no WT control	Stable transfection + proliferation assay, Northern blot, temperature sensitive assay at 32,5°C	323	Yamato K;Yamamoto M;Hirano Y;Tsuchida N;	A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes	1995	Oncogene	11	1	7624116
4263	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	Upregulation (WAF1, MDM2)	NA	NA	Yes mut_H (WAF1, MDM2)	37°C 	Human	Saos-2	no WT control	Northern Blot, temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4259	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	37°C 	Human	Saos-2, HeLA	WT control	CAT assay, temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4254	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	Yes mut_H (TRANSF+)	37°C 	Other	REF	WT control	Transformation assay, , temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4541	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4557	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	TA (11 different p53-RE)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4172	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	TA (WAF1, RGC)	TA (BAX) partial	NA	NA	Yes mut_H (WAF1, BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
864	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	TA (MDM2, WAF1 5')	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
945	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	TA (WAF1)	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
1773	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	112	Lomax ME;Barnes DM;Gilchrist R;Picksley SM;Varley JM;Camplejohn RS;	Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family	1997	Oncogene	14	1869	9150393
2985	p.A138V	A138V	138	Ala	Val	033034	NDBL/beta-sheets	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
713	p.K139E	K139E	139	Lys	Glu	044766	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
273	p.K139E	K139E	139	Lys	Glu	044766	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
742	p.K139N	K139N	139	Lys	Asn	005882	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4288	[p.K139R;H168R;N239Y;R249S]	K139R/H168R/N239Y/R249S	139	Lys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1291	p.T140A	T140A	140	Thr	Ala	044770	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2879	p.C141R	C141R	141	Cys	Arg	044775	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
4558	p.C141W	C141W	141	Cys	Trp	044777	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
2867	p.C141*	C141X	141	Cys	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
1471	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5')] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4351	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	TA (GML, KILLER/DR5, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
3952	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	249	Hachiya M;Chumakov A;Miller CW;Akashi M;Said J;Koeffler HP;	Mutant p53 proteins behave in a dominant, negative fashion in vivo	1994	Anticancer Res 	14	1853	7847818
2074	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	155	Chumakov AM;Miller CW;Chen DL;Koeffler HP;	Analysis of p53 transactivation through high-affinity binding sites	1993	Oncogene	8	3005	8414502
2732	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
1901	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2963	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3197	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1446	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5', WAF1 3')]	NA	No (Cyclin G, WAF1 3', 14-3-3s, p53AIP1, S100A2); Yes mut_H (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', type IV collagenase, B99, RGC)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4308	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4606	p.C141Y	C141Y	141	Cys	Tyr	005886	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, WAF1); TA (PUMA) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4352	[p.C141Y;D228A;N235K;N239M]	C141Y/D228A/N235K/N239M	141	Cys	NA		NDBL/beta-sheets	NA	TA (KILLER/DR5) supertrans; TA (GML)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4302	[p.C141Y;D228A;N235K;N239M]	C141Y/D228A/N235K/N239M	141	Cys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4389	[p.C141Y;D228E;N235K;Y236N;N239L]	C141Y/D228E/N235K/Y236N/N239L	141	Cys	NA		NDBL/beta-sheets	NA	TA (KILLER/DR5)	TA (GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4303	[p.C141Y;D228E;N235K;Y236N;N239L]	C141Y/D228E/N235K/Y236N/N239L	141	Cys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4408	[p.C141Y;N235K;N239Y]	C141Y/N235K/N239Y	141	Cys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4376	[p.C141Y;N235K;S240T]	C141Y/N235K/S240T	141	Cys	NA		NDBL/beta-sheets	NA	TA (KILLER/DR5); TA (GML, WAF1) supertrans	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4305	[p.C141Y;N235K;S240T]	C141Y/N235K/S240T	141	Cys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4407	[p.C141Y;N239Y]	C141Y/N239Y	141	Cys	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
3948	[p.C141Y;R273H]	C141Y/R273H	141	Cys	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	249	Hachiya M;Chumakov A;Miller CW;Akashi M;Said J;Koeffler HP;	Mutant p53 proteins behave in a dominant, negative fashion in vivo	1994	Anticancer Res 	14	1853	7847818
4375	[p.C141Y;T232V;H233R;Y234F;N235K;N239L]	C141Y/T232V/H233R/Y234F/N235K/N239L	141	Cys	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4304	[p.C141Y;T232V;H233R;Y234F;N235K;N239L]	C141Y/T232V/H233R/Y234F/N235K/N239L	141	Cys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
3851	p.P142L	P142L	142	Pro	Leu	044780	NDBL/beta-sheets	R 	NA	NA	NA	No (p73 interference); no (p73 binding); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, co-IP, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3852	p.P142L	P142L	142	Pro	Leu	044780	NDBL/beta-sheets	P 	NA	NA	NA	No (p73 interference); no (p73 binding); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, co-IP, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4090	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Daxx interference (weak)	NA	37°C 	Human	293	WT control	ASK1 activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
2185	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	TA (PTHrP)	NA	37°C 	Human	A253	WT control	CAT assay	166	Foley J;King CS;Jimenez JA;Wysolmerski JJ;Philbrick WM;	Activation of PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the tumor suppressor p53	2000	Oncol Res	12	71	11132926
4028	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Gamma-irradiation resistance	NA	37°C 	Human	A2780	no WT control	Gamma-irradiation treatment	269	McIlwrath AJ;Vasey PA;Ross GM;Brown R;	Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity	1994	Cancer Res 	54	3718	8033090
4029	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	CDDP, DOX and ara-C resistance; No (TAX and CPT resistance)	NA	37°C 	Human	A2780	no WT control	Treatment with cisplatin, doxorubicin, ara-C, taxol or camptothecin	270	Vasey PA;Jones NA;Jenkins S;Dive C;Brown R;	Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance	1996	Mol Pharmacol 	50	1536	8967975
3984	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	No (culture in soft agar or plastic, TUMOR+, TGF-beta resistance)	NA	37°C 	Human	AA/C1	no WT control	CFA on plastic and in agar, tumorigenicity assay, treatment with TGF-beta	259	Williams AC;Browne SJ;Manning AM;Daffada P;Collard TJ;Paraskeva C;	Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-beta 1	1994	Oncogene	9	1479	8152811
3988	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	No (gamma-irradiation resistance)	NA	37°C 	Human	AA/C1	no WT control	Gamma-irradiation treatment	260	Williams AC;Miller JC;Collard TJ;Bracey TS;Cosulich S;Paraskeva C;	Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation	1995	Oncogene	11	141	7624121
1951	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13)	NA	TA (HIV)	NA	37°C 	Human	Akata	WT control	CAT assay	133	Gualberto A;Hixon ML;Finco TS;Perkins ND;Nabel GJ;Baldwin AS;	A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat	1995	Mol Cell Biol	15	3450	7760842
1964	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	Ag T superbinding	GS; TGF-beta1 sensitivity	NA	hsp70 binding; TGF-beta1 resistance (moderate); TUMOR+	NA	37°C 	Human	BEAS-2B	WT control	Co-IP, CFA, TGF-beta1 treatment, tumorigenicity assay	136	Gerwin BI;Spillare E;Forrester K;Lehman TA;Kispert J;Welsh JA;Pfeifer AM;Lechner JF;Baker SJ;Vogelstein B;.;	Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1	1992	Proc Natl Acad Sci U S A	89	2759	1557382
1966	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (HPV-18)	Yes [TR (HPV-18)]	NA	NA	37°C 	Human	C33A	WT control	CAT assay	137	Alvarez-Salas LM;Velazquez A;Lopez-Bayghen E;Woodworth CD;Garrido E;Gariglio P;DiPaolo JA;	Transcriptional repression in normal human keratinocytes by wild-type and mutant p53	1995	Cancer Lett	91	85	7750099
3937	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (MDR-1)	NA	TA (MDR-1); no [TA (MRP1)]	NA	37°C 	Human	CACO2	no WT control	Luciferase assay	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
394	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX); GS; APO	Yes [TA (BAX)]; No [TA (WAF1)]; No (GS, APO)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
36	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	Calu-6, VAMT-1, 21MT-1	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
3963	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS partial	NA	NA	NA	37°C 	Human	EJ	WT control	CFA	253	Sharma S;Schwarte-Waldhoff I;Oberhuber H;Schafer R;	Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes	1993	Cell Growth Differ 	4	861	8274455
1778	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (eIF4E)	NA	TA (eIF4E)	NA	37°C 	Human	EU-4	WT control	Luciferase assay	114	Zhu N;Gu L;Findley HW;Zhou M;	Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53	2005	Biochem Biophys Res Commun	335	1272	16112647
1743	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (TP53) partial; TA (MDM2)	NA	RB18A inhibition	NA	37°C 	Human	H1299	WT control	CAT or luciferase assay	104	Lottin-Divoux S;Barel M;Frade R;	RB18A enhances expression of mutant p53 protein in human cells	2005	FEBS Lett	579	2323	15848166
1636	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX); TA (CD95-Fas) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	84	Munsch D;Watanabe-Fukunaga R;Bourdon JC;Nagata S;May E;Yonish-Rouach E;Reisdorf P;	Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis	2000	J Biol Chem	275	3867	10660538
1981	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC, p53CON)	NA	NA	No (RGC); Yes mut_H (p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
2142	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	DNAb (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
3308	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RPS27L)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	222	He H;Sun Y;	Ribosomal protein S27L is a direct p53 target that regulates apoptosis	2006	Oncogene			17057733
3142	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	NA	NA	NA	Yes mut_H (RGC)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 32,5°C	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
896	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	APO	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	53	Friedlander P;Haupt Y;Prives C;Oren M;	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis	1996	Mol Cell Biol	16	4961	8756655
4076	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	NA	Upregulation (p21waf1); GS; GA; APO	NA	No (p73beta interference, p73beta binding)	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
4077	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	Upregulation (p21waf1); GS; GA; APO	NA	No (p73beta interference, p73beta binding)	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
4060	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	CDDP and X-ray radiation sensitivity	NA	No (CDDP and X-ray radiation resistance)	NA	37°C 	Human	H1299	WT control	Treatment with cisplatin or X-ray irradiation	279	Ohnishi K;Ota I;Takahashi A;Yane K;Matsumoto H;Ohnishi T;	Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck	2002	Apoptosis 	7	367	12101396
3459	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TA (GADD45, WAF1, MDM2)	APO; TA (BAX, IGF-BP3-boxA&B)	NA	NA	NA	32°C 	Human	H1299	WT control	FACS analysis, luciferase assay	53	Friedlander P;Haupt Y;Prives C;Oren M;	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis	1996	Mol Cell Biol	16	4961	8756655
4217	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	Upregulation (p21waf1) DOX-induced	DOX sensitivity	NA	NA	Yes mut_L (DOX sensitivity); Yes mut_H [upregulation (p21waf1) DOX-induced]	32°C 	Human	H1299	no WT control	DOX treatment + FACS analysis, CFA, temperature sensitive assay at 32°C and 38°C, western blot	300	Lin YC;Wang FF;	Mechanisms underlying the pro-survival pathway of p53 in suppressing mitotic death induced by adriamycin	2008	Cell Signal 	20	258	18006273
81	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	HCT-116	WT control	CAT assay	11	Kern SE;Pietenpol JA;Thiagalingam S;Seymour A;Kinzler KW;Vogelstein B;	Oncogenic forms of p53 inhibit p53-regulated gene expression	1992	Science	256	827	1589764
3369	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
4106	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Rb phosphorylation; Cyclin E and cdk2 activity increase; upregulation (cdk2, cdk6); No [upregulation (Cyclin E, Cyclin D1, cdk4)]; No [downregulation (p21waf1)]	NA	37°C 	Human	HDF	no WT control	Western blot	287	Wyllie F;Haughton M;Bartek J;Rowson J;Wynford-Thomas D;	Mutant p53 can delay growth arrest and loss of CDK2 activity in senescing human fibroblasts without reducing p21(WAF1) expression	2003	Exp Cell Res 	285	236	12706118
3980	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Upregulation (p21waf1) BLEO-dependent	NA	BLEO resistance (moderate)	NA	37°C 	Human	HDF	no WT control	Bleomycin treatment	257	Bond JA;Blaydes JP;Rowson J;Haughton MF;Smith JR;Wynford-Thomas D;Wyllie FS;	Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1	1995	Cancer Res 	55	2404	7538902
3981	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	Upregulation (p21waf1) UV-dependent	NA	NA	NA	NA	37°C 	Human	HDF	no WT control	UV irradiation treatment	257	Bond JA;Blaydes JP;Rowson J;Haughton MF;Smith JR;Wynford-Thomas D;Wyllie FS;	Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1	1995	Cancer Res 	55	2404	7538902
3956	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	HDF	no WT control	Stable transfection	251	Bond JA;Wyllie FS;Wynford-Thomas D;	Escape from senescence in human diploid fibroblasts induced directly by mutant p53	1994	Oncogene	9	1885	8208534
4093	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Daxx and Ask1 interference (weak)	NA	37°C 	Human	HeLa	no WT control	JNK activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
920	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (PCNA); TR (RSV, HTLV); TR (HSV1-UL9) partial	NA	TA (PCNA); TA (HTLV)	NA	37°C 	Human	HeLa	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1953	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (HSV1-TK) partial; TR (SV40)	NA	NA	NA	37°C 	Human	HeLa	WT control	CAT assay	134	Subler MA;Martin DW;Deb S;	Inhibition of viral and cellular promoters by human wild-type p53	1992	J Virol	66	4757	1352831
2062	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (IL-6, C-FOS, B-ACTIN) partial	NA	NA	NA	37°C 	Human	HeLa	WT control	CAT assay	149	Santhanam U;Ray A;Sehgal PB;	Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product	1991	Proc Natl Acad Sci U S A	88	7605	1652755
2063	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (IL-6)	NA	NA	No (IL-6)	37°C 	Human	HeLa	WT control	CAT assay, temperature sensitive assay at 32°C	150	Margulies L;Sehgal PB;	Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species	1993	J Biol Chem	268	15096	8325885
1643	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	TA (BAG-1)	NA	37°C 	Human	HeLa	WT control	Luciferase assay	85	Yang X;Pater A;Tang SC;	Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	1999	Oncogene	18	4546	10467399
827	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	No [TA(HsMAD1)]	NA	37°C 	Human	HeLa, HCT-116, HCT-116 (p53-null)	WT control	Luciferase assay	4	Iwanaga Y;Jeang KT;	Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant	2002	Cancer Res	62	2618	11980658
2109	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13)	No [TA (PG13)]	NA	NA	37°C 	Human	Hep3B	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
3484	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	Hep3B	WT control	CFA	159	Puisieux A;Ponchel F;Ozturk M;	p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells	1993	Oncogene	8	487	8381223
4001	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Monocytic differentiation induction; sensitivity to serum depletion; ETO sensitivity	NA	No (ETO resistance)	NA	37°C 	Human	HL-60	WT control	Stable transfection + analysis of markers of differentiation or serum depletion or ETO treatment	262	Banerjee D;Lenz HJ;Schnieders B;Manno DJ;Ju JF;Spears CP;Hochhauser D;Danenberg K;Danenberg P;Bertino JR;	Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress	1995	Cell Growth Differ 	6	1405	8562479
3959	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS partial	No (GS)	NA	NA	37°C 	Human	HT-1080	WT control	BrdU incorporation assay, CFA	253	Sharma S;Schwarte-Waldhoff I;Oberhuber H;Schafer R;	Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes	1993	Cell Growth Differ 	4	861	8274455
4040	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Downregulation (TCR/CD3)	Yes mut_H (downregulation TCR/CD3)	37°C 	Human	Jurkat	no WT control	FACS analysis, temperature sensitive assay at 32°C	272	Iwamoto KS;Mizuno T;Seyama T;Kyoizumi S;	Mutant p53: epigenetic mutator of the T-cell receptor via induction of methylation	1999	Mol Carcinog 	25	113	10365913
3929	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Upregulation (Fas); GA	NA	NA	Mut_H (Fas)	37°C 	Human	K562	no WT control	FACS analysis, temperature sensitive assay at 32°C	241	Owen-Schaub LB;Zhang W;Cusack JC;Angelo LS;Santee SM;Fujiwara T;Roth JA;Deisseroth AB;Zhang WW;Kruzel E;.;	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression	1995	Mol Cell Biol 	15	3032	7539102
3930	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	GA	NA	NA	NA	NA	32°C 	Human	K562	no WT control	FACS analysis	241	Owen-Schaub LB;Zhang W;Cusack JC;Angelo LS;Santee SM;Fujiwara T;Roth JA;Deisseroth AB;Zhang WW;Kruzel E;.;	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression	1995	Mol Cell Biol 	15	3032	7539102
3143	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	TA (RGC, p53CON) supertrans; superDNAb (p53CON)	GS partial	NA	NA	NA	32°C 	Human	K-562	WT control	Luciferase assay, CFA, EMSA	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
3139	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	GS	NA	NA	Yes mut_H (RGC, p53CON)	37°C 	Human	K-562	WT control	Luciferase assay, CFA, temperature sensitive assay at 32,5°C	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
1	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	DNAb (p53CON)	TA (p53CON) partial; TA (RGC)	NA	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay, EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
4026	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS; upregulation (p21waf1); gamma-irradiation, VIN, TAX, VM26, CDDP, BCNU and TOP sensitivity	NA	No (growth advantage); No (gamma-irradiation resistance)	NA	37°C 	Human	LN-18	no WT control	Proliferation assay, CFA, western blot, treatment with gamma-irradiation, VIN, TAX, VM26, CIS, BCNU or TOP	268	Bartussek C;Naumann U;Weller M;	Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status	1999	Exp Cell Res 	253	432	10585266
4023	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	VM26 and BCNU sensitivity	GS partial; upregulation (p21waf1); gamma-irradiation, CDDP and TOP sensitivity	NA	No (growth advantage); downregulation (p21waf1); No (gamma-irradiation, CDDP and TOP resistance)	NA	37°C 	Human	LN-229	no WT control	Prolife assay, CFA, western blot, treatment with gamma-irradiation, VIN, TAX, VM26, CIS, BCNU or TOP	268	Bartussek C;Naumann U;Weller M;	Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status	1999	Exp Cell Res 	253	432	10585266
3982	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Upregulation (p21waf1)	NA	NA	NA	37°C 	Human	LN-308	WT control	Western blot	258	Jung JM;Li H;Kobayashi T;Kyritsis AP;Langford LA;Bruner JM;Levin VA;Zhang W;	Inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53	1995	Cell Growth Differ 	6	909	8547219
4025	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS; upregulation (p21waf1); gamma-irradiation, VIN, TAX, CDDP, BCNU, TOP sensitivity	NA	Growth advantage; No (gamma-irradiation resistance)	NA	37°C 	Human	LN-308	no WT control	Proliferation assay, CFA, western blot, treatment with gamma-irradiation, VIN, TAX, VM26, CIS, BCNU or TOP	268	Bartussek C;Naumann U;Weller M;	Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status	1999	Exp Cell Res 	253	432	10585266
4218	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PTGF-beta, WAF1)	NA	TR (PTGF-beta, WAF1)	NA	37°C 	Human	MCF-7	WT control	Luciferase assay	301	Liu DX;Lobie PE;	Transcriptional activation of p53 by Pitx1	2007	Cell Death Differ 	14	1893	17762884
3944	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	MKN-28	WT control	CFA	247	Matozaki T;Sakamoto C;Suzuki T;Matsuda K;Uchida T;Nakano O;Wada K;Nishisaki H;Konda Y;Nagao M;.;	p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells	1992	Cancer Res 	52	4335	1322785
3945	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	DNA synthesis inhibition	NA	NA	NA	37°C 	Human	MKN45	WT control	[3H] Thymidine incorporation assay	247	Matozaki T;Sakamoto C;Suzuki T;Matsuda K;Uchida T;Nakano O;Wada K;Nishisaki H;Konda Y;Nagao M;.;	p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells	1992	Cancer Res 	52	4335	1322785
14	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Spindle checkpoint	NA	NA	NA	37°C 	Human	NHF	WT control	Colcemid treatment	5	Gualberto A;Aldape K;Kozakiewicz K;Tlsty TD;	An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control	1998	Proc Natl Acad Sci U S A	95	5166	9560247
1965	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TR (HPV-18)	NA	No [TR (HPV-18)]	NA	NA	37°C 	Human	NHK	WT control	CAT assay	137	Alvarez-Salas LM;Velazquez A;Lopez-Bayghen E;Woodworth CD;Garrido E;Gariglio P;DiPaolo JA;	Transcriptional repression in normal human keratinocytes by wild-type and mutant p53	1995	Cancer Lett	91	85	7750099
3779	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13); upregulation (WAF1)	NA	Extended lifespan; downregulation (WAF1, TP53)	No (extended lifespan)	37°C 	Human	NHOK	no WT control	Proliferation assay, temperature sensitive assay at 32°C, luciferase assay, northern blot	126	Liu X;Nishitani J;McQuirter JL;Baluda MA;Park NH;	The temperature sensitive mutant p53-143ala extends in vitro life span, promotes errors in DNA replication and impairs DNA repair in normal human oral keratinocytes	2001	Cell Mol Biol	47	1169	11838964
3947	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	Pancreas cells	no WT control	Stable transfection	248	Wyllie FS;Lemoine NR;Barton CM;Dawson T;Bond J;Wynford-Thomas D;	Direct growth stimulation of normal human epithelial cells by mutant p53	1993	Mol Carcinog 	7	83	8457292
4154	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	37°C 	Human	PC-3	WT control	Luciferase assay, temperature sensitive assay at 32°C	290	Bajgelman MC;Strauss BE;	Development of an adenoviral vector with robust expression driven by p53	2008	Virology	371	8	18076963
37	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13)	Yes [TA (PG13)] moderate	NA	NA	37°C 	Human	PC-3, Saos-2, SK-OV-3, Hep3B, 21NT, 21PT, 21MT-2	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
51	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX); upregulation (p21waf1); GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
102	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	TA (MDR-1) moderate	NA	37°C 	Human	Saos-2	WT control	Stable transfection, CAT assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
149	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (hMMP-13, hMMP1)	Yes [TR (hMMP-13)]; No [TR (hMMP1)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	24	Sun Y;Cheung JM;Martel-Pelletier J;Pelletier JP;Wenger L;Altman RD;Howell DS;Cheung HS;	Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	2000	J Biol Chem	275	11327	10753945
919	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (PCNA)	NA	TA (PCNA)	NA	37°C 	Human	Saos-2	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
954	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TETR	GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, cross-link of proteins with glutaraldehyde + SDS/PAGE	70	Ishioka C;Shimodaira H;Englert C;Shimada A;Osada M;Jia LQ;Suzuki T;Gamo M;Kanamaru R;	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells	1997	Biochem Biophys Res Commun	232	54	9125151
933	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TR (SV40)	TA (WAF1, MDM2); TR (ASNS, hTERT); DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
1146	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	p73beta binding	NA	NA	p73alpha binding	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1147	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	No p73beta binding	NA	NA	p73alpha binding (low affinity)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1962	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (HIV)	NA	TA (HIV)	NA	37°C 	Human	Saos-2	WT control	CAT assay	135	Subler MA;Martin DW;Deb S;	Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53	1994	J Virol	68	103	8254719
2061	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	ets-1 binding	NA	37°C 	Human	Saos-2	WT control	Co-IP	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
2066	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NIM sensitivity	NA	CDDP resistance (moderate); no (NIM, DOX, BLEO resistance)	NA	37°C 	Human	Saos-2	WT control	Treatment with cisplatin, nimustine, doxorubicin or bleomycin	152	Wang LH;Okaichi K;Ihara M;Okumura Y;	Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point	1998	Anticancer Res	18	321	9568097
2031	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC); GA; GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, FACS analysis, CFA	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
2157	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (HLA-B7)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	161	Griffioen M;Steegenga WT;Ouwerkerk IJ;Peltenburg LT;Jochemsen AG;Schrier PI;	Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms	1998	Mol Immunol	35	829	9839551
2115	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1); TR (C-JUN)	NA	hsp70 binding	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
1703	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (IGFI-R)	NA	TA (IGFI-R)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	98	Werner H;Karnieli E;Rauscher FJ;LeRoith D;	Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene	1996	Proc Natl Acad Sci U S A	93	8318	8710868
1668	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TA (EGFR) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	89	Ludes-Meyers JH;Subler MA;Shivakumar CV;Munoz RM;Jiang P;Bigger JE;Brown DR;Deb SP;Deb S;	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53	1996	Mol Cell Biol	16	6009	8887630
1501	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
3164	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (S100A2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	211	Tan M;Heizmann CW;Guan K;Schafer BW;Sun Y;	Transcriptional activation of the human S100A2 promoter by wild-type p53	1999	FEBS Lett 	445	265	10094469
3152	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
3313	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (CDC25A)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	223	Rother K;Kirschner R;Sanger K;Bohlig L;Mossner J;Engeland K;	p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A	2007	Oncogene	26	1949	17001315
3251	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PTGF-beta)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	213	Tan M;Wang Y;Guan K;Sun Y;	PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway	2000	Proc Natl Acad Sci U S A	97	109	10618379
3170	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (type IV collagenase)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	212	Bian J;Sun Y;	Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter	1997	Mol Cell Biol 	17	6330	9343394
4084	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Daxx binding (low); No (culture in soft agar)	NA	37°C 	Human	Saos-2	WT control	Co-IP, culture in soft agar	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4098	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	No (Daxx interference)	NA	37°C 	Human	Saos-2	no WT control	CFA	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4102	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	Upregulation (VEGF); VEGF production	NA	37°C 	Human	Saos-2	WT control	RT-PCR, study of supernatant	285	Narendran A;Ganjavi H;Morson N;Connor A;Barlow JW;Keystone E;Malkin D;Freedman MH;	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth	2003	Exp Hematol 	31	693	12901974
4033	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	No (culture in soft agar); No (TUMOR+)	NA	37°C 	Human	Saos-2	no WT control	Culture in soft agar, tumorigenicity assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
4003	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Stable transfection	263	van Laar T;Schouten R;Jochemsen AG;Terleth C;van der Eb AJ;	Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cells	1996	Cytometry	25	21	8875051
4004	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GA; APO	NA	NA	Yes mut_H [upregulation (p21waf1, mdm2, gadd45)]; Yes mut_H (GA); No (APO)	37°C 	Human	Saos-2	no WT control	Temperature sensitive assay at 32°C + western blot or FACS analysis	263	van Laar T;Schouten R;Jochemsen AG;Terleth C;van der Eb AJ;	Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cells	1996	Cytometry	25	21	8875051
4018	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Ionizing radiation sensitivity	NA	No (ionizing radiation resistance)	NA	37°C 	Human	Saos-2	WT control	X-ray irradiation	266	Okaichi K;Wang LH;Ihara M;Okumura Y;	Sensitivity to ionizing radiation in Saos-2 cells transfected with mutant p53 genes depends on the mutation position	1998	J Radiat Res (Tokyo)	39	111	9735599
3953	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC)	Yes [TA (RGC)]; No (GS)	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, CFA	250	Frebourg T;Sadelain M;Ng YS;Kassel J;Friend SH;	Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype	1994	Cancer Res 	54	878	8313374
3809	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	NA	NA	p73 interference	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay, EMSA, CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3810	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3719	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TA (RGC), upregulation (MDM2)	NA	NA	NA	NA	30°C 	Human	Saos-2	no WT control	Luciferase assay, northern blot	240	Buckbinder L;Talbott R;Seizinger BR;Kley N;	Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes	1994	Proc Natl Acad Sci U S A	91	10640	7938006
3402	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX); APO	Yes [TA (BAX)]; No [TA (WAF1)]; No (APO)	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
4281	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	Upregulation (WAF1)	NA	NA	Yes mut_H (WAF1)	37°C 	Human	Saos-2	no WT control	RT-qPCR, temperature sensitive assay at 32°C	320	Zhou X;Yang G;Huang R;Chen X;Hu G;	SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53	2007	FEBS Lett 	581	4943	17904127
4515	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (uPA); TA (PAI-1)	NA	No [TA (uPA)]; no [TR (PAI-1)]	NA	37°C 	Human	Saos-2	WT control	CAT assay	329	Kunz C;Pebler S;Otte J;von der AD;	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53	1995	Nucleic Acids Res 	23	3710	7479001
1331	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1972	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	Saos-2, U2OS, KHOS-24OS	WT control	CFA	139	Diller L;Kassel J;Nelson CE;Gryka MA;Litwak G;Gebhardt M;Bressac B;Ozturk M;Baker SJ;Vogelstein B;.;	p53 functions as a cell cycle control protein in osteosarcomas	1990	Mol Cell Biol	10	5772	2233717
3962	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	SW480	WT control	CFA	253	Sharma S;Schwarte-Waldhoff I;Oberhuber H;Schafer R;	Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes	1993	Cell Growth Differ 	4	861	8274455
3162	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	SW480, SW837, RKO	WT control	CFA	210	Baker SJ;Markowitz S;Fearon ER;Willson JK;Vogelstein B;	Suppression of human colorectal carcinoma cell growth by wild-type p53	1990	Science	249	912	2144057
4220	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (HGFIN)	NA	NA	NA	37°C 	Human	T47D, MDA-MB-231	WT control	Luciferase assay	303	Metz RL;Patel PS;Hameed M;Bryan M;Rameshwar P;	Role of human HGFIN/nmb in breast cancer	2007	Breast Cancer Res 	9		17845721
4027	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS; upregulation (p21waf1); gamma-irradiation, VIN, TAX, VM26, CDDP, BCNU and TOP sensitivity	NA	Growth advantage; No (gamma-irradiation resistance)	NA	37°C 	Human	T98G	no WT control	CFA, western blot, treatment with gamma-irradiation, VIN, TAX, VM26, CIS, BCNU or TOP	268	Bartussek C;Naumann U;Weller M;	Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status	1999	Exp Cell Res 	253	432	10585266
4052	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	DOX and CDDP sensitivity	NA	37°C 	Human	TCCSUP	no WT control	Treatment with cisplatin or doxorubicin	277	Chang FL;Lai MD;	Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells	2001	J Urol 	166	304	11435891
3946	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	Thyroid cells	no WT control	Stable transfection	248	Wyllie FS;Lemoine NR;Barton CM;Dawson T;Bond J;Wynford-Thomas D;	Direct growth stimulation of normal human epithelial cells by mutant p53	1993	Mol Carcinog 	7	83	8457292
4024	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	GS; upregulation (p21waf1); gamma-irradiation, VIN, TAX, VM26, CDDP, BCNU and TOP sensitivity	NA	No (growth advantage); gamma-irradiation resistance (moderate)	NA	37°C 	Human	U-87MG	no WT control	Proliferation assay, CFA, western blot, treatment with gamma-irradiation, VIN, TAX, VM26, CIS, BCNU or TOP	268	Bartussek C;Naumann U;Weller M;	Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status	1999	Exp Cell Res 	253	432	10585266
1696	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TR (bFGF, EGFR)	NA	TA (bFGF); No [TA (EGFR)]	NA	37°C 	Human	U-87MG	WT control	CAT assay	96	Ueba T;Nosaka T;Takahashi JA;Shibata F;Florkiewicz RZ;Vogelstein B;Oda Y;Kikuchi H;Hatanaka M;	Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells	1994	Proc Natl Acad Sci U S A	91	9009	8090761
4030	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	GS	Upregulation (WAF1) partial; TUMOR- (partial)	NA	NA	NA	37°C 	Human	UISO-MEL-4	WT control	RT-PCR, CFA, Tumorigenicity assay	271	Rauth S;Green A;Kichina J;Shilkaitis A;	Suppression of tumorigenic and metastatic potentials of human melanoma cell lines by mutated (143 Val-Ala) p53	1998	Br J Cancer	77	2215	9649136
4031	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	GS	TUMOR- (partial)	NA	NA	NA	37°C 	Human	UISO-MEL-6	no WT control	CFA; Tumorigenicity assay	271	Rauth S;Green A;Kichina J;Shilkaitis A;	Suppression of tumorigenic and metastatic potentials of human melanoma cell lines by mutated (143 Val-Ala) p53	1998	Br J Cancer	77	2215	9649136
3146	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	TRANSF- (partial)	NA	NA	NA	37°C 	Other	Rat-1	WT control	Transformation assay	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
3147	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	TRANSF- (partial)	NA	NA	NA	32°C 	Other	Rat-1	WT control	Transformation assay	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
2010	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	NA	TRANSF-	NA	TRANSF+; hsc70 binding	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
3970	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	157	Hinds PW;Finlay CA;Quartin RS;Baker SJ;Fearon ER;Vogelstein B;Levine AJ;	Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes	1990	Cell Growth Differ	1	571	2288874
3822	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	NA	NA	TRANSF+	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3823	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3401	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1 5', MDM2)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
2039	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
2026	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
1716	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
1902	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3230	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2816	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
1345	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1424	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 5', WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
361	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	NA	TA (p53CON) partial	No [TA (p53CON)]	NA	Yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
267	p.V143A	V143A	143	Val	Ala	005887	NDBL/beta-sheets	NA	TA (WAF1, p53CON)	TA (RGC, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	Yes mut_H (p53CON, WAF1); No (MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
962	[p.V143A;K351*]	V143A/K351*	143	Val	NA		NDBL/beta-sheets	NA	TETR	GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, cross-link of proteins with glutaraldehyde + SDS/PAGE	70	Ishioka C;Shimodaira H;Englert C;Shimada A;Osada M;Jia LQ;Suzuki T;Gamo M;Kanamaru R;	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells	1997	Biochem Biophys Res Commun	232	54	9125151
1619	[p.V143A;N239Y]	V143A/N239Y	143	Val	NA		NDBL/beta-sheets	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1595	[p.V143A;N239Y]	V143A/N239Y	143	Val	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1332	[p. V143A;N268D]	V143A/N268D	143	Val	NA		NDBL/beta-sheets	NA	NA	TA (PG13, WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1330	[p. V143A;N268D]	V143A/N268D	143	Val	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1628	[p.V143A;S240N]	V143A/S240N	143	Val	NA		NDBL/beta-sheets	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1606	[p.V143A;S240N]	V143A/S240N	143	Val	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	Yes mut_L & H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
2019	[p.V143A;S315A]	V143A/S315A	143	Val	NA		NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
2171	[p.V143A;S315D]	V143A/S315D	143	Val	NA		NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
2018	[p.V143A;S392A]	V143A/S392A	143	Val	NA		NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
2910	p.V143E	V143E	143	Val	Glu	044784	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
3020	p.V143M	V143M	143	Val	Met	044787	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
947	p.V143M	V143M	143	Val	Met	044787	NDBL/beta-sheets	NA	TA (WAF1)	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
871	p.V143M	V143M	143	Val	Met	044787	NDBL/beta-sheets	NA	TA (WAF1 5')	TA (MDM2)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
4655	p.Q144L	Q144L	144	Gln	Leu	044790	NDBL/beta-sheets	NA	TA (WAF1)	TA (MDM2, BAX, PUMA) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
85	p.Q144P	Q144P	144	Gln	Pro	005888	NDBL/beta-sheets	NA	NA	GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1208	p.Q144P	Q144P	144	Gln	Pro	005888	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
701	p.Q144P	Q144P	144	Gln	Pro	005888	NDBL/beta-sheets	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3016	p.Q144*	Q144X	144	Gln	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2862	p.Q144*	Q144X	144	Gln	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3086	p.Q144*	Q144X	144	Gln	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3017	p.L145P	L145P	145	Leu	Pro	005889	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
1293	p.L145P	L145P	145	Leu	Pro	005889	NDBL/beta-sheets	P 	NA	TA (RGC, WAF1 5', WAF1 3', p53CON, P53R2, GADD45, CD95-Fas, PCNA, MDM2, BAX, PUMA, AIP1, NOXA)	NA	NA	Yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1903	p.L145R	L145R	145	Leu	Arg	044793	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1292	p.L145V	L145V	145	Leu	Val	044794	NDBL/beta-sheets	P 	TA (RGC, WAF1 5', p53CON, P53R2, GADD45, CD95-Fas, PCNA, MDM2, BAX, PUMA, AIP1, NOXA)	TA (WAF1 3')	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
591	p.W146G	W146G	146	Trp	Gly	044796	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
511	p.W146G	W146G	146	Trp	Gly	044796	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (P53R2); No (WAF1, GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1294	p.W146R	W146R	146	Trp	Arg	044798	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC)	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4046	p.W146*	W146X	146	Trp	Stop		NDBL/beta-sheets	NA	NA	JNK, Mdm2 and p14ARF binding	NA	NA	NA	37°C 	Human	NCI-H520 (endo)	Endogenous Mutant	Co-IP	274	Buschmann T;Minamoto T;Wagle N;Fuchs SY;Adler V;Mai M;Ronai Z;	Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability	2000	J Mol Biol 	295	1009	10656807
314	p.W146*	W146X	146	Trp	Stop		NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
2720	p.W146*	W146X	146	Trp	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
3018	p.W146*	W146X	146	Trp	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
3001	p.W146*	W146X	146	Trp	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2971	p.W146*	W146X	146	Trp	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2810	p.D148V	D148V	148	Asp	Val	044808	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
86	p.T150I	T150I	150	Thr	Ile	044813	NDBL/beta-sheets	NA	TA (PIG3) supertrans; GS; APO	TA (WAF1, MDM2, IGF-BP3-boxA, BAX) partial; upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1209	p.T150I	T150I	150	Thr	Ile	044813	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1203	p.T150I	T150I	150	Thr	Ile	044813	NDBL/beta-sheets	NA	TA (WAF1 5', GADD45, CD95-Fas, AIP1, NOXA, PUMA, BAX)	TA (P53R2) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection (low expression of mutant p53)	76	Inga A;Storici F;Darden TA;Resnick MA;	Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence	2002	Mol Cell Biol	22	8612	12446780
1246	p.T150I	T150I	150	Thr	Ile	044813	NDBL/beta-sheets	P 	TA (WAF1 3', MDM2, MDM2-RE2, RGC, IGF-BP3, PA26)	TA (14-3-3s, AIP1) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
805	p.T150I	T150I	150	Thr	Ile	044813	NDBL/beta-sheets	R 	TA (RGC)	NA	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
702	p.T150I	T150I	150	Thr	Ile	044813	NDBL/beta-sheets	R 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
512	p.P151A	P151A	151	Pro	Ala	005894	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1904	p.P151A	P151A	151	Pro	Ala	005894	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4559	p.P151A	P151A	151	Pro	Ala	005894	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4560	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	NA	TA (11 different p53-RE)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
3411	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3412	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
2808	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3221	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
649	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
339	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
275	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1418	p.P151H	P151H	151	Pro	His	044818	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1629	[p.P151H;N239Y]	P151H/N239Y	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1596	[p.P151H;N239Y]	P151H/N239Y	151	Pro	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	Yes mut_L & H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1631	[p.P151H;N268D]	P151H/N268D	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1614	[p.P151H;N268D]	P151H/N268D	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1630	[p.P151H;S240N]	P151H/S240N	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1607	[p.P151H;S240N]	P151H/S240N	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
3241	p.P151R	P151R	151	Pro	Arg	044820	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1435	p.P151R	P151R	151	Pro	Arg	044820	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
338	p.P151R	P151R	151	Pro	Arg	044820	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1615	[p.P151R;N268D]	P151R/N268D	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1608	[p.P151R;S240N]	P151R/S240N	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1472	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5')] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3732	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1) moderate; no (androgen-independent cell growth)	NA	37°C 	Human	LNCaP	no WT control	Western blot, proliferation assay	52	Nesslinger NJ;Shi XB;deVere White RW;	Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53	2003	Cancer Res	63	2228	12727844
3738	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	NA	NA	No [regulation (RLN2)]; DNAb (RLN2) moderate	NA	37°C 	Human	LNCaP	no WT control	RT-PCR, ChIP assay	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
4115	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1); No [upregulation (IL-6)]; No (culture in soft agar)	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
20	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	TA (PCNA); GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
274	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
648	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
513	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
402	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1398	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, MDM2, WAF1 3', type IV collagenase)]; No [TA (GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3199	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3413	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3414	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4648	p.P151S	P151S	151	Pro	Ser	005895	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4409	[p.P151S;N235K]	P151S/N235K	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4411	[p.P151S;N235K,N239Y]	P151S/N235K/N239Y	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4410	[p.P151S;N239Y]	P151S/N239Y	151	Pro	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4649	p.P151T	P151T	151	Pro	Thr	005896	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4650	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3415	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3416	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
2835	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2865	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2967	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3024	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2707	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
650	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
211	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
185	p.P152L	P152L	152	Pro	Leu	005897	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3853	p.P152Q	P152Q	152	Pro	Gln	044822	NDBL/beta-sheets	R 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3854	p.P152Q	P152Q	152	Pro	Gln	044822	NDBL/beta-sheets	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3417	p.P152T	P152T	152	Pro	Thr	044824	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3418	p.P152T	P152T	152	Pro	Thr	044824	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
186	p.P152T	P152T	152	Pro	Thr	044824	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
234	p.P152T	P152T	152	Pro	Thr	044824	NDBL/beta-sheets	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
514	p.P152T	P152T	152	Pro	Thr	044824	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2853	p.P152T	P152T	152	Pro	Thr	044824	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
3270	p.P153T	P153T	153	Pro	Thr	005899	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
1295	p.G154A	G154A	154	Gly	Ala	044830	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3062	p.G154D	G154D	154	Gly	Asp	044832	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
4561	p.G154S	G154S	154	Gly	Ser	044833	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
1980	p.G154V	G154V	154	Gly	Val	005900	NDBL/beta-sheets	NA	NA	TA (RGC, p53CON)	NA	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
2863	p.G154V	G154V	154	Gly	Val	005900	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
515	p.G154V	G154V	154	Gly	Val	005900	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
362	p.G154V	G154V	154	Gly	Val	005900	NDBL/beta-sheets	NA	TA (p53CON)	NA	No [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
4621	p.G154V	G154V	154	Gly	Val	005900	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
320	p.T155I	T155I	155	Thr	Ile	044834	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
516	p.T155I	T155I	155	Thr	Ile	044834	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
651	p.T155I	T155I	155	Thr	Ile	044834	NDBL/beta-sheets	NA	NA	NA	Yes [TA (BAX)]; No [TA (WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
720	p.T155I	T155I	155	Thr	Ile	044834	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
517	p.T155N	T155N	155	Thr	Asn	044836	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4693	p.T155N	T155N	155	Thr	Asn	044836	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (WAF1)]; No [TA (MDM2, BAX, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
518	p.T155P	T155P	155	Thr	Pro	044837	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2807	p.T155P	T155P	155	Thr	Pro	044837	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
519	p.R156G	R156G	156	Arg	Gly	044840	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1502	p.R156H	R156H	156	Arg	His	044841	NDBL/beta-sheets	NA	GS	Upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot, CFA	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
1496	p.R156H	R156H	156	Arg	His	044841	NDBL/beta-sheets	NA	TA (RGC)	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
738	p.R156H	R156H	156	Arg	His	044841	NDBL/beta-sheets	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4657	p.R156H	R156H	156	Arg	His	044841	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1505	[p.R156H;R267Q]	R156H/R267Q	156	Arg	NA		NDBL/beta-sheets	NA	NA	Upregulation (p21waf1); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot, CFA	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
1500	[p.R156H;R267Q]	R156H/R267Q	156	Arg	NA		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
3836	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	NA	NA	No (p38 and p42 binding)	NA	37°C 	Human	HOS-SL (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
3789	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	DNAb (p53CON)	NA	NA	NA	37°C 	Human	HOS-SL (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
4270	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	Transfection	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
4279	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	NA	NA	Reduced dependence on serum factors	NA	37°C 	Human	K-562	no WT control	Culture in 1% serum medium	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
2082	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	TR (HSP70)	NA	TA (HSP70); hsc70 binding	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2094	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2040	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
1717	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
806	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
520	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
721	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
652	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	P 	NA	NA	Yes [TA (BAX)]; No [TA (WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
276	p.R156P	R156P	156	Arg	Pro	005902	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3034	p.V157D	V157D	157	Val	Asp	005903	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
1468	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5')] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2070	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (MDM2) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	154	Gorgoulis VG;Zacharatos PV;Manolis E;Ikonomopoulos JA;Damalas A;Lamprinopoulos C;Rassidakis GZ;Zoumpourlis V;Kotsinas A;Rassidakis AN;Halazonetis TD;Kittas C;	Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene	1998	Br J Cancer	77	374	9472631
4377	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (GML, KILLER/DR5, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
932	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	TR (SV40)	TA (WAF1, MDM2); TR (ASNS, hTERT); DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
3306	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	Upregulation (WAF1, BAX); APO	NA	Upregulation (GEF-H1)	NA	37°C 	Human	U2OS	WT control	RT-qPCR	221	Mizuarai S;Yamanaka K;Kotani H;	Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells	2006	Cancer Res 	66	6319	16778209
3186	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3085	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2757	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
3012	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2993	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
2909	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
2739	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
1444	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2); Yes mut_H (GADD45, GML, KILLER/DR5)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4307	p.V157F	V157F	157	Val	Phe	005904	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4379	[p.V157F;N235K;N239R]	V157F/N235K/N239R	157	Val	NA		NDBL/beta-sheets	NA	TA (WAF1) supertrans	TA (KILLER/DR5,GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4310	[p.V157F;N235K;N239R]	V157F/N235K/N239R	157	Val	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4412	[p.V157F;N235K;N239Y]	V157F/N235K/N239Y	157	Val	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4380	[p.V157F;N239Y]	V157F/N239Y	157	Val	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4311	[p.V157F;N239Y]	V157F/N239Y	157	Val	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4378	[p.V157F;Y234F;N239L]	V157F/Y234F/N239L	157	Val	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4309	[p.V157F;Y234F;N239L]	V157F/Y234F/N239L	157	Val	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1905	p.V157L	V157L	157	Val	Leu	044846	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1296	p.R158C	R158C	158	Arg	Cys	005905	NDBL/beta-sheets	P 	TA (WAF1 5', p53CON, P53R2, GADD45, CD95-Fas, MDM2, BAX, PUMA)	TA (RGC, PCNA, AIP1, NOXA, WAF1 3') partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
212	p.R158C	R158C	158	Arg	Cys	005905	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
521	p.R158C	R158C	158	Arg	Cys	005905	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3419	p.R158C	R158C	158	Arg	Cys	005905	NDBL/beta-sheets	P 	NA	TA (RGC) partial	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
2186	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	NA	NA	NA	NA	TA (PTHrP)	NA	37°C 	Human	A253	WT control	CAT assay	166	Foley J;King CS;Jimenez JA;Wysolmerski JJ;Philbrick WM;	Activation of PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the tumor suppressor p53	2000	Oncol Res	12	71	11132926
3855	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	R 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3856	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3420	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4658	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX); TA (PUMA, WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2669	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
2912	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
3101	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
522	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
213	p.R158G	R158G	158	Arg	Gly	005906	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
87	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, IGF-BP3-boxA, PIG3, BAX); upregulation (p21waf1); GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1210	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1247	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	P 	TA (WAF1 3')	TA (WAF1 5', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26) partial; TA (BAX)	No [TA (WAF1 5', WAF1 3', CD95-Fas, PCNA, MDM2, RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
214	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
236	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
523	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2670	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
2680	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
1695	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	95	Campomenosi P;Fronza G;Ottaggio L;Roncella S;Inga A;Bogliolo M;Monti P;Assereto P;Moro F;Cutrona G;Bozzo S;Chiorazzi N;Abbondandolo A;Ferrarini M;	Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements	1997	Int J Cancer	73	816	9399658
4659	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, WAF1) partial; TA (PUMA)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3421	p.R158H	R158H	158	Arg	His	005907	NDBL/beta-sheets	R 	NA	TA (RGC) partial	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4381	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1470	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5', KILLER/DR5)] low; Yes [TA (NOXA, PCNA)] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3084	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3196	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2933	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2811	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
524	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1396	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2,WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4312	p.R158L	R158L	158	Arg	Leu	044847	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4382	[p.R158L;H233Y;N239Y]	R158L/H233Y/N239Y	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4313	[p.R158L;H233Y;N239Y]	R158L/H233Y/N239Y	158	Arg	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4413	[p.R158L;N235K;N239Y]	R158L/N235K/N239Y	158	Arg	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4383	[p.R158L;N239F]	R158L/N239F	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, WAF1) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4314	[p.R158L;N239F]	R158L/N239F	158	Arg	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4384	[p.R158L;N239Y]	R158L/N239Y	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4306	[p.R158L;N239Y]	R158L/N239Y	158	Arg	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4385	[p.R158L;N239Y;S240Q]	R158L/N239Y/S240Q	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4317	[p.R158L;N239Y;S240Q]	R158L/N239Y/S240Q	158	Arg	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1429	p.R158P	R158P	158	Arg	Pro	044848	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
176	p.R158P	R158P	158	Arg	Pro	044848	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
2902	p.R158P	R158P	158	Arg	Pro	044848	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
3235	p.R158P	R158P	158	Arg	Pro	044848	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2682	p.R158P	R158P	158	Arg	Pro	044848	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
1597	[p.R158P;N239Y]	R158P/N239Y	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1616	[p.R158P;N268D]	R158P/N268D	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1609	[p.R158P;S240N]	R158P/S240N	158	Arg	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
491	p.A159G	A159G	159	Ala	Gly	044852	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3075	p.A159P	A159P	159	Ala	Pro	044853	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
4505	[p.A159T;G245S]	A159T/G245S	159	Ala	NA		NDBL/beta-sheets	NA	TA (P53R2)	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4484	[p.A159T;G245S]	A159T/G245S	159	Ala	NA		NDBL/beta-sheets	NA	TA (P53R2)	TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4173	p.A159V	A159V	159	Ala	Val	044856	NDBL/beta-sheets	NA	TA (WAF1, BAX, RGC)	NA	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
1906	p.A159V	A159V	159	Ala	Val	044856	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2676	p.M160I	M160I	160	Met	Ile	005908	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	169	Waridel F;Estreicher A;Bron L;Flaman JM;Fontolliet C;Monnier P;Frebourg T;Iggo R;	Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract	1997	Oncogene	14	163	9010218
525	p.M160I	M160I	160	Met	Ile	005908	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
430	[p.M160I;A161T]	M160I/A161T	160	Met	NA	047162	NDBL/beta-sheets	NA	TA (WAF1, P53CON, Cyclin G)	TA (RGC, BAX, IGF-BP3-boxA&B); TA (MDM2, GADD45) partial	NA	NA	Yes mut_H (MDM2, GADD45); No (p53CON, WAF1, Cyclin G, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
592	p.M160K	M160K	160	Met	Lys	044857	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, P53R2); No (WAF1, 14-3-3s, GADD45)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
526	p.M160K	M160K	160	Met	Lys	044857	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
593	p.M160R	M160R	160	Met	Arg		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (BAX); No (WAF1, MDM2, 14-3-3s, GADD45,  P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
439	p.M160R	M160R	160	Met	Arg		NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, 14-3-3s, AIP1); No (MDM2, BAX, GADD45, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
527	p.M160T	M160T	160	Met	Thr	044858	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3030	p.M160V	M160V	160	Met	Val	044859	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2915	p.A161D	A161D	161	Ala	Asp	044860	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
1907	p.A161D	A161D	161	Ala	Asp	044860	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
767	p.A161D	A161D	161	Ala	Asp	044860	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
739	p.A161G	A161G	161	Ala	Gly	044861	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
528	p.A161G	A161G	161	Ala	Gly	044861	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2651	p.A161G	A161G	161	Ala	Gly	044861	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	167	Tada M;Iggo RD;Ishii N;Shinohe Y;Sakuma S;Estreicher A;Sawamura Y;Abe H;	Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay	1996	Int J Cancer	67	447	8707423
529	p.A161S	A161S	161	Ala	Ser	005909	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (AIP1); No (WAF1, GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3371	p.A161T	A161T	161	Ala	Thr	044863	NDBL/beta-sheets	NA	TA (WAF1) supertrans	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
867	p.A161T	A161T	161	Ala	Thr	044863	NDBL/beta-sheets	NA	TA (MDM2, WAF1 5')	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
946	p.A161T	A161T	161	Ala	Thr	044863	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
2954	p.A161T	A161T	161	Ala	Thr	044863	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3857	p.A161V	A161V	161	Ala	Val	044864	NDBL/beta-sheets	R 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3858	p.A161V	A161V	161	Ala	Val	044864	NDBL/beta-sheets	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
768	p.A161V	A161V	161	Ala	Val	044864	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
530	p.A161V	A161V	161	Ala	Val	044864	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
653	p.I162F	I162F	162	Ile	Phe	044865	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
321	p.I162F	I162F	162	Ile	Phe	044865	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3032	p.I162F	I162F	162	Ile	Phe	044865	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
4633	p.I162N	I162N	162	Ile	Asn	044867	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1297	p.I162T	I162T	162	Ile	Thr	044868	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2139	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	H1299	WT control	CFA	27	Pan Y;Haines DS;	Identification of a tumor-derived p53 mutant with novel transactivating selectivity	2000	Oncogene	19	3095	10871862
1474	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5', KILLER/DR5, GML, MDM2)] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4386	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
931	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2); TR (ASNS, hTERT); TR (SV40) partial; DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
740	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1392	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2718	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
3191	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3014	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2979	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2805	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2750	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	180	Gong ZY;Wong KW;Li Y;Mao YR;Lung ML;	p53 inactivating mutations in chinese breast carcinomas	2000	Oncol Rep	7	381	10671690
4343	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4241	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (PG13, RGC, BAX, WAF1)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	FASAY	310	Toscano F;Parmentier B;Fajoui ZE;Estornes Y;Chayvialle JA;Saurin JC;Abello J;	p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells	2007	Biochem Pharmacol 	74	392	17559811
4702	p.Y163C	Y163C	163	Tyr	Cys	033035	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA)]; No [TA (MDM2, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4388	[p.Y163C;H233Y;N235K;N239Y]	Y163C/H233Y/N235K/N239Y	163	Tyr	NA		NDBL/beta-sheets	NA	TA (KILLER/DR5); TA (WAF1) supertrans	TA (GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4335	[p.Y163C;H233Y;N235K;N239Y]	Y163C/H233Y/N235K/N239Y	163	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4372	[p.Y163C;N235K;N239Y]	Y163C/N235K/N239Y	163	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4336	[p.Y163C;N235K;N239Y]	Y163C/N235K/N239Y	163	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4390	[p.Y163C;N235S;N239Y;S240N	Y163C/N235S/N239Y/S240N	163	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4337	[p.Y163C;N235S;N239Y;S240N	Y163C/N235S/N239Y/S240N	163	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4239	p.Y163H	Y163H	163	Tyr	His	005912	NDBL/beta-sheets	NA	No (CDDP response)	(OXA sensitivity) partial	NA	NA	NA	37°C 	Human	ISRECO1 (endo)	Endogenous Mutant	siRNA and oxaliplatin or cisplatin treatment	310	Toscano F;Parmentier B;Fajoui ZE;Estornes Y;Chayvialle JA;Saurin JC;Abello J;	p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells	2007	Biochem Pharmacol 	74	392	17559811
3968	p.Y163H	Y163H	163	Tyr	His	005912	NDBL/beta-sheets	NA	NA	TRANSF-	NA	No (TRANSF+)	NA	NA   	Other	BRK	WT control	Transformation assay	254	Farrell PJ;Allan GJ;Shanahan F;Vousden KH;Crook T;	p53 is frequently mutated in Burkitt's lymphoma cell lines	1991	EMBO J 	10	2879	1915267
3033	p.Y163H	Y163H	163	Tyr	His	005912	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
277	p.Y163H	Y163H	163	Tyr	His	005912	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
654	p.Y163H	Y163H	163	Tyr	His	005912	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
88	p.Y163N	Y163N	163	Tyr	Asn	044871	NDBL/beta-sheets	NA	NA	GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1211	p.Y163N	Y163N	163	Tyr	Asn	044871	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
807	p.Y163N	Y163N	163	Tyr	Asn	044871	NDBL/beta-sheets	R 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
703	p.Y163N	Y163N	163	Tyr	Asn	044871	NDBL/beta-sheets	R 	NA	NA	Yes [TA (BAX, PIG3)]; No [TA (WAF1 5’)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
1298	p.K164E	K164E	164	Lys	Glu	044873	L2/L3	P 	NA	TA (RGC, WAF1 5')	NA	NA	yes mut_L (WAF1 5')	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
531	p.Q165L	Q165L	165	Gln	Leu	005915	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
498	p.Q165P	Q165P	165	Gln	Pro	044879	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, AIP1); No (MDM2, BAX, 14-3-3s, GADD45, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
532	p.Q165R	Q165R	165	Gln	Arg	005916	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2990	p.S166*	S166X	166	Ser	Stop		L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
4656	p.Q167K	Q167K	167	Gln	Lys	044885	L2/L3	NA	TA (WAF1)	TA (MDM2, BAX, PUMA) partial	Yes [TA (MDM2)]; No [TA (BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1248	p.Q167R	Q167R	167	Gln	Arg	044887	L2/L3	P 	TA (WAF1 5', WAF1 3', P53R2, 14-3-3s, PCNA, IGF-BP3)	TA (GADD45, CD95-Fas, AIP1, MDM2, RGC, PA26, BAX) partial; TA (MDM2-RE2)	No [TA (P53R2, GADD45, CD95-Fas, PCNA, MDM2, IGF-BP3, WAF1 3', BAX, NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
808	p.Q167R	Q167R	167	Gln	Arg	044887	L2/L3	P 	NA	TA (RGC) partial	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
769	p.Q167R	Q167R	167	Gln	Arg	044887	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
844	p.Q167R	Q167R	167	Gln	Arg	044887	L2/L3	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
741	p.Q167*	Q167X	167	Gln	Stop		L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4534	p.Q167*	Q167X	167	Gln	Stop		L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
492	p.H168N	H168N	168	His	Asn	044890	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, AIP1); No (MDM2, BAX, 14-3-3s, GADD45, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
786	p.H168P	H168P	168	His	Pro	044891	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
771	p.H168Q	H168Q	168	His	Gln	044892	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
770	p.H168R	H168R	168	His	Arg	005918	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1448	p.H168R	H168R	168	His	Arg	005918	L2/L3	P 	TA (GADD45, GML, KILLER/DR5, WAF1 5')	TA (CSR, Cyclin G, CD95-Fas, MDM2, WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 5', WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5)]	NA	No (CSR, Cyclin G, CD95-Fas, MDM2, WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2); Yes mut_H (GADD45, GML, KILLER/DR5, WAF1 5')	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3227	p.H168R	H168R	168	His	Arg	005918	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1343	[p.H168R;R249S]	H168R/R249S	168	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
4289	[p.H168R;T231I;R249S]	H168R/T231I/R249S	168	His	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
3859	p.H168Y	H168Y	168	His	Tyr	044893	L2/L3	R 	NA	NA	NA	No (p73 interference); CDDP resistance (weak)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3860	p.H168Y	H168Y	168	His	Tyr	044893	L2/L3	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
89	p.H168Y	H168Y	168	His	Tyr	044893	L2/L3	NA	NA	GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1212	p.H168Y	H168Y	168	His	Tyr	044893	L2/L3	NA	NA	TRANSF-	NA	TRANSF+	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
809	p.H168Y	H168Y	168	His	Tyr	044893	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
704	p.H168Y	H168Y	168	His	Tyr	044893	L2/L3	R 	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
714	p.T170R	T170R	170	Thr	Arg		L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
655	p.T170R	T170R	170	Thr	Arg		L2/L3	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
322	p.T170R	T170R	170	Thr	Arg		L2/L3	NA	TA (WAF1)	TA (PIG3); TA (BAX) partial	NA	NA	Yes mut_L (BAX); No (WAF1, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3031	p.T170S	T170S	170	Thr	Ser	005922	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
533	p.E171A	E171A	171	Glu	Ala	044899	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
845	p.E171K	E171K	171	Glu	Lys	044902	L2/L3	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
534	p.E171V	E171V	171	Glu	Val	044904	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3861	p.V172A	V172A	172	Val	Ala	005923	L2/L3	R 	NA	NA	NA	No (p73 interference); CDDP resistance (weak)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3862	p.V172A	V172A	172	Val	Ala	005923	L2/L3	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
535	p.V172A	V172A	172	Val	Ala	005923	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, AIP1); No (GADD45, MDM2, BAX, 14-3-3s,  Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4695	p.V172F	V172F	172	Val	Phe	044906	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
594	p.V172G	V172G	172	Val	Gly	044907	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, 14-3-3s); No (WAF1, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
450	p.V172G	V172G	172	Val	Gly	044907	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2, GADD45, AIP1, Noxa); No (WAF1, BAX, 14-3-3s, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
536	p.V172L	V172L	172	Val	Leu		L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, AIP1); No (GADD45, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3942	p.V173A	V173A	173	Val	Ala	044909	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	MKN-1, MKN-28	WT control	CFA	247	Matozaki T;Sakamoto C;Suzuki T;Matsuda K;Uchida T;Nakano O;Wada K;Nishisaki H;Konda Y;Nagao M;.;	p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells	1992	Cancer Res 	52	4335	1322785
1299	p.V173A	V173A	173	Val	Ala	044909	L2/L3	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3029	p.V173A	V173A	173	Val	Ala	044909	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
1820	[p.V173A;M246R;H365R]	V173A/M246R/H365R	173	Val	NA		L2/L3	P 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
2072	p.V173E	V173E	173	Val	Glu	005924	L2/L3	NA	NA	TA (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	154	Gorgoulis VG;Zacharatos PV;Manolis E;Ikonomopoulos JA;Damalas A;Lamprinopoulos C;Rassidakis GZ;Zoumpourlis V;Kotsinas A;Rassidakis AN;Halazonetis TD;Kittas C;	Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene	1998	Br J Cancer	77	374	9472631
2652	p.V173G	V173G	173	Val	Gly	044910	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	167	Tada M;Iggo RD;Ishii N;Shinohe Y;Sakuma S;Estreicher A;Sawamura Y;Abe H;	Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay	1996	Int J Cancer	67	447	8707423
743	p.V173G	V173G	173	Val	Gly	044910	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
3422	p.V173G	V173G	173	Val	Gly	044910	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3395	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	GA; APO	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
4391	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
167	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
1979	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (RGC, p53CON)	Yes [TA (RGC, p53CON)]	NA	No (RGC); Yes mut_H (p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
3391	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (WAF1, BAX, IGF-BP3-boxB); GA; APO	NA	NA	NA	37°C 	Human	H358	WT control	Luciferase assay, FACS analysis	28	Ludwig RL;Bates S;Vousden KH;	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function	1996	Mol Cell Biol	16	4952	8756654
1231	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	APO	NA	NA	NA	37°C 	Human	HeLa	WT control	FACS analysis	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
4462	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TR (BCL-2)	NA	TA (BCL-2) moderate	NA	37°C 	Human	MCF-7	no WT control	Luciferase assay	324	Pratt MA;White D;Kushwaha N;Tibbo E;Niu MY;	Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells	2007	Apoptosis 	12	657	17252199
3396	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	Upregulation (mdm2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
3863	p.V173L	V173L	173	Val	Leu	005925	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3864	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3816	p.V173L	V173L	173	Val	Leu	005925	L2/L3	R 	NA	NA	NA	p73 interference	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3817	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1159	p.V173L	V173L	173	Val	Leu	005925	L2/L3	R 	NA	NA	NA	p73alpha binding	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1160	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	NA	NA	p73alpha binding (low affinity)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
163	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (WAF1, BAX, IGF-BP3-boxA&B); upregulation (p21waf1); GA; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis	28	Ludwig RL;Bates S;Vousden KH;	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function	1996	Mol Cell Biol	16	4952	8756654
111	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (MDM2, PG13); TR (C-FOS); GS	Yes [TA (PG13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1522	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	NA	Yes (APO) moderate	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
1523	p.V173L	V173L	173	Val	Leu	005925	L2/L3	R 	NA	APO	Yes (APO) moderate	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3289	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TR (HPSE)	NA	No [TA (HPSE)]	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	218	Baraz L;Haupt Y;Elkin M;Peretz T;Vlodavsky I;	Tumor suppressor p53 regulates heparanase gene expression	2006	Oncogene	25	3939	16474844
4053	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	NA	NA	DOX and CDDP sensitivity	NA	37°C 	Human	TCCSUP	no WT control	Treatment with cisplatin or doxorubicin	277	Chang FL;Lai MD;	Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells	2001	J Urol 	166	304	11435891
4521	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (APAF-1)	NA	NA	NA	37°C 	Human	U2OS	WT control	Luciferase assay	331	Moroni MC;Hickman ES;Lazzerini DE;Caprara G;Colli E;Cecconi F;Muller H;Helin K;	Apaf-1 is a transcriptional target for E2F and p53	2001	Nat Cell Biol 	3	552	11389439
2137	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
2136	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
1229	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	REF	WT control	Transformation assay	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
3824	p.V173L	V173L	173	Val	Leu	005925	L2/L3	R 	NA	NA	NA	TRANSF+	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3825	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3423	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3424	p.V173L	V173L	173	Val	Leu	005925	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4562	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4338	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1399	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
787	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
363	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (p53CON) partial	Yes [TA (p53CON)] moderate	NA	yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
1867	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
3200	p.V173L	V173L	173	Val	Leu	005925	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3102	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
2901	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
2800	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2868	p.V173L	V173L	173	Val	Leu	005925	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
4392	[p.V173L;D228N;N239Y]	V173L/D228N/N239Y	173	Val	NA		L2/L3	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4339	[p.V173L;D228N;N239Y]	V173L/D228N/N239Y	173	Val	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4414	[p.V173L;N235K;N239Y]	V173L/N235K/N239Y	173	Val	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4393	[p.V173L;N239Y]	V173L/N239Y	173	Val	NA		L2/L3	NA	TA (WAF1)	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4340	[p.V173L;N239Y]	V173L/N239Y	173	Val	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4394	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4167	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TR (FAK); TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	294	Golubovskaya VM;Finch R;Kweh F;Massoll NA;Campbell-Thompson M;Wallace MR;Cance WG;	p53 regulates FAK expression in human tumor cells	2008	Mol Carcinog 	47	373	17999388
4262	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4256	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	NA	NA	TRANSF+	No (TRANSF+)	37°C 	Other	REF	WT control	Transformation assay, , temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4315	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4523	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selectionn	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4696	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3208	p.V173M	V173M	173	Val	Met	005926	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1870	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
772	p.V173M	V173M	173	Val	Met	005926	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
879	p.V173M	V173M	173	Val	Met	005926	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
1405	p.V173M	V173M	173	Val	Met	005926	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4395	[p.V173M;N235K;N239Y]	V173M/N235K/N239Y	173	Val	NA		L2/L3	NA	NA	TA (KILLER/DR5, WAF1) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4342	[p.V173M;N235K;N239Y]	V173M/N235K/N239Y	173	Val	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4660	p.R174G	R174G	174	Arg	Gly	044911	L2/L3	NA	TA (MDM2, PUMA, WAF1)	TA (BAX) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1300	p.R174G	R174G	174	Arg	Gly	044911	L2/L3	P 	TA (WAF1 5', RGC)	NA	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4563	p.R174K	R174K	174	Arg	Lys	005927	L2/L3	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4564	p.R174W	R174W	174	Arg	Trp	044915	L2/L3	NA	TA (11 different p53-RE)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
2119	[p.R175_E180del;N239Y]	R175_E180del/N239Y	175	Arg	NA		L2/L3	NA	NA	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	19	Blagosklonny MV;Giannakakou P;Romanova LY;Ryan KM;Vousden KH;Fojo T;	Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions	2001	Carcinogenesis	22	861	11375890
1599	[p.R175_E180del;N239Y]	R175_E180del/N239Y	175	Arg	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1611	[p.R175_E180del;S240N]	R175_E180del/S240N	175	Arg	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
128	p.R175C	R175C	175	Arg	Cys	005928	L2/L3	NA	TA (PG13); TR (HRE)	NA	NA	NA	NA	37°C 	Human	PC-3, MCF-7	WT control	Luciferase assay	19	Blagosklonny MV;Giannakakou P;Romanova LY;Ryan KM;Vousden KH;Fojo T;	Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions	2001	Carcinogenesis	22	861	11375890
66	p.R175C	R175C	175	Arg	Cys	005928	L2/L3	R 	TA (PG13); TA (WAF1) supertrans; GS; TR (C-JUN)	NA	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
880	p.R175C	R175C	175	Arg	Cys	005928	L2/L3	NA	GA; APO; TR (C-FOS); upregulation (p21waf1)	TA (BAX, IGF-BP3-boxB)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, western blot	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3131	p.R175C	R175C	175	Arg	Cys	005928	L2/L3	NA	TA (WAF1 5')	TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
67	p.R175G	R175G	175	Arg	Gly	005929	L2/L3	R 	NA	TA (WAF1, PG13); GS; TR (C-JUN)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
595	p.R175G	R175G	175	Arg	Gly	005929	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45, P53R2); No (BAX)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
537	p.R175G	R175G	175	Arg	Gly	005929	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (MDM2, Noxa); No (WAF1, GADD45, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3103	p.R175G	R175G	175	Arg	Gly	005929	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
4661	p.R175G	R175G	175	Arg	Gly	005929	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3900	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	ETO resistance	NA	37°C 	Human	21PT	no WT control	Etoposide treatment	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
4091	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Daxx interference	NA	37°C 	Human	293	WT control	ASK1 activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
2187	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	TA (PTHrP)	NA	37°C 	Human	A253	WT control	CAT assay	166	Foley J;King CS;Jimenez JA;Wysolmerski JJ;Philbrick WM;	Activation of PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the tumor suppressor p53	2000	Oncol Res	12	71	11132926
3987	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	No (culture in soft agar or plastic, TUMOR+, TGF-beta or gamma-irradiation resistance)	NA	37°C 	Human	AA/C1	no WT control	CFA on plastic and in agar, tumorigenicity assay, TGF-beta or gamma-irradiation treatment	260	Williams AC;Miller JC;Collard TJ;Bracey TS;Cosulich S;Paraskeva C;	Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation	1995	Oncogene	11	141	7624121
3761	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS; TUMOR-	NA	Growth advantage; colony formation; TUMOR+	NA	37°C 	Human	Be-13	no WT control	Proliferation assay, CFA in methylcellulose, tumorigenicity assay	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3938	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (MDR-1)	NA	TA (MDR-1); no [TA (MRP1)]	NA	37°C 	Human	CACO2	no WT control	Luciferase assay	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
395	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, BAX); GS	Yes [TA (BAX)]; No [TA (WAF1)]; No (GS)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
39	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	Calu-6, VAMT-1, 21MT-1, 21MT-2	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
3773	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	Growth advantage; colony formation (moderate)	NA	37°C 	Human	CEM	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3748	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	p73 binding; p73 interference	NA	37°C 	Human	H1299	no WT control	Co-IP, luciferase assay	25	Strano S;Munarriz E;Rossi M;Cristofanelli B;Shaul Y;Castagnoli L;Levine AJ;Sacchi A;Cesareni G;Oren M;Blandino G;	Physical and functional interaction between p53 mutants and different isoforms of p73	2000	J Biol Chem	275	29503	10884390
3745	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS; ETO sensitivity	NA	ETO resistance	NA	37°C 	Human	H1299	no WT control	CFA, etoposide treatment, FACS analysis	15	Blandino G;Levine AJ;Oren M;	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy	1999	Oncogene	18	477	9927204
3808	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	p73 binding (weak)	NA	37°C 	Human	H1299	no WT control	Co-IP	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
3342	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, P53RFP, AIP1, BAX, PUMA, NOXA, P53DINP1, P53R2, P53RDL1, SEMA3F)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	229	Nakamura Y;Futamura M;Kamino H;Yoshida K;Nakamura Y;Arakawa H;	Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis	2006	Cancer Sci 	97	633	16827804
3330	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Downregulation (Vrk1)	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot	226	Valbuena A;Vega FM;Blanco S;Lazo PA;	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop	2006	Mol Cell Biol 	26	4782	16782868
3472	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	H1299	WT control	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3476	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (mdm2 , p21waf1); Upregulation (MDM2, WAF1, BAX, CyclinG, CD95-Fas, PIR121)	NA	NA	NA		Human	H1299	WT control	Western blot, northern blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
3460	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	APO	NA	NA	NA	32°C 	Human	H1299	WT control	FACS analysis	53	Friedlander P;Haupt Y;Prives C;Oren M;	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis	1996	Mol Cell Biol	16	4961	8756655
3489	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT)	NA	Upregulation (MDR-1); no [TA (hTERT)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3490	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT) partial	NA	No [upregulation (MDR-1)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3936	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GA	NA	No (growth advantage)	NA	37°C 	Human	H1299	no WT control	CFA	81	Gallagher WM;Argentini M;Sierra V;Bracco L;Debussche L;Conseiller E;	MBP1: a novel mutant p53-specific protein partner with oncogenic properties	1999	Oncogene	18	3608	10380882
3897	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	ETO resistance	NA	37°C 	Human	H1299	no WT control	Etoposide treatment	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
3903	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3904	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
4078	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	Upregulation (p21waf1); gGS; GA; APO	NA	No (p73beta interference, p73beta binding)	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
4079	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	Upregulation (p21waf1); GS; GA; APO	NA	No (p73beta interference); p73beta binding	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
4197	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (MMP2, WAF1) TGF-beta1 dependent; promotion of transcriptional TGF-beta1 response	NA	Repression of transcriptional TGF-beta1 response	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
4155	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	(3' -> 5' exonuclease activity) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Exonuclease assay	291	Bakhanashvili M;Gedelovich R;Grinberg S;Rahav G;	Exonucleolytic degradation of RNA by p53 protein in cytoplasm	2008	J Mol Med 	86	75	17701148
4107	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Downregulation (MST); TR (MST); ETO resistance	NA	37°C 	Human	H1299	no WT control	qRT-PCR, luciferase assay, treatment with etoposide	288	Zalcenstein A;Weisz L;Stambolsky P;Bar J;Rotter V;Oren M;	Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53	2006	Oncogene	25	359	16170349
4109	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	superDNAb (MSP)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	ChIP assay	288	Zalcenstein A;Weisz L;Stambolsky P;Bar J;Rotter V;Oren M;	Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53	2006	Oncogene	25	359	16170349
4264	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Enhanced TNFalpha-induced NFkappaB activity; TNFalpha resistance (partial)	NA	37°C 	Human	H1299	no WT control	Stable & inducible transfection, luciferase assay, FACS analysis	315	Weisz L;Damalas A;Liontos M;Karakaidos P;Fontemaggi G;Maor-Aloni R;Kalis M;Levrero M;Strano S;Gorgoulis VG;Rotter V;Blandino G;Oren M;	Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells	2007	Cancer Res 	67	2396	17363555
4219	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	Mdm2 binding	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Co-IP	302	Lukashchuk N;Vousden KH;	Ubiquitination and degradation of mutant p53	2007	Mol Cell Biol 	27	8284	17908790
4194	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Attenuation of TGF-beta1 response; downregulation (TGF-betaRII); no [downregulation (TGF-betaRI)]; DNAb (TGF-betaRII)	NA	37°C 	Human	H1299	WT control	Stable transfection, cell migration & zymography assays, RT-PCR, siRNA assay, western blot, ChIP ass	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
4205	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	TR (TGF-betaRII)	NA	37°C 	Human	H1299	no WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
132	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (WAF1 5')	Yes [TA (WAF1 5')] moderate	p63 and p73 binding; p63 and p73 interference; hsp70 binding	NA	37°C 	Human	H1299	WT control	Co-IP, luciferase assay	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
897	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	APO	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	53	Friedlander P;Haupt Y;Prives C;Oren M;	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis	1996	Mol Cell Biol	16	4961	8756655
901	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	DNAb (MDR-1, CD95-Fas)	DNAb (WAF1, p53CON)	NA	NA	NA	37°C 	Human	H1299	WT control	Southwestern blotting, ChIP	54	Zalcenstein A;Stambolsky P;Weisz L;Muller M;Wallach D;Goncharov TM;Krammer PH;Rotter V;Oren M;	Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	2003	Oncogene	22	5667	12944915
924	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	GS; GA	Yes [upregulation (p21waf1)]; Yes [upregulation (FDXR)]; Yes [TA (WAF1, MDM2, PIG3)]; Yes (GA) partial	NA	NA	37°C 	Human	H1299	WT control	Western blot, Northern blot + ChiP assay, FACS analysis	60	Willis A;Jung EJ;Wakefield T;Chen X;	Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes	2004	Oncogene	23	2330	14743206
2164	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GA	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	163	Chen X;Ko LJ;Jayaraman L;Prives C;	p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells	1996	Genes Dev	10	2438	8843196
1978	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC, p53CON)	NA	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
1949	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (BAX); APO	Yes [TA (BAX)] moderate; Yes (APO)	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, FACS analysis	132	Di Como CJ;Gaiddon C;Prives C;	p73 function is inhibited by tumor-derived p53 mutants in mammalian cells	1999	Mol Cell Biol	19	1438	9891077
1635	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	84	Munsch D;Watanabe-Fukunaga R;Bourdon JC;Nagata S;May E;Yonish-Rouach E;Reisdorf P;	Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis	2000	J Biol Chem	275	3867	10660538
1480	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Mdm2 stabilization	NA	37°C 	Human	H1299	WT control	Western blot, IF	80	Peng Y;Chen L;Li C;Lu W;Agrawal S;Chen J;	Stabilization of the MDM2 oncoprotein by mutant p53	2001	J Biol Chem	276	6874	11152666
1491	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	MBP1 binding	NA	37°C 	Human	H1299	WT control	Co-IP	81	Gallagher WM;Argentini M;Sierra V;Bracco L;Debussche L;Conseiller E;	MBP1: a novel mutant p53-specific protein partner with oncogenic properties	1999	Oncogene	18	3608	10380882
1883	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	DNAb (WAF1, MDM2, BAX, PIG3, AIP1, PUMA); TA (WAF1, MDM2, BAX, PIG3)	NA	NA	NA	37°C 	Human	H1299	WT control	ChIP, RT-qPCR	102	Kaeser MD;Iggo RD;	Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo	2002	Proc Natl Acad Sci U S A	99	95	11756653
1842	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	RPA binding	HR repression	NA	NA	NA	37°C 	Human	H1299	WT control	Transfection + IP, homologous recombination (HR) assay	121	Romanova LY;Willers H;Blagosklonny MV;Powell SN;	The interaction of p53 with replication protein A mediates suppression of homologous recombination	2004	Oncogene	23	9025	15489903
1744	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (TP53) partial; TA (MDM2)	NA	RB18A inhibition	NA	37°C 	Human	H1299	WT control	CAT or luciferase assay	104	Lottin-Divoux S;Barel M;Frade R;	RB18A enhances expression of mutant p53 protein in human cells	2005	FEBS Lett	579	2323	15848166
1780	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1781	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1836	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	CHIP sensitivity	NA	NA	hsc70 binding	NA	37°C 	Human	H1299	WT control	IP	119	Esser C;Scheffner M;Hohfeld J;	The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation	2005	J Biol Chem	280	27443	15911628
3292	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NF-Y binding	TR (CDC25, CCNA)	NA	TA (CDC25, CCNA)	NA	37°C 	Human	H1299	WT control	Co-IP, luciferase assay	219	Di Agostino S;Strano S;Emiliozzi V;Zerbini V;Mottolese M;Sacchi A;Blandino G;Piaggio G;	Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation	2006	Cancer Cell	10	191	16959611
3309	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RPS27L)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	222	He H;Sun Y;	Ribosomal protein S27L is a direct p53 target that regulates apoptosis	2006	Oncogene			17057733
9	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Upregulation (dUTPase, C-MYC)	NA	37°C 	Human	H1299, SK-OV-3	WT control	RT-PCR	2	Pugacheva EN;Ivanov AV;Kravchenko JE;Kopnin BP;Levine AJ;Chumakov PM;	Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil	2002	Oncogene	21	4595	12096336
82	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	HCT-116	WT control	CAT assay	11	Kern SE;Pietenpol JA;Thiagalingam S;Seymour A;Kinzler KW;Vogelstein B;	Oncogenic forms of p53 inhibit p53-regulated gene expression	1992	Science	256	827	1589764
1793	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1759	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (RECQ4)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	107	Sengupta S;Shimamoto A;Koshiji M;Pedeux R;Rusin M;Spillare EA;Shen JC;Huang LE;Lindor NM;Furuichi Y;Harris CC;	Tumor suppressor p53 represses transcription of RECQ4 helicase	2005	Oncogene	24	1738	15674334
4156	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	3' -> 5' exonuclease activity	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Exonuclease assay	291	Bakhanashvili M;Gedelovich R;Grinberg S;Rahav G;	Exonucleolytic degradation of RNA by p53 protein in cytoplasm	2008	J Mol Med 	86	75	17701148
4164	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (FAK); TA (WAF1); DNAb (FAK)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay, ChIP assay	294	Golubovskaya VM;Finch R;Kweh F;Massoll NA;Campbell-Thompson M;Wallace MR;Cance WG;	p53 regulates FAK expression in human tumor cells	2008	Mol Carcinog 	47	373	17999388
3374	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
4094	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Daxx interference; Ask1 interference (weak)	NA	37°C 	Human	HeLa	no WT control	JNK and Fas activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
1954	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (HSV1-TK) partial	NA	NA	NA	37°C 	Human	HeLa	WT control	CAT assay	134	Subler MA;Martin DW;Deb S;	Inhibition of viral and cellular promoters by human wild-type p53	1992	J Virol	66	4757	1352831
915	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (PCNA); TR (CMV, HTLV, RSV); TR (HSV1-UL9) partial	NA	TA (PCNA); TA (CMV, RSV, HTLV)	NA	37°C 	Human	HeLa	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1958	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (HIV)	NA	TA (HIV)	NA	37°C 	Human	HeLa, Saos-2	WT control	CAT assay	135	Subler MA;Martin DW;Deb S;	Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53	1994	J Virol	68	103	8254719
3376	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	Mortalin binding	NA	NA	NA	NA	37°C 	Human	HeLa1	WT control	Co-IP	237	Ma Z;Izumi H;Kanai M;Kabuyama Y;Ahn NG;Fukasawa K;	Mortalin controls centrosome duplication via modulating centrosomal localization of p53	2006	Oncogene	25	5377	16619038
2110	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)] moderate	NA	NA	37°C 	Human	Hep3B	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
1851	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS (partial); TA (PG13)	NA	NA	NA	37°C 	Human	Hep3B	WT control	CAT assay	125	Stahler F;Roemer K;	Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	1998	Oncogene	17	3507	10030675
1993	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	Growth advantage	NA	37°C 	Human	HSC3, Ca9-22	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
3961	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	No (GS)	NA	NA	37°C 	Human	HT-1080	WT control	BrdU incorporation assay	253	Sharma S;Schwarte-Waldhoff I;Oberhuber H;Schafer R;	Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes	1993	Cell Growth Differ 	4	861	8274455
3931	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (Fas)	NA	NA	No (Fas)	37°C 	Human	K562	no WT control	FACS analysis, temperature sensitive assay at 32°C	241	Owen-Schaub LB;Zhang W;Cusack JC;Angelo LS;Santee SM;Fujiwara T;Roth JA;Deisseroth AB;Zhang WW;Kruzel E;.;	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression	1995	Mol Cell Biol 	15	3032	7539102
4276	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Decrease of some differentiation markers; reduced dependence on serum factors	NA	37°C 	Human	K-562	no WT control	FACS analysis, culture in 1% serum medium	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
4272	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	Transfection	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
1848	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	HR repression (partial)	NA	NA	NA	37°C 	Human	K-562	WT control	Homologous recombination (HR) assay	124	Akyuz N;Boehden GS;Susse S;Rimek A;Preuss U;Scheidtmann KH;Wiesmuller L;	DNA substrate dependence of p53-mediated regulation of double-strand break repair	2002	Mol Cell Biol	22	6306	12167722
3136	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	Yes [TA (RGC)] moderate; No [TA (p53CON)]	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay	207	Zhang W;Shay JW;Deisseroth A;	Inactive p53 mutants may enhance the transcriptional activity of wild-type p53	1993	Cancer Res 	53	4772	8402659
3144	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	CFA	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
2	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	DNAb (p53CON)	TA (p53CON, RGC)	NA	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay, EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
1765	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1); TR (CaM2)	NA	TA (CaM2)	NA	37°C 	Human	LFS041	WT control	Luciferase assay	110	Knaup KX;Roemer K;	Cell type-specific regulation of calmodulin 2 expression by mutant p53	2004	FEBS Lett	569	70	15225611
3739	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	DNAb (RLN2) moderate	NA	37°C 	Human	LNCaP	no WT control	ChIP assay	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
3400	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PG13)	NA	NA	NA	37°C 	Human	LoVo	WT control	Luciferase assay	32	Chene P;Ory K;Ruedi D;Soussi T;Hegi ME;	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome	1999	Int J Cancer	82	17	10360814
4104	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	AG337 resistance; downregulation (CD95/Fas, FASL); No (Fas-induced APO resistance)	NA	37°C 	Human	LoVo	no WT control	Treatment with AG337 or CH11, IHC	286	Backus HH;Wouters D;Ferreira CG;van Houten VM;Brakenhoff RH;Pinedo HM;Peters GJ;	Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines	2003	Eur J Cancer	39	1310	12763222
4048	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	TA (HIV)	NA	37°C 	Human	MDAH041	no WT control	Luciferase assay	275	Chicas A;Molina P;Bargonetti J;	Mutant p53 forms a complex with Sp1 on HIV-LTR DNA	2000	Biochem Biophys Res Commun 	279	383	11118296
1992	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	No (growth advantage)	NA	37°C 	Human	MG63	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
3767	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	Growth advantage; colony formation	NA	37°C 	Human	MOLT-4	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
15	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Spindle checkpoint	NA	NA	NA	37°C 	Human	NHF	WT control	Colcemid treatment	5	Gualberto A;Aldape K;Kozakiewicz K;Tlsty TD;	An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control	1998	Proc Natl Acad Sci U S A	95	5166	9560247
3803	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (CD95/Fas); upregulation (Fas); TA (CD95/Fas)	NA	Downregulation (CD95/Fas); downregulation (Fas); TR (CD95/Fas)	NA	37°C 	Human	PC-3	no WT control	RT-qPCR, FACS analysis, luciferase assay	54	Zalcenstein A;Stambolsky P;Weisz L;Muller M;Wallach D;Goncharov TM;Krammer PH;Rotter V;Oren M;	Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	2003	Oncogene	22	5667	12944915
4142	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4130	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4222	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Interference with Beta-catenin-dependent TCF signalling	NA	NA	NA	37°C 	Human	PC-3, 22Rv1	WT control	Luciferase assay	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
40	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)] moderate	NA	NA	37°C 	Human	PC-3, Saos-2, SK-OV-3, Hep3B, 21PT, 21NT	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
21	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PCNA); GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
103	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	Stable transfection, CAT assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
68	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (WAF1, PG13); GS; TR (C-JUN)	NA	hsp70 binding	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
123	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	RNA pol III repression	NA	RNA pol III activation	NA	37°C 	Human	Saos-2	WT control	Study of VA1 expression	17	Stein T;Crighton D;Boyle JM;Varley JM;White RJ;	RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	2002	Oncogene	21	2961	12082526
150	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (hMMP-13, hMMP1)	Yes [TR (hMMP-13)]; No [TR (hMMP1)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	24	Sun Y;Cheung JM;Martel-Pelletier J;Pelletier JP;Wenger L;Altman RD;Howell DS;Cheung HS;	Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	2000	J Biol Chem	275	11327	10753945
419	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	Yes [TA (WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay	45	Chene P;Bechter E;	p53 mutants without a functional tetramerisation domain are not oncogenic	1999	J Mol Biol	286	1269	10064694
434	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (WAF1, MDM2, 14-3-3s, GADD45, BAX, P53R2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	47	Kato S;Han SY;Liu W;Otsuka K;Shibata H;Kanamaru R;Ishioka C;	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis	2003	Proc Natl Acad Sci U S A	100	8424	12826609
415	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, BAX); GS; TR (MDR-1)	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
930	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, MDM2); TR (ASNS, hTERT, SV40); DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT); no [TA(SV40)]	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
911	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (PCNA)	NA	TA (PCNA)	NA	37°C 	Human	Saos-2	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1161	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	NA	NA	p73alpha binding	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1162	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	NA	NA	p73alpha binding (low affinity)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
950	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	69	Kakudo Y;	Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s	2005	Cancer Res	65	2108	15781620
1985	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC, p53CON); TR (C-FOS); GS	NA	TA (C-FOS); growth advantage	No (RGC, p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitivity assay at 30°C, CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
2067	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NIM sensitivity	NA	CDDP resistance (moderate); no (NIM, DOX, BLEO resistance)	NA	37°C 	Human	Saos-2	WT control	Treatment with cisplatin, nimustine, doxorubicin or bleomycin	152	Wang LH;Okaichi K;Ihara M;Okumura Y;	Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point	1998	Anticancer Res	18	321	9568097
2163	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	APO; GA	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	163	Chen X;Ko LJ;Jayaraman L;Prives C;	p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells	1996	Genes Dev	10	2438	8843196
2145	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (C-MYC)	NA	TA (C-MYC)	NA	37°C 	Human	Saos-2	WT control	CAT assay	74	Brown DR;Deb D;Frum R;Hickes L;Munoz R;Deb S;Deb SP;	The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants	2001	Int J Oncol	18	449	11179471
1770	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (ANGPT1, EBAG-9, ITGA6, Cyclin B2, POLD2, E2F-5)	NA	TA (ANGPT1, EBAG-9, ITGA6, Cyclin B2, POLD2, E2F-5)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	111	Scian MJ;Stagliano KE;Ellis MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Modulation of gene expression by tumor-derived p53 mutants	2004	Cancer Res	64	7447	15492269
1853	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	Saos-2	WT control		125	Stahler F;Roemer K;	Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	1998	Oncogene	17	3507	10030675
1524	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	NA	Yes (APO)	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
1525	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	NA	Yes (APO)	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
1711	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (NFkB2-P2)	NA	TA (NFkB2-P2)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
1669	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	TA (EGFR) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	89	Ludes-Meyers JH;Subler MA;Shivakumar CV;Munoz RM;Jiang P;Bigger JE;Brown DR;Deb SP;Deb S;	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53	1996	Mol Cell Biol	16	6009	8887630
3165	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (S100A2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	211	Tan M;Heizmann CW;Guan K;Schafer BW;Sun Y;	Transcriptional activation of the human S100A2 promoter by wild-type p53	1999	FEBS Lett 	445	265	10094469
3290	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (HPSE)	NA	TA (HPSE)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	218	Baraz L;Haupt Y;Elkin M;Peretz T;Vlodavsky I;	Tumor suppressor p53 regulates heparanase gene expression	2006	Oncogene	25	3939	16474844
3252	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (PTGF-beta)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	213	Tan M;Wang Y;Guan K;Sun Y;	PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway	2000	Proc Natl Acad Sci U S A	97	109	10618379
3171	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (type IV collagenase)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	212	Bian J;Sun Y;	Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter	1997	Mol Cell Biol 	17	6330	9343394
4260	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4516	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TR (uPA); TA (PAI-1)	NA	No [TA (uPA)]; no [TR (PAI-1)]	NA	37°C 	Human	Saos-2	WT control	CAT assay	329	Kunz C;Pebler S;Otte J;von der AD;	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53	1995	Nucleic Acids Res 	23	3710	7479001
4068	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	HR repression	NA	NA	NA	NA	37°C 	Human	Saos-2	no WT control	Ionizing irradiation + homologous recombination (HR) assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4072	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4099	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Daxx interference	NA	37°C 	Human	Saos-2	no WT control	CFA	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4116	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1); No [upregulation (IL-6)]; culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4085	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Daxx binding; culture in soft agar	NA	37°C 	Human	Saos-2	WT control	Co-IP, culture in soft agar	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4019	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Ionizing radiation sensitivity	NA	No (ionizing radiation resistance)	NA	37°C 	Human	Saos-2	WT control	X-ray irradiation	266	Okaichi K;Wang LH;Ihara M;Okumura Y;	Sensitivity to ionizing radiation in Saos-2 cells transfected with mutant p53 genes depends on the mutation position	1998	J Radiat Res (Tokyo)	39	111	9735599
4034	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Culture in soft agar (moderate); No (TUMOR+)	NA	37°C 	Human	Saos-2	no WT control	Culture in soft agar, tumorigenicity assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
3757	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	DOX, CDDP, gamma-irradiation resistance	NA	37°C 	Human	Saos-2	no WT control	Doxorubicin, cisplatin or gamma-irradiation treatment	68	Tsang WP;Ho FY;Fung KP;Kong SK;Kwok TT;	p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis	2005	Int J Cancer	114	331	15578696
3814	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	NA	NA	p73 interference	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3815	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3865	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3866	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3398	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, PG13)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	32	Chene P;Ory K;Ruedi D;Soussi T;Hegi ME;	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome	1999	Int J Cancer	82	17	10360814
3403	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, BAX); APO	Yes [TA (BAX)]; No [TA (WAF1)]; No (APO)	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
3345	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (p21waf1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot	230	Ferrone M;Perrone F;Tamborini E;Paneni MS;Fermeglia M;Suardi S;Pastore E;Delia D;Pierotti MA;Pricl S;Pilotti S;	Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y)	2006	Mol Cancer Ther 	5	1467	16818505
3725	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	DNAb (RGC, WAF1)	NA	NA	No (DNAb)	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	EMSA, temperature sensitive assay at 4 and 32°C	242	Brazda V;Muller P;Brozkova K;Vojtesek B;	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity	2006	Biochem Biophys Res Commun 	351	499	17070499
3843	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3750	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	p73 binding	NA	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	Co-IP	25	Strano S;Munarriz E;Rossi M;Cristofanelli B;Shaul Y;Castagnoli L;Levine AJ;Sacchi A;Cesareni G;Oren M;Blandino G;	Physical and functional interaction between p53 mutants and different isoforms of p73	2000	J Biol Chem	275	29503	10884390
3780	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Growth advantage; TUMOR+; drug resistance	NA	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	siRNA	138	Bossi G;Lapi E;Strano S;Rinaldo C;Blandino G;Sacchi A;	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression	2006	Oncogene	25	304	16170357
3785	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Bcl2 binding	NA	NA	NA	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	Co-IP	245	Tomita Y;Marchenko N;Erster S;Nemajerova A;Dehner A;Klein C;Pan H;Kessler H;Pancoska P;Moll UM;	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization	2006	J Biol Chem 	281	8600	16443602
3921	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	DNAb (CCNA2, CCNB1, CCNB2, CDC2, CDC25C)	NA	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	DOX treatment + ChIP	219	Di Agostino S;Strano S;Emiliozzi V;Zerbini V;Mottolese M;Sacchi A;Blandino G;Piaggio G;	Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation	2006	Cancer Cell	10	191	16959611
4265	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Enhanced TNFalpha-induced NFkappaB activity; TNFalpha resistance	NA	37°C 	Human	SK-BR3 (endo)	Endogenous Mutant	siRNA, luciferase assay, FACS analysis	315	Weisz L;Damalas A;Liontos M;Karakaidos P;Fontemaggi G;Maor-Aloni R;Kalis M;Levrero M;Strano S;Gorgoulis VG;Rotter V;Blandino G;Oren M;	Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells	2007	Cancer Res 	67	2396	17363555
4195	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Attenuation of TGF-beta1 response; downregulation (TGF-betaRII); no [downregulation (TGF-betaRI)]	NA	37°C 	Human	SK-OV-3	WT control	Stable transfection, RT-PCR	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
3924	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Downregulation (ATF3); downregulation (Atf3); cell death inhibition	NA	37°C 	Human	SK-OV-3	no WT control	TPA treatment + western blot, RT-qPCR, cell proliferation assay, FACS analysis	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
3949	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	Yes [TA (p53CON)] moderate	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	249	Hachiya M;Chumakov A;Miller CW;Akashi M;Said J;Koeffler HP;	Mutant p53 proteins behave in a dominant, negative fashion in vivo	1994	Anticancer Res 	14	1853	7847818
4201	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	Repression of transcriptional TGF-beta1 response; TR (TGF-betaRII)	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
3501	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	TR (ATF3) moderate	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
2075	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Human	SK-OV-3, COS-1, 293	WT control	CAT assay	155	Chumakov AM;Miller CW;Chen DL;Koeffler HP;	Analysis of p53 transactivation through high-affinity binding sites	1993	Oncogene	8	3005	8414502
3304	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (WAF1, BAX); APO	NA	Upregulation (GEF-H1)	NA	37°C 	Human	U2OS	WT control	RT-qPCR	221	Mizuarai S;Yamanaka K;Kotani H;	Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells	2006	Cancer Res 	66	6319	16778209
3314	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TR (DNp63)	NA	TA (DNp63) moderate	NA	37°C 	Human	U2OS	WT control	Luciferase assay	224	Lanza M;Marinari B;Papoutsaki M;Giustizieri ML;D'Alessandra Y;Chimenti S;Guerrini L;Costanzo A;	Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants	2006	Cell Cycle	5	1996	16931914
3315	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TR (DNp63)	NA	TA (DNp63) moderate	NA	37°C 	Human	U2OS	WT control	Luciferase assay	224	Lanza M;Marinari B;Papoutsaki M;Giustizieri ML;D'Alessandra Y;Chimenti S;Guerrini L;Costanzo A;	Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants	2006	Cell Cycle	5	1996	16931914
3316	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TR (DNp63)	NA	TA (DNp63) moderate	NA	37°C 	Human	U2OS	WT control	DOX treatment + luciferase assay	224	Lanza M;Marinari B;Papoutsaki M;Giustizieri ML;D'Alessandra Y;Chimenti S;Guerrini L;Costanzo A;	Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants	2006	Cell Cycle	5	1996	16931914
3317	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TR (DNp63)	NA	TA (DNp63)	NA	37°C 	Human	U2OS	WT control	DOX treatment + luciferase assay	224	Lanza M;Marinari B;Papoutsaki M;Giustizieri ML;D'Alessandra Y;Chimenti S;Guerrini L;Costanzo A;	Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants	2006	Cell Cycle	5	1996	16931914
4057	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	X-ray radiation sensitivity	NA	X-ray radiation resistance	NA	37°C 	Human	U-87MG	no WT control	Treatment with X-ray irradiation	278	Yount GL;Haas-Kogan DA;Vidair CA;Haas M;Dewey WC;Israel MA;	Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells	1996	Cancer Res 	56	500	8564961
3923	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1)	NA	37°C 	Human	WI-38, HT-1080	no WT control	Western blot	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
3148	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TRANSF- (partial)	NA	NA	NA	37°C 	Other	Rat-1	WT control	Transformation assay	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
2008	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	NA	NA	TRANSF+; hsc70 binding	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
3989	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	TRANSF+	NA	37°C 	Other	REF	WT control	transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
3826	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	NA	NA	TRANSF+	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3827	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
4257	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	NA	TRANSF+	No (TRANSF+)	37°C 	Other	REF	WT control	Transformation assay, , temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4662	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, PUMA)]; No [TA (BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4174	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	No (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
2047	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	146	Scharer E;Iggo R;	Mammalian p53 can function as a transcription factor in yeast	1992	Nucleic Acids Res	20	1539	1579447
2036	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
2660	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
2742	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
1857	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
1908	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1909	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1742	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
3104	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3081	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3258	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
3175	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2869	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2836	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2814	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2851	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
2749	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	180	Gong ZY;Wong KW;Li Y;Mao YR;Lung ML;	p53 inactivating mutations in chinese breast carcinomas	2000	Oncol Rep	7	381	10671690
2775	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
2903	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
2895	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2931	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2941	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3013	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2997	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	199	M'kacher R;Bennaceur A;Farace F;Lauge A;Plassa LF;Wittmer E;Dossou J;Violot D;Deutsch E;Bourhis J;Stoppa-Lyonnet D;Ribrag V;Carde P;Parmentier C;Bernheim A;Turhan AG;	Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma	2003	Oncogene	22	5961	12970738
1249	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1380	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
942	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC, WAF1)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
433	p.R175H	R175H	175	Arg	His	005932	L2/L3	P 	NA	TA (WAF1, MDM2, 14-3-3s, GADD45, BAX, P53R2)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Fluorescence intensity	47	Kato S;Han SY;Liu W;Otsuka K;Shibata H;Kanamaru R;Ishioka C;	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis	2003	Proc Natl Acad Sci U S A	100	8424	12826609
194	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC, p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
201	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
177	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
260	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
252	p.R175H	R175H	175	Arg	His	005932	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
215	p.R175H	R175H	175	Arg	His	005932	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1805	[p.R175H;K373E]	R175H/K373E	175	Arg	NA		L2/L3	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
4415	[p.R175H;N235K]	R175H/N235K	175	Arg	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4416	[p.R175H;N235K;N239Y]	R175H/N235K/N239Y	175	Arg	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
1632	[p.R175H;N239Y]	R175H/N239Y	175	Arg	NA		L2/L3	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1598	[p.R175H;N239Y]	R175H/N239Y	175	Arg	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	Yes mut_L & H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1617	[p.R175H;N268D]	R175H/N268D	175	Arg	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1610	[p.R175H;S240N]	R175H/S240N	175	Arg	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
129	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	NA	TA (PG13); TR (HRE)	NA	NA	NA	NA	37°C 	Human	PC-3, MCF-7	WT control	Luciferase assay	19	Blagosklonny MV;Giannakakou P;Romanova LY;Ryan KM;Vousden KH;Fojo T;	Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions	2001	Carcinogenesis	22	861	11375890
69	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	R 	TA (WAF1) supertrans; GS; TR (C-JUN)	TA (PG13) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
596	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, 14-3-3s); No (WAF1, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
883	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	NA	NA	TA (BAX, IGF-BP3-boxB); APO; GA partial; TR (C-FOS); upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, western blot	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3303	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	NA	APO	NA	NA	NA	NA	32°C 	Human	Saos-2	WT control	FACS analysis	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3225	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (NOXA); Yes mut_H (BAI1, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2823	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	NA	TA (WAF1 5', PIG3)	TA (BAX)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
1456	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	P 	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	NA	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3')]; Yes [TA (type IV collagenase)]	NA	No (CSR, Cyclin G, GADD45, GML, KILLER/DR5, WAF1 5'); Yes mut_H (CD95-Fas, MDM2, WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
452	p.R175L	R175L	175	Arg	Leu	005930	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, BAX, AIP1); No (MDM2, 14-3-3s, GADD45, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
142	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (MDM2)	TA (PIG3) partial; TR (RSV) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
159	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	Upregulation (mdm2); super-upregulation (WAF1, BTG2, PIG3)	GS partial	NA	NA	NA	37°C 	Human	H1299	WT control	CFA, western blot, northern blot	27	Pan Y;Haines DS;	Identification of a tumor-derived p53 mutant with novel transactivating selectivity	2000	Oncogene	19	3095	10871862
168	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (WAF1); no upregulation (Bax)	GS partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, western blot	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
1634	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (WAF1)	TA (BAX); TA (CD95-Fas) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	84	Munsch D;Watanabe-Fukunaga R;Bourdon JC;Nagata S;May E;Yonish-Rouach E;Reisdorf P;	Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis	2000	J Biol Chem	275	3867	10660538
3394	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	GA	APO	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
3392	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (WAF1); GA	TA (BAX, IGF-BP3-boxB); APO	NA	NA	NA	37°C 	Human	H358	WT control	Luciferase assay, FACS analysis	28	Ludwig RL;Bates S;Vousden KH;	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function	1996	Mol Cell Biol	16	4952	8756654
1644	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	NA	NA	TA (BAG-1)	NA	37°C 	Human	HeLa	WT control	Luciferase assay	85	Yang X;Pater A;Tang SC;	Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	1999	Oncogene	18	4546	10467399
1232	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	APO partial	NA	NA	NA	37°C 	Human	HeLa	WT control	FACS analysis	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
130	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (PG13) supertrans; TR (HRE)	TA (BAX)	No [TA (BAX)]	NA	NA	37°C 	Human	PC-3, MCF-7	WT control	Luciferase assay	19	Blagosklonny MV;Giannakakou P;Romanova LY;Ryan KM;Vousden KH;Fojo T;	Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions	2001	Carcinogenesis	22	861	11375890
124	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	RNA pol III repression	NA	No (RNA pol III activation)	NA	37°C 	Human	Saos-2	WT control	Study of VA1 expression	17	Stein T;Crighton D;Boyle JM;Varley JM;White RJ;	RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	2002	Oncogene	21	2961	12082526
164	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (WAF1); upregulation (p21waf1); GA	TA (BAX, IGF-BP3-boxA&B); APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis	28	Ludwig RL;Bates S;Vousden KH;	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function	1996	Mol Cell Biol	16	4952	8756654
70	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	R 	TA (PG13); TA (WAF1) supertrans; GS; TR (C-JUN)	NA	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
112	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (PG13); GS	TA (MDM2); TR (C-FOS)	No [TA (PG13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1158	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	NA	NA	No (p73 binding)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
881	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	Upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, western blot	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3300	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	APO partial	NA	NA	NA	32°C 	Human	Saos-2	WT control	FACS analysis	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3397	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	Upregulation (mdm2); no upregulation (bax)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
3811	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	EMSA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
2138	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
1230	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	REF	WT control	Transformation assay	29	Rowan S;Ludwig RL;Haupt Y;Bates S;Lu X;Oren M;Vousden KH;	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant	1996	EMBO J	15	827	8631304
1222	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	NA	TRANSF-	NA	TRANSF+	NA	NA   	Other	REF	WT control	transformation assay	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
261	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (p53CON)	NA	No [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
375	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (WAF1 5')	TA (BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
3128	p.R175P	R175P	175	Arg	Pro	005931	L2/L3	NA	TA (WAF1 5')	TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
131	p.R175Q	R175Q	175	Arg	Gln	044916	L2/L3	NA	TA (PG13)	TR (HRE) partial	NA	NA	NA	37°C 	Human	PC-3, MCF-7	WT control	Luciferase assay	19	Blagosklonny MV;Giannakakou P;Romanova LY;Ryan KM;Vousden KH;Fojo T;	Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions	2001	Carcinogenesis	22	861	11375890
71	p.R175Q	R175Q	175	Arg	Gln	044916	L2/L3	R 	TA (WAF1) supertrans; GS; TR (C-JUN)	TA (PG13) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
884	p.R175Q	R175Q	175	Arg	Gln	044916	L2/L3	NA	NA	TA (BAX, IGF-BP3-boxB); APO; GA partial; TR (C-FOS); upregulation (p21waf1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, western blot	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3302	p.R175Q	R175Q	175	Arg	Gln	044916	L2/L3	NA	APO	NA	NA	NA	NA	32°C 	Human	Saos-2	WT control	FACS analysis	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
3301	p.R175S	R175S	175	Arg	Ser	044917	L2/L3	NA	APO	NA	NA	NA	NA	32°C 	Human	Saos-2	WT control	FACS analysis	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
882	p.R175S	R175S	175	Arg	Ser	044917	L2/L3	NA	GA; upregulation (p21waf1)	TA (BAX, IGF-BP3-boxB); APO; TR (C-FOS)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, western blot	50	Ryan KM;Vousden KH;	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest	1998	Mol Cell Biol	18	3692	9632751
72	p.R175S	R175S	175	Arg	Ser	044917	L2/L3	R 	TA (PG13); TA (WAF1) supertrans; GS; TR (C-JUN)	NA	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
3132	p.R175S	R175S	175	Arg	Ser	044917	L2/L3	NA	TA (WAF1 5')	TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
4134	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4146	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4117	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1)	NA	37°C 	Human	Saos-2	no WT control	Western blot	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
22	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
251	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
220	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1387	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3184	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2772	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
2962	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
1910	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4535	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4565	p.C176F	C176F	176	Cys	Phe	005933	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4417	[p.C176F;N235K]	C176F/N235K	176	Cys	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4419	[p.C176F;N235K;N239Y]	C176F/N235K/N239Y	176	Cys	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4418	[p.C176F;N239Y]	C176F/N239Y	176	Cys	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
3242	p.C176R	C176R	176	Cys	Arg	044919	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3061	p.C176R	C176R	176	Cys	Arg	044919	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
1436	p.C176R	C176R	176	Cys	Arg	044919	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
788	p.C176R	C176R	176	Cys	Arg	044919	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
178	p.C176R	C176R	176	Cys	Arg	044919	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1600	[p.C176R;N239Y]	C176R/N239Y	176	Cys	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
2184	[p.C176R;R213*]	C176R/R213X	176	Cys	NA		L2/L3	NA	NA	TA (BAX); upregulation (BAX)	Yes [TA (BAX)]; Yes [upregulation (BAX)]	NA	NA	37°C 	Human	HS68	WT control	Luciferase assay, northern blot	165	Han Z;Boyle DL;Shi Y;Green DR;Firestein GS;	Dominant-negative p53 mutations in rheumatoid arthritis	1999	Arthritis Rheum	42	1088	10366100
1612	[p.C176R;S240N]	C176R/S240N	176	Cys	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
23	p.C176S	C176S	176	Cys	Ser	044920	L2/L3	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4118	p.C176S	C176S	176	Cys	Ser	044920	L2/L3	NA	Upregulation (p21waf1)	NA	NA	Upregulation (IL-6); No (culture in soft agar)	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
221	p.C176S	C176S	176	Cys	Ser	044920	L2/L3	P 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
253	p.C176S	C176S	176	Cys	Ser	044920	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
3049	p.C176S	C176S	176	Cys	Ser	044920	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
2795	p.C176W	C176W	176	Cys	Trp	005934	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2693	p.C176W	C176W	176	Cys	Trp	005934	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	174	Kashiwazaki H;Tonoki H;Tada M;Chiba I;Shindoh M;Totsuka Y;Iggo R;Moriuchi T;	High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay	1997	Oncogene	15	2667	9400993
3867	p.C176Y	C176Y	176	Cys	Tyr	044921	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3868	p.C176Y	C176Y	176	Cys	Tyr	044921	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (weak)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4532	p.C176Y	C176Y	176	Cys	Tyr	044921	L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
2949	p.C176Y	C176Y	176	Cys	Tyr	044921	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
222	p.C176Y	C176Y	176	Cys	Tyr	044921	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
202	p.C176Y	C176Y	176	Cys	Tyr	044921	L2/L3	NA	NA	TA (MDM2,WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
279	p.P177F	P177F	177	Pro	Phe	045803	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
657	p.P177F	P177F	177	Pro	Phe	045803	L2/L3	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
436	p.P177H	P177H	177	Pro	His	044923	L2/L3	P 	TA (P53R2, WAF1, GADD45, MDM2)	TA (BAX, 14-3-3s) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	47	Kato S;Han SY;Liu W;Otsuka K;Shibata H;Kanamaru R;Ishioka C;	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis	2003	Proc Natl Acad Sci U S A	100	8424	12826609
435	p.P177H	P177H	177	Pro	His	044923	L2/L3	P 	TA (P53R2)	TA (MDM2);  TA (WAF1, 14-3-3s, GADD45, BAX) partial	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Fluorescence intensity	47	Kato S;Han SY;Liu W;Otsuka K;Shibata H;Kanamaru R;Ishioka C;	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis	2003	Proc Natl Acad Sci U S A	100	8424	12826609
658	p.P177H	P177H	177	Pro	His	044923	L2/L3	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
722	p.P177H	P177H	177	Pro	His	044923	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
280	p.P177H	P177H	177	Pro	His	044923	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1250	p.P177H	P177H	177	Pro	His	044923	L2/L3	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	Yes[TA (WAF1 5', P53R2, GADD45, CD95-Fas, MDM2, RGC, BAX)] moderate; Yes [TA (PCNA, IGF-BP3, WAF1 3', NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1420	p.P177L	P177L	177	Pro	Leu	005935	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]; No [TA (GML)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
425	p.P177L	P177L	177	Pro	Leu	005935	L2/L3	NA	TA (WAF1, p53CON)	TA (RGC, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
2817	p.P177L	P177L	177	Pro	Leu	005935	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3037	p.P177L	P177L	177	Pro	Leu	005935	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
3223	p.P177L	P177L	177	Pro	Leu	005935	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2675	p.P177L	P177L	177	Pro	Leu	005935	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	169	Waridel F;Estreicher A;Bron L;Flaman JM;Fontolliet C;Monnier P;Frebourg T;Iggo R;	Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract	1997	Oncogene	14	163	9010218
3038	p.P177R	P177R	177	Pro	Arg	036505	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2838	p.P177R	P177R	177	Pro	Arg	036505	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2891	p.P177R	P177R	177	Pro	Arg	036505	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
3040	p.P177S	P177S	177	Pro	Ser	044924	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
656	p.P177S	P177S	177	Pro	Ser	044924	L2/L3	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
278	p.P177S	P177S	177	Pro	Ser	044924	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
376	p.P177S	P177S	177	Pro	Ser	044924	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
773	p.P177S	P177S	177	Pro	Ser	044924	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
744	p.H178P	H178P	178	His	Pro	044929	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2664	p.H178P	H178P	178	His	Pro	044929	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
3797	p.H178P/R290H	H178P/R290H	178	His	NA		L2/L3	NA	NA	DNAb (p53CON)	NA	NA	NA	37°C 	Human	AML3 (endo)	Endogenous Mutant	EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
3869	p.H178Y	H178Y	178	His	Tyr	044932	L2/L3	R 	NA	NA	NA	No (p73 interference); CDDP resistance (weak)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3870	p.H178Y	H178Y	178	His	Tyr	044932	L2/L3	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4493	p.H178Y	H178Y	178	His	Tyr	044932	L2/L3	NA	TA (BAX); TETR	TA (WAF1, MDM2, GADD45, 14-3-3s) partial; APO partial	No [TA(WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, cross-link of proteins with glutaraldehyde + SDS/PAGE	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
3281	p.H178Y	H178Y	178	His	Tyr	044932	L2/L3	NA	APO	GS partial; GA; UV sensitivity (partial)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV treatment	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
846	p.H178Y	H178Y	178	His	Tyr	044932	L2/L3	NA	TA (WAF1, RGC, PIG3, BAX) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
4499	[p.H178Y;G245S]	H178Y/G245S	178	His	NA		L2/L3	NA	TA (14-3-3s, P53R2) supertrans; TA (WAF1)	TA (MDM2, GADD45, BAX) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4482	[p.H178Y;G245S]	H178Y/G245S	178	His	NA		L2/L3	NA	TA (AIP1, P53R2); TETR	TA (WAF1, GADD45, NOXA) partial; TA (BAX, MDM2, 14-3-3s)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity, ross-link of proteins with glutaraldehyde + SDS/PAGE	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4512	[p.H178Y;G245S]	H178Y/L344P	178	His	NA		L2/L3	NA	NA	TETR (monomer)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Cross-link of proteins with glutaraldehyde + SDS/PAGE	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4510	[p.H178Y;R273H]	H178Y/R273H	178	His	NA		L2/L3	NA	NA	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s, P53R2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4491	[p.H178Y;R273H]	H178Y/R273H	178	His	NA		L2/L3	NA	NA	TA (P53R2) partial; TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4292	[p.H178Y;S240R;R273C]	H178Y/S240R/R273C	178	His	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1416	p.H179L	H179L	179	His	Leu	044934	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3219	p.H179L	H179L	179	His	Leu	044934	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3105	p.H179L	H179L	179	His	Leu	044934	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
2914	p.H179L	H179L	179	His	Leu	044934	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
2939	p.H179L	H179L	179	His	Leu	044934	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2768	p.H179N	H179N	179	His	Asn	044935	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
3080	p.H179N	H179N	179	His	Asn	044935	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3231	p.H179N	H179N	179	His	Asn	044935	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1425	p.H179N	H179N	179	His	Asn	044935	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
797	p.H179N	H179N	179	His	Asn	044935	L2/L3	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
340	p.H179N	H179N	179	His	Asn	044935	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1601	[p.H179N;N239Y]	H179N/N239Y	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1745	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	TR (TP53) partial; TA (MDM2)	NA	RB18A inhibition	NA	37°C 	Human	H1299	WT control	CAT or luciferase assay	104	Lottin-Divoux S;Barel M;Frade R;	RB18A enhances expression of mutant p53 protein in human cells	2005	FEBS Lett	579	2323	15848166
1977	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	TA (RGC, p53CON)	Yes [TA (RGC, p53CON)]	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
3971	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	DNAb (p53CON)	Yes (DNAb)	NA	NA	37°C 	Human	H358	WT control	EMSA	255	Unger T;Mietz JA;Scheffner M;Yee CL;Howley PM;	Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression	1993	Mol Cell Biol 	13	5186	8355677
3812	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	NA	NA	p73 interference (moderate)	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3291	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	TR (HPSE)	NA	No [TA (HPSE)]	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	218	Baraz L;Haupt Y;Elkin M;Peretz T;Vlodavsky I;	Tumor suppressor p53 regulates heparanase gene expression	2006	Oncogene	25	3939	16474844
1154	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	NA	NA	p73alpha binding (weak)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1163	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	R 	NA	NA	NA	No (p73alpha binding)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1166	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	P 	NA	NA	NA	No (p73alpha binding)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
4054	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	NA	NA	DOX and CDDP sensitivity	NA	37°C 	Human	TCCSUP	no WT control	Treatment with cisplatin or doxorubicin	277	Chang FL;Lai MD;	Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells	2001	J Urol 	166	304	11435891
3974	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	TRANSF-	NA	No (TRANSF+)	NA	37°C 	Other	REF	WT control	Transformation assay	255	Unger T;Mietz JA;Scheffner M;Yee CL;Howley PM;	Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression	1993	Mol Cell Biol 	13	5186	8355677
364	p.H179Q	H179Q	179	His	Gln	044937	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
4198	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	Promotion of transcriptional TGF-beta1 response	NA	Repression of transcriptional TGF-beta1 response	NA	37°C 	Human	H1299	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
4206	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	NA	NA	TR (TGF-betaRII)	NA	37°C 	Human	H1299	no WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
3871	p.H179R	H179R	179	His	Arg	044938	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3872	p.H179R	H179R	179	His	Arg	044938	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4202	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	NA	NA	Repression of transcriptional TGF-beta1 response (moderate)	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
4526	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4566	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
1389	p.H179R	H179R	179	His	Arg	044938	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
745	p.H179R	H179R	179	His	Arg	044938	L2/L3	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
3188	p.H179R	H179R	179	His	Arg	044938	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3079	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2783	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2834	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2880	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2976	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2726	p.H179R	H179R	179	His	Arg	044938	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
4420	[p.H179R;N235K]	H179R/N235K	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4422	[p.H179R;N235K;N239Y]	H179R/N235K/N239Y	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4421	[p.H179R;N239Y]	H179R/N239Y	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
388	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (WAF1, BAX, MDM2); GS partial; DNAb (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
133	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	NA	NA	p63 and p73 binding	NA	37°C 	Human	H1299	WT control	Co-IP	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
4280	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	Downregulation (CDK2)	GS; downregulation (CYCLIN A); downregulation (CYCLIN E) partial; downregulation (cyclin A, cyclin E, cdk2); upregulation (WAF1); upregulation (p21waf1)	NA	Growth advantage; upregulation (CYCLIN A, CDK4); upregulation (cyclin A, cdk4)	NA	37°C 	Human	HELF	WT control	Proliferation assay, FACS analysis, RT-PCR, western blot	319	Yang D;Qi Y;Chen Q;Wang Z;Jin X;Gao J;Fu J;Xiao X;Zhou Z;	The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells	2007	Mol Cell Biochem 	304	219	17530187
4261	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
3873	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	R 	NA	NA	NA	p73 interference; p73 binding; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, co-IP, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3874	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	P 	NA	NA	NA	p73 interference (moderate); no (p73 binding); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, co-IP, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
929	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (WAF1, MDM2); TR (ASNS, hTERT); TR (SV40) partial; DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
1532	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	P 	NA	NA	Yes (APO) moderate	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
1533	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	R 	NA	NA	Yes (APO) moderate	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4255	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	NA	NA	TRANSF+	No (TRANSF+)	37°C 	Other	REF	WT control	Transformation assay, , temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
2917	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2881	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2828	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
3106	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3192	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
796	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
1393	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
281	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
659	p.H179Y	H179Y	179	His	Tyr	044939	L2/L3	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4423	[p.H179Y;N235K]	H179Y/N235K	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4425	[p.H179Y;N235K;N239Y]	H179Y/N235K/N239Y	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4424	[p.H179Y;N239Y]	H179Y/N239Y	179	His	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
3078	p.E180D	E180D	180	Glu	Asp	044941	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2711	p.E180D	E180D	180	Glu	Asp	044941	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
3002	p.E180K	E180K	180	Glu	Lys	044943	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
660	p.E180K	E180K	180	Glu	Lys	044943	L2/L3	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
382	p.E180K	E180K	180	Glu	Lys	044943	L2/L3	NA	TA (WAF1 5')	TA (BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
323	p.E180K	E180K	180	Glu	Lys	044943	L2/L3	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4615	p.E180K	E180K	180	Glu	Lys	044943	L2/L3	NA	NA	TA (MDM2), TA (BAX, PUMA, WAF1) partial	Yes [TA (PUMA)]; No [TA (MDM2, BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3021	p.E180*	E180X	180	Glu	Stop		L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
90	p.R181C	R181C	181	Arg	Cys	044946	L2/L3	NA	TA (WAF1, PIG3); GS; APO	Upregulation (p21waf1) partial; TA (MDM2, BAX, IGF-BP3-boxA)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1213	p.R181C	R181C	181	Arg	Cys	044946	L2/L3	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1251	p.R181C	R181C	181	Arg	Cys	044946	L2/L3	P 	NA	TA (WAF1 5') partial; TA (WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	Yes [TA (IGF-BP3, WAF1 3', NOXA, PUMA)] moderate	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
705	p.R181C	R181C	181	Arg	Cys	044946	L2/L3	NA	NA	NA	Yes [TA (BAX)]; No [TA (WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4663	p.R181C	R181C	181	Arg	Cys	044946	L2/L3	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	Yes [TA (MDM2, BAX)]; No [TA (PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3425	p.R181C	R181C	181	Arg	Cys	044946	L2/L3	R 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
661	p.R181G	R181G	181	Arg	Gly	044947	L2/L3	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
282	p.R181G	R181G	181	Arg	Gly	044947	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_L (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4064	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	NA	TA (MDR1)	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay	281	Goldsmith ME;Gudas JM;Schneider E;Cowan KH;	Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line	1995	J Biol Chem 	270	1894	7829527
3153	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	TA (RGC) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
1674	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	GS; Ag T binding	NA	NA	No (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
3129	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	TA (WAF1 5')	TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
2741	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
283	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_L (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
662	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4664	p.R181H	R181H	181	Arg	His	044948	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX)]; No [TA (PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
160	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	Upregulation (mdm2); super-upregulation (WAF1, BTG2, PIG3)	GS partial	NA	NA	NA	37°C 	Human	H1299	WT control	CFA, western blot, northern blot	27	Pan Y;Haines DS;	Identification of a tumor-derived p53 mutant with novel transactivating selectivity	2000	Oncogene	19	3095	10871862
3393	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	TA (WAF1, BAX); GA	TA (IGF-BP3-boxB); APO partial	NA	NA	NA	37°C 	Human	H358	WT control	Luciferase assay, FACS analysis	28	Ludwig RL;Bates S;Vousden KH;	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function	1996	Mol Cell Biol	16	4952	8756654
165	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	TA (WAF1, BAX, IGF-BP3-boxA); upregulation (p21waf1); GA	TA (IGF-BP3-boxB); APO partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis	28	Ludwig RL;Bates S;Vousden KH;	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function	1996	Mol Cell Biol	16	4952	8756654
113	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	TA (MDM2, PG13); GS	TR (C-FOS)	No [TA (PG13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
2116	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	RNA pol III repression	NA	NA	No (RNA pol III activation)	NA	37°C 	Human	Saos-2	WT control	Study of VA1 expression	17	Stein T;Crighton D;Boyle JM;Varley JM;White RJ;	RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	2002	Oncogene	21	2961	12082526
2135	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
1223	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	NA	TRANSF-	NA	TRANSF+	NA	NA   	Other	REF	WT control	transformation assay	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1252	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	P 	TA (AIP1, MDM2-RE2)	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, MDM2, RGC, IGF-BP3, PA26) partial; TA (BAX)	No [TA (P53R2, GADD45, PCNA, RGC, WAF1 3')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
774	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
365	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	TA (p53CON)	NA	No [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
3133	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	TA(WAF1 5'); DNAb (WAF1)	TA (BAX); DNAb (BAX) partial	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection, EMSA	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3426	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	P 	NA	TA (RGC) partial	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4665	p.R181L	R181L	181	Arg	Leu	005937	L2/L3	NA	TA (PUMA, WAF1)	TA (MDM2, BAX) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4666	p.R181P	R181P	181	Arg	Pro	044949	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2)]; No [TA (BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4567	p.R181P	R181P	181	Arg	Pro	044949	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
746	p.R181P	R181P	181	Arg	Pro	044949	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4494	p.C182F	C182F	182	Cys	Phe		L2/L3	NA	TA (BAX)	TA (WAF1, MDM2, GADD45, 14-3-3s) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4500	[p.C182F;G245S]	C182F/G245S	182	Cys	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, MDM2, GADD45, 14-3-3s) partial; TA (BAX)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4485	[p.C182F;G245S]	C182F/G245S	182	Cys	NA		L2/L3	NA	NA	TA (P53R2) partial; TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4506	[p.C182Y;G245S]	C182Y/G245S	182	Cys	NA		L2/L3	NA	NA	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s); TA (p53R2) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4568	p.S183L	S183L	183	Ser	Leu	044953	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
847	p.S183L	S183L	183	Ser	Leu	044953	L2/L3	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
4495	p.S183P	S183P	183	Ser	Pro	044954	L2/L3	NA	TA (BAX)	TA (WAF1, MDM2, 14-3-3s) partial; TA (GADD45)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4501	[p.S183P;G245S]	S183P/G245S	183	Ser	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4483	[p.S183P;G245S]	S183P/G245S	183	Ser	NA		L2/L3	NA	TA (WAF1, AIP1, MDM2, P53R2)	TA (BAX, 14-3-3s, GADD45, NOXA) partial	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4298	[p.S183T;S240R;R273H]	S183T/S240R/R273H	183	Ser	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
3077	p.S183*	S183X	183	Ser	Stop		L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
4496	p.D184A	D184A	184	Asp	Ala		L2/L3	NA	TA (BAX)	TA (WAF1); TA (MDM2, GADD45, 14-3-3s) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4502	[p.D184A;G245S]	D184A/G245S	184	Asp	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4486	[p.D184A;G245S]	D184A/G245S	184	Asp	NA		L2/L3	NA	NA	TA (P53R2) partial; TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4497	p.D184G	D184G	184	Asp	Gly	044955	L2/L3	NA	TA (BAX)	TA (WAF1); TA (MDM2, GADD45, 14-3-3s) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
856	p.D184G	D184G	184	Asp	Gly	044955	L2/L3	NA	TA (WAF1, PIG3, BAX); TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
4503	[p.D184G;G245S]	D184G/G245S	184	Asp	NA		L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45); TA (P53R2) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4507	[p.D184N;G245S]	D184N/G245S	184	Asp	NA		L2/L3	NA	NA	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s); TA (p53R2) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4487	[p.D184N;G245S]	D184N/G245S	184	Asp	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
848	p.D184Y	D184Y	184	Asp	Tyr	005939	L2/L3	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
2830	p.D186G	D186G	186	Asp	Gly	044965	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
4498	p.D186N	D186N	186	Asp	Asn	044967	L2/L3	NA	TA (MDM2, BAX)	TA (WAF1, GADD45, 14-3-3s) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4504	[p.D186N;G245S]	D186N/G245S	186	Asp	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4488	[p.D186N;G245S]	D186N/G245S	186	Asp	NA		L2/L3	NA	NA	TA (P53R2) partial; TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4489	[p.G187S;G245S]	G187S/G245S	187	Gly	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4508	[p.L188R;G245S]	L188R/G245S	188	Leu	NA		L2/L3	NA	NA	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s); TA (p53R2) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4490	[p.L188R;G245S]	L188R/G245S	188	Leu	NA		L2/L3	NA	TA (P53R2)	TA (WAF1, BAX, AIP1, MDM2, 14-3-3s, GADD45, NOXA)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection & fluorescence intensity	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
480	p.A189D	A189D	189	Ala	Asp	044974	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
488	p.A189G	A189G	189	Ala	Gly	044975	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
538	p.A189P	A189P	189	Ala	Pro	005943	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
460	p.A189S	A189S	189	Ala	Ser	044976	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4605	p.A189V	A189V	189	Ala	Val	044978	L2/L3	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
775	p.P190H	P190H	190	Pro	His	044980	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
810	p.P190H	P190H	190	Pro	His	044980	L2/L3	P 	NA	TA (RGC) partial	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
2938	p.P190L	P190L	190	Pro	Leu	005944	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
4569	p.P190L	P190L	190	Pro	Leu	005944	L2/L3	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
1253	p.P190R	P190R	190	Pro	Arg	044981	L2/L3	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26) partial; TA (BAX)	No [TA (PCNA, RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
597	p.P190T	P190T	190	Pro	Thr	044983	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
539	p.P190T	P190T	190	Pro	Thr	044983	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (AIP1, Noxa); No (WAF1, GADD45, MDM2, BAX, 14-3-3s, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
494	p.P191H	P191H	191	Pro	His	044984	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
850	p.P191L	P191L	191	Pro	Leu	044985	L2/L3	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1814	[p.I195N/K321E]	I195N/K321E	192	Gln	NA		L2/L3	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
2701	p.Q192*	Q192X	192	Gln	Stop		L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
2787	p.Q192*	Q192X	192	Gln	Stop		L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3076	p.Q192*	Q192X	192	Gln	Stop		L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2876	p.H193L	H193L	193	His	Leu	044992	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2951	p.H193L	H193L	193	His	Leu	044992	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
747	p.H193L	H193L	193	His	Leu	044992	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4531	p.H193L	H193L	193	His	Leu	044992	L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4209	[p.H193L;G279E]	H193L/G279E	193	His	NA		L2/L3	NA	NA	TA (WAF1, MDM2, BAX, PUMA, AIP1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	298	Kawamata H;Omotehara F;Nakashiro K;Uchida D;Shinagawa Y;Tachibana M;Imai Y;Fujimori T;	Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage	2007	Int J Oncol 	30	1089	17390010
461	p.H193Q	H193Q	193	His	Gln	044995	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3161	p.H193R	H193R	193	His	Arg	005948	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
3107	p.H193R	H193R	193	His	Arg	005948	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3095	p.H193R	H193R	193	His	Arg	005948	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3207	p.H193R	H193R	193	His	Arg	005948	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2873	p.H193R	H193R	193	His	Arg	005948	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
1911	p.H193R	H193R	193	His	Arg	005948	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
431	p.H193R	H193R	193	His	Arg	005948	L2/L3	NA	NA	TA (RGC, P53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	Yes mut_H (P53CON, WAF1); No (MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
789	p.H193R	H193R	193	His	Arg	005948	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
1404	p.H193R	H193R	193	His	Arg	005948	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4630	p.H193R	H193R	193	His	Arg	005948	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, PUMA)]; No [TA (BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
598	p.H193Y	H193Y	193	His	Tyr	044996	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
466	p.H193Y	H193Y	193	His	Tyr	044996	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (GADD45, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2944	p.H193Y	H193Y	193	His	Tyr	044996	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3473	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	H1299	WT control	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3724	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	 DNAb (RGC, WAF1) partial	NA	NA	Mut_H (DNAb)	37°C 	Human	T47D (endo)	Endogenous Mutant	EMSA, temperature sensitive assay at 4 and 32°C	242	Brazda V;Muller P;Brozkova K;Vojtesek B;	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity	2006	Biochem Biophys Res Commun 	351	499	17070499
3844	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	T47D (endo)	Endogenous Mutant	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3833	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	NA	NA	p38 and p42 binding	NA	37°C 	Human	T47D (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
3786	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	Bcl2 binding	NA	NA	NA	37°C 	Human	T47D (endo)	Endogenous Mutant	Co-IP	245	Tomita Y;Marchenko N;Erster S;Nemajerova A;Dehner A;Klein C;Pan H;Kessler H;Pancoska P;Moll UM;	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization	2006	J Biol Chem 	281	8600	16443602
3749	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	NA	NA	p73 binding	NA	37°C 	Human	T47D (endo)	Endogenous Mutant	Co-IP	25	Strano S;Munarriz E;Rossi M;Cristofanelli B;Shaul Y;Castagnoli L;Levine AJ;Sacchi A;Cesareni G;Oren M;Blandino G;	Physical and functional interaction between p53 mutants and different isoforms of p73	2000	J Biol Chem	275	29503	10884390
3927	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	NA	NA	Downregulation (GADD45); downregulation (WAF1) moderate; no [regulation (PIG3, TAp73, C-JUN)]	NA	37°C 	Human	T47D (endo)	Endogenous Mutant	siRNA, RT-PCR	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
2995	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
863	p.L194F	L194F	194	Leu	Phe	044997	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
4277	p.L194H	L194H	194	Leu	His	044998	L2/L3	NA	NA	NA	NA	Decrease of some differentiation markers; reduced dependence on serum factors	NA	37°C 	Human	K-562	no WT control	FACS analysis, culture in 1% serum medium	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
4271	p.L194H	L194H	194	Leu	His	044998	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	Transfection	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
366	p.L194H	L194H	194	Leu	His	044998	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
2875	p.L194P	L194P	194	Leu	Pro	005949	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
4570	p.L194P	L194P	194	Leu	Pro	005949	L2/L3	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
393	p.L194R	L194R	194	Leu	Arg	005950	L2/L3	NA	NA	TA (WAF1, BAX, MDM2); GS; DNAb (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
928	p.L194R	L194R	194	Leu	Arg	005950	L2/L3	NA	NA	TA (WAF1, MDM2); TR (ASNS, hTERT); TR (SV40) partial; DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
2953	p.L194R	L194R	194	Leu	Arg	005950	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
4571	p.L194R	L194R	194	Leu	Arg	005950	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4543	p.L194R	L194R	194	Leu	Arg	005950	L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4544	p.I195F	I195F	195	Ile	Phe	045001	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
2784	p.I195F	I195F	195	Ile	Phe	045001	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2761	p.I195F	I195F	195	Ile	Phe	045001	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
3083	p.I195N	I195N	195	Ile	Asn	045002	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
1912	p.I195N	I195N	195	Ile	Asn	045002	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1913	p.I195S	I195S	195	Ile	Ser	045003	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1914	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1868	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
2721	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2952	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2930	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
790	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
4175	p.I195T	I195T	195	Ile	Thr	005951	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX); TA (RGC) partial	NA	NA	Yes mut_H (RGC); Yes (WAF1, BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
540	p.R196L	R196L	196	Arg	Leu	045006	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4667	p.R196P	R196P	196	Arg	Pro	045007	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2)]; No [TA (BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
216	p.R196Q	R196Q	196	Arg	Gln	045008	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
811	p.R196Q	R196Q	196	Arg	Gln	045008	NDBL/beta-sheets	R 	NA	TA (RGC) partial	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3766	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage); no (colony formation)	NA	37°C 	Human	Be-13	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3778	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	CEM	no WT control	Proliferation assay	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3772	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage); no (colony formation)	NA	37°C 	Human	MOLT-4	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
4533	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
217	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2935	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2735	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2702	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
1944	p.R196*	R196X	196	Arg	Stop		NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4697	p.V197E	V197E	197	Val	Glu	045010	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (WAF1)]; No [TA (MDM2, BAX, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
748	p.V197L	V197L	197	Val	Leu	045012	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
541	p.V197M	V197M	197	Val	Met	045013	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4698	p.V197M	V197M	197	Val	Met	045013	NDBL/beta-sheets	NA	TA (MDM2, PUMA, WAF1)	TA (BAX) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1301	p.E198D	E198D	198	Glu	Asp	045014	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
857	p.E198V	E198V	198	Glu	Val	045017	NDBL/beta-sheets	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
2703	p.E198*	E198X	198	Glu	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
91	p.G199R	G199R	199	Gly	Arg	045020	NDBL/beta-sheets	NA	TA (WAF1, PIG3); GS; APO	TA (MDM2, IGF-BP3-boxA, BAX) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1214	p.G199R	G199R	199	Gly	Arg	045020	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1204	p.G199R	G199R	199	Gly	Arg	045020	NDBL/beta-sheets	NA	TA (NOXA); TA (AIP1) supertrans	TA (WAF1 5', P53R2, GADD45, CD95-Fas, PUMA) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection (low expression of mutant p53)	76	Inga A;Storici F;Darden TA;Resnick MA;	Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence	2002	Mol Cell Biol	22	8612	12446780
1254	p.G199R	G199R	199	Gly	Arg	045020	NDBL/beta-sheets	P 	TA (14-3-3s, IGF-BP3); TA (MDM2, WAF1 3', PA26) supertrans	TA (RGC, MDM2-RE2) partial	No [TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, PCNA, MDM2, RGC, IGF-BP3, NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
812	p.G199R	G199R	199	Gly	Arg	045020	NDBL/beta-sheets	R 	TA (RGC)	NA	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
706	p.G199R	G199R	199	Gly	Arg	045020	NDBL/beta-sheets	R 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3384	p.G199*	G199X	199	Gly	Stop		NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	HeLa	WT control	MTT assay	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
144	p.G199*	G199X	199	Gly	Stop		NDBL/beta-sheets	NA	NA	TA (MDM2, WAF1); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay, CFA	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
1815	p.N200D	N200D	200	Asn	Asp	045022	NDBL/beta-sheets	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1302	p.N200D	N200D	200	Asn	Asp	045022	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
599	p.N200Y	N200Y	200	Asn	Tyr		NDBL/beta-sheets	NA	NA	NA	NA	NA	No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
462	p.N200Y	N200Y	200	Asn	Tyr		NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2); No (WAF1, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
700	p.L201*	L201X	201	Leu	Stop		NDBL/beta-sheets	P 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
315	p.L201*	L201X	201	Leu	Stop		NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
813	p.L201*	L201X	201	Leu	Stop		NDBL/beta-sheets	P 	NA	TA (RGC)	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3057	p.L201*	L201X	201	Leu	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
92	p.R202S	R202S	202	Arg	Ser	045035	NDBL/beta-sheets	NA	TA (WAF1, MDM2, PIG3); TA (IGF-BP3) supertrans; GS; APO	Upregulation (p21waf1) partial; TA (BAX) partial	NA	strong TA (IGF-BP3)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1215	p.R202S	R202S	202	Arg	Ser	045035	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1205	p.R202S	R202S	202	Arg	Ser	045035	NDBL/beta-sheets	NA	TA (WAF1 5')	TA (P53R2, GADD45, CD95-Fas, AIP1, PCNA, NOXA, BAX) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection (low expression of mutant p53)	76	Inga A;Storici F;Darden TA;Resnick MA;	Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence	2002	Mol Cell Biol	22	8612	12446780
1255	p.R202S	R202S	202	Arg	Ser	045035	NDBL/beta-sheets	P 	TA (WAF1 3'); TA (MDM2) supertrans	TA (14-3-3s, RGC, IGF-BP3, MDM2-RE2, PA26) partial	No [TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, PCNA, MDM2, RGC, IGF-BP3, NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
814	p.R202S	R202S	202	Arg	Ser	045035	NDBL/beta-sheets	R 	TA (RGC)	NA	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
707	p.R202S	R202S	202	Arg	Ser	045035	NDBL/beta-sheets	R 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
1945	p.E204*	E204X	204	Glu	Stop		NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1469	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5')] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4396	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
2083	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TR (HSP70)	NA	TA (HSP70); hsc70 binding	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2095	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
4258	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	No (TRANSF+)	37°C 	Other	REF	WT control	Transformation assay, , temperature sensitive assay at 32°C	314	Hirano Y;Yamato K;Tsuchida N;	A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down	1995	Oncogene	10	1879	7761089
4332	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4176	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1, RGC); Yes mut_H (BAX) low	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
3097	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3194	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2961	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3023	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2785	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
1394	p.Y205C	Y205C	205	Tyr	Cys	005953	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5', WAF1 3', type IV collagenase)]; Yes [TA (MDM2)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4397	[p.Y205C;D228E;N239Y]	Y205C/D228E/N239Y	205	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4344	[p.Y205C;D228E;N239Y]	Y205C/D228E/N239Y	205	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4398	[p.Y205C;N235K;N239W]	Y205C/N235K/N239W	205	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML); TA (WAF1) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4345	[p.Y205C;N235K;N239W]	Y205C/N235K/N239W	205	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4426	[p.Y205C;N235K;N239Y]	Y205C/N235K/N239Y	205	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
2710	p.Y205D	Y205D	205	Tyr	Asp	005954	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
542	p.Y205H	Y205H	205	Tyr	His	045046	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (GADD45, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
284	p.Y205N	Y205N	205	Tyr	Asn	045047	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
493	p.L206F	L206F	206	Leu	Phe	045049	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
600	p.D208A	D208A	208	Asp	Ala		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45); No (P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
444	p.D208A	D208A	208	Asp	Ala		NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45); No (BAX, P53R2, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
601	p.D208V	D208V	208	Asp	Val	045061	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
446	p.D208V	D208V	208	Asp	Val	045061	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45, AIP1, Noxa); No (BAX, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2071	p.R209T	R209T	209	Arg	Thr	045066	NDBL/beta-sheets	NA	NA	TA (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	154	Gorgoulis VG;Zacharatos PV;Manolis E;Ikonomopoulos JA;Damalas A;Lamprinopoulos C;Rassidakis GZ;Zoumpourlis V;Kotsinas A;Rassidakis AN;Halazonetis TD;Kittas C;	Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene	1998	Br J Cancer	77	374	9472631
1303	p.N210D	N210D	210	Asn	Asp	045067	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4645	p.N210Y	N210Y	210	Asn	Tyr	045073	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
602	p.T211A	T211A	211	Thr	Ala	045074	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (BAX, 14-3-3s); No (WAF1, MDM2, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
445	p.T211A	T211A	211	Thr	Ala	045074	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, Noxa); No (BAX, 14-3-3s, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
449	p.T211I	T211I	211	Thr	Ile	045075	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2773	p.T211I	T211I	211	Thr	Ile	045075	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
603	p.T211P	T211P	211	Thr	Pro	045077	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (14-3-3s); No (WAF1, MDM2, BAX,  GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
447	p.T211P	T211P	211	Thr	Pro	045077	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, GADD45); No (BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1304	p.F212L	F212L	212	Phe	Leu	045080	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
473	p.F212V	F212V	212	Phe	Val	045082	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2, 14-3-3s, Noxa); No (WAF1, BAX, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
604	p.R213G	R213G	213	Arg	Gly	045084	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2, 14-3-3s); No (WAF1, BAX, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
543	p.R213G	R213G	213	Arg	Gly	045084	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2764	p.R213L	R213L	213	Arg	Leu	045085	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2688	p.R213L	R213L	213	Arg	Leu	045085	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
605	p.R213P	R213P	213	Arg	Pro	036506	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, 14-3-3s, GADD45); No (WAF1, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
544	p.R213P	R213P	213	Arg	Pro	036506	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45, P53R2); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4668	p.R213P	R213P	213	Arg	Pro	036506	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	Yes [TA (BAX)]; No [TA (MDM2, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3763	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	GS; TUMOR-	NA	Growth advantage (moderate); no (colony formation); TUMOR+	NA	37°C 	Human	Be-13	no WT control	Proliferation assay, CFA in methylcellulose, tumorigenicity assay	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3775	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	GS	NA	Growth advantage; no (colony formation)	NA	37°C 	Human	CEM	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
161	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	TA (MDM2); DNAb (MDM2); upregulation (mdm2)	GS; upregulation (WAF1, BTG2, PIG3) partial	NA	NA	NA	37°C 	Human	H1299	WT control	CFA, RT-PCR/Western Blot + ChIP, Northern Blot	27	Pan Y;Haines DS;	Identification of a tumor-derived p53 mutant with novel transactivating selectivity	2000	Oncogene	19	3095	10871862
4249	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	Upregulation (WAF1, BAX, MDM2, MASPIN, PAI-1, KAI1); TA (WAF1, BAX, MDM2)	NA	No (growth advantage, cell mobility advantage); no [downregulation (MASPIN, PAI-1, KAI1)]	NA	37°C 	Human	HHUA	no WT control	RT-qPCR, luciferase assay, proliferation assay, in vitro invasion and cell migration assay	313	Dong P;Tada M;Hamada J;Nakamura A;Moriuchi T;Sakuragi N;	p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells	2007	Clin Exp Metastasis	24	471	17636407
4251	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage; cell mobility advantage)	NA	37°C 	Human	HOUA	no WT control	proliferation assay, in vitro invasion and cell migration assay	313	Dong P;Tada M;Hamada J;Nakamura A;Moriuchi T;Sakuragi N;	p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells	2007	Clin Exp Metastasis	24	471	17636407
3769	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage); no (colony formation)	NA	37°C 	Human	MOLT-4	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3969	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	TRANSF- (partial)	NA	No (TRANSF+)	NA	NA   	Other	BRK	WT control	Transformation assay	254	Farrell PJ;Allan GJ;Shanahan F;Vousden KH;Crook T;	p53 is frequently mutated in Burkitt's lymphoma cell lines	1991	EMBO J 	10	2879	1915267
4669	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	TA (MDM2, WAF1) partial; TA (BAX, PUMA)	Yes [TA (BAX)]; No [TA (MDM2, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
206	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
223	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2937	p.R213Q	R213Q	213	Arg	Gln	005955	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
3990	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	NA	NA	No (TUMOR+)	NA	37°C 	Other	REF	no WT control	transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
2946	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3019	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2786	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3099	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (WAF1, BAX)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	205	Dekairelle AF;Brichard B;Delhez H;Gala JL;	Identification of a transcriptionally inactive p53 mutant by functional analysis of separated alleles in yeasts (FASAY) in a child osteosarcoma tumor: a case report	2004	Pediatr Hematol Oncol	21	321	15205094
2722	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2656	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
1723	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
224	p.R213*	R213X	213	Arg	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
606	p.H214D	H214D	214	His	Asp	045087	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45); No (P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
471	p.H214D	H214D	214	His	Asp	045087	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45); No (BAX, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
607	p.H214L	H214L	214	His	Leu		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, 14-3-3s, GADD45); No (WAF1, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
545	p.H214L	H214L	214	His	Leu		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
546	p.H214N	H214N	214	His	Asn		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2); No (GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4152	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4140	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4119	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	Upregulation (p21waf1)	NA	NA	Upregulation (IL-6); culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
608	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, 14-3-3s, GADD45, P53R2); No (WAF1)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
25	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
476	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s, GADD45, AIP1); No (WAF1, MDM2, BAX, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
403	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	TA (RGC) partial	No [TA (RGC)]	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1873	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
3108	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
2777	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	TA (RGC)	NA	NA	NA	Yes mut_H (RGC)	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
4572	p.H214R	H214R	214	His	Arg	045089	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
609	p.H214Y	H214Y	214	His	Tyr	045090	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (14-3-3s); No (WAF1, MDM2, BAX, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
479	p.H214Y	H214Y	214	His	Tyr	045090	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
93	p.S215C	S215C	215	Ser	Cys	045091	NDBL/beta-sheets	NA	TA (WAF1, PIG3); GS; APO	TA (MDM2, IGF-BP3-boxA, BAX) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1216	p.S215C	S215C	215	Ser	Cys	045091	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1206	p.S215C	S215C	215	Ser	Cys	045091	NDBL/beta-sheets	NA	TA (WAF1 5', CD95-Fas, NOXA); TA (GADD45, PCNA, PUMA, BAX) supertrans	TA (P53R2) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection (low expression of mutant p53)	76	Inga A;Storici F;Darden TA;Resnick MA;	Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence	2002	Mol Cell Biol	22	8612	12446780
1256	p.S215C	S215C	215	Ser	Cys	045091	NDBL/beta-sheets	P 	TA (RGC, MDM2-RE2); TA (14-3-3s, MDM2, IGF-BP3, PA26) supertrans	TA (WAF1 3') partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
815	p.S215C	S215C	215	Ser	Cys	045091	NDBL/beta-sheets	R 	TA (RGC)	NA	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
708	p.S215C	S215C	215	Ser	Cys	045091	NDBL/beta-sheets	R 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3798	p.S215G	S215G	215	Ser	Gly	045092	NDBL/beta-sheets	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	KBM7 (endo)	Endogenous Mutant	EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
610	p.S215G	S215G	215	Ser	Gly	045092	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, BAX, 14-3-3s, GADD45, P53R2); No (MDM2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
474	p.S215G	S215G	215	Ser	Gly	045092	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s, GADD45, AIP1, Noxa); No (WAF1, MDM2, BAX, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2982	p.S215G	S215G	215	Ser	Gly	045092	NDBL/beta-sheets	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
3050	p.S215G	S215G	215	Ser	Gly	045092	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
4177	p.S215G	S215G	215	Ser	Gly	045092	NDBL/beta-sheets	NA	TA (WAF1, RGC)	TA (BAX) partial	NA	NA	Yes mut_H (WAF1, BAX)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
4269	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	A549 (with induced mutation)	Endogenous Mutant	FACS analysis	317	Wu YH;Tsai Chang JH;Cheng YW;Wu TC;Chen CY;Lee H;	Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers	2007	Oncogene	26	4761	17325666
4268	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	NA	TA (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	317	Wu YH;Tsai Chang JH;Cheng YW;Wu TC;Chen CY;Lee H;	Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers	2007	Oncogene	26	4761	17325666
611	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45, P53R2); No (BAX)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
475	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2, 14-3-3s, GADD45, AIP1); No (WAF1, BAX, P53R2, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
547	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45, MDM2, 14-3-3s, AIP1); No (WAF1, BAX, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
860	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	TA (MDM2, WAF1 5')	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
943	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	NA	TA (WAF1)	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
1915	p.S215I	S215I	215	Ser	Ile	045093	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
612	p.S215N	S215N	215	Ser	Asn	045094	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45); No (BAX, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
472	p.S215N	S215N	215	Ser	Asn	045094	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, 14-3-3s, GADD45, Noxa); No (MDM2, BAX, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
490	p.S215T	S215T	215	Ser	Thr	045096	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
852	p.S215T	S215T	215	Ser	Thr	045096	NDBL/beta-sheets	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
3111	p.R21*	S215X	215	Ser	Stop		NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
1806	p.V216A	V216A	216	Val	Ala	045097	NDBL/beta-sheets	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1602	[p.V216del;N239Y]	V216del/N239Y	216	Val	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1618	[p.V216del;N268D]	V216del/N268D	216	Val	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1613	[p.V216del;S240N]	V216del/S240N	216	Val	NA		NDBL/beta-sheets	NA	NA	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1917	p.V216E	V216E	216	Val	Glu	045098	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
613	p.V216L	V216L	216	Val	Leu	045100	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45); No (P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
548	p.V216L	V216L	216	Val	Leu	045100	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1916	p.V216M	V216M	216	Val	Met	005956	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2973	p.V216M	V216M	216	Val	Met	005956	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	196	Fulci G;Labuhn M;Maier D;Lachat Y;Hausmann O;Hegi ME;Janzer RC;Merlo A;Van Meir EG;	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	2000	Oncogene	19	3816	10949938
2906	p.V216M	V216M	216	Val	Met	005956	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
4178	p.V216M	V216M	216	Val	Met	005956	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
549	p.V217G	V217G	217	Val	Gly	045103	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45, AIP1, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
478	p.V217G	V217G	217	Val	Gly	045103	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (GADD45, AIP1, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2905	p.P219C	P219C	219	Pro	Cys	045812	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
94	p.P219H	P219H	219	Pro	His	045111	NDBL/beta-sheets	NA	NA	TA (MDM2, IGF-BP3-boxA, PIG3, BAX); TA (WAF1) partial; upregulation (p21waf1); APO; GS partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1217	p.P219H	P219H	219	Pro	His	045111	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1258	p.P219H	P219H	219	Pro	His	045111	NDBL/beta-sheets	P 	NA	TA (WAF1 5', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, RGC, IGF-BP3, PA26) partial; TA (WAF1 3', MDM2-RE2, BAX)	No [TA (GADD45, CD95-Fas, PCNA, MDM2, RGC, NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
709	p.P219H	P219H	219	Pro	His	045111	NDBL/beta-sheets	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3427	p.P219H	P219H	219	Pro	His	045111	NDBL/beta-sheets	R 	NA	TA (RGC) partial	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3428	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	P 	NA	TA (RGC) partial	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3429	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	R 	NA	TA (RGC) partial	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
723	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
663	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
383	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	NA	TA (WAF1 5', PIG3)	TA (BAX, RGC) partial	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
324	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX), TA (PIG3) partial	NA	NA	Yes mut_H (WAF1, PIG3); No (BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1257	p.P219L	P219L	219	Pro	Leu	045112	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, RGC, IGF-BP3, PA26) partial; TA (WAF1 3', MDM2-RE2, BAX)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
614	p.P219S	P219S	219	Pro	Ser	045114	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, BAX); No (MDM2, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
550	p.P219S	P219S	219	Pro	Ser	045114	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (AIP1); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1305	p.P219S	P219S	219	Pro	Ser	045114	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4651	p.P219S	P219S	219	Pro	Ser	045114	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4399	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
134	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	P 	NA	TA (WAF1 5')	Yes [TA (WAF1 5')] moderate	p63 and p73 binding; p63 and p73 interference; hsp70 binding	NA	37°C 	Human	H1299	WT control	Co-IP, luciferase assay	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
1467	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	P 	NA	NA	Yes [TA (WAF1 5', KILLER/DR5, GML)] moderate; Yes [TA (MDM2)]	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4233	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	NA	NA	Upregulation (stathmin)	NA	37°C 	Human	HuH-7 (endo)	Endogenous Mutant	siRNA and western blot	307	Singer S;Ehemann V;Brauckhoff A;Keith M;Vreden S;Schirmacher P;Breuhahn K;	Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis	2007	Hepatology	46	759	17663418
3926	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	NA	NA	Downregulation (GADD45, PTEN, PERP); no [regulation (PIG3, WAF1, TAp73, C-JUN)]; downregulation (Gadd45, Pten)	NA	37°C 	Human	HuH-7 (endo)	Endogenous Mutant	siRNA, RT-PCR, western blot	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3875	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3876	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4179	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (WAF1, RGC) partial; TA (BAX)	NA	NA	Yes mut_H (WAF1, RGC); Yes (BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
4346	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4573	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4703	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	Yes [TA (PUMA)]; No [TA (MDM2, BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1918	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2663	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
2671	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	169	Waridel F;Estreicher A;Bron L;Flaman JM;Fontolliet C;Monnier P;Frebourg T;Iggo R;	Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract	1997	Oncogene	14	163	9010218
2744	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
2700	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
2936	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
3003	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2758	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2788	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2781	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
2860	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3096	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3183	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
195	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	NA	TA (WAF1, p53CON)	TA (RGC, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	Yes mut_H (MDM2, Cyclin G, GADD45); No (WAF1, p53CON, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
225	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1443	p.Y220C	Y220C	220	Tyr	Cys	005957	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2); Yes mut_H (GADD45)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4427	[p.Y220C;N235K;N239Y]	Y220C/N235K/N239Y	220	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4400	[p.Y220C;N235K;S240N]	Y220C/N235K/S240N	220	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML); TA (WAF1) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4347	[p.Y220C;N235K;S240N]	Y220C/N235K/S240N	220	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4401	[p.Y220C;N239Y]	Y220C/N239Y	220	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4348	[p.Y220C;N239Y]	Y220C/N239Y	220	Tyr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
2084	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	NA	NA	TR (HSP70)	NA	TA (HSP70); hsc70 binding	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2096	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2690	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	173	Nozaki M;Tada M;Matsumoto R;Sawamura Y;Abe H;Iggo RD;	Rare occurrence of inactivating p53 gene mutations in primary non- astrocytic tumors of the central nervous system: reappraisal by yeast functional assay	1998	Acta Neuropathol (Berl)	95	291	9542595
226	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
237	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
187	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4530	p.Y220H	Y220H	220	Tyr	His	005958	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4704	p.Y220S	Y220S	220	Tyr	Ser	005959	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, PUMA)]; No [TA (BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2727	p.Y220S	Y220S	220	Tyr	Ser	005959	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2898	p.Y220S	Y220S	220	Tyr	Ser	005959	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2705	p.Y220*	Y220X	220	Tyr	Stop		NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
551	p.E221G	E221G	221	Glu	Gly	045121	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1306	p.E221G	E221G	221	Glu	Gly	045121	NDBL/beta-sheets	P 	TA (RGC, WAF1 5')	NA	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1307	p.P222L	P222L	222	Pro	Leu	045125	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2832	p.P222L	P222L	222	Pro	Leu	045125	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
4180	p.P222L	P222L	222	Pro	Leu	045125	NDBL/beta-sheets	NA	TA (WAF1, BAX, RGC)	NA	NA	NA	No (WAF1); Yes mut_L (BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
552	p.P223A	P223A	223	Pro	Ala	047179	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
553	p.P223H	P223H	223	Pro	His	045130	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4514	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	TA (p53CON); upregulation (WAF1, MDM2, GADD45, PCNA, SLUG, HUNTINGTIN) ; upregulation (p21waf1) partial; downregulation (SURVIVIN)	NA	NA	Yes mut_H (p53CON); Yes mut_H (WAF1, MDM2, GADD45); Yes mut_H (p21waf1); No (PCNA, SLUG, SURVIVIN, HUNTINGTIN)	37°C 	Human	PC3	no WT control	Northern blot, RT-qPCR, western blot, temperature sensitive assay at 32°C	328	Bajgelman MC;Strauss BE;	The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53	2006	Prostate	66	1455	16741917
4151	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4153	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	37°C 	Human	PC-3	WT control	Luciferase assay, temperature sensitive assay at 32°C	290	Bajgelman MC;Strauss BE;	Development of an adenoviral vector with robust expression driven by p53	2008	Virology	371	8	18076963
4139	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
905	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	GS	No (GS)	NA	NA	37°C 	Human	PC-3	WT control	CFA	56	Gurova KV;Rokhlin OW;Budanov AV;Burdelya LG;Chumakov PM;Cohen MB;Gudkov AV;	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells	2003	Cancer Res	63	2905	12782597
907	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	GS; APO	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis	56	Gurova KV;Rokhlin OW;Budanov AV;Burdelya LG;Chumakov PM;Cohen MB;Gudkov AV;	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells	2003	Cancer Res	63	2905	12782597
26	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	TA (PCNA) supertrans	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4120	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	Upregulation (p21waf1)	NA	NA	Upregulation (IL-6) low; No (culture in soft agar)	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
3790	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	WRO (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
554	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
404	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	NA	NA	TA (RGC) partial	No [TA (RGC)]	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1308	p.P223L	P223L	223	Pro	Leu	045131	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
555	p.P223R	P223R	223	Pro	Arg	045132	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
556	p.P223T	P223T	223	Pro	Thr	045134	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4299	[p.E224G;S240R;R273H]	E224G/S240R/R273H	224	Glu	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
664	p.E224K	E224K	224	Glu	Lys	045137	NDBL/beta-sheets	P 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
715	p.E224K	E224K	224	Glu	Lys	045137	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
325	p.E224K	E224K	224	Glu	Lys	045137	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_L (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
816	p.E224K	E224K	224	Glu	Lys	045137	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
1724	[p.V225_Q331del]	V225_Q331del	225	Val	NA		NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
557	p.S227A	S227A	227	Ser	Ala		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
776	p.S227C	S227C	227	Ser	Cys	045148	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4285	[p.S227P;N239Y;G245S]	S227P/N239Y/G245S	227	Ser	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4689	p.S227T	S227T	227	Ser	Thr	045151	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4356	[p.S227T;N235K;N239Y;R249M]	S227T/N235K/N239Y/R249M	227	Ser	NA		NDBL/beta-sheets	NA	TA (KILLER/DR5); TA (WAF1) supertrans	TA (GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4319	[p.S227T;N235K;N239Y;R249M]	S227T/N235K/N239Y/R249M	227	Ser	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4361	[p.D228E;C229W;N235K;N239Y;S240R;R273L]	D228E/C229W/N235K/N239Y/S240R/R273L	228	Asp	NA		NDBL/beta-sheets	NA	TA (KILLER/DR5, WAF1)	TA (GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4330	[p.D228E;C229W;N235K;N239Y;S240R;R273L]	D228E/C229W/N235K/N239Y/S240R/R273L	228	Asp	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
3457	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	P 	NA	TA (RGC) partial	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3458	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	R 	NA	TA (RGC) partial	No [TA (RGC)]	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
817	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	P 	NA	TA (RGC) partial	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
716	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
665	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	P 	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
326	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX, PIG3) partial	NA	NA	Yes mut_L (BAX, PIG3); No (WAF1)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
384	p.D228V	D228V	228	Asp	Val	045156	NDBL/beta-sheets	NA	TA (WAF1 5', PIG3)	TA (BAX, RGC) partial	NA	NA	Yes mut_L (WAF1 5', BAX, PIG3, RGC)	33°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 33°C and 37°C	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
558	p.C229G	C229G	229	Cys	Gly	045158	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4368	[p.C229W;N239R;S240R;R273C]	C229W/N239R/S240R/R273C	229	Cys	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4333	[p.C229W;N239R;S240R;R273C]	C229W/N239R/S240R/R273C	229	Cys	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1818	p.T230I	T230I	230	Thr	Ile	005961	NDBL/beta-sheets	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
2965	p.T230I	T230I	230	Thr	Ile	005961	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
666	p.T230S	T230S	230	Thr	Ser	045165	NDBL/beta-sheets	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
717	p.T230S	T230S	230	Thr	Ser	045165	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
285	p.T230S	T230S	230	Thr	Ser	045165	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4354	[p.T230S;N239Y;G245S]	T230S/N239Y/G245S	230	Thr	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4350	[p.T230S;N239Y;G245S]	T230S/N239Y/G245S	230	Thr	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1824	p.T231A	T231A	231	Thr	Ala	045166	NDBL/beta-sheets	P 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
487	p.T231A	T231A	231	Thr	Ala	045166	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
849	p.T231I	T231I	231	Thr	Ile	045167	NDBL/beta-sheets	NA	TA (WAF1); TA(RGC, PIG3, BAX) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
496	p.T231N	T231N	231	Thr	Asn	045168	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
615	p.T231P	T231P	231	Thr	Pro		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (BAX, 14-3-3s, P53R2); No (WAF1, MDM2, GADD45)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
477	p.T231P	T231P	231	Thr	Pro		NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (AIP1, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
559	p.T231S	T231S	231	Thr	Ser	045169	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
616	p.I232F	I232F	232	Ile	Phe	045170	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
455	p.I232F	I232F	232	Ile	Phe	045170	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, AIP1, Noxa); No (BAX, GADD45, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2792	p.I232F	I232F	232	Ile	Phe	045170	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
560	p.I232M	I232M	232	Ile	Met		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
114	p.I232T	I232T	232	Ile	Thr	005962	NDBL/beta-sheets	NA	NA	TA (MDM2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
2133	p.I232T	I232T	232	Ile	Thr	005962	NDBL/beta-sheets	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
2132	p.I232T	I232T	232	Ile	Thr	005962	NDBL/beta-sheets	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
367	p.I232T	I232T	232	Ile	Thr	005962	NDBL/beta-sheets	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
4364	[p.T232V;N239H;S240R;R273H]	T232V/N239H/S240R/R273H	232	Ile	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4328	[p.T232V;N239H;S240R;R273H]	T232V/N239H/S240R/R273H	232	Ile	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4631	p.H233D	H233D	233	His	Asp	045175	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1309	p.H233R	H233R	233	His	Arg	047181	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4370	[p.H233R;N235S;N239R;S240R;R273C]	H233R/N235S/N239R/S240R/R273C	233	His	NA		NDBL/beta-sheets	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4334	[p.H233R;N235S;N239R;S240R;R273C]	H233R/N235S/N239R/S240R/R273C	233	His	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4300	[p.H233R;S240R;R273H]	H233R/S240R/R273H	233	His	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1461	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	P 	NA	TA (WAF1 5', NOXA)	Yes [TA (WAF1 5', KILLER/DR5, NOXA, PCNA)] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
95	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
617	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1218	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TRANSF-	NA	TRANSF+	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1445	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	P 	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', 14-3-3s, RGC, S100A2)	TA (type IV collagenase, B99, p53AIP1)	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]; Yes [TA (MDM2, WAF1 3', type IV collagenase)]	NA	No (type IV collagenase, B99, p53AIP1); Yes mut_H (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', 14-3-3s, RGC); Yes mut_L & H (S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
470	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, BAX, GADD45, AIP1); No (14-3-3s, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1919	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2704	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
2747	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
2831	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2916	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	192	Denk C;Butz K;Schneider A;Durst M;Hoppe-Seyler F;	p53 mutations are rare events in recurrent cervical cancer	2001	J Mol Med	79	283	11485021
3193	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3263	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
4705	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (PUMA)]; No [TA (MDM2, BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4181	p.Y234C	Y234C	234	Tyr	Cys	005963	NDBL/beta-sheets	NA	TA (BAX, RGC)	TA (WAF1)	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
3764	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	TUMOR-	GS	NA	Growth advantage (moderate); colony formation (moderate); no TUMOR+	NA	37°C 	Human	Be-13	no WT control	Proliferation assay, CFA in methylcellulose, tumorigenicity assay	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3776	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	NA	GS	NA	Growth advantage; no (colony formation)	NA	37°C 	Human	CEM	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
162	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	NA	TA (MDM2); DNAb (MDM2); upregulation (mdm2) after DNA damage; GS	NA	NA	NA	37°C 	Human	H1299	WT control	CFA, RT-PCR/WB + ChIP	27	Pan Y;Haines DS;	Identification of a tumor-derived p53 mutant with novel transactivating selectivity	2000	Oncogene	19	3095	10871862
3770	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	NA	GS	NA	Growth advantage (moderate); colony formation	NA	37°C 	Human	MOLT-4	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
96	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	NA	APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
286	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
667	p.Y234H	Y234H	234	Tyr	His	005964	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4646	p.N235D	N235D	235	Asn	Asp	047182	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4429	[p.N235K;G245D]	N235K/G245D	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4367	[p.N235K;N239W;E286K]	N235K/N239W/E286K	235	Asn	NA		NDBL/beta-sheets	NA	TA (WAF1) supertrans	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4323	[p.N235K;N239W;E286K]	N235K/N239W/E286K	235	Asn	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4459	[p.N235K;N239Y;E286K]	N235K/N239Y/E286K	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4428	[p.N235K;N239Y;G245C]	N235K/N239Y/G245C	235	Asn	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4431	[p.N235K;N239Y;G245D]	N235K/N239Y/G245D	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4432	[p.N235K;N239Y;G245S]	N235K/N239Y/G245S	235	Asn	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4452	[p.N235K;N239Y;P278L]	N235K/N239Y/P278L	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4438	[p.N235K;N239Y;R248L]	N235K/N239Y/R248L	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4435	[p.N235K;N239Y;R248Q]	N235K/N239Y/R248Q	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4441	[p.N235K;N239Y;R248W]	N235K/N239Y/R248W	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4442	[p.N235K;N239Y;R249M]	N235K/N239Y/R249M	235	Asn	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4445	[p.N235K;N239Y;R249S]	N235K/N239Y/R249S	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4447	[p.N235K;N239Y;R273C]	N235K/N239Y/R273C	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4448	[p.N235Y;N239Y;R273H]	N235K/N239Y/R273H	235	Asn	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4449	[p.N235K;N239Y;R273L]	N235K/N239Y/R273L	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4455	[p.N235K;N239Y;R280T]	N235K/N239Y/R280T	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4458	[p.N235K;N239Y;R282W]	N235K/N239Y/R282W	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4446	[p.N235K;N239Y;V272M]	N235K/N239Y/V272M	235	Asn	NA		NDBL/beta-sheets	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4450	[p.N235K;P278L]	N235K/P278L	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4436	[p.N235K;R248L]	N235K/R248L	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4433	[p.N235K;R248Q]	N235K/R248Q	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4439	[p.N235K;R248W]	N235K/R248W	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4443	[p.N235K;R249S]	N235K/R249S	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4453	[p.N235K;R280T]	N235K/R280T	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4456	[p.N235K;N239Y;R282W]	N235K/R282W	235	Asn	NA		NDBL/beta-sheets	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4647	p.N235S	N235S	235	Asn	Ser	045186	NDBL/beta-sheets	NA	TA (WAF1)	TA (MDM2, BAX, PUMA) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3372	p.Y236C	Y236C	236	Tyr	Cys	045189	NDBL/beta-sheets	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
4706	p.Y236C	Y236C	236	Tyr	Cys	045189	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA)]; No [TA (MDM2, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3264	p.Y236C	Y236C	236	Tyr	Cys	045189	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
2794	p.Y236C	Y236C	236	Tyr	Cys	045189	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3247	p.Y236D	Y236D	236	Tyr	Asp	045190	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
341	p.Y236D	Y236D	236	Tyr	Asp	045190	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1440	p.Y236D	Y236D	236	Tyr	Asp	045190	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3399	p.Y236del	Y236del	236	Tyr	NA		NDBL/beta-sheets	NA	NA	TA (PG13)	NA	NA	NA	37°C 	Human	LoVo	WT control	Luciferase assay	32	Chene P;Ory K;Ruedi D;Soussi T;Hegi ME;	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome	1999	Int J Cancer	82	17	10360814
174	p.Y236del	Y236del	236	Tyr	NA		NDBL/beta-sheets	NA	TETR	TA (WAF1, PG13)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	32	Chene P;Ory K;Ruedi D;Soussi T;Hegi ME;	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome	1999	Int J Cancer	82	17	10360814
3042	p.Y236H	Y236H	236	Tyr	His	045192	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2793	p.Y236S	Y236S	236	Tyr	Ser	045194	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
287	p.Y236S	Y236S	236	Tyr	Ser	045194	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
668	p.Y236S	Y236S	236	Tyr	Ser	045194	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4014	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (RGC); APO	NA	NA	No (RGC); No (APO)	37°C 	Human	Hep3B	WT control	CAT assay, FACS analysis, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4007	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (RGC)	NA	NA	No (RGC)	37°C 	Human	HepG2, MCF-7, Saos-2	WT control	CAT assay, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
2085	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TR (HSP70)	NA	TA (HSP70); hsc70 binding	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
4193	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	Downregulation (DNMT1); DNAb (DNMT1)	NA	No [upregulation (DNMT1)]; no [downregulation (p16)]	NA	37°C 	Human	WTK1 (endo)	Endogenous Mutant	siRNA, western blot, ChIP assay	296	Guo Z;Tsai MH;Shiao YH;Chen LH;Wei ML;Lv X;Gius D;Little JB;Mitchell JB;Chuang EY;	DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16(ink4A) down-regulation	2008	J Biomed Sci 	15	163	18038118
3964	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	TRANSF-	NA	NA	No (TRANSF+)	NA	NA   	Other	BRK	WT control	Transformation assay	254	Farrell PJ;Allan GJ;Shanahan F;Vousden KH;Crook T;	p53 is frequently mutated in Burkitt's lymphoma cell lines	1991	EMBO J 	10	2879	1915267
2097	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
1920	p.M237I	M237I	237	Met	Ile	005965	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2969	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3109	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3098	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3185	p.M237I	M237I	237	Met	Ile	005965	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1388	p.M237I	M237I	237	Met	Ile	005965	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
791	p.M237I	M237I	237	Met	Ile	005965	L2/L3	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
4643	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, PUMA, WAF1)]; No [TA (BAX)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4574	p.M237I	M237I	237	Met	Ile	005965	L2/L3	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4182	p.M237K	M237K	237	Met	Lys	045195	L2/L3	NA	TA (WAF1)	TA (BAX); TA (RGC) partial	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
3275	p.M237K	M237K	237	Met	Lys	045195	L2/L3	NA	NA	TA (RGC) partial	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	215	Smardova J;Pavlova S;Svitakova M;Grochova D;Ravcukova B;	Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124	2005	Oncol Rep 	14	901	16142349
3094	p.M237K	M237K	237	Met	Lys	045195	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3741	p.M237L	M237L	237	Met	Leu	045196	L2/L3	NA	NA	TUMOR-	NA	TUMOR+	NA	37°C 	Human	LNCaP	no WT control	Tumorigenicity assay	244	Perryman LA;Blair JM;Kingsley EA;Szymanska B;Ow KT;Wen VW;MacKenzie KL;Vermeulen PB;Jackson P;Russell PJ;	Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo	2006	Biochem Biophys Res Commun 	345	1207	16723121
27	p.M237L	M237L	237	Met	Leu	045196	L2/L3	NA	TA (PCNA) supertrans; GS	NA	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
561	p.M237L	M237L	237	Met	Leu	045196	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
405	p.M237L	M237L	237	Met	Leu	045196	L2/L3	NA	NA	TA (RGC) partial	No [TA (RGC)]	NA	Yes mut_L (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1311	p.M237L	M237L	237	Met	Leu	045196	L2/L3	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1464	p.M237R	M237R	237	Met	Arg	045197	L2/L3	P 	TA (WAF1 5')	TA (NOXA) partial	NA	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4013	p.M237R	M237R	237	Met	Arg	045197	L2/L3	NA	TA (RGC)	APO partial	NA	NA	No (RGC); No (APO)	37°C 	Human	Hep3B	WT control	CAT assay, FACS analysis, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4009	p.M237R	M237R	237	Met	Arg	045197	L2/L3	NA	TA (RGC)	NA	NA	NA	Yes mut_L (RGC)	37°C 	Human	HepG2	WT control	CAT assay, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4010	p.M237R	M237R	237	Met	Arg	045197	L2/L3	NA	NA	TA (RGC) partial	NA	NA	NA	32°C 	Human	HepG2	WT control	CAT assay	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4006	p.M237R	M237R	237	Met	Arg	045197	L2/L3	NA	TA (RGC)	NA	NA	NA	No (RGC)	37°C 	Human	MCF-7, Saos-2	WT control	CAT assay, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
3248	p.M237R	M237R	237	Met	Arg	045197	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01); Yes mut_H (BAI1)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1457	p.M237R	M237R	237	Met	Arg	045197	L2/L3	P 	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, RGC, S100A2)	TA (p53AIP1)	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', B99, p53AIP1); Yes mut_H (type IV collagenase, 14-3-3s, RGC); Yes mut_L & H (Cyclin G, WAF1 3', S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
459	p.M237R	M237R	237	Met	Arg	045197	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2); No (BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1310	p.M237T	M237T	237	Met	Thr	045198	L2/L3	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3053	p.M237V	M237V	237	Met	Val	045199	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
3112	p.C238F	C238F	238	Cys	Phe	005966	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3218	p.C238F	C238F	238	Cys	Phe	005966	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2717	p.C238F	C238F	238	Cys	Phe	005966	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
1415	p.C238F	C238F	238	Cys	Phe	005966	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4575	p.C238F	C238F	238	Cys	Phe	005966	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4607	p.C238G	C238G	238	Cys	Gly	045200	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX)]; No [TA (PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3992	p.C238R	C238R	238	Cys	Arg	045201	L2/L3	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
288	p.C238R	C238R	238	Cys	Arg	045201	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1921	p.C238R	C238R	238	Cys	Arg	045201	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3036	p.C238R	C238R	238	Cys	Arg	045201	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2911	p.C238R	C238R	238	Cys	Arg	045201	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
1869	p.C238S	C238S	238	Cys	Ser	045202	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
4608	p.C238S	C238S	238	Cys	Ser	045202	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA, WAF1)]; No [TA (MDM2)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
289	p.C238W	C238W	238	Cys	Trp	045203	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
316	p.C238*	C238X	238	Cys	Stop		L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3344	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	Upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot	230	Ferrone M;Perrone F;Tamborini E;Paneni MS;Fermeglia M;Suardi S;Pastore E;Delia D;Pierotti MA;Pricl S;Pilotti S;	Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y)	2006	Mol Cancer Ther 	5	1467	16818505
3966	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	NA	TRANSF- (partial)	NA	No (TRANSF+)	NA	NA   	Other	BRK	WT control	Transformation assay	254	Farrell PJ;Allan GJ;Shanahan F;Vousden KH;Crook T;	p53 is frequently mutated in Burkitt's lymphoma cell lines	1991	EMBO J 	10	2879	1915267
3991	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
4609	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1400	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
878	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
1922	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2940	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	194	Shibata T;Nakata D;Chiba I;Yamashita T;Abiko Y;Tada M;Moriuchi T;	Detection of TP53 mutation in ameloblastoma by the use of a yeast functional assay	2002	J Oral Pathol Med	31	534	12269992
2871	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3202	p.C238Y	C238Y	238	Cys	Tyr	005967	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3113	p.N239D	N239D	239	Asn	Asp	045204	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3092	p.N239D	N239D	239	Asn	Asp	045204	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2677	p.N239D	N239D	239	Asn	Asp	045204	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	170	Mihara K;Miyazaki M;Kondo T;Fushimi K;Tsuji T;Inoue Y;Fukaya K;Ishioka C;Namba M;	Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory	1997	Acta Med Okayama	51	261	9359923
4576	p.N239D	N239D	239	Asn	Asp	045204	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
368	p.N239del	N239del	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
4353	[p.N239F;G245S]	N239F/G245S	239	Asn	NA		L2/L3	NA	TA (KILLER/DR5, GML); TA (WAF1) supertrans	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4325	[p.N239F;G245S]	N239F/G245S	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4366	[p.N239F;S240R;R273C]	N239F/S240R/R273C	239	Asn	NA		L2/L3	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4327	[p.N239F;S240R;R273C]	N239F/S240R/R273C	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
875	p.N239K	N239K	239	Asn	Lys	045207	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
2955	p.N239K	N239K	239	Asn	Lys	045207	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
4357	[p.N239L;S240R;R273C]	N239L/S240R/R273C	239	Asn	NA		L2/L3	NA	TA (KILLER/DR5); TA (WAF1) supertrans	TA (GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4326	[p.N239L;S240R;R273C]	N239L/S240R/R273C	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4369	[p.N239R;S240R;R273C]	N239R/S240R/R273C	239	Asn	NA		L2/L3	NA	TA (KILLER/DR5)	TA (GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4324	[p.N239R;S240R;R273C]	N239R/S240R/R273C	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
2183	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	NA	NA	TA (BAX); upregulation (BAX)	Yes [TA (BAX)]; Yes [upregulation (BAX)]	NA	NA	37°C 	Human	HS68	WT control	Luciferase assay, northern blot	165	Han Z;Boyle DL;Shi Y;Green DR;Firestein GS;	Dominant-negative p53 mutations in rheumatoid arthritis	1999	Arthritis Rheum	42	1088	10366100
2799	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2752	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	180	Gong ZY;Wong KW;Li Y;Mao YR;Lung ML;	p53 inactivating mutations in chinese breast carcinomas	2000	Oncol Rep	7	381	10671690
3222	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1419	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
290	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
669	p.N239S	N239S	239	Asn	Ser	045208	L2/L3	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4577	p.N239T	N239T	239	Asn	Thr	045209	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4403	[p.N239W;V272M]	N239W/V272M	239	Asn	NA		L2/L3	NA	TA (WAF1) supertrans	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4322	[p.N239W;V272M]	N239W/V272M	239	Asn	NA		L2/L3	NA	TA (p53CON) supertrans	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4387	[p.N239Y;G245C]	N239Y/G245C	239	Asn	NA		L2/L3	NA	TA (WAF1) supertrans	TA (KILLER/DR5, GML) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4341	[p.N239Y;G245C]	N239Y/G245C	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4430	[p.N239Y;G245D]	N239Y/G245D	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
1339	[p.N239Y;G245S]	N239Y/G245S	239	Asn	NA		L2/L3	NA	TA (WAF1)	TA (PG13) partial	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1338	[p.N239Y;G245S]	N239Y/G245S	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
4451	[p.N239Y;P278L]	N239Y/P278L	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4437	[p.N239Y;R248L]	N239Y/R248L	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4434	[p.N239Y;R248Q]	N239Y/R248Q	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4440	[p.N239Y;R248W]	N239Y/R248W	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4374	[p.N239Y;R249M]	N239Y/R249M	239	Asn	NA		L2/L3	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4320	[p.N239Y;R249M]	N239Y/R249M	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4444	[p.N239Y;R249S]	N239Y/R249S	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4454	[p.N239Y;R280T]	N239Y/R280T	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4457	[p.N239Y;R282W]	N239Y/R282W	239	Asn	NA		L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Yeast	Yeast	no WT control	Growth selection	322	Danziger SA;Zeng J;Wang Y;Brachmann RK;Lathrop RH;	Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants	2007	Bioinformatics 	23		17646286
4360	[p.N239Y;S240R;R273L]	N239Y/S240R/R273L	239	Asn	NA		L2/L3	NA	NA	TA (KILLER/DR5, GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4331	[p.N239Y;S240R;R273L]	N239Y/S240R/R273L	239	Asn	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1259	p.S240G	S240G	240	Ser	Gly	045212	L2/L3	P 	NA	TA (WAF1 5', P53R2, GADD45, CD95-Fas, PCNA, AIP1, MDM2, MDM2-RE2, IGF-BP3, PA26) partial; TA (14-3-3s, RGC, WAF1 3', BAX)	Yes [TA (P53R2, WAF1 3')] moderate; No [TA (GADD45, CD95-Fas, MDM2, NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2844	p.S240G	S240G	240	Ser	Gly	045212	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
3385	p.S240I	S240I	240	Ser	Ile	005968	L2/L3	NA	Growth inhibition	NA	NA	NA	NA	37°C 	Human	HeLa	WT control	MTT assay	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
145	p.S240I	S240I	240	Ser	Ile	005968	L2/L3	NA	GS	TA (MDM2, WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay, CFA	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
888	p.S240N	S240N	240	Ser	Asn	045213	L2/L3	NA	TA (WAF1, MDM2, BAX); GS; upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, western blot	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
851	p.S240N	S240N	240	Ser	Asn	045213	L2/L3	NA	TA (WAF1); TA (RGC, PIG3, BAX) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1341	[p.S240N;G245S]	S240N/G245S	240	Ser	NA		L2/L3	NA	TA (PG13, WAF1)	NA	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1340	[p.S240N;G245S]	S240N/G245S	240	Ser	NA		L2/L3	NA	NA	TA (p53CON) partial	NA	NA	Yes mut_L (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
389	p.S240R	S240R	240	Ser	Arg	045215	L2/L3	NA	GS; DNAb (MDM2)	TA (WAF1, BAX); TA (MDM2) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
97	p.S240R	S240R	240	Ser	Arg	045215	L2/L3	NA	NA	TA (WAF1, MDM2, IGF-BP3-boxA, PIG3, BAX); upregulation (p21waf1); GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1219	p.S240R	S240R	240	Ser	Arg	045215	L2/L3	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
451	p.S240R	S240R	240	Ser	Arg	045215	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4363	[p.S240R;R273H]	S240R/R273H	240	Ser	NA		L2/L3	NA	NA	TA (KILLER/DR5, WAF1) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4301	[p.S240R;R273H]	S240R/R273H	240	Ser	NA		L2/L3	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1875	[p.S240V;S241_M243del]	S240V/S241_M243del	240	Ser	NA		L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
1923	p.S241A	S241A	241	Ser	Ala	033036	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1729	p.S241A	S241A	241	Ser	Ala	033036	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
2708	p.S241A	S241A	241	Ser	Ala	033036	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
2748	p.S241A	S241A	241	Ser	Ala	033036	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
4578	p.S241C	S241C	241	Ser	Cys	045217	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4690	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2842	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
671	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	P 	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
724	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
342	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
292	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
818	p.S241F	S241F	241	Ser	Phe	005969	L2/L3	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3272	p.S241P	S241P	241	Ser	Pro	045218	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	215	Smardova J;Pavlova S;Svitakova M;Grochova D;Ravcukova B;	Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124	2005	Oncol Rep 	14	901	16142349
291	p.S241T	S241T	241	Ser	Thr	047183	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
670	p.S241T	S241T	241	Ser	Thr	047183	L2/L3	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4691	p.S241T	S241T	241	Ser	Thr	047183	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4579	p.C242F	C242F	242	Cys	Phe	005970	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
175	p.C242F	C242F	242	Cys	Phe	005970	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1401	p.C242F	C242F	242	Cys	Phe	005970	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3203	p.C242F	C242F	242	Cys	Phe	005970	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3091	p.C242F	C242F	242	Cys	Phe	005970	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2716	p.C242F	C242F	242	Cys	Phe	005970	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
3047	p.C242R	C242R	242	Cys	Arg	045221	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2698	p.C242S	C242S	242	Cys	Ser	045222	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
4580	p.C242S	C242S	242	Cys	Ser	045222	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
3877	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3878	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4581	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4610	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA)]; No [TA (WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2719	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2847	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
1260	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	Yes [TA (WAF1 5', WAF1 3', GADD45, CD95-Fas, PCNA, MDM2, RGC, IGF-BP3, BAX, NOXA)] moderate	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
819	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
239	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	P 	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
188	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
207	p.C242Y	C242Y	242	Cys	Tyr	045224	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
3035	p.M243K	M243K	243	Met	Lys	045226	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2839	p.M243L	M243L	243	Met	Leu	045227	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
4582	p.M243T	M243T	243	Met	Thr	045229	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
438	p.M243V	M243V	243	Met	Val	045230	L2/L3	P 	TA (GADD45, MDM2, P53R2, WAF1)	TA (BAX); TA (14-3-3s) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	47	Kato S;Han SY;Liu W;Otsuka K;Shibata H;Kanamaru R;Ishioka C;	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis	2003	Proc Natl Acad Sci U S A	100	8424	12826609
437	p.M243V	M243V	243	Met	Val	045230	L2/L3	P 	TA (GADD45, P53R2)	TA (BAX, MDM2); TA (WAF1, 14-3-3s) partial	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Fluorescence intensity	47	Kato S;Han SY;Liu W;Otsuka K;Shibata H;Kanamaru R;Ishioka C;	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis	2003	Proc Natl Acad Sci U S A	100	8424	12826609
3044	p.G244A	G244A	244	Gly	Ala	047186	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2706	p.G244C	G244C	244	Gly	Cys	045231	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
1620	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	NA	NA	TA (PG13, WAF1) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1726	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
1924	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1925	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3211	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
343	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1408	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1312	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	P 	NA	TA (RGC, WAF1 5', WAF1 3', GADD45, CD95-Fas, PCNA, MDM2, BAX, PUMA, AIP1, NOXA); TA (p53CON, P53R2) partial	NA	NA	Yes mut_L (WAF1 5')	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4622	p.G244D	G244D	244	Gly	Asp	045232	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, WAF1)]; No [TA (PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1623	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (PG13, WAF1) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
2684	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
2715	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
3209	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2759	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2789	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
1406	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
869	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
344	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
293	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
672	p.G244S	G244S	244	Gly	Ser	045235	L2/L3	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
2713	p.G244V	G244V	244	Gly	Val	045236	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
4623	p.G244V	G244V	244	Gly	Val	045236	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, WAF1)]; No [TA (PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4583	p.G244V	G244V	244	Gly	Val	045236	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
3025	p.G245A	G245A	245	Gly	Ala	005971	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
396	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (WAF1, BAX); GS	Yes [TA (BAX)]; No [TA (WAF1)]; No (GS)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
4402	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
3404	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (WAF1, BAX); APO	Yes [TA (BAX)]; Yes (APO); No [TA (WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
3954	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]; No (GS)	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, CFA	250	Frebourg T;Sadelain M;Ng YS;Kassel J;Friend SH;	Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype	1994	Cancer Res 	54	878	8313374
3154	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
1675	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	Ag T binding	GS	NA	hsc70 binding (weak)	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
1858	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
2041	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
3090	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2818	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
4349	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4624	p.G245C	G245C	245	Gly	Cys	005972	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA, WAF1)]; No [TA (MDM2)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4520	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (MASPIN)	NA	NA	NA	37°C 	Human	PC3, LNCaP, DU-145	WT control	Luciferase assay	330	Zou Z;Gao C;Nagaich AK;Connell T;Saito S;Moul JW;Seth P;Appella E;Srivastava S;	p53 regulates the expression of the tumor suppressor gene maspin	2000	J Biol Chem 	275	6051	10692390
3879	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	R 	NA	NA	NA	p73 interference; p73 binding; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, co-IP, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3880	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	P 	NA	NA	NA	p73 interference (moderate); no (p73 binding); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, co-IP, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4238	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	No (CDDP response)	(OXA sensitivity) partial	NA	NA	NA	37°C 	Human	V9P (endo)	Endogenous Mutant	siRNA and oxaliplatin or cisplatin treatment	310	Toscano F;Parmentier B;Fajoui ZE;Estornes Y;Chayvialle JA;Saurin JC;Abello J;	p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells	2007	Biochem Pharmacol 	74	392	17559811
3994	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	NA	NA	TRANSF+ (low)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
3432	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4240	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (PG13, RGC, BAX, WAF1)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	FASAY	310	Toscano F;Parmentier B;Fajoui ZE;Estornes Y;Chayvialle JA;Saurin JC;Abello J;	p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells	2007	Biochem Pharmacol 	74	392	17559811
4525	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4625	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA, WAF1)]; No [TA (MDM2)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2782	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2837	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
3028	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2948	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3189	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2699	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	177	Leung CS;Lung ML;	Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assays	1999	Anticancer Res	19	625	10226610
2674	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	169	Waridel F;Estreicher A;Bron L;Flaman JM;Fontolliet C;Monnier P;Frebourg T;Iggo R;	Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract	1997	Oncogene	14	163	9010218
1926	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
241	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
227	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
208	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
203	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
196	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (RGC, p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
189	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
179	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1390	p.G245D	G245D	245	Gly	Asp	005973	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5',  WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1432	p.G245R	G245R	245	Gly	Arg	045238	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
180	p.G245R	G245R	245	Gly	Arg	045238	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
3238	p.G245R	G245R	245	Gly	Arg	045238	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3799	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	AML2 (endo)	Endogenous Mutant	EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
3491	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45); TA (CyclinG) partial; TR (hTERT) partial	NA	No [upregulation (MDR-1)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3492	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT) partial	NA	No [upregulation (MDR-1)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3905	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3906	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
4359	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (KILLER/DR5) partial; TA (GML)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1782	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1783	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3728	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1) moderate; androgen-independent cell growth	NA	37°C 	Human	LNCaP	no WT control	Western blot, proliferation assay	52	Nesslinger NJ;Shi XB;deVere White RW;	Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53	2003	Cancer Res	63	2228	12727844
3735	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	NA	Upregulation (RLN2); no [regulation (H2relaxin)]	NA	37°C 	Human	LNCaP	no WT control	RT-PCR, western blot	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
4131	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4143	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
3744	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	NA	Topoisomerase I and hsp70 binding; no (topoisomerase II binding); gene amplification	NA	37°C 	Human	Saos-2	no WT control	Co-IP	13	El Hizawi S;Lagowski JP;Kulesz-Martin M;Albor A;	Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins	2002	Cancer Res	62	3264	12036943
3881	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3882	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4492	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	TETR	TA (WAF1, MDM2, GADD45, BAX, 14-3-3s); TA (P53R2) partial; APO partial	No [TA (WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, cross-link of proteins with glutaraldehyde + SDS/PAGE	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
3284	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	GS; APO; GA; UV sensitivity; gamma-irradiation resistance	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
28	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1335	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (PG13, WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
3993	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	NA	TRANSF+ (low)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
3430	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3431	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4626	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4536	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4584	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
1346	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1386	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
181	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
190	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
209	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
228	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
243	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
254	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
3276	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	215	Smardova J;Pavlova S;Svitakova M;Grochova D;Ravcukova B;	Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124	2005	Oncol Rep 	14	901	16142349
3182	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2925	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2974	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	196	Fulci G;Labuhn M;Maier D;Lachat Y;Hausmann O;Hegi ME;Janzer RC;Merlo A;Van Meir EG;	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	2000	Oncogene	19	3816	10949938
2964	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2845	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
1927	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2733	p.G245S	G245S	245	Gly	Ser	005974	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
1798	[p.G245S;K292E]	G245S/K292E	245	Gly	NA		L2/L3	R 	NA	TA (PG13) partial	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
4511	[p.G245S;L344P]	G245S/L344P	245	Gly	NA		L2/L3	NA	NA	TETR (monomer)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Cross-link of proteins with glutaraldehyde + SDS/PAGE	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
3834	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	NA	NA	p38 and p42 binding	NA	37°C 	Human	HT-3 (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
115	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (MDM2, PG13); GS	No [TA (PG13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
2129	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
2128	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
3995	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
4627	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1739	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
1928	p.G245V	G245V	245	Gly	Val	005975	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2855	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2790	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2754	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
3266	p.G245V	G245V	245	Gly	Val	005975	L2/L3	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
262	p.G245V	G245V	245	Gly	Val	005975	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
143	p.M246I	M246I	246	Met	Ile	045239	L2/L3	NA	NA	DNAb (PIG3); TA (PIG3); TA (MDM2) partial; TR (RSV) partial; APO	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, TUNEL assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
1625	p.M246I	M246I	246	Met	Ile	045239	L2/L3	NA	TA (WAF1) supertrans	TA (PG13) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
3215	p.M246I	M246I	246	Met	Ile	045239	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2774	p.M246I	M246I	246	Met	Ile	045239	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
345	p.M246I	M246I	246	Met	Ile	045239	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1412	p.M246I	M246I	246	Met	Ile	045239	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]; No [TA (GML)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
820	p.M246L	M246L	246	Met	Leu	044020	L2/L3	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
294	p.M246L	M246L	246	Met	Leu	044020	L2/L3	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
673	p.M246L	M246L	246	Met	Leu	044020	L2/L3	P 	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
1800	p.M246R	M246R	246	Met	Arg	005976	L2/L3	P 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
3239	p.M246R	M246R	246	Met	Arg	005976	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
346	p.M246R	M246R	246	Met	Arg	005976	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
749	p.M246R	M246R	246	Met	Arg	005976	L2/L3	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1433	p.M246R	M246R	246	Met	Arg	005976	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4585	p.M246T	M246T	246	Met	Thr	005977	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4021	p.M246V	M246V	246	Met	Val	005978	L2/L3	NA	NA	CDDP and gamma-irradiation sensitivity	NA	NA	NA	37°C 	Human	GM607	no WT control	Cisplatin or gamma-irradiation treatment + FACS analysis	267	Piovesan B;Pennell N;Berinstein NL;	Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity	1998	Oncogene	17	2339	9811465
618	p.M246V	M246V	246	Met	Val	005978	L2/L3	NA	NA	NA	NA	NA	No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2161	p.M246V	M246V	246	Met	Val	005978	L2/L3	P 	NA	NA	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	Transformation assay	162	Slingerland JM;Benchimol S;	Transforming activity of mutant human p53 alleles	1991	J Cell Physiol	148	391	1918170
3213	p.M246V	M246V	246	Met	Val	005978	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2812	p.M246V	M246V	246	Met	Val	005978	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2926	p.M246V	M246V	246	Met	Val	005978	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
562	p.M246V	M246V	246	Met	Val	005978	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (P53R2); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1410	p.M246V	M246V	246	Met	Val	005978	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1313	p.M246V	M246V	246	Met	Val	005978	L2/L3	P 	NA	TA (RGC, WAF1 5')	NA	NA	Yes mut_L (WAF1 5')	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4644	p.M246V	M246V	246	Met	Val	005978	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1976	p.N247I	N247I	247	Asn	Ile	005980	L2/L3	NA	NA	TA (RGC, p53CON)	NA	NA	No (RGC); Yes mut_H (p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
3720	p.N247I	N247I	247	Asn	Ile	005980	L2/L3	NA	TA (RGC)	NA	NA	NA	NA	30°C 	Human	Saos-2	no WT control	Luciferase assay	240	Buckbinder L;Talbott R;Seizinger BR;Kley N;	Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes	1994	Proc Natl Acad Sci U S A	91	10640	7938006
4055	p.N247I	N247I	247	Asn	Ile	005980	L2/L3	NA	NA	NA	NA	DOX and CDDP sensitivity	NA	37°C 	Human	TCCSUP	no WT control	Treatment with cisplatin or doxorubicin	277	Chang FL;Lai MD;	Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells	2001	J Urol 	166	304	11435891
370	p.N247I	N247I	247	Asn	Ile	005980	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
1817	p.N247S	N247S	247	Asn	Ser	045243	L2/L3	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
468	p.N247Y	N247Y	247	Asn	Tyr	045244	L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2); No (WAF1, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4148	p.R248G	R248G	248	Arg	Gly	005981	L2/L3	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4136	p.R248G	R248G	248	Arg	Gly	005981	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4123	p.R248G	R248G	248	Arg	Gly	005981	L2/L3	NA	Upregulation (p21waf1)	NA	NA	No [upregulation (IL-6)]; No (culture in soft agar)	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
29	p.R248G	R248G	248	Arg	Gly	005981	L2/L3	NA	TA (PCNA)	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
255	p.R248G	R248G	248	Arg	Gly	005981	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1741	p.R248G	R248G	248	Arg	Gly	005981	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
4042	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	NA	JNK, Mdm2 and p14ARF binding	NA	NA	NA	NA	37°C 	Human	NCI-H322 (endo)	Endogenous Mutant	Co-IP	274	Buschmann T;Minamoto T;Wagle N;Fuchs SY;Adler V;Mai M;Ronai Z;	Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability	2000	J Mol Biol 	295	1009	10656807
73	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	R 	NA	TA (WAF1); GS; TR (C-JUN) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
1395	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2819	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2756	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2857	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3195	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3089	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
4586	p.R248L	R248L	248	Arg	Leu	005982	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
74	p.R248P	R248P	248	Arg	Pro	045246	L2/L3	R 	NA	TA (WAF1); GS; TR (C-JUN)	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
3114	p.R248P	R248P	248	Arg	Pro	045246	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3762	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	GS; TUMOR-	NA	Growth advantage; colony formation; TUMOR+	NA	37°C 	Human	Be-13	no WT control	Proliferation assay, CFA in methylcellulose, tumorigenicity assay	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3774	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	GS	NA	Growth advantage; colony formation	NA	37°C 	Human	CEM	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
1465	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	P 	NA	NA	Yes [TA (KILLER/DR5, WAF1 5', NOXA, PCNA)]	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4061	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	NA	NA	DOX and TAX resistance; upregulation (P-gp)	NA	37°C 	Human	Hep3B	no WT control	Western blot, treatment with doxorubicin or paclitaxel + CFA and FACS analysis	280	Chan KT;Lung ML;	Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line	2004	Cancer Chemother Pharmacol 	53	519	15004724
4231	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	DNAb (p53CON) partial; upregulation (WAF1, PUMA, COX-2)	NA	In vitro PRIMA-1 sensitivity; No (in vivo PRIMA-1 sensitivity); No (PRIMA-1 induced reactivation)	NA	37°C 	Human	Hep3B	no WT control	TransAM assay, RT-qPCR, PRIMA-1 treatment + FACS analysis, xenograft	306	Shi H;Lambert J;Hautefeuille A;Bykov V;Wiman K;Hainaut P;Caron de FC;	In vitro and in vivo cytotoxic effects of PRIMA-1 on Hepatocellular Carcinoma cells expressing mutant p53ser249	2007	Carcinogenesis			18048389
3768	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	GS	NA	Growth advantage; colony formation	NA	37°C 	Human	MOLT-4	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3467	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	APO; TA (BAX); GS	NA	Growth advantage	NA	37°C 	Human	Saos-2	WT control	FACS analysis, luciferase assay	62	Lomax ME;Barnes DM;Hupp TR;Picksley SM;Camplejohn RS;	Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	1998	Oncogene	17	643	9704930
4470	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
2086	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TR (HSP70)	NA	TA (HSP70); no (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
3160	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
75	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	R 	NA	TA (WAF1); GS; TR (C-JUN) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
3305	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	Upregulation (WAF1, BAX); APO	NA	Upregulation (GEF-H1)	NA	37°C 	Human	U2OS	WT control	RT-qPCR	221	Mizuarai S;Yamanaka K;Kotani H;	Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells	2006	Cancer Res 	66	6319	16778209
3965	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TRANSF- (partial)	NA	No (TRANSF+)	NA	NA   	Other	BRK	WT control	Transformation assay	254	Farrell PJ;Allan GJ;Shanahan F;Vousden KH;Crook T;	p53 is frequently mutated in Burkitt's lymphoma cell lines	1991	EMBO J 	10	2879	1915267
3996	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
2098	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2042	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
2649	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	167	Tada M;Iggo RD;Ishii N;Shinohe Y;Sakuma S;Estreicher A;Sawamura Y;Abe H;	Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay	1996	Int J Cancer	67	447	8707423
2738	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
2714	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2685	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
1931	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3273	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	215	Smardova J;Pavlova S;Svitakova M;Grochova D;Ravcukova B;	Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124	2005	Oncol Rep 	14	901	16142349
3176	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2846	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
2760	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2803	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2896	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2943	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2932	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
3027	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
218	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1381	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3433	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3434	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	P 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4524	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	NA	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4670	p.R248Q	R248Q	248	Arg	Gln	005983	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4472	[p.R248Q;A364_D393del]	R248Q/A364_D393del	248	Arg	NA		L2/L3	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4471	[p.R248Q;T284R]	R248Q/T284R	248	Arg	NA		L2/L3	NA	GS	TA (p53CON)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4473	[p.R248Q;T284R;A364_D393del]	R248Q/T284R/A364_D393del	248	Arg	NA		L2/L3	NA	GS	TA (p53CON) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
3754	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Downregulation (PTHRP) moderate	NA	37°C 	Human	A253	no WT control	RNase protection assay	66	Foley J;Wysolmerski JJ;Broadus AE;Philbrick WM;	Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53	1996	Cancer Res	56	4056	8752179
3986	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	No (culture in soft agar or plastic, TUMOR+, TGF-beta or gamma-irradiation resistance)	NA	37°C 	Human	AA/C1	no WT control	CFA on plastic and in agar, tumorigenicity assay, TGF-beta or gamma-irradiation treatment	260	Williams AC;Miller JC;Collard TJ;Bracey TS;Cosulich S;Paraskeva C;	Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation	1995	Oncogene	11	141	7624121
1952	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	TA (HIV)	NA	37°C 	Human	Akata	WT control	CAT assay	133	Gualberto A;Hixon ML;Finco TS;Perkins ND;Nabel GJ;Baldwin AS;	A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat	1995	Mol Cell Biol	15	3450	7760842
3939	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (MDR-1)	NA	TA (MDR-1); no [TA (MRP1)]	NA	37°C 	Human	CACO2	no WT control	Luciferase assay	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
397	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1, BAX); GS	Yes [TA (BAX)]; No [TA (WAF1); No (GS)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
42	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	Calu-6, VAMT-1	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
4113	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Mre11 binding	NA	37°C 	Human	Colo320 (endo)	Endogenous Mutant	Co-IP	289	Song H;Hollstein M;Xu Y;	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM	2007	Nat Cell Biol 	9	573	17417627
1779	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (eIF4E)	NA	TA (eIF4E)	NA	37°C 	Human	EU-4	WT control	Luciferase assay	114	Zhu N;Gu L;Findley HW;Zhou M;	Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53	2005	Biochem Biophys Res Commun	335	1272	16112647
1684	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	BLM and WRN binding	NA	NA	NA	NA	37°C 	Human	GM01310	WT control	IP	93	Yang Q;Zhang R;Wang XW;Spillare EA;Linke SP;Subramanian D;Griffith JD;Li JL;Hickson ID;Shen JC;Loeb LA;Mazur SJ;Appella E;Brosh RM;Karmakar P;Bohr VA;Harris CC;	The processing of Holliday junctions by BLM and WRN helicases is regulated by p53	2002	J Biol Chem	277	31980	12080066
1481	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Mdm2 stabilization	NA	37°C 	Human	H1299	WT control	Western blot, IF	80	Peng Y;Chen L;Li C;Lu W;Agrawal S;Chen J;	Stabilization of the MDM2 oncoprotein by mutant p53	2001	J Biol Chem	276	6874	11152666
1493	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	MBP1 binding (low affinity)	NA	37°C 	Human	H1299	WT control	Co-IP	81	Gallagher WM;Argentini M;Sierra V;Bracco L;Debussche L;Conseiller E;	MBP1: a novel mutant p53-specific protein partner with oncogenic properties	1999	Oncogene	18	3608	10380882
1749	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	DNp63alpha interference	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	106	Fei JW;Wei QX;Angel P;de Villiers EM;	Differential enhancement of a cutaneous HPV promoter by DeltaNP63alpha, Jun and mutant p53	2005	Cell Cycle	4	689	15846070
1784	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1785	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1950	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1 5', BAX); APO	Yes [TA (WAF1 5')]; Yes [TA (BAX)] moderate; Yes (APO)	p73 interference (moderate)	NA	37°C 	Human	H1299	WT control	Luciferase assay, FACS analysis	132	Di Como CJ;Gaiddon C;Prives C;	p73 function is inhibited by tumor-derived p53 mutants in mammalian cells	1999	Mol Cell Biol	19	1438	9891077
3310	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RPS27L)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	222	He H;Sun Y;	Ribosomal protein S27L is a direct p53 target that regulates apoptosis	2006	Oncogene			17057733
1178	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	NA	NA	p63 and p73 binding; hsp70 binding (low affinity)	NA	37°C 	Human	H1299	WT control	co-IP	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
898	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	APO	NA	NA	NA	37°C 	Human	H1299	WT control	FACS analysis	53	Friedlander P;Haupt Y;Prives C;Oren M;	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis	1996	Mol Cell Biol	16	4961	8756655
922	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	GS; GA	Yes [upregulation (p21waf1)]; Yes (GA) partial	NA	NA	37°C 	Human	H1299	WT control	Western blot, FACS analysis	60	Willis A;Jung EJ;Wakefield T;Chen X;	Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes	2004	Oncogene	23	2330	14743206
4199	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Promotion of transcriptional TGF-beta1 response	NA	Repression of transcriptional TGF-beta1 response	NA	37°C 	Human	H1299	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
4059	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	CDDP and X-ray radiation sensitivity	NA	No (CDDP and X-ray radiation resistance)	NA	37°C 	Human	H1299	WT control	Treatment with cisplatin or X-ray irradiation	279	Ohnishi K;Ota I;Takahashi A;Yane K;Matsumoto H;Ohnishi T;	Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck	2002	Apoptosis 	7	367	12101396
4083	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	Upregulation (p21waf1); GS; GA; APO partial	NA	No (p73beta interference, p73beta binding)	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
3907	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3908	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3747	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	ETO sensitivity	NA	ETO resistance (moderate)	NA	37°C 	Human	H1299	no WT control	Etoposide treatment, FACS analysis	15	Blandino G;Levine AJ;Oren M;	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy	1999	Oncogene	18	477	9927204
3331	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Downregulation (Vrk1)	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot	226	Valbuena A;Vega FM;Blanco S;Lazo PA;	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop	2006	Mol Cell Biol 	26	4782	16782868
3461	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	APO	NA	NA	NA	32°C 	Human	H1299	WT control	FACS analysis	53	Friedlander P;Haupt Y;Prives C;Oren M;	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis	1996	Mol Cell Biol	16	4961	8756655
3493	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	Upregulation (WAF1, GADD45); upregulation (p53R2) partial) TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT) partial	NA	No [upregulation (MDR-1)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3494	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1) partial;TA (IGF-BP3) partial; TA (p53R2, GADD45, CyclinG); TR (hTERT)	NA	No [TA (hTERT)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
4196	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Attenuation of TGF-beta1 response; TR (TGF-betaRII)	NA	37°C 	Human	H1299	no WT control	RT-PCR, luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
10	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Upregulation (dUTPase, C-MYC)	NA	37°C 	Human	H1299, SK-OV-3	WT control	RT-PCR	2	Pugacheva EN;Ivanov AV;Kravchenko JE;Kopnin BP;Levine AJ;Chumakov PM;	Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil	2002	Oncogene	21	4595	12096336
3972	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	DNAb (p53CON)	Yes (DNAb) partial	NA	NA	37°C 	Human	H358	WT control	EMSA	255	Unger T;Mietz JA;Scheffner M;Yee CL;Howley PM;	Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression	1993	Mol Cell Biol 	13	5186	8355677
83	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	HCT-116	WT control	CAT assay	11	Kern SE;Pietenpol JA;Thiagalingam S;Seymour A;Kinzler KW;Vogelstein B;	Oncogenic forms of p53 inhibit p53-regulated gene expression	1992	Science	256	827	1589764
1760	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (RECQ4) partial	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	107	Sengupta S;Shimamoto A;Koshiji M;Pedeux R;Rusin M;Spillare EA;Shen JC;Huang LE;Lindor NM;Furuichi Y;Harris CC;	Tumor suppressor p53 represses transcription of RECQ4 helicase	2005	Oncogene	24	1738	15674334
4163	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (FAK); TA (WAF1); DNAb (FAK)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay, ChIP assay	294	Golubovskaya VM;Finch R;Kweh F;Massoll NA;Campbell-Thompson M;Wallace MR;Cance WG;	p53 regulates FAK expression in human tumor cells	2008	Mol Carcinog 	47	373	17999388
4095	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Daxx interference (weak)	NA	37°C 	Human	HeLa	no WT control	JNK activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
3979	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (p53CON)	NA	TR (p53CON)	NA	37°C 	Human	HeLa	WT control	Luciferase assay	256	Hoppe-Seyler F;Butz K;	Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53	1993	J Virol 	67	3111	8388491
1645	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	TA (BAG-1)	NA	37°C 	Human	HeLa	WT control	Luciferase assay	85	Yang X;Pater A;Tang SC;	Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	1999	Oncogene	18	4546	10467399
1955	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (HSV1-TK) partial	NA	NA	NA	37°C 	Human	HeLa	WT control	CAT assay	134	Subler MA;Martin DW;Deb S;	Inhibition of viral and cellular promoters by human wild-type p53	1992	J Virol	66	4757	1352831
916	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (PCNA); TR (CMV, RSV, HTLV); TR (HSV1-UL9) partial	NA	TA (PCNA); TA (RSV, HTLV); no [TA(CMV)]	NA	37°C 	Human	HeLa	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1959	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (HIV)	NA	TA (HIV)	NA	37°C 	Human	HeLa, Saos-2	WT control	CAT assay	135	Subler MA;Martin DW;Deb S;	Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53	1994	J Virol	68	103	8254719
172	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	IGF-II repression; TR (IGF-II)	NA	Upregulation (IGF-II); TA (IGF-II)	NA	37°C 	Human	Hep3B	WT control	Northern blot, CAT assay	31	Lee YI;Lee S;Das GC;Park US;Park SM;Lee YI;	Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma	2000	Oncogene	19	3717	10949925
4002	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Monocytic differentiation induction; sensitivity to serum depletion; ETO sensitivity	NA	No (ETO resistance)	NA	37°C 	Human	HL-60	WT control	Stable transfection + analysis of markers of differentiation or serum depletion or ETO treatment	262	Banerjee D;Lenz HJ;Schnieders B;Manno DJ;Ju JF;Spears CP;Hochhauser D;Danenberg K;Danenberg P;Bertino JR;	Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress	1995	Cell Growth Differ 	6	1405	8562479
1995	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS	NA	Growth advantage	NA	37°C 	Human	HSC3, Ca299	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
3932	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Upregulation (Fas)	NA	NA	No (Fas)	37°C 	Human	K562	no WT control	FACS analysis, temperature sensitive assay at 32°C	241	Owen-Schaub LB;Zhang W;Cusack JC;Angelo LS;Santee SM;Fujiwara T;Roth JA;Deisseroth AB;Zhang WW;Kruzel E;.;	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression	1995	Mol Cell Biol 	15	3032	7539102
4278	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	Dependence on serum factors	NA	NA	Decrease of some differentiation markers	NA	37°C 	Human	K-562	no WT control	FACS analysis, culture in 1% serum medium	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
4273	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	Transfection	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
1849	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	HR repression	NA	NA	NA	37°C 	Human	K-562	WT control	Homologous recombination (HR) assay	124	Akyuz N;Boehden GS;Susse S;Rimek A;Preuss U;Scheidtmann KH;Wiesmuller L;	DNA substrate dependence of p53-mediated regulation of double-strand break repair	2002	Mol Cell Biol	22	6306	12167722
3137	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	Yes [TA (RGC)] moderate; No [TA (p53CON)]	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay	207	Zhang W;Shay JW;Deisseroth A;	Inactive p53 mutants may enhance the transcriptional activity of wild-type p53	1993	Cancer Res 	53	4772	8402659
3145	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	CFA	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
6	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	DNAb (p53CON); TA (p53CON, RGC)	NA	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay, EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
3983	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Upregulation (p21waf1); GS	NA	Attenuation of p21waf1 inhibitory effect	NA	37°C 	Human	LN-308	WT control	Western blot, CFA	258	Jung JM;Li H;Kobayashi T;Kyritsis AP;Langford LA;Bruner JM;Levin VA;Zhang W;	Inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53	1995	Cell Growth Differ 	6	909	8547219
3729	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1) moderate; androgen-independent cell growth	NA	37°C 	Human	LNCaP	no WT control	Western blot,  proliferation assay	52	Nesslinger NJ;Shi XB;deVere White RW;	Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53	2003	Cancer Res	63	2228	12727844
3736	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Upregulation (RLN2); DNAb (RLN2) moderate; no [regulation (H2relaxin)]	NA	37°C 	Human	LNCaP	no WT control	RT-PCR, ChIP assay, western blot	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
1994	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS partial	NA	NA	NA	37°C 	Human	MG63	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
3805	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (CD95/Fas)	NA	TR (CD95/Fas) partially	NA	37°C 	Human	PC-3	no WT control	Luciferase assay	54	Zalcenstein A;Stambolsky P;Weisz L;Muller M;Wallach D;Goncharov TM;Krammer PH;Rotter V;Oren M;	Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	2003	Oncogene	22	5667	12944915
4132	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4144	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
43	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	Yes [TA (PG13)] moderate	NA	NA	37°C 	Human	PC-3, Saos-2, 21PT, 21NT, 21MT-2	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
3791	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	DNAb (p53CON)	NA	NA	NA	37°C 	Human	RD (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
3818	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	NA	NA	p73 interference (weak)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3819	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3405	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1, BAX); APO	Yes [TA (BAX)]; Yes (APO); No [TA (WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
4110	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	ATM inactivation	NA	37°C 	Human	Saos-2	no WT control	Treatment with gamma-irradiation + study of SMC-1, NBS1 and H2AX phosphorylation	289	Song H;Hollstein M;Xu Y;	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM	2007	Nat Cell Biol 	9	573	17417627
4086	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Daxx binding (moderate); No (culture in soft agar)	NA	37°C 	Human	Saos-2	WT control	Co-IP, culture in soft agar	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4074	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4124	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	Upregulation (p21waf1)	NA	No [downregulation (p21waf1)]	NA	37°C 	Human	Saos-2	no WT control	Western blot	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4070	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	HR repression	NA	NA	NA	NA	37°C 	Human	Saos-2	no WT control	Ionizing irradiation + homologous recombination (HR) assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4035	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	No (culture in soft agar); No (TUMOR+)	NA	37°C 	Human	Saos-2	no WT control	Culture in soft agar, tumorigenicity assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
3885	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3886	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4517	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (uPA); TA (PAI-1)	NA	No [TA (uPA)]; no [TR (PAI-1)]	NA	37°C 	Human	Saos-2	WT control	CAT assay	329	Kunz C;Pebler S;Otte J;von der AD;	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53	1995	Nucleic Acids Res 	23	3710	7479001
30	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
104	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	Stable transfection, CAT assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
76	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	TA (WAF1); GS; TR (C-JUN) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
98	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1); upregulation (p21waf1); GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
151	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (hMMP-13) partial	Yes [TR (hMMP-13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	24	Sun Y;Cheung JM;Martel-Pelletier J;Pelletier JP;Wenger L;Altman RD;Howell DS;Cheung HS;	Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	2000	J Biol Chem	275	11327	10753945
912	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (PCNA)	NA	TA (PCNA)	NA	37°C 	Human	Saos-2	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1167	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	NA	NA	p73alpha binding (low affinity)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1155	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	NA	NA	No (p73alpha binding)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1986	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC, p53CON); TR (C-FOS); GS	NA	TA (C-FOS); no (growth advantage)	No (RGC, p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitivity assay at 30°C	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
2087	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (HSP70)	NA	No [TA (HSP70)]; no (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2146	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (C-MYC)	NA	TA (C-MYC)	NA	37°C 	Human	Saos-2	WT control	CAT assay	74	Brown DR;Deb D;Frum R;Hickes L;Munoz R;Deb S;Deb SP;	The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants	2001	Int J Oncol	18	449	11179471
2143	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	DNAb (WAF1, RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
1676	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	GS; Ag T binding	NA	No (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
1670	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	TA (EGFR) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	89	Ludes-Meyers JH;Subler MA;Shivakumar CV;Munoz RM;Jiang P;Bigger JE;Brown DR;Deb SP;Deb S;	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53	1996	Mol Cell Biol	16	6009	8887630
1704	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TR (IGFI-R)	NA	TA (IGFI-R)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	98	Werner H;Karnieli E;Rauscher FJ;LeRoith D;	Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene	1996	Proc Natl Acad Sci U S A	93	8318	8710868
3166	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (S100A2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	211	Tan M;Heizmann CW;Guan K;Schafer BW;Sun Y;	Transcriptional activation of the human S100A2 promoter by wild-type p53	1999	FEBS Lett 	445	265	10094469
3155	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
3253	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (PTGF-beta)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	213	Tan M;Wang Y;Guan K;Sun Y;	PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway	2000	Proc Natl Acad Sci U S A	97	109	10618379
3172	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (type IV collagenase)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	212	Bian J;Sun Y;	Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter	1997	Mol Cell Biol 	17	6330	9343394
4058	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	CDDP and X-ray radiation resistance	NA	37°C 	Human	SAS	no WT control	Treatment with cisplatin or X-ray irradiation	279	Ohnishi K;Ota I;Takahashi A;Yane K;Matsumoto H;Ohnishi T;	Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck	2002	Apoptosis 	7	367	12101396
4051	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Heat resistance	NA	37°C 	Human	SAS	no WT control	Heat treatment	276	Ota I;Ohnishi K;Takahashi A;Yane K;Kanata H;Miyahara H;Ohnishi T;Hosoi H;	Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma	2000	Int J Radiat Oncol Biol Phys 	47	495	10802378
4203	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	Repression of transcriptional TGF-beta1 response	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
3925	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	GA	NA	NA	Downregulation (ATF3); downregulation (Atf3)	NA	37°C 	Human	SK-OV-3	no WT control	TPA treatment + western blot, RT-qPCR, FACS analysis	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
3950	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	249	Hachiya M;Chumakov A;Miller CW;Akashi M;Said J;Koeffler HP;	Mutant p53 proteins behave in a dominant, negative fashion in vivo	1994	Anticancer Res 	14	1853	7847818
3502	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	TR (ATF3) moderate	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
2076	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	155	Chumakov AM;Miller CW;Chen DL;Koeffler HP;	Analysis of p53 transactivation through high-affinity binding sites	1993	Oncogene	8	3005	8414502
2108	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (PG13)	No [TA (PG13)]	NA	NA	37°C 	Human	SK-OV-3, Hep3B, 21MT-1	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
3835	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	p38 and p42 binding	NA	37°C 	Human	SW837 (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
1893	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	TR (TIMP-3)	NA	NA	NA	NA	37°C 	Human	T98G, U2OS	WT control	Luciferase assay	129	Loging WT;Reisman D;	Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53	1999	Oncogene	18	7608	10602522
3149	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TRANSF- (partial)	NA	NA	NA	37°C 	Other	Rat-1	WT control	Transformation assay	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
2099	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
1220	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
3828	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	NA	NA	TRANSF+ (weak)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3829	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	NA	NA	TRANSF+ (weak)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3997	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
4183	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	No (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
3435	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4671	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1261	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1383	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
798	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
197	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC, p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
182	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
256	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
245	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
263	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
377	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3, RGC)	NA	NA	No (WAF1 5', BAX, PIG3, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 33°C and 35°C	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
2048	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	146	Scharer E;Iggo R;	Mammalian p53 can function as a transcription factor in yeast	1992	Nucleic Acids Res	20	1539	1579447
1929	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1930	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1859	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
3178	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3026	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
3009	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2945	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2927	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2813	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2746	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
2779	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
2769	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2833	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2858	p.R248W	R248W	248	Arg	Trp	005984	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2840	p.R249G	R249G	249	Arg	Gly	005985	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
4587	p.R249G	R249G	249	Arg	Gly	005985	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
563	p.R249K	R249K	249	Arg	Lys	045248	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4355	p.R249M	R249M	249	Arg	Met	033037	L2/L3	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4166	p.R249M	R249M	249	Arg	Met	033037	L2/L3	NA	NA	TR (FAK); TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	294	Golubovskaya VM;Finch R;Kweh F;Massoll NA;Campbell-Thompson M;Wallace MR;Cance WG;	p53 regulates FAK expression in human tumor cells	2008	Mol Carcinog 	47	373	17999388
4318	p.R249M	R249M	249	Arg	Met	033037	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1407	p.R249M	R249M	249	Arg	Met	033037	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3210	p.R249M	R249M	249	Arg	Met	033037	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3064	p.R249M	R249M	249	Arg	Met	033037	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2687	p.R249M	R249M	249	Arg	Met	033037	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
2112	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (PG13)	No [TA (PG13)]	NA	NA	37°C 	Human	21PT	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
4224	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	Interference with Beta-catenin-dependent TCF signalling (partial)	NA	NA	NA	37°C 	Human	22Rv1	WT control	Luciferase assay	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
3727	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	DNAb (RGC, WAF1)	NA	NA	No (DNAb)	37°C 	Human	BT-549 (endo)	Endogenous Mutant	EMSA, temperature sensitive assay at 4 and 32°C	242	Brazda V;Muller P;Brozkova K;Vojtesek B;	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity	2006	Biochem Biophys Res Commun 	351	499	17070499
45	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	Calu-6, VAMT-1	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
136	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	NA	NA	p63 and p73 binding (low affinity); hsp70 binding	NA	37°C 	Human	H1299	WT control	Co-IP	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
390	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (WAF1, BAX, MDM2); GS; DNAb (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
1894	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	TR (TIMP-3)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	130	Thomas S;Reisman D;	Localization of a mutant p53 response element on the Tissue Inhibitor of Metalloproteinase-3 promoter: Mutant p53 activities are distinct from wild-type	2005	Cancer Lett			16236433
1786	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1787	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	R 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1482	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	NA	NA	Mdm2 stabilization	NA	37°C 	Human	H1299	WT control	Western blot, IF	80	Peng Y;Chen L;Li C;Lu W;Agrawal S;Chen J;	Stabilization of the MDM2 oncoprotein by mutant p53	2001	J Biol Chem	276	6874	11152666
3488	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	Upregulation (WAF1, MDM2, GADD45, BAX, CD95-Fas, PIG3)	NA	NA	NA	37°C 	Human	H1299	WT control	Northern blot	235	Zhu J;Jiang J;Zhou W;Zhu K;Chen X;	Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity	1999	Oncogene	18	2149	10321740
3495	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT)	NA	Upregulation (MDR-1); no [TA (hTERT)]	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3496	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	R 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT)	NA	Upregulation (MDR-1); TA (hTERT)	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
4080	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	R 	NA	Upregulation (p21waf1); GS; GA; APO	NA	No (p73beta interference, p73beta binding)	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
3909	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	R 	NA	GS; CDDP and DOX sensitivity	NA	CDDP and DOX resistance; no (GEM, VIN and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3910	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	GS; CDDP and DOX sensitivity	NA	CDDP resistance; DOX resistance (moderate); no (GEM, VIN and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3375	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
3957	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	GS; TA (RGC)	NA	Growth advantage	NA	37°C 	Human	Hep3B	WT control	CFA, beta-gal assay	252	Ponchel F;Puisieux A;Tabone E;Michot JP;Froschl G;Morel AP;Frebourg T;Fontaniere B;Oberhammer F;Ozturk M;	Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis	1994	Cancer Res 	54	2064	8174105
3958	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	TGF-beta1 sensitivity	NA	NA	TUMOR+ (moderate)	NA	37°C 	Human	Hep3B	no WT control	Tumorigenicity assay	252	Ponchel F;Puisieux A;Tabone E;Michot JP;Froschl G;Morel AP;Frebourg T;Fontaniere B;Oberhammer F;Ozturk M;	Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis	1994	Cancer Res 	54	2064	8174105
4230	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	DNAb (p53CON); upregulation (WAF1, PUMA, COX-2)	NA	In vitro and in vivo PRIMA-1 sensitivity; No (PRIMA-1 induced reactivation)	NA	37°C 	Human	Hep3B	no WT control	TransAM assay, RT-qPCR, PRIMA-1 treatment + FACS analysis, xenograft	306	Shi H;Lambert J;Hautefeuille A;Bykov V;Wiman K;Hainaut P;Caron de FC;	In vitro and in vivo cytotoxic effects of PRIMA-1 on Hepatocellular Carcinoma cells expressing mutant p53ser249	2007	Carcinogenesis			18048389
3351	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TR (HNF4alpha)	NA	NA	NA	37°C 	Human	HepG2	WT control	Luciferase assay	233	Maeda Y;Hwang-Verslues WW;Wei G;Fukazawa T;Durbin ML;Owen LB;Liu X;Sladek FM;	Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene	2006	Biochem J 	400	303	16895524
4237	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (WTH3)	NA	NA	NA	37°C 	Human	MCF-7, HEK293	WT control	Luciferase assay	309	Tian K;Wang Y;Xu H;	WTH3 is a direct target of the p53 protein	2007	Br J Cancer	96	1579	17426708
4223	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	Interference with Beta-catenin-dependent TCF signalling	NA	NA	NA	NA	37°C 	Human	PC-3	WT control	Luciferase assay	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
46	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (PG13)	Yes [TA (PG13)] moderate	NA	NA	37°C 	Human	PC-3, Saos-2, SK-OV-3, Hep3B, 21NT, 21MT-1 and 2	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
4232	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	NA	NA	PRIMA-1 resistance (partial)	NA	37°C 	Human	PLC/PRF/5 (endo)	Endogenous Mutant	siRNA and PRIMA-1 treatment + FACS analysis	306	Shi H;Lambert J;Hautefeuille A;Bykov V;Wiman K;Hainaut P;Caron de FC;	In vitro and in vivo cytotoxic effects of PRIMA-1 on Hepatocellular Carcinoma cells expressing mutant p53ser249	2007	Carcinogenesis			18048389
3883	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3884	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3915	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	R 	NA	NA	NA	p73 interference	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3916	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	NA	NA	p73 interference (moderate)	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3841	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	Saos-2	no WT control	Proliferation assay	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
116	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (MDM2, PG13); TR (C-FOS) ; GS	No [TA (PG13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1348	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (PG13, WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1660	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	Upregulation (WAF1); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	RNase protection assay, CFA	87	Freeman J;Schmidt S;Scharer E;Iggo R;	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein	1994	EMBO J	13	5393	7957105
3156	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
2162	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	APO; GA	NA	NA	NA	37°C 	Human	Saos-2, H1299	WT control	FACS analysis	163	Chen X;Ko LJ;Jayaraman L;Prives C;	p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells	1996	Genes Dev	10	2438	8843196
2131	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
2130	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
2043	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
1860	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
3115	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3069	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3059	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
3181	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2864	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2994	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
1347	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	78	Brachmann RK;Yu K;Eby Y;Pavletich NP;Boeke JD;	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations	1998	EMBO J	17	1847	9524109
1385	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
183	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
198	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC, p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
264	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
229	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4588	p.R249S	R249S	249	Arg	Ser	005986	L2/L3	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
173	p.R249T	R249T	249	Arg	Thr	045249	L2/L3	NA	NA	IGF-II repression; TR (IGF-II)	NA	Upregulation (IGF-II); TA (IGF-II)	NA	37°C 	Human	Hep3B	WT control	Northern blot, CAT assay	31	Lee YI;Lee S;Das GC;Park US;Park SM;Lee YI;	Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma	2000	Oncogene	19	3717	10949925
1933	p.R249T	R249T	249	Arg	Thr	045249	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1932	p.R249W	R249W	249	Arg	Trp	045250	L2/L3	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3220	p.R249W	R249W	249	Arg	Trp	045250	L2/L3	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3071	p.R249W	R249W	249	Arg	Trp	045250	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3116	p.R249W	R249W	249	Arg	Trp	045250	L2/L3	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
1417	p.R249W	R249W	249	Arg	Trp	045250	L2/L3	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3386	p.P250A	P250A	250	Pro	Ala	045251	L2/L3	NA	Growth inhibition	NA	NA	NA	NA	37°C 	Human	HeLa	WT control	MTT assay	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
146	p.P250A	P250A	250	Pro	Ala	045251	L2/L3	NA	TA (MDM2); TA (WAF1) supertrans ; GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay, CFA	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
619	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
674	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
564	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	NA	NA	NA	NA	NA	Yes mut_H (GADD45, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
385	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	NA	NA	TA (BAX, PIG3, RGC); TA (WAF1 5') partial	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
327	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1314	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2894	p.P250L	P250L	250	Pro	Leu	047192	L2/L3	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
485	p.P250R	P250R	250	Pro	Arg		L2/L3	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
859	p.P250S	P250S	250	Pro	Ser	045254	L2/L3	NA	TA (MDM2, WAF1 5')	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
862	p.P250T	P250T	250	Pro	Thr	045255	L2/L3	NA	TA (MDM2, WAF1 5')	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
944	p.P250T	P250T	250	Pro	Thr	045255	L2/L3	NA	TA (WAF1)	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
2934	p.I251F	I251F	251	Ile	Phe	045256	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
3943	p.I251L	I251L	251	Ile	Leu	045257	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	MKN-1	WT control	CFA	247	Matozaki T;Sakamoto C;Suzuki T;Matsuda K;Uchida T;Nakano O;Wada K;Nishisaki H;Konda Y;Nagao M;.;	p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells	1992	Cancer Res 	52	4335	1322785
620	p.I251L	I251L	251	Ile	Leu	045257	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, P53R2); No (BAX, 14-3-3s, GADD45)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
565	p.I251L	I251L	251	Ile	Leu	045257	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (P53R2); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4634	p.I251M	I251M	251	Ile	Met	045258	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1) partial	Yes [TA (PUMA)]; No [TA (MDM2, BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1934	p.I251S	I251S	251	Ile	Ser	033038	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2696	p.I251S	I251S	251	Ile	Ser	033038	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	176	Lung ML;Hu Y;Cheng Y;Li MF;Tang CM;SK O;Iggo RD;	p53 inactivating mutations in Chinese nasopharyngeal carcinomas	1998	Cancer Lett	133	89	9929165
482	p.I251T	I251T	251	Ile	Thr	045259	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s); No (WAF1, MDM2, BAX,  GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
675	p.L252F	L252F	252	Leu	Phe	045261	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
295	p.L252F	L252F	252	Leu	Phe	045261	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
497	p.L252H	L252H	252	Leu	His	045262	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
347	p.L252I	L252I	252	Leu	Ile	045263	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
4065	p.L252P	L252P	252	Leu	Pro	005988	NDBL/beta-sheets	NA	NA	TA (MDR1)	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay	281	Goldsmith ME;Gudas JM;Schneider E;Cowan KH;	Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line	1995	J Biol Chem 	270	1894	7829527
1677	p.L252P	L252P	252	Leu	Pro	005988	NDBL/beta-sheets	NA	NA	Ag T binding	NA	hsc70 binding	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
1861	p.L252P	L252P	252	Leu	Pro	005988	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
1796	p.T253A	T253A	253	Thr	Ala	045265	NDBL/beta-sheets	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
457	p.T253A	T253A	253	Thr	Ala	045265	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s, Noxa); No (WAF1, MDM2, BAX, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
621	p.T253I	T253I	253	Thr	Ile	045266	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (BAX, 14-3-3s); No (WAF1, MDM2, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
483	p.T253I	T253I	253	Thr	Ile	045266	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s, Noxa); No (WAF1, MDM2, BAX, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
495	p.T253N	T253N	253	Thr	Asn	045267	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
622	p.T253S	T253S	253	Thr	Ser	045268	NDBL/beta-sheets	NA	NA	NA	NA	NA	No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
456	p.T253S	T253S	253	Thr	Ser	045268	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3967	p.I254D	I254D	254	Ile	Asp	045859	NDBL/beta-sheets	NA	TRANSF-	NA	NA	No (TRANSF+)	NA	NA   	Other	BRK	WT control	Transformation assay	254	Farrell PJ;Allan GJ;Shanahan F;Vousden KH;Crook T;	p53 is frequently mutated in Burkitt's lymphoma cell lines	1991	EMBO J 	10	2879	1915267
623	p.I254F	I254F	254	Ile	Phe	045269	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (BAX); No (WAF1, MDM2, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
458	p.I254F	I254F	254	Ile	Phe	045269	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, BAX, 14-3-3s, AIP1, Noxa, P53R2); No (MDM2, GADD45)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
432	p.I254F	I254F	254	Ile	Phe	045269	NDBL/beta-sheets	NA	TA (WAF1, p53CON)	TA (MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	Yes mut_H (MDM2, Cyclin G, GADD45); No (WAF1, p53CON, BAX)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
3130	p.I254F	I254F	254	Ile	Phe	045269	NDBL/beta-sheets	NA	TA (WAF1 5')	TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
566	p.I254M	I254M	254	Ile	Met	045271	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4184	p.I254N	I254N	254	Ile	Asn	017908	NDBL/beta-sheets	NA	TA (WAF1, RGC)	TA (BAX)	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
624	p.I254T	I254T	254	Ile	Thr	017909	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX, 14-3-3s, GADD45); No (WAF1, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
481	p.I254T	I254T	254	Ile	Thr	017909	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s, AIP1, Noxa, P53R2); No (WAF1, MDM2, BAX, GADD45)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
625	p.I255F	I255F	255	Ile	Phe	045274	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45, P53R2); No (BAX)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
567	p.I255F	I255F	255	Ile	Phe	045274	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1315	p.I255F	I255F	255	Ile	Phe	045274	NDBL/beta-sheets	P 	TA (WAF1 5', p53CON-A, P53R2, GADD45, CD95-Fas, PUMA, MDM2, BAX, PCNA, AIP1)	TA (RGC, NOXA, WAF1 3') partial	NA	NA	yes mut_H (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2798	p.I255F	I255F	255	Ile	Phe	045274	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
568	p.I255M	I255M	255	Ile	Met	045275	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2689	p.I255T	I255T	255	Ile	Thr	045278	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
626	p.T256A	T256A	256	Thr	Ala		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (BAX); No (WAF1, MDM2, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
499	p.T256A	T256A	256	Thr	Ala		NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1); No (MDM2, BAX, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1458	p.T256A	T256A	256	Thr	Ala		NDBL/beta-sheets	P 	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	NA	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5'); Yes mut_H (Cyclin G, WAF1 3', type IV collagenase, 14-3-3s, B99, RGC); Yes mut_L & H (p53AIP1, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3249	p.T256A	T256A	256	Thr	Ala		NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01); Yes mut_H (BAI1)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
627	p.T256I	T256I	256	Thr	Ile	045280	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, BAX); No (MDM2, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
454	p.T256I	T256I	256	Thr	Ile	045280	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, BAX); No (14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4694	p.T256I	T256I	256	Thr	Ile	045280	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
569	p.T256R	T256R	256	Thr	Arg		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
676	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	NA	NA	NA	Yes [TA (RGC, BAX, PIG3)]; No [TA (WAF1 5’)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
348	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
296	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1437	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
872	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
3243	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1740	p.L257P	L257P	257	Leu	Pro	005989	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
3240	p.L257Q	L257Q	257	Leu	Gln	045284	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1434	p.L257Q	L257Q	257	Leu	Gln	045284	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
349	p.L257Q	L257Q	257	Leu	Gln	045284	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
4638	p.L257Q	L257Q	257	Leu	Gln	045284	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4545	p.L257Q	L257Q	257	Leu	Gln	045284	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
628	p.L257V	L257V	257	Leu	Val	045286	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
570	p.L257V	L257V	257	Leu	Val	045286	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2972	p.E258A	E258A	258	Glu	Ala	045287	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	196	Fulci G;Labuhn M;Maier D;Lachat Y;Hausmann O;Hegi ME;Janzer RC;Merlo A;Van Meir EG;	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	2000	Oncogene	19	3816	10949938
2743	p.E258D	E258D	258	Glu	Asp	005990	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
792	p.E258G	E258G	258	Glu	Gly	045288	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
4066	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (MDR1)	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay	281	Goldsmith ME;Gudas JM;Schneider E;Cowan KH;	Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line	1995	J Biol Chem 	270	1894	7829527
3955	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (RGC)	Yes [TA (RGC)] moderate; No (GS)	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, CFA	250	Frebourg T;Sadelain M;Ng YS;Kassel J;Friend SH;	Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype	1994	Cancer Res 	54	878	8313374
1678	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	Ag T binding	GS	NA	hsc70 binding	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
3157	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
2893	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2820	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2753	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	181	Takahashi M;Tonoki H;Tada M;Kashiwazaki H;Furuuchi K;Hamada J;Fujioka Y;Sato Y;Takahashi H;Todo S;Sakuragi N;Moriuchi T;	Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers	2000	Int J Cancer	89	92	10719737
1862	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
2044	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
1262	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	Yes [TA (WAF1 5', WAF1 3', P53R2, CD95-Fas, PCNA, MDM2, RGC, NOXA, PUMA)] moderate	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
725	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
371	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (p53CON) partial	Yes [TA (p53CON)]	NA	yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
297	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4616	p.E258K	E258K	258	Glu	Lys	005991	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA)]; No [TA (WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2892	p.E258Q	E258Q	258	Glu	Gln	045289	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
1316	p.D259G	D259G	259	Asp	Gly	045292	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
386	p.D259N	D259N	259	Asp	Asn	045294	NDBL/beta-sheets	NA	TA (WAF1 5')	TA (BAX, PIG3); TA (RGC) partial	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
328	p.D259N	D259N	259	Asp	Asn	045294	NDBL/beta-sheets	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
726	p.D259N	D259N	259	Asp	Asn	045294	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
679	p.D259N	D259N	259	Asp	Asn	045294	NDBL/beta-sheets	NA	NA	NA	No [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3436	p.D259N	D259N	259	Asp	Asn	045294	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3437	p.D259V	D259V	259	Asp	Val	045295	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4589	p.D259V	D259V	259	Asp	Val	045295	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
678	p.D259V	D259V	259	Asp	Val	045295	NDBL/beta-sheets	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
378	p.D259V	D259V	259	Asp	Val	045295	NDBL/beta-sheets	NA	NA	TA (WAF1 5', BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
298	p.D259V	D259V	259	Asp	Val	045295	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
2841	p.D259V	D259V	259	Asp	Val	045295	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
3236	p.D259Y	D259Y	259	Asp	Tyr	033039	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
350	p.D259Y	D259Y	259	Asp	Tyr	033039	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1430	p.D259Y	D259Y	259	Asp	Tyr	033039	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1317	p.S260P	S260P	260	Ser	Pro	045299	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1983	p.V216_N268del	S261_N268del	261	Ser	NA		NDBL/beta-sheets	NA	NA	TA (RGC, p53CON)	No [TA (RGC, p53CON)]	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
3349	p.S261fs	S261fs	261	Ser	NA		NDBL/beta-sheets	NA	NA	TA (MDM2); upregulation (p21waf1, mdm2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, western blot	232	Feuerborn A;Moritz C;Von Bonin F;Dobbelstein M;Trumper L;Sturzenhofecker B;Kube D;	Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma	2006	Leuk Lymphoma	47	1932	17065008
2922	p.S261R	S261R	261	Ser	Arg	045306	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
777	p.G262C	G262C	262	Gly	Cys	045307	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
299	p.G262D	G262D	262	Gly	Asp	047196	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
718	p.G262D	G262D	262	Gly	Asp	047196	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
2695	p.G262S	G262S	262	Gly	Ser	045308	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	175	Takahashi M;	[Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining]	1998	Hokkaido Igaku Zasshi	73	275	9719952
1318	p.N263D	N263D	263	Asn	Asp	045310	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1731	p.L264R	L264R	264	Leu	Arg	045318	NDBL/beta-sheets	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
2801	p.L265P	L265P	265	Leu	Pro	045321	NDBL/beta-sheets	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3232	p.L265P	L265P	265	Leu	Pro	045321	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1426	p.L265P	L265P	265	Leu	Pro	045321	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
351	p.L265P	L265P	265	Leu	Pro	045321	NDBL/beta-sheets	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
4639	p.L265P	L265P	265	Leu	Pro	045321	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA)]; No [TA (MDM2, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
571	p.L265V	L265V	265	Leu	Val		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
682	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
301	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
752	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2899	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	190	Bonnefoi H;Ducraux A;Movarekhi S;Pelte MF;Bongard S;Lurati E;Iggo R;	p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients	2002	Br J Cancer	86	750	11875738
1935	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4546	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
3438	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3439	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4185	p.G266E	G266E	266	Gly	Glu	045324	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1, RGC); Yes mut_H (BAX) low	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
3373	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
3440	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3441	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4590	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
2712	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2866	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2874	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
750	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
300	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
727	p.G266R	G266R	266	Gly	Arg	045325	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
372	p.G266V	G266V	266	Gly	Val	045326	NDBL/beta-sheets	NA	NA	TA (p53CON) partial	No [TA (p53CON)]	NA	yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
751	p.G266V	G266V	266	Gly	Val	045326	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
572	p.R267G	R267G	267	Arg	Gly	045327	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (GADD45, P53R2); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2904	p.R267P	R267P	267	Arg	Pro	045329	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
3065	p.R267P	R267P	267	Arg	Pro	045329	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
1503	p.R267Q	R267Q	267	Arg	Gln	045330	NDBL/beta-sheets	NA	NA	Upregulation (p21waf1); GS partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot, CFA	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
1497	p.R267Q	R267Q	267	Arg	Gln	045330	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
4591	p.R267Q	R267Q	267	Arg	Gln	045330	NDBL/beta-sheets	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4672	p.R267Q	R267Q	267	Arg	Gln	045330	NDBL/beta-sheets	NA	TA (WAF1)	TA (MDM2, BAX) partial; TA (PUMA)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4540	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
2740	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
1936	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3228	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2919	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
426	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	NA	TA (WAF1, p53CON)	TA (RGC, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
1423	p.R267W	R267W	267	Arg	Trp	036507	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
629	p.N268I	N268I	268	Asn	Ile	045332	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45); No (P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
465	p.N268I	N268I	268	Asn	Ile	045332	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (14-3-3s, Noxa); No (WAF1, MDM2, BAX, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
573	p.N268T	N268T	268	Asn	Thr		NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2); No (WAF1, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
574	p.S269G	S269G	269	Ser	Gly	045337	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
575	p.S269I	S269I	269	Ser	Ile	047198	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (MDM2); No (WAF1, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
486	p.S269R	S269R	269	Ser	Arg	045339	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3041	p.S269R	S269R	269	Ser	Arg	045339	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
3229	p.F270C	F270C	270	Phe	Cys	045341	NDBL/beta-sheets	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3006	p.F270C	F270C	270	Phe	Cys	045341	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
1449	p.F270C	F270C	270	Phe	Cys	045341	NDBL/beta-sheets	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2); Yes mut_L (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
630	p.F270I	F270I	270	Phe	Ile	045342	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
464	p.F270I	F270I	270	Phe	Ile	045342	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2, Noxa); No (WAF1, BAX, 14-3-3s, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2968	p.F270L	F270L	270	Phe	Leu	045343	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
753	p.F270S	F270S	270	Phe	Ser	045344	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
821	p.F270S	F270S	270	Phe	Ser	045344	NDBL/beta-sheets	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
631	p.F270V	F270V	270	Phe	Val	045345	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
463	p.F270V	F270V	270	Phe	Val	045345	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (BAX, 14-3-3s, Noxa); No (WAF1, MDM2, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
2683	p.F270V	F270V	270	Phe	Val	045345	NDBL/beta-sheets	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
576	p.E271A	E271A	271	Glu	Ala	045347	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2); No (GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
577	p.E271G	E271G	271	Glu	Gly	045349	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3265	p.E271K	E271K	271	Glu	Lys	036508	NDBL/beta-sheets	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
632	p.E271V	E271V	271	Glu	Val	047199	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
442	p.E271V	E271V	271	Glu	Val	047199	NDBL/beta-sheets	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, Noxa, P53R2); No (BAX, GADD45, AIP1)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4617	p.E271V	E271V	271	Glu	Val	047199	NDBL/beta-sheets	NA	NA	TA (MDM2, BAX) partial; TA (PUMA)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3887	p.V272A	V272A	272	Val	Ala	045351	L1/S/H2	R 	NA	NA	NA	No (p73 interference); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3888	p.V272A	V272A	272	Val	Ala	045351	L1/S/H2	P 	NA	NA	NA	No (p73 interference); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
633	p.V272A	V272A	272	Val	Ala	045351	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (MDM2, BAX); No (WAF1, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
484	p.V272A	V272A	272	Val	Ala	045351	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (Noxa); No (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
793	p.V272A	V272A	272	Val	Ala	045351	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
754	p.V272G	V272G	272	Val	Gly	045353	L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4186	p.V272G	V272G	272	Val	Gly	045353	L1/S/H2	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1, RGC); Yes mut_H (BAX) low	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
634	p.V272L	V272L	272	Val	Leu	005992	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
578	p.V272L	V272L	272	Val	Leu	005992	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3117	p.V272L	V272L	272	Val	Leu	005992	L1/S/H2	NA	NA	TA (WAF1 5', BAX); DNAb (WAF1, BAX) partial	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection, EMSA	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
1871	p.V272L	V272L	272	Val	Leu	005992	L1/S/H2	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
4699	p.V272L	V272L	272	Val	Leu	005992	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4592	p.V272L	V272L	272	Val	Leu	005992	L1/S/H2	NA	TA (11 different p53-RE)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4365	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1462	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	P 	NA	TA (WAF1 5', NOXA)	Yes [TA (WAF1 5')] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4015	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (RGC); APO	NA	NA	Yes mut_H (RGC); No (APO)	37°C 	Human	Hep3B	WT control	CAT assay, FACS analysis, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4016	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (RGC) partial	NA	NA	NA	32°C 	Human	Hep3B	WT control	CAT assay	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4008	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (RGC)	NA	NA	Yes mut_H (RGC)	37°C 	Human	HepG2, Saos-2	WT control	CAT assay, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4011	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (RGC) partial	NA	NA	NA	32°C 	Human	HepG2, Saos-2	WT control	CAT assay	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4012	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (RGC)	NA	NA	No (RGC)	37°C 	Human	MCF-7	WT control	CAT assay, temperature sensitive assay at 32°C	265	Ponchel F;Milner J;	Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo	1998	Br J Cancer	77	1555	9635828
4321	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1453	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	P 	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, RGC, S100A2)	TA (p53AIP1)	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]; Yes [TA (MDM2, WAF1 3', type IV collagenase)]	NA	Yes mut_H (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', type IV collagenase, 14-3-3s, B99, RGC); Yes mut_L & H (Cyclin G, WAF1 3', S100A2); No (p53AIP1)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1937	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3201	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2802	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
421	p.V272M	V272M	272	Val	Met	045354	L1/S/H2	NA	TA (WAF1 5')	TA (RGC, PIG3) partial; TA (BAX)	NA	NA	Yes mut_H (WAF1 5', BAX, PIG3, RGC)	33°C 	Yeast	Yeast	WT control	color selection, temperature sensitive assay at 33°C and 35°C	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
1702	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	GS	NA	NA	NA	NA	37°C 	Human	BE-13	WT control	CFA	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3765	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	TUMOR-	NA	NA	No (growth advantage); no (colony formation); no (TUMOR+)	NA	37°C 	Human	Be-13	no WT control	Proliferation assay, CFA in methylcellulose, tumorigenicity assay	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
3718	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	Resistance to chemotherapy	NA	37°C 	Human	C33A (endo)	Endogenous Mutant	siRNA	160	Irwin MS;Kondo K;Marin MC;Cheng LS;Hahn WC;Kaelin WG;	Chemosensitivity linked to p73 function	2003	Cancer Cell	3	403	12726865
3777	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	No (growth advantage); no (colony formation)	NA	37°C 	Human	CEM	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
4371	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1466	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	P 	NA	NA	Yes [TA (WAF1 5', KILLER/DR5, NOXA, PCNA)]	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4062	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	No (DOX and TAX resistance); No [upregulation (P-gp)]	NA	37°C 	Human	Hep3B	no WT control	Western blot, treatment with doxorubicin or paclitaxel + CFA and FACS analysis	280	Chan KT;Lung ML;	Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line	2004	Cancer Chemother Pharmacol 	53	519	15004724
3941	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	DNAb (p53CON)	NA	NA	NA	37°C 	Human	HTB31 (endo)	Endogenous Mutant	EMSA	246	Srivastava S;Wang S;Tong YA;Hao ZM;Chang EH;	Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis	1993	Cancer Res 	53	4452	8402611
3737	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	Upregulation (RLN2) moderate; no [regulation (H2relaxin)]	NA	37°C 	Human	LNCaP	no WT control	RT-PCR, western blot	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
3731	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1) moderate; androgen-independent cell growth	NA	37°C 	Human	LNCaP	no WT control	Western blot, proliferation assay	52	Nesslinger NJ;Shi XB;deVere White RW;	Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53	2003	Cancer Res	63	2228	12727844
3771	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	MOLT-4	no WT control	Proliferation assay, CFA in methylcellulose	97	Hsiao M;Low J;Dorn E;Ku D;Pattengale P;Yeargin J;Haas M;	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness	1994	Am J Pathol	145	702	8080050
4138	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4150	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	No (growth advantage)	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4125	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1); No [upregulation (IL-6)]; culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
3889	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	R 	NA	NA	NA	p73 interference; CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3890	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	P 	NA	NA	NA	p73 interference (moderate); CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4478	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
2117	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	RNA pol III repression	NA	No (RNA pol III activation)	NA	37°C 	Human	Saos-2	WT control	Study of VA1 expression	17	Stein T;Crighton D;Boyle JM;Varley JM;White RJ;	RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	2002	Oncogene	21	2961	12082526
117	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (MDM2, PG13); TR (C-FOS) ; GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
77	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	R 	NA	TA (WAF1); GS; TR (C-JUN) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
31	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
2127	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
2126	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
3998	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	NA	TRANSF+	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
3442	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4290	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4593	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4673	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2666	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
2678	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	171	Tada M;Matsumoto R;Iggo RD;Onimaru R;Shirato H;Sawamura Y;Shinohe Y;	Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations	1998	Cancer Res	58	1793	9581814
2745	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	179	Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	1999	Oncogene	18	5870	10557074
2046	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
1866	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
1738	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
2804	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2770	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2827	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2929	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2956	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3179	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3118	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
210	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
204	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
191	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
265	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
230	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
246	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
257	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
1384	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1263	p.R273C	R273C	273	Arg	Cys	005993	L1/S/H2	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX)	Yes [TA (WAF1 5', P53R2, GADD45, CD95-Fas, MDM2, RGC, BAX)] moderate; Yes [TA (PCNA, IGF-BP3, WAF1 3', NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
4479	[p.R273C;A364_D393del]	R273C/A364_D393del	273	Arg	NA		L1/S/H2	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4293	[p.R273C;D281G;E285G;G325R;E343V]	R273C/D281G/E285G/G325R/E343V	273	Arg	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4294	[p.R273C;E285K;E294G;E346G]	R273C/E285K/E294G/E346G]	273	Arg	NA		L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4480	[p.R273C;T284R]	R273C/T284R	273	Arg	NA		L1/S/H2	NA	NA	TA (p53CON) partial; GS partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4481	[p.R273C;T284R;A364_D393del]	R273C/T284R/A364_D393del	273	Arg	NA		L1/S/H2	NA	GS	TA (p53CON) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4674	p.R273G	R273G	273	Arg	Gly	005994	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3068	p.R273G	R273G	273	Arg	Gly	005994	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
2920	p.R273G	R273G	273	Arg	Gly	005994	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2978	p.R273G	R273G	273	Arg	Gly	005994	L1/S/H2	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2822	p.R273G	R273G	273	Arg	Gly	005994	L1/S/H2	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3901	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	ETO resistance	NA	37°C 	Human	21PT	no WT control	Etoposide treatment	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
4225	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	Interference with Beta-catenin-dependent TCF signalling	NA	NA	NA	NA	37°C 	Human	22Rv1	WT control	Luciferase assay	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
3734	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Upregulation (RLN2)	NA	37°C 	Human	22Rv1, DU-145	no WT control	RT-PCR	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
4092	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Daxx interference	NA	37°C 	Human	293	WT control	ASK1 activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
2081	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	TA (p53CON) supertrans	NA	NA	NA	NA	37°C 	Human	293	WT control	CAT assay	155	Chumakov AM;Miller CW;Chen DL;Koeffler HP;	Analysis of p53 transactivation through high-affinity binding sites	1993	Oncogene	8	3005	8414502
3755	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Downregulation (PTHRP) moderate	NA	37°C 	Human	A253	no WT control	RNase protection assay	66	Foley J;Wysolmerski JJ;Broadus AE;Philbrick WM;	Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53	1996	Cancer Res	56	4056	8752179
3756	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Downregulation (PTHRP)	NA	37°C 	Human	A431 (endo)	Endogenous Mutant	Inhibition by E1B	66	Foley J;Wysolmerski JJ;Broadus AE;Philbrick WM;	Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53	1996	Cancer Res	56	4056	8752179
3800	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	A431 (endo)	Endogenous Mutant	EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
4266	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	DOX and MTX resistance (partial); downregulation (procaspase-3); upregulation (procaspase-8 and 9)	NA	37°C 	Human	A431 (endo)	Endogenous Mutant	siRNA + drug treatment + DNA fragmentation study, western blot	316	Wong RP;Tsang WP;Chau PY;Co NN;Tsang TY;Kwok TT;	p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3	2007	Mol Cancer Ther 	6	1054	17363498
3832	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	NA	NA	p38 and p42 binding; growth advantage	NA	37°C 	Human	A673 (endo)	Endogenous Mutant	Co-IP, proliferation assay	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
3985	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (culture in soft agar or plastic, TUMOR+, TGF-beta); gamma-irradiation resistance	NA	37°C 	Human	AA/C1	no WT control	CFA on plastic and in agar, tumorigenicity assay, TGF-beta or gamma-irradiation treatment	260	Williams AC;Miller JC;Collard TJ;Bracey TS;Cosulich S;Paraskeva C;	Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation	1995	Oncogene	11	141	7624121
3801	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	AML1 (endo)	Endogenous Mutant	EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
3940	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (MDR-1)	NA	TA (MDR-1); no [TA (MRP1)]	NA	37°C 	Human	CACO2	no WT control	Luciferase assay	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
398	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1, BAX); GS; APO	Yes [TA (BAX)]; Yes (APO); No [TA (WAF1)]; No (GS)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
48	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	Calu-6, VAMT-1	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
2080	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (p53CON) partial	NA	NA	NA	37°C 	Human	COS-1	WT control	CAT assay	155	Chumakov AM;Miller CW;Chen DL;Koeffler HP;	Analysis of p53 transactivation through high-affinity binding sites	1993	Oncogene	8	3005	8414502
1685	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	BLM and WRN binding (partial)	NA	NA	NA	37°C 	Human	GM01310	WT control	IP	93	Yang Q;Zhang R;Wang XW;Spillare EA;Linke SP;Subramanian D;Griffith JD;Li JL;Hickson ID;Shen JC;Loeb LA;Mazur SJ;Appella E;Brosh RM;Karmakar P;Bohr VA;Harris CC;	The processing of Holliday junctions by BLM and WRN helicases is regulated by p53	2002	J Biol Chem	277	31980	12080066
1483	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Mdm2 stabilization	NA	37°C 	Human	H1299	WT control	Western blot, IF	80	Peng Y;Chen L;Li C;Lu W;Agrawal S;Chen J;	Stabilization of the MDM2 oncoprotein by mutant p53	2001	J Biol Chem	276	6874	11152666
1492	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	MBP1 binding (low affinity)	NA	37°C 	Human	H1299	WT control	Co-IP	81	Gallagher WM;Argentini M;Sierra V;Bracco L;Debussche L;Conseiller E;	MBP1: a novel mutant p53-specific protein partner with oncogenic properties	1999	Oncogene	18	3608	10380882
1788	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1789	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1843	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	RPA binding	HR repression	NA	NA	NA	37°C 	Human	H1299	WT control	Transfection + IP, homologous recombination (HR) assay	121	Romanova LY;Willers H;Blagosklonny MV;Powell SN;	The interaction of p53 with replication protein A mediates suppression of homologous recombination	2004	Oncogene	23	9025	15489903
2064	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (MDM2, BAX-A, WAF1 5')	Yes [TA (BAX-A, WAF1 5')]	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	151	Zacharatos PV;Gorgoulis VG;Kotsinas A;Manolis EN;Liloglou T;Rassidakis AN;Kanavaros P;Field JD;Halazonetis T;Kittas C;	Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1	1999	Anticancer Res	19	579	10226602
1974	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	TA (p53CON)	TA (RGC)	No [TA (p53CON)]	NA	No (RGC); Yes mut_L (p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
3311	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RPS27L)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	222	He H;Sun Y;	Ribosomal protein S27L is a direct p53 target that regulates apoptosis	2006	Oncogene			17057733
3294	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (CDC25)	NA	TA (CDC25)	NA	37°C 	Human	H1299	WT control	Luciferase assay	219	Di Agostino S;Strano S;Emiliozzi V;Zerbini V;Mottolese M;Sacchi A;Blandino G;Piaggio G;	Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation	2006	Cancer Cell	10	191	16959611
137	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	NA	NA	p63 and p73 binding	NA	37°C 	Human	H1299	WT control	Co-IP	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
923	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	GS; GA	Yes [upregulation (p21waf1)]; Yes [upregulation (FDXR )]; Yes [TA (WAF1, MDM2, PIG3)]; Yes (GA) partial	NA	NA	37°C 	Human	H1299	WT control	Western blot, Northern blot + ChiP assay, FACS analysis	60	Willis A;Jung EJ;Wakefield T;Chen X;	Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes	2004	Oncogene	23	2330	14743206
3911	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3912	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3898	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	ETO resistance	NA	37°C 	Human	H1299	no WT control	Etoposide treatment	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
4081	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	Upregulation (p21waf1); GS; GA partial; APO partial	NA	No (p73beta interference); p73beta binding	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
4082	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	Upregulation (p21waf1); GS; GA; APO	NA	No (p73beta interference, p73beta binding)	NA	37°C 	Human	H1299	WT control	Western blot, co-IP, Proliferation assay, FACS analysis	283	Willis AC;Pipes T;Zhu J;Chen X;	p73 can suppress the proliferation of cells that express mutant p53	2003	Oncogene	22	5481	12934108
4108	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Downregulation (MSP)	NA	37°C 	Human	H1299	no WT control	RT-PCR	288	Zalcenstein A;Weisz L;Stambolsky P;Bar J;Rotter V;Oren M;	Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53	2006	Oncogene	25	359	16170349
4200	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Promotion of transcriptional TGF-beta1 response	NA	Repression of transcriptional TGF-beta1 response	NA	37°C 	Human	H1299	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
3746	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS; ETO sensitivity	NA	ETO resistance (moderate)	NA	37°C 	Human	H1299	no WT control	CFA, etoposide treatment, FACS analysis	15	Blandino G;Levine AJ;Oren M;	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy	1999	Oncogene	18	477	9927204
3807	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Upregulation (Asns); DNAb (ASNS, hTERT); p73 binding (weak)	NA	37°C 	Human	H1299	no WT control	Western blot, ChIP assay, co-IP	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
3332	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Downregulation (Vrk1)	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot	226	Valbuena A;Vega FM;Blanco S;Lazo PA;	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop	2006	Mol Cell Biol 	26	4782	16782868
3497	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	Upregulation (WAF1, GADD45, p53R2); downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT) partial	NA	Upregulation (MDR-1)	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3498	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	Upregulation (WAF1, GADD45); upregulation (p53R2) partial; downregulation (MDR-1) partial; TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT)	NA	TA (hTERT)	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3474	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	H1299	WT control	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
4358	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
11	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Upregulation (C-MYC); no [upregulation (dUTPase)]	NA	37°C 	Human	H1299, SK-OV-3	WT control	RT-PCR	2	Pugacheva EN;Ivanov AV;Kravchenko JE;Kopnin BP;Levine AJ;Chumakov PM;	Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil	2002	Oncogene	21	4595	12096336
4063	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PG13, MDR1)	NA	NA	NA	37°C 	Human	H358	WT control	CAT assay	281	Goldsmith ME;Gudas JM;Schneider E;Cowan KH;	Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line	1995	J Biol Chem 	270	1894	7829527
3973	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	DNAb (p53CON)	NA	NA	NA	37°C 	Human	H358	WT control	EMSA	255	Unger T;Mietz JA;Scheffner M;Yee CL;Howley PM;	Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression	1993	Mol Cell Biol 	13	5186	8355677
84	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PG13)	Yes [TA (PG13)]	NA	NA	37°C 	Human	HCT-116	WT control	CAT assay	11	Kern SE;Pietenpol JA;Thiagalingam S;Seymour A;Kinzler KW;Vogelstein B;	Oncogenic forms of p53 inhibit p53-regulated gene expression	1992	Science	256	827	1589764
4162	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (FAK); TA (WAF1); DNAb (FAK)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay, ChIP assay	294	Golubovskaya VM;Finch R;Kweh F;Massoll NA;Campbell-Thompson M;Wallace MR;Cance WG;	p53 regulates FAK expression in human tumor cells	2008	Mol Carcinog 	47	373	17999388
3370	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	236	Okada M;Tessier A;Bai L;Merchant JL;	P53 mutants suppress ZBP-89 function	2006	Anticancer Res 	26	2023	16827139
4096	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Daxx interference; No (Ask1 interference)	NA	37°C 	Human	HeLa	no WT control	JNK activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4519	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PAI-1)	NA	TR (PAI-1) moderate	NA	37°C 	Human	HeLa	WT control	CAT assay	329	Kunz C;Pebler S;Otte J;von der AD;	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53	1995	Nucleic Acids Res 	23	3710	7479001
917	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (PCNA); TR (CMV, HSV1-UL9, RSV, HTLV)	NA	TA (PCNA); TA (RSV, HTLV); no [TA(CMV, HSV1-UL9)]	NA	37°C 	Human	HeLa	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1956	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (HSV1-TK) partial	NA	NA	NA	37°C 	Human	HeLa	WT control	CAT assay	134	Subler MA;Martin DW;Deb S;	Inhibition of viral and cellular promoters by human wild-type p53	1992	J Virol	66	4757	1352831
1646	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	TA (BAG-1)	NA	37°C 	Human	HeLa	WT control	Luciferase assay	85	Yang X;Pater A;Tang SC;	Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	1999	Oncogene	18	4546	10467399
1960	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (HIV)	NA	TA (HIV)	NA	37°C 	Human	HeLa, Saos-2	WT control	CAT assay	135	Subler MA;Martin DW;Deb S;	Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53	1994	J Virol	68	103	8254719
1852	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS (partial); TA (PG13)	NA	NA	NA	37°C 	Human	Hep3B	WT control	CAT assay	125	Stahler F;Roemer K;	Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	1998	Oncogene	17	3507	10030675
4250	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Upregulation (WAF1, BAX, MDM2, MASPIN, PAI-1, KAI1); TA (WAF1, BAX, MDM2)	NA	Growth advantage; cell mobility advantage; downregulation (MASPIN, PAI-1, KAI1)	NA	37°C 	Human	HHUA	no WT control	RT-qPCR, luciferase assay, proliferation assay, in vitro invasion and cell migration assay	313	Dong P;Tada M;Hamada J;Nakamura A;Moriuchi T;Sakuragi N;	p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells	2007	Clin Exp Metastasis	24	471	17636407
4252	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Growth advantage; cell mobility advantage	NA	37°C 	Human	HHUA	no WT control	proliferation assay, in vitro invasion and cell migration assay	313	Dong P;Tada M;Hamada J;Nakamura A;Moriuchi T;Sakuragi N;	p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells	2007	Clin Exp Metastasis	24	471	17636407
3960	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	No (GS)	NA	NA	37°C 	Human	HT-1080	WT control	BrdU incorporation assay	253	Sharma S;Schwarte-Waldhoff I;Oberhuber H;Schafer R;	Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes	1993	Cell Growth Differ 	4	861	8274455
3837	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	p38 and p42 binding	NA	37°C 	Human	HT29 (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
3802	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	p73 binding	NA	37°C 	Human	HT-29 (endo)	Endogenous Mutant	Co-IP	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
3794	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	HT-29 (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
3781	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Growth advantage; TUMOR+; drug resistance	NA	37°C 	Human	HT-29 (endo)	Endogenous Mutant	siRNA	138	Bossi G;Lapi E;Strano S;Rinaldo C;Blandino G;Sacchi A;	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression	2006	Oncogene	25	304	16170357
4041	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	Topoisomerase I binding	NA	NA	Constitutive topoisomerase I binding	NA	37°C 	Human	HT-29 (endo)	Endogenous Mutant	Co-IP + topoisomerase I activity study	273	Gobert C;Skladanowski A;Larsen AK;	The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53	1999	Proc Natl Acad Sci U S A	96	10355	10468612
4044	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	JNK, Mdm2 and p14ARF binding	NA	NA	NA	NA	37°C 	Human	HT-29 (endo)	Endogenous Mutant	Co-IP	274	Buschmann T;Minamoto T;Wagle N;Fuchs SY;Adler V;Mai M;Ronai Z;	Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability	2000	J Mol Biol 	295	1009	10656807
4089	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	NA	NA	37°C 	Human	HT-29 (endo)	Endogenous Mutant	Co-IP	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
3933	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Upregulation (Fas)	NA	NA	No (Fas)	37°C 	Human	K562	no WT control	FACS analysis, temperature sensitive assay at 32°C	241	Owen-Schaub LB;Zhang W;Cusack JC;Angelo LS;Santee SM;Fujiwara T;Roth JA;Deisseroth AB;Zhang WW;Kruzel E;.;	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression	1995	Mol Cell Biol 	15	3032	7539102
4274	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	K-562	WT control	Transfection	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
4275	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	Dependence on serum factors	NA	NA	Production of some differentiation markers	NA	37°C 	Human	K-562	no WT control	FACS analysis, culture in 1% serum medium	318	Kremenetskaya OS;Logacheva NP;Baryshnikov AY;Chumakov PM;Kopnin BP;	Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells	1997	Oncol Res 	9	155	9268986
1846	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	HR repression	NA	NA	NA	37°C 	Human	K-562	WT control	Homologous recombination (HR) assay	123	Boehden GS;Akyuz N;Roemer K;Wiesmuller L;	p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair	2003	Oncogene	22	4111	12821945
1847	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	HR repression (partial)	NA	NA	NA	37°C 	Human	K-562	WT control	Homologous recombination (HR) assay	124	Akyuz N;Boehden GS;Susse S;Rimek A;Preuss U;Scheidtmann KH;Wiesmuller L;	DNA substrate dependence of p53-mediated regulation of double-strand break repair	2002	Mol Cell Biol	22	6306	12167722
3140	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	NA	NA	NA	No (RGC, p53CON)	37°C 	Human	K-562	WT control	Luciferase assay, temperature sensitive assay at 32,5°C	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
7	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (p53CON)	TA (p53CON) partial; TA (RGC)	NA	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay, EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
1844	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Inhibition of hRad51 polymerization	NA	NA	NA	37°C 	Human	LFS041	WT control	Microscopy	122	Linke SP;Sengupta S;Khabie N;Jeffries BA;Buchhop S;Miska S;Henning W;Pedeux R;Wang XW;Hofseth LJ;Yang Q;Garfield SH;Sturzbecher HW;Harris CC;	p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination	2003	Cancer Res	63	2596	12750285
3742	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TUMOR-	NA	TUMOR+	NA	37°C 	Human	LNCaP	no WT control	Tumorigenicity assay	244	Perryman LA;Blair JM;Kingsley EA;Szymanska B;Ow KT;Wen VW;MacKenzie KL;Vermeulen PB;Jackson P;Russell PJ;	Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo	2006	Biochem Biophys Res Commun 	345	1207	16723121
3733	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Androgen-independent TUMOR+; DNAb (RLN2); TA (RLN2)	NA	37°C 	Human	LNCaP	no WT control	Tumorigenicity assay, RT-PCR, western blot, ChIP assay	243	Vinall RL;Tepper CG;Shi XB;Xue LA;Gandour-Edwards R;Vere White RW;	The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	2006	Oncogene	25	2082	16434975
3730	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1) moderate; androgen-independent cell growth	NA	37°C 	Human	LNCaP	no WT control	Western blot, proliferation assay	52	Nesslinger NJ;Shi XB;deVere White RW;	Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53	2003	Cancer Res	63	2228	12727844
4105	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (AG337 resistance)	NA	37°C 	Human	LoVo	no WT control	Treatment with AG337	286	Backus HH;Wouters D;Ferreira CG;van Houten VM;Brakenhoff RH;Pinedo HM;Peters GJ;	Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines	2003	Eur J Cancer	39	1310	12763222
3787	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	DNAb (WAF1, MDM2, BAX, PUMA, AIP1)	NA	NA	NA	37°C 	Human	LX-1 (endo)	Endogenous Mutant	ChIP assay	239	Magrini R;Russo D;Fronza G;Inga A;Menichini P;	The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage	2007	J Cell Biochem 	100	1276	17063487
3838	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	p38 and p42 binding	NA	37°C 	Human	MB-468 (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
4047	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	TA (HIV)	NA	37°C 	Human	MDAH041	no WT control	Luciferase assay	275	Chicas A;Molina P;Bargonetti J;	Mutant p53 forms a complex with Sp1 on HIV-LTR DNA	2000	Biochem Biophys Res Commun 	279	383	11118296
4049	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	TA (p53CON)	NA	NA	NA	NA	37°C 	Human	MDA-MB-468 (endo)	Endogenous Mutant	EMSA	275	Chicas A;Molina P;Bargonetti J;	Mutant p53 forms a complex with Sp1 on HIV-LTR DNA	2000	Biochem Biophys Res Commun 	279	383	11118296
4005	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (RGC, p53CON); TA (p53CON)	TA (RGC)	NA	NA	NA	37°C 	Human	MDA-MB-468 (endo)	Endogenous Mutant	EMSA	264	Prasad KA;Church JG;	Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells	1997	Biochem Biophys Res Commun 	232	14	9125118
3845	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	MDA-MB-468 (endo)	Endogenous Mutant	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3795	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	MDA-MB-468 (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
3784	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Bcl2 binding	NA	NA	NA	37°C 	Human	MDA-MB-468 (endo)	Endogenous Mutant	Co-IP	245	Tomita Y;Marchenko N;Erster S;Nemajerova A;Dehner A;Klein C;Pan H;Kessler H;Pancoska P;Moll UM;	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization	2006	J Biol Chem 	281	8600	16443602
3726	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	DNAb (RGC, WAF1)	NA	NA	No (DNAb)	37°C 	Human	MDA-MB-468 (endo)	Endogenous Mutant	EMSA, temperature sensitive assay at 4 and 32°C	242	Brazda V;Muller P;Brozkova K;Vojtesek B;	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity	2006	Biochem Biophys Res Commun 	351	499	17070499
1998	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS partial	NA	NA	NA	37°C 	Human	MG63, HSC3, Ca922	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
3804	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (CD95/Fas)	NA	TR (CD95/Fas) partially	NA	37°C 	Human	PC-3	no WT control	Luciferase assay	54	Zalcenstein A;Stambolsky P;Weisz L;Muller M;Wallach D;Goncharov TM;Krammer PH;Rotter V;Oren M;	Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	2003	Oncogene	22	5667	12944915
4133	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4145	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4221	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	Interference with Beta-catenin-dependent TCF signalling; downregulation (beta-catenin)	NA	NA	NA	NA	37°C 	Human	PC-3	WT control	Luciferase assay, western blot	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
49	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PG13)	Yes [TA (PG13)] moderate	NA	NA	37°C 	Human	PC-3, Saos-2	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
32	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PCNA) partial; GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
105	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	Stable transfection, CAT assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
118	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (MDM2, PG13); TR (C-FOS) ; GS	No [TA (PG13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
78	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	TA (WAF1); GS; TR (C-JUN) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
152	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (hMMP-13)	Yes [TR (hMMP-13)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	24	Sun Y;Cheung JM;Martel-Pelletier J;Pelletier JP;Wenger L;Altman RD;Howell DS;Cheung HS;	Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	2000	J Biol Chem	275	11327	10753945
927	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1, MDM2); TR (ASNS, hTERT); TR (SV40) partial; DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
913	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (PCNA)	NA	TA (PCNA)	NA	37°C 	Human	Saos-2	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1156	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (p73alpha binding)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
1988	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	TA (p53CON)	TA (RGC); TR (C-FOS); GS partial	NA	TA (C-FOS)	No (RGC, p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitivity assay at 30°C	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
2068	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NIM sensitivity	NA	CDDP resistance (moderate); no (NIM, DOX, BLEO resistance)	NA	37°C 	Human	Saos-2	WT control	Treatment with cisplatin, nimustine, doxorubicin or bleomycin	152	Wang LH;Okaichi K;Ihara M;Okumura Y;	Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point	1998	Anticancer Res	18	321	9568097
2054	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	Ag T binding; TUMOR-	No (TUMOR-)	No (TUMOR+); growth advantage	NA	37°C 	Human	Saos-2	WT control	IP, saturation density study, tumorigenicity assay	147	Chen PL;Chen YM;Bookstein R;Lee WH;	Genetic mechanisms of tumor suppression by the human p53 gene	1990	Science	250	1576	2274789
2088	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (HSP70)	NA	No [TA (HSP70)]; no (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2158	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (HLA-B7)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	161	Griffioen M;Steegenga WT;Ouwerkerk IJ;Peltenburg LT;Jochemsen AG;Schrier PI;	Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms	1998	Mol Immunol	35	829	9839551
1854	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	Saos-2	WT control		125	Stahler F;Roemer K;	Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	1998	Oncogene	17	3507	10030675
1769	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (ANGPT1, EBAG-9, ITGA6, Cyclin B2, POLD2, E2F-5)	NA	TA (ANGPT1, EBAG-9, ITGA6, Cyclin B2, POLD2, E2F-5)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	111	Scian MJ;Stagliano KE;Ellis MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Modulation of gene expression by tumor-derived p53 mutants	2004	Cancer Res	64	7447	15492269
1679	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS; Ag T binding	NA	No (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
1671	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	TA (EGFR) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	89	Ludes-Meyers JH;Subler MA;Shivakumar CV;Munoz RM;Jiang P;Bigger JE;Brown DR;Deb SP;Deb S;	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53	1996	Mol Cell Biol	16	6009	8887630
1705	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (IGFI-R)	NA	TA (IGFI-R)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	98	Werner H;Karnieli E;Rauscher FJ;LeRoith D;	Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene	1996	Proc Natl Acad Sci U S A	93	8318	8710868
1712	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (NFkB2-P2)	NA	TA (NFkB2-P2)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
3167	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (S100A2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	211	Tan M;Heizmann CW;Guan K;Schafer BW;Sun Y;	Transcriptional activation of the human S100A2 promoter by wild-type p53	1999	FEBS Lett 	445	265	10094469
3158	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
3254	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PTGF-beta)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	213	Tan M;Wang Y;Guan K;Sun Y;	PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway	2000	Proc Natl Acad Sci U S A	97	109	10618379
3173	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (type IV collagenase)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	212	Bian J;Sun Y;	Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter	1997	Mol Cell Biol 	17	6330	9343394
4267	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	DOX and MTX resistance; downregulation (procaspase-3); downregulation (PROCASPASE-3); upregulation (procaspase-8 and 9)	NA	37°C 	Human	Saos-2	no WT control	Drug treatment + DNA fragmentation study, western blot, RT-PCR	316	Wong RP;Tsang WP;Chau PY;Co NN;Tsang TY;Kwok TT;	p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3	2007	Mol Cancer Ther 	6	1054	17363498
4509	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (P53R2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	327	Otsuka K;Kato S;Kakudo Y;Mashiko S;Shibata H;Ishioka C;	The screening of the second-site suppressor mutations of the common p53 mutants	2007	Int J Cancer	121	559	17417775
4474	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4518	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TR (uPA) partial; TA (PAI-1)	NA	TR (PAI-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay	329	Kunz C;Pebler S;Otte J;von der AD;	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53	1995	Nucleic Acids Res 	23	3710	7479001
4069	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	Homologous recombination (HR) assay	NA	NA	NA	NA	37°C 	Human	Saos-2	no WT control	Ionizing irradiation + homologous recombination (HR) assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4073	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4100	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Daxx interference	NA	37°C 	Human	Saos-2	no WT control	CFA	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4087	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Daxx binding; culture in soft agar	NA	37°C 	Human	Saos-2	WT control	Co-IP, culture in soft agar	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4020	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Ionizing radiation sensitivity	NA	no (ionizing radiation resistance)	NA	37°C 	Human	Saos-2	WT control	X-ray irradiation	266	Okaichi K;Wang LH;Ihara M;Okumura Y;	Sensitivity to ionizing radiation in Saos-2 cells transfected with mutant p53 genes depends on the mutation position	1998	J Radiat Res (Tokyo)	39	111	9735599
4036	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Culture in soft agar (moderate); No (TUMOR+)	NA	37°C 	Human	Saos-2	no WT control	Culture in soft agar, tumorigenicity assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
3842	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	Saos-2	no WT control	Proliferation assay	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
3917	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	NA	NA	p73 interference	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3918	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3743	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Topoisomerase I binding; gene amplification	NA	37°C 	Human	Saos-2	no WT control	Co-IP	13	El Hizawi S;Lagowski JP;Kulesz-Martin M;Albor A;	Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins	2002	Cancer Res	62	3264	12036943
3813	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3471	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	p38 and p42 binding; growth advantage	NA	37°C 	Human	Saos-2	WT control	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
3406	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1, BAX); APO	Yes [TA (BAX)]; Yes (APO); No [TA (WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
1973	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	Saos-2, U2OS, KHOS-24OS	WT control	CFA	139	Diller L;Kassel J;Nelson CE;Gryka MA;Litwak G;Gebhardt M;Bressac B;Ozturk M;Baker SJ;Vogelstein B;.;	p53 functions as a cell cycle control protein in osteosarcomas	1990	Mol Cell Biol	10	5772	2233717
938	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	Yes [TA (RGC)]	No (p73 and p63 interference)	NA	37°C 	Human	SK-N-AS	WT control	Luciferase assay	64	Davison TS;Vagner C;Kaghad M;Ayed A;Caput D;Arrowsmith CH;	p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53	1999	J Biol Chem	274	18709	10373484
910	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Upregulation (PIG3, MDM2); TA (MDM2, PIG3, RGC); APO	NA	NA	NA	37°C 	Human	SK-N-MC	WT control	Northern blot, luciferase assay, FACS analysis	57	Pospisilova S;Siligan C;Ban J;Jug G;Kovar H;	Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y	2004	Mol Cancer Res	2	296	15192123
2069	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (p53CON) partial; TA (RGC)	NA	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	153	Park DJ;Chumakov AM;Miller CW;Pham EY;Koeffler HP;	p53 transactivation through various p53-responsive elements	1996	Mol Carcinog	16	101	8645424
3504	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No [TR (ATF3)]	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
3951	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	No [TA (p53CON)]	NA	NA	37°C 	Human	SK-OV-3	WT control	CAT assay	249	Hachiya M;Chumakov A;Miller CW;Akashi M;Said J;Koeffler HP;	Mutant p53 proteins behave in a dominant, negative fashion in vivo	1994	Anticancer Res 	14	1853	7847818
4204	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Repression of transcriptional TGF-beta1 response	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	297	Kalo E;Buganim Y;Shapira KE;Besserglick H;Goldfinger N;Weisz L;Stambolsky P;Henis YI;Rotter V;	Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II	2007	Mol Cell Biol 	27	8228	17875924
50	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (PG13)	No [TA (PG13)]	NA	NA	37°C 	Human	SK-OV-3, Hep3B, 21NT, 21PT, 21MT-1, 21MT-2	WT control	CAT assay	7	Forrester K;Lupold SE;Ott VL;Chay CH;Band V;Wang XW;Harris CC;	Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent	1995	Oncogene	10	2103	7784055
4253	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	Upregulation (MASPIN, PAI-1, KAI1)	NA	No (cell mobility advantage); no [downregulation (MASPIN, PAI-1, KAI1)]	NA	37°C 	Human	SK-OV-3, Saos-2	no WT control	In vitro invasion and cell migration assay, RT-qPCR	313	Dong P;Tada M;Hamada J;Nakamura A;Moriuchi T;Sakuragi N;	p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells	2007	Clin Exp Metastasis	24	471	17636407
4067	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (MDR1)	NA	NA	NA	37°C 	Human	SW620	WT control	CAT assay	281	Goldsmith ME;Gudas JM;Schneider E;Cowan KH;	Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line	1995	J Biol Chem 	270	1894	7829527
4112	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	Mre11 binding	NA	37°C 	Human	SW620 (endo)	Endogenous Mutant	Co-IP	289	Song H;Hollstein M;Xu Y;	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM	2007	Nat Cell Biol 	9	573	17417627
3793	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	SW620 (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
3839	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	p38 and p42 binding	NA	37°C 	Human	SW-620 (endo)	Endogenous Mutant	Co-IP	73	Chen Y;Chen PL;Lee WH;	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle	1994	Mol Cell Biol	14	6764	7935394
1762	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	APO partial	NA	NA	NA	37°C 	Human	T98G	WT control	TUNEL assay	108	Oda K;Arakawa H;Tanaka T;Matsuda K;Tanikawa C;Mori T;Nishimori H;Tamai K;Tokino T;Nakamura Y;Taya Y;	p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53	2000	Cell	102	849	11030628
3465	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	APO	NA	NA	NA	37°C 	Human	TC252, IARC-EW2	WT control	FACS analysis	57	Pospisilova S;Siligan C;Ban J;Jug G;Kovar H;	Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y	2004	Mol Cancer Res	2	296	15192123
4056	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (DOX and CDDP sensitivity)	NA	37°C 	Human	TCCSUP	no WT control	Treatment with cisplatin or doxorubicin	277	Chang FL;Lai MD;	Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells	2001	J Urol 	166	304	11435891
2134	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TRANSF-	NA	NA	NA	NA   	Other	BRK	WT control	Transformation assay	158	Crook T;Vousden KH;	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens	1992	EMBO J	11	3935	1327751
3150	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TRANSF- (partial)	NA	NA	NA	37°C 	Other	Rat-1	WT control	Transformation assay	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
2160	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	162	Slingerland JM;Benchimol S;	Transforming activity of mutant human p53 alleles	1991	J Cell Physiol	148	391	1918170
2107	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	Transformation assay	157	Hinds PW;Finlay CA;Quartin RS;Baker SJ;Fearon ER;Vogelstein B;Levine AJ;	Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes	1990	Cell Growth Differ	1	571	2288874
2100	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2014	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TRANSF- (partial)	NA	TRANSF+ (moderate); no (hsc70 binding)	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
1224	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	TRANSF+	NA	NA   	Other	REF	WT control	transformation assay	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
3999	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
3443	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3444	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4295	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4594	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4675	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1382	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
948	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	67	Kovvali GK;Mehta B;Epstein CB;Lutzker SG;	Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay	2001	Nucleic Acids Res	29		11222779
205	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
199	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC, p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
258	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
231	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
266	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
1938	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1939	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2038	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	145	Ishioka C;Frebourg T;Yan YX;Vidal M;Friend SH;Schmidt S;Iggo R;	Screening patients for heterozygous p53 mutations using a functional assay in yeast	1993	Nat Genet	5	124	8252037
2049	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	146	Scharer E;Iggo R;	Mammalian p53 can function as a transcription factor in yeast	1992	Nucleic Acids Res	20	1539	1579447
2673	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	169	Waridel F;Estreicher A;Bron L;Flaman JM;Fontolliet C;Monnier P;Frebourg T;Iggo R;	Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract	1997	Oncogene	14	163	9010218
2654	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	167	Tada M;Iggo RD;Ishii N;Shinohe Y;Sakuma S;Estreicher A;Sawamura Y;Abe H;	Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay	1996	Int J Cancer	67	447	8707423
1730	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
1772	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	112	Lomax ME;Barnes DM;Gilchrist R;Picksley SM;Varley JM;Camplejohn RS;	Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family	1997	Oncogene	14	1869	9150393
1863	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
3067	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3177	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2829	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
2856	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2751	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	180	Gong ZY;Wong KW;Li Y;Mao YR;Lung ML;	p53 inactivating mutations in chinese breast carcinomas	2000	Oncol Rep	7	381	10671690
2821	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2983	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
3011	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2928	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2950	p.R273H	R273H	273	Arg	His	005995	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
4475	[p.R273H;A364_D393del]	R273H/A364_D393del	273	Arg	NA		L1/S/H2	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
1997	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	NA	GS	NA	Growth advantage	NA	37°C 	Human	HSC3, Ca922	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
1996	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	NA	GS partial	NA	NA	NA	37°C 	Human	MG63	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
1987	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	TA (p53CON)	TA (RGC); TR (C-FOS); GS	NA	TA (C-FOS); no (growth advantage)	No (RGC, p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitivity assay at 30°C	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
3717	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	NA	NA	NA	p73 binding; resistance to chemotherapy	NA	37°C 	Human	SW480 (endo)	Endogenous Mutant	co-IP, siRNA	160	Irwin MS;Kondo K;Marin MC;Cheng LS;Hahn WC;Kaelin WG;	Chemosensitivity linked to p73 function	2003	Cancer Cell	3	403	12726865
3792	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	DNAb (p53CON)	NA	NA	NA	NA	37°C 	Human	SW480 (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
3782	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	NA	NA	NA	Growth advantage; TUMOR+; drug resistance	NA	37°C 	Human	SW480 (endo)	Endogenous Mutant	siRNA	138	Bossi G;Lapi E;Strano S;Rinaldo C;Blandino G;Sacchi A;	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression	2006	Oncogene	25	304	16170357
4043	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	JNK, Mdm2 and p14ARF binding	NA	NA	NA	NA	37°C 	Human	SW480 (endo)	Endogenous Mutant	Co-IP	274	Buschmann T;Minamoto T;Wagle N;Fuchs SY;Adler V;Mai M;Ronai Z;	Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability	2000	J Mol Biol 	295	1009	10656807
4111	[p.R273H;P309S]	R273H/P309S	273	Arg	NA		L1/S/H2	NA	NA	NA	NA	Mre11 binding	NA	37°C 	Human	SW480 (endo)	Endogenous Mutant	Co-IP	289	Song H;Hollstein M;Xu Y;	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM	2007	Nat Cell Biol 	9	573	17417627
4476	[p.R273H;T284R]	R273H/T284R	273	Arg	NA		L1/S/H2	NA	GS	TA (p53CON) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4477	[p.R273H;T284R;A364_D393del]	R273H/T284R/A364_D393del	273	Arg	NA		L1/S/H2	NA	TA (p53CON); GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4362	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
1975	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (RGC, p53CON)	Yes [TA (RGC, p53CON)] partial	NA	No (RGC, p53CON)	37°C 	Human	H1299	WT control	Luciferase assay, temperature sensitive assay at 30°C	140	Chen JY;Funk WD;Wright WE;Shay JW;Minna JD;	Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences	1993	Oncogene	8	2159	8336941
2001	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	GS	NA	NA	NA	NA	37°C 	Human	MG63, HSC3, Ca922	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
1990	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (RGC, p53CON); TR (C-FOS); GS partial	NA	TA (C-FOS)	No (RGC, p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitive assay at 30°C	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
79	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	R 	NA	TA (WAF1); GS; TR (C-JUN) partial	NA	No (hsp70 binding)	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
192	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_L (PIG3); No (WAF1, BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
232	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1391	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1940	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2681	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	172	Fujimoto H;Sasaki J;Matsumoto M;Suga M;Ando Y;Iggo R;Tada M;Saya H;Ando M;	Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma	1998	Jpn J Cancer Res	89	696	9738975
2986	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2806	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3190	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3260	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	P 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
3070	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3119	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
4329	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4676	p.R273L	R273L	273	Arg	Leu	036509	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, PUMA, WAF1)]; No [TA (MDM2)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2000	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	NA	NA	GS	NA	Growth advantage	NA	37°C 	Human	HSC3, Ca299	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
1999	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	NA	NA	GS partial	NA	NA	NA	37°C 	Human	MG63	WT control	CFA	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
1989	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	NA	NA	TA (RGC, p53CON); TR (C-FOS); GS	NA	TA (C-FOS); no (growth advantage)	No (RGC, p53CON)	37°C 	Human	Saos-2	WT control	CAT assay, temperature sensitivity assay at 30°C	141	Kawamura M;Yamashita T;Segawa K;Kaneuchi M;Shindoh M;Fujinaga K;	The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	1996	Oncogene	12	2361	8649776
80	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	R 	NA	TA (WAF1); GS;  TR (C-JUN)	NA	hsp70 binding	NA	37°C 	Human	Saos-2	WT control	CAT assay	10	Ory K;Legros Y;Auguin C;Soussi T;	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation	1994	EMBO J	13	3496	8062826
3820	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	R 	NA	NA	NA	p73 interference (weak)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3821	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	P 	NA	NA	NA	No (p73 interference)	NA	37°C 	Human	Saos-2	no WT control	CFA	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3830	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	R 	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3831	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	P 	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	no WT control	Transformation assay	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
184	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1421	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3120	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3224	p.R273P	R273P	273	Arg	Pro	045355	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2999	p.R273S	R273S	273	Arg	Ser	045357	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	200	Mitsumoto Y;Nakajima T;Marutani M;Kashiwazaki H;Moriguchi M;Kimura H;Okanoue T;Kagawa K;Tada M;	Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry	2004	Hum Pathol	35	350	15017592
3445	p.R273S	R273S	273	Arg	Ser	045357	L1/S/H2	P 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4677	p.R273S	R273S	273	Arg	Ser	045357	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
889	p.V274A	V274A	274	Val	Ala	045358	L1/S/H2	NA	NA	TA (WAF1, BAX, MDM2); GS; upregulation (p21waf1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA, western blot	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
635	p.V274A	V274A	274	Val	Ala	045358	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
440	p.V274A	V274A	274	Val	Ala	045358	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, BAX, P53R2, Noxa); No (14-3-3s, GADD45, AIP1)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
858	p.V274A	V274A	274	Val	Ala	045358	L1/S/H2	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1941	p.V274D	V274D	274	Val	Asp	045359	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
4513	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	TA (p53CON); upregulation (WAF1, MDM2, GADD45, PCNA, SLUG, HUNTINGTIN); upregulation (p21waf1); downregulation (SURVIVIN)	NA	NA	No (p53CON); No (WAF1, MDM2, GADD45, PCNA, SLUG, SURVIVIN, HUNTINGTIN)	37°C 	Human	PC3	no WT control	EGFP assay, Northern blot, RT-qPCR, Western blot, temperature sensitive assay at 32°C	328	Bajgelman MC;Strauss BE;	The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53	2006	Prostate	66	1455	16741917
906	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	GS	No (GS)	NA	NA	37°C 	Human	PC-3	WT control	CFA	56	Gurova KV;Rokhlin OW;Budanov AV;Burdelya LG;Chumakov PM;Cohen MB;Gudkov AV;	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells	2003	Cancer Res	63	2905	12782597
908	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis	56	Gurova KV;Rokhlin OW;Budanov AV;Burdelya LG;Chumakov PM;Cohen MB;Gudkov AV;	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells	2003	Cancer Res	63	2905	12782597
33	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	TA (PCNA); GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4127	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	Upregulation (p21waf1)	NA	Downregulation (p21waf1); upregulation (IL-6) low; culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	Western blot, ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
302	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
406	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
683	p.V274F	V274F	274	Val	Phe	005997	L1/S/H2	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4187	p.V274G	V274G	274	Val	Gly	047200	L1/S/H2	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
794	p.V274L	V274L	274	Val	Leu	045361	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
2984	p.V274L	V274L	274	Val	Leu	045361	L1/S/H2	NA	NA	TA (RGC)	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2957	p.V274L	V274L	274	Val	Leu	045361	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3072	p.C275F	C275F	275	Cys	Phe	045362	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3052	p.C275F	C275F	275	Cys	Phe	045362	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
2657	p.C275F	C275F	275	Cys	Phe	045362	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
822	p.C275F	C275F	275	Cys	Phe	045362	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
756	p.C275F	C275F	275	Cys	Phe	045362	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4547	p.C275R	C275R	275	Cys	Arg	045364	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
2736	p.C275W	C275W	275	Cys	Trp	005999	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
3891	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	R 	NA	NA	NA	No (p73 interference); CDDP resistance (weak)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3892	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	P 	NA	NA	NA	No (p73 interference); no (drug resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
2009	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	P 	NA	NA	NA	TRANSF+; hsc70 binding	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
2661	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
3051	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
3046	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
3121	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
755	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
373	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	NA	NA	TA (p53CON)	Yes [TA (p53CON)]	NA	No (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection	40	Waddell S;Jenkins JR;Proikas-Cezanne T;	A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	2001	Oncogene	20	6001	11593407
4611	p.C275Y	C275Y	275	Cys	Tyr	005998	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (PUMA, WAF1)]; No [TA (MDM2, BAX)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
391	p.A276D	A276D	276	Ala	Asp	045366	L1/S/H2	NA	NA	TA (WAF1, BAX, MDM2); GS; DNAb (MDM2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
304	p.A276G	A276G	276	Ala	Gly	045367	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1320	p.A276G	A276G	276	Ala	Gly	045367	L1/S/H2	P 	NA	TA (RGC, WAF1 5')	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1427	p.A276P	A276P	276	Ala	Pro	045368	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3233	p.A276P	A276P	276	Ala	Pro	045368	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3045	p.A276V	A276V	276	Ala	Val	045371	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
3054	p.A276V	A276V	276	Ala	Val	045371	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
1319	p.A276V	A276V	276	Ala	Val	045371	L1/S/H2	P 	NA	TA (RGC, WAF1 5')	NA	NA	Yes mut_L (WAF1 5')	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
303	p.A276V	A276V	276	Ala	Val	045371	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
684	p.A276V	A276V	276	Ala	Val	045371	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
3055	p.C277F	C277F	277	Cys	Phe	045372	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
2924	p.C277F	C277F	277	Cys	Phe	045372	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
1885	p.C277R	C277R	277	Cys	Arg	045373	L1/S/H2	NA	DNAb (MDM2, PIG3); TA (PIG3)	DNAb (WAF1); DNAb (BAX, AIP1, PUMA) partial; TA (WAF1); TA (MDM2, BAX) partial	NA	NA	NA	37°C 	Human	H1299	WT control	ChIP, RT-qPCR	102	Kaeser MD;Iggo RD;	Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo	2002	Proc Natl Acad Sci U S A	99	95	11756653
3478	p.C277R	C277R	277	Cys	Arg	045373	L1/S/H2	NA	Upregulation (mdm2, p21WAF1); upregulation (MDM2, CyclinG, CD95-Fas)	Upregulation (WAF1) partial; upregulation (BAX, PIR121)	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot, northern blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
1682	p.C277R	C277R	277	Cys	Arg	045373	L1/S/H2	NA	TA (MDM2)	APO partial; upregulation (PIR121)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, northern blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
3482	p.C277R	C277R	277	Cys	Arg	045373	L1/S/H2	NA	NA	Upregulation (PIR121)	NA	NA	NA	37°C 	Human	U2OS	WT control	Northern blot	92	Saller E;Tom E;Brunori M;Otter M;Estreicher A;Mack DH;Iggo R;	Increased apoptosis induction by 121F mutant p53	1999	EMBO J	18	4424	10449408
1264	p.C277R	C277R	277	Cys	Arg	045373	L1/S/H2	P 	TA (WAF1 5', MDM2, MDM2-RE2, PA26) supertrans; TA (14-3-3s)	TA (P53R2, GADD45) partial; TA (CD95-Fas, PCNA, AIP1, RGC, IGF-BP3, WAF1 3', BAX)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1265	p.C277W	C277W	277	Cys	Trp	047201	L1/S/H2	P 	TA (WAF1 5') supertrans	TA (P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, RGC, IGF-BP3, WAF1 3', PA26, BAX); TA (MDM2-RE2) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
138	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	P 	NA	TA (WAF1 5')	Yes [TA (WAF1 5')] moderate	No (p63 and p73 binding, p63 and p73 interference, hsp70 binding)	NA	37°C 	Human	H1299	WT control	Co-IP, luciferase assay	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
3464	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	NA	APO partial	NA	NA	NA	37°C 	Human	IARC-EW2	WT control	FACS analysis	57	Pospisilova S;Siligan C;Ban J;Jug G;Kovar H;	Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y	2004	Mol Cancer Res	2	296	15192123
909	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	Upregulation (PIG3); TA  (MDM2); TA (PIG3) supertrans	Upregulation (MDM2) partial; TA (RGC); APO partial	NA	NA	NA	37°C 	Human	SK-N-MC	WT control	Northern blot, luciferase assay, FACS analysis	57	Pospisilova S;Siligan C;Ban J;Jug G;Kovar H;	Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y	2004	Mol Cancer Res	2	296	15192123
3463	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	APO	NA	NA	NA	NA	37°C 	Human	TC252	WT control	FACS analysis	57	Pospisilova S;Siligan C;Ban J;Jug G;Kovar H;	Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y	2004	Mol Cancer Res	2	296	15192123
4612	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
868	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
778	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1422	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]; No [TA (GADD45)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
352	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
427	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	TA (WAF1)	TA (RGC, P53CON, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
3122	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	NA	NA	TA (WAF1 5', BAX); DNAb (WAF1) partial; DNAb (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection, EMSA	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3226	p.C277Y	C277Y	277	Cys	Tyr	045375	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
4595	p.P278A	P278A	278	Pro	Ala	006001	L1/S/H2	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
3244	p.P278H	P278H	278	Pro	His	006002	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3043	p.P278H	P278H	278	Pro	His	006002	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
2737	p.P278H	P278H	278	Pro	His	006002	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
353	p.P278H	P278H	278	Pro	His	006002	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1438	p.P278H	P278H	278	Pro	His	006002	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1473	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	P 	NA	NA	Yes [TA (WAF1 5')] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3204	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2907	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
2975	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	196	Fulci G;Labuhn M;Maier D;Lachat Y;Hausmann O;Hegi ME;Janzer RC;Merlo A;Van Meir EG;	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	2000	Oncogene	19	3816	10949938
2849	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
1447	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	Yes mut_H (GADD45); No (CSR, Cyclin G, CD95-Fas, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
870	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
4652	p.P278L	P278L	278	Pro	Leu	006003	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (WAF1)]; No [TA (MDM2, BAX, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4542	p.P278R	P278R	278	Pro	Arg	045376	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
3056	p.P278R	P278R	278	Pro	Arg	045376	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
3073	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
3123	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3205	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2848	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
876	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
1402	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, MDM2, WAF1 3', type IV collagenase)]; No [TA (CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5')]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
354	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
305	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
728	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
4653	p.P278S	P278S	278	Pro	Ser	006004	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX)]; No [TA (PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4548	p.P278T	P278T	278	Pro	Thr	006005	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
2859	p.P278T	P278T	278	Pro	Thr	006005	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3283	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	GS; APO; GA; UV sensitivity; gamma-irradiation resistance; DNAb (WAF1, MDM2, BAX, MSH2); upregulation (p21waf1, mdm2, bax, msh2); TA (WAF1, MDM2, MSH2, BAX)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment, ChIP, western blot, luciferase assay	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
2089	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	TR (HSP70)	NA	No [TA (HSP70)]; no (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
890	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	GS; upregulation (p21waf1)	No (GS)	NA	NA	37°C 	Human	Saos-2	WT control	CFA, western blot	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
2101	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
3216	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1413	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1266	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, NOXA, PUMA, C-FOS, RGC)	Yes [TA (WAF1 5', P53R2, GADD45, CD95-Fas, RGC)] moderate; Yes [TA (PCNA, MDM2, IGF-BP3, WAF1 3', BAX, NOXA, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
729	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
686	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
306	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
355	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
379	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	NA	NA	TA (BAX, PIG3, RGC); TA (WAF1 5') partial	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
3446	p.G279E	G279E	279	Gly	Glu	006006	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3282	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	NA	APO	GS partial; GA; UV sensitivity (partial); gamma-irradiation resistance (partial); DNAb (WAF1, MDM2) partial; DNAb (BAX, MSH2); upregulation (p21waf1, mdm2)  partial;  upregulation (bax, msh2); TA (WAF1) partial; TA (MDM2, MSH2, BAX)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment, ChIP, western blot, luciferase assay	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
329	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
687	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	NA	NA	NA	Yes [TA (RGC, BAX, PIG3)]; No [TA (WAF1 5’)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
381	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	NA	TA (WAF1 5')	TA (BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
579	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (P53R2); No (WAF1, MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1267	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	P 	TA (WAF1 5', GADD45, MDM2-RE2, PA26, PUMA) supertrans	TA (P53R2, MDM2, BAX) partial; TA (CD95-Fas, 14-3-3s, PCNA, AIP1, RGC, IGF-BP3, WAF1 3', BAX, NOXA)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3447	p.G279R	G279R	279	Gly	Arg	045377	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3448	p.G279V	G279V	279	Gly	Val	045378	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
688	p.G279V	G279V	279	Gly	Val	045378	L1/S/H2	NA	NA	NA	Yes [TA (RGC, BAX, PIG3)]; No [TA (WAF1 5’)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
330	p.G279V	G279V	279	Gly	Val	045378	L1/S/H2	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
380	p.G279V	G279V	279	Gly	Val	045378	L1/S/H2	NA	TA (WAF1 5')	TA (BAX, PIG3, RGC)	NA	NA	NA	33°C 	Yeast	Yeast	WT control	Color selection	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
1808	p.R280G	R280G	280	Arg	Gly	045380	L1/S/H2	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1734	p.R280G	R280G	280	Arg	Gly	045380	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
2852	p.R280G	R280G	280	Arg	Gly	045380	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
2923	p.R280G	R280G	280	Arg	Gly	045380	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
1732	p.R280I	R280I	280	Arg	Ile	006008	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
3333	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	Downregulation (Vrk1)	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot, IF	226	Valbuena A;Vega FM;Blanco S;Lazo PA;	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop	2006	Mol Cell Biol 	26	4782	16782868
3475	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	H1299	WT control	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3483	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TR (RAD51)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	120	Arias-Lopez C;Lazaro-Trueba I;Kerr P;Lord CJ;Dexter T;Iravani M;Ashworth A;Silva A;	p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene	2006	EMBO Rep	7	219	16322760
1837	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	Upregulation (p21waf1); APO; downregulation (RAD51);  Rad51 foci formation	NA	NA	NA	37°C 	Human	H24	WT control	Western blot, FACS analysis, RT-qPCR	120	Arias-Lopez C;Lazaro-Trueba I;Kerr P;Lord CJ;Dexter T;Iravani M;Ashworth A;Silva A;	p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene	2006	EMBO Rep	7	219	16322760
3723	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	 DNAb (RGC, WAF1) partial	NA	NA	Mut_H (DNAb)	37°C 	Human	MDA-MB-231 (endo)	Endogenous Mutant	EMSA, temperature sensitive assay at 4 and 32°C	242	Brazda V;Muller P;Brozkova K;Vojtesek B;	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity	2006	Biochem Biophys Res Commun 	351	499	17070499
3846	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	BclXL binding	NA	NA	NA	37°C 	Human	MDA-MB-231 (endo)	Endogenous Mutant	Co-IP	75	Mihara M;Erster S;Zaika A;Petrenko O;Chittenden T;Pancoska P;Moll UM;	p53 has a direct apoptogenic role at the mitochondria	2003	Mol Cell	11	577	12667443
3783	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	Bcl2 binding	NA	NA	NA	37°C 	Human	MDA-MB-231 (endo)	Endogenous Mutant	Co-IP	245	Tomita Y;Marchenko N;Erster S;Nemajerova A;Dehner A;Klein C;Pan H;Kessler H;Pancoska P;Moll UM;	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization	2006	J Biol Chem 	281	8600	16443602
3796	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	DNAb (p53CON)	NA	NA	NA	37°C 	Human	MDA-MB-231 (endo)	Endogenous Mutant	EMSA	238	Park DJ;Nakamura H;Chumakov AM;Said JW;Miller CW;Chen DL;Koeffler HP;	Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines	1994	Oncogene	9	1899	8208536
3788	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	DNAb (WAF1, MDM2, BAX, PUMA, AIP1)	NA	NA	NA	37°C 	Human	SK-MES-1 (endo)	Endogenous Mutant	ChIP assay	239	Magrini R;Russo D;Fronza G;Inga A;Menichini P;	The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage	2007	J Cell Biochem 	100	1276	17063487
4678	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2921	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
2991	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
3004	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
3039	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	202	Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;	A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value	2004	BJU Int	94	996	15541116
874	p.R280K	R280K	280	Arg	Lys	006007	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
1812	[p.R280K/A347T]	R280K/A347T	280	Arg	NA		L1/S/H2	R 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1737	p.R280S	R280S	280	Arg	Ser	045382	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
3234	p.R280S	R280S	280	Arg	Ser	045382	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1428	p.R280S	R280S	280	Arg	Ser	045382	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
357	p.R280S	R280S	280	Arg	Ser	045382	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
3928	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	NA	NA	Downregulation (WAF1); no [regulation (PIG3, GADD45, TAp73, C-JUN)]	NA	37°C 	Human	CNE-2 (endo)	Endogenous Mutant	siRNA, RT-PCR	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3312	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TA (RPS27L)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	222	He H;Sun Y;	Ribosomal protein S27L is a direct p53 target that regulates apoptosis	2006	Oncogene			17057733
1807	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	P 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1856	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	GS	Yes (GS)	Growth advantage	NA	37°C 	Human	Saos-2	WT control		90	Sun Y;Nakamura K;Wendel E;Colburn N;	Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma	1993	Proc Natl Acad Sci U S A	90	2827	8464896
3255	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TA (PTGF-beta)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	213	Tan M;Wang Y;Guan K;Sun Y;	PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway	2000	Proc Natl Acad Sci U S A	97	109	10618379
3168	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TA (S100A2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	211	Tan M;Heizmann CW;Guan K;Schafer BW;Sun Y;	Transcriptional activation of the human S100A2 promoter by wild-type p53	1999	FEBS Lett 	445	265	10094469
153	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TR (hMMP-13, hMMP1)	Yes [TR (hMMP-13)]; No [TR (hMMP1)]	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	24	Sun Y;Cheung JM;Martel-Pelletier J;Pelletier JP;Wenger L;Altman RD;Howell DS;Cheung HS;	Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	2000	J Biol Chem	275	11327	10753945
3339	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TA (PG13); GS	Yes [TA (PG13)]; Yes (GS)	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay, CFA	228	Sun Y;Dong Z;Nakamura K;Colburn NH;	Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma	1993	FASEB J 	7	944	8344492
4529	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	NA	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
356	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
1397	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3198	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2987	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
2966	p.R280T	R280T	280	Arg	Thr	006009	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
1810	[p.R280T;N288I;K319E;F338L]	R280T/N288I/K319E/F338L	280	Arg	NA		L1/S/H2	P 	NA	TA (PG13)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
2090	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	TR (HSP70)	NA	No [TA (HSP70)]; no (hsc70 binding)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, co-IP	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2102	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2697	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	176	Lung ML;Hu Y;Cheng Y;Li MF;Tang CM;SK O;Iggo RD;	p53 inactivating mutations in Chinese nasopharyngeal carcinomas	1998	Cancer Lett	133	89	9929165
1864	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
799	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	R 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
308	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
690	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	NA	Yes [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
4596	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
3451	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	P 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3452	p.D281E	D281E	281	Asp	Glu	006011	L1/S/H2	R 	NA	TA (RGC)	Yes [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3902	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	ETO resistance	NA	37°C 	Human	21PT	no WT control	Etoposide treatment	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
2055	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	C6-ceramide sensitivity	TR (MDR-1); ETO sensitivity	NA	TA (MDR-1); upregulation (Mdr-1); no [TA(MRP1)]; no [upregulation (Mrp1, Mrp4)]; ETO resistance	NA	37°C 	Human	CACO2	no WT control	Luciferase assay, western blot, etoposide or C6-ceramide treatment	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
1484	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	Mdm2 stabilization	NA	37°C 	Human	H1299	WT control	Western blot, IF	80	Peng Y;Chen L;Li C;Lu W;Agrawal S;Chen J;	Stabilization of the MDM2 oncoprotein by mutant p53	2001	J Biol Chem	276	6874	11152666
1494	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	MBP1 binding (moderate affinity)	NA	37°C 	Human	H1299	WT control	Co-IP	81	Gallagher WM;Argentini M;Sierra V;Bracco L;Debussche L;Conseiller E;	MBP1: a novel mutant p53-specific protein partner with oncogenic properties	1999	Oncogene	18	3608	10380882
3295	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (CDC25)	NA	TA (CDC25)	NA	37°C 	Human	H1299	WT control	Luciferase assay	219	Di Agostino S;Strano S;Emiliozzi V;Zerbini V;Mottolese M;Sacchi A;Blandino G;Piaggio G;	Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation	2006	Cancer Cell	10	191	16959611
3899	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	ETO resistance	NA	37°C 	Human	H1299	no WT control	Etoposide treatment	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
3466	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	Downregulation (ASNS, hTERT)	NA	Upregulation (ASNS, hTERT)	NA	37°C 	Human	H1299	WT control	RT-qPCR	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
3751	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	p73 binding; p73 interference	NA	37°C 	Human	H1299	no WT control	Co-IP, luciferase assay	25	Strano S;Munarriz E;Rossi M;Cristofanelli B;Shaul Y;Castagnoli L;Levine AJ;Sacchi A;Cesareni G;Oren M;Blandino G;	Physical and functional interaction between p53 mutants and different isoforms of p73	2000	J Biol Chem	275	29503	10884390
3806	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	GS	NA	Growth advantage; p73 binding (weak)	NA	37°C 	Human	H1299	no WT control	Proliferation assay, co-IP	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
4097	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	Daxx interference (moderate)	NA	37°C 	Human	HeLa	no WT control	JNK activity measurement	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
1647	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TA (BAG-1)	NA	37°C 	Human	HeLa	WT control	Luciferase assay	85	Yang X;Pater A;Tang SC;	Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	1999	Oncogene	18	4546	10467399
1957	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (HSV1-TK) partial	NA	NA	NA	37°C 	Human	HeLa	WT control	CAT assay	134	Subler MA;Martin DW;Deb S;	Inhibition of viral and cellular promoters by human wild-type p53	1992	J Virol	66	4757	1352831
918	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TA (PCNA); TR (CMV, HSV1-UL9, RSV, HTLV)	NA	TA (PCNA); TA (HSV1-UL9, RSV, HTLV); no [TA(CMV)]	NA	37°C 	Human	HeLa	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
13	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TA (HsMAD1)	NA	37°C 	Human	HeLa, HCT-116, HCT-116 (p53-null)	WT control	Luciferase assay	4	Iwanaga Y;Jeang KT;	Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant	2002	Cancer Res	62	2618	11980658
1961	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (HIV)	Yes [TR (HIV)]	TA (HIV)	NA	37°C 	Human	HeLa, Saos-2	WT control	CAT assay	135	Subler MA;Martin DW;Deb S;	Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53	1994	J Virol	68	103	8254719
3934	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	Upregulation (Fas)	NA	NA	No (Fas)	37°C 	Human	K562	no WT control	FACS analysis, temperature sensitive assay at 32°C	241	Owen-Schaub LB;Zhang W;Cusack JC;Angelo LS;Santee SM;Fujiwara T;Roth JA;Deisseroth AB;Zhang WW;Kruzel E;.;	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression	1995	Mol Cell Biol 	15	3032	7539102
3141	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	P 	NA	NA	NA	NA	No (RGC, p53CON)	37°C 	Human	K-562	WT control	Luciferase assay, temperature sensitive assay at 32,5°C	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
3138	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	Yes [TA (RGC)] moderate; No [TA (p53CON)]	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay	207	Zhang W;Shay JW;Deisseroth A;	Inactive p53 mutants may enhance the transcriptional activity of wild-type p53	1993	Cancer Res 	53	4772	8402659
8	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	DNAb (p53CON); TA (p53CON, RGC)	NA	NA	NA	37°C 	Human	K-562	WT control	Luciferase assay, EMSA	1	Zhang W;Funk WD;Wright WE;Shay JW;Deisseroth AB;	Novel DNA binding of p53 mutants and their role in transcriptional activation	1993	Oncogene	8	2555	8361764
3753	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TETR+	NA	37°C 	Human	NA	no WT control	Glutaraldehyde cross-linking assay	59	Deb D;Scian M;Roth KE;Li W;Keiger J;Chakraborti AS;Deb SP;Deb S;	Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants	2002	Oncogene	21	176	11803461
18	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	Spindle checkpoint	NA	NA	NA	37°C 	Human	NHF	WT control	Colcemid treatment	5	Gualberto A;Aldape K;Kozakiewicz K;Tlsty TD;	An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control	1998	Proc Natl Acad Sci U S A	95	5166	9560247
12	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	APO	Upregulation (fas, bax); upregulation (WAF1); GA	NA	APO independent of Bcl-2/BAX	NA	37°C 	Human	PC-3	WT control	FACS analysis, western blot	3	He M;Rennie PS;Dragowska V;Nelson CC;Jia W;	A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53	2002	FEBS Lett	517	151	12062426
106	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	Stable transfection, CAT assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
154	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (hMMP-13, hMMP1)	Yes [TR (hMMP-13, hMMP1)]	hMMP-13 induction	NA	37°C 	Human	Saos-2	WT control	CAT assay	24	Sun Y;Cheung JM;Martel-Pelletier J;Pelletier JP;Wenger L;Altman RD;Howell DS;Cheung HS;	Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)	2000	J Biol Chem	275	11327	10753945
416	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	TETR	TR (MDR-1)	Yes [TA (WAF1)] moderate	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay	45	Chene P;Bechter E;	p53 mutants without a functional tetramerisation domain are not oncogenic	1999	J Mol Biol	286	1269	10064694
926	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TA (WAF1, MDM2); TR (ASNS, hTERT, SV40); DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT, SV40)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
914	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (PCNA)	NA	TA (PCNA)	NA	37°C 	Human	Saos-2	WT control	CAT assay	58	Deb S;Jackson CT;Subler MA;Martin DW;	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells	1992	J Virol	66	6164	1356162
1157	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	No (p73alpha binding)	NA	37°C 	Human	Saos-2	WT control	Co-IP	72	Marin MC;Jost CA;Brooks LA;Irwin MS;O'Nions J;Tidy JA;James N;McGregor JM;Harwood CA;Yulug IG;Vousden KH;Allday MJ;Gusterson B;Ikawa S;Hinds PW;Crook T;Kaelin WG;	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	2000	Nat Genet	25	47	10802655
3169	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TA (S100A2)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	211	Tan M;Heizmann CW;Guan K;Schafer BW;Sun Y;	Transcriptional activation of the human S100A2 promoter by wild-type p53	1999	FEBS Lett 	445	265	10094469
3256	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	TA (PTGF-beta)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	213	Tan M;Wang Y;Guan K;Sun Y;	PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway	2000	Proc Natl Acad Sci U S A	97	109	10618379
3174	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TA (type IV collagenase)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	212	Bian J;Sun Y;	Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter	1997	Mol Cell Biol 	17	6330	9343394
2060	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	ets-1 binding	NA	37°C 	Human	Saos-2	WT control	Co-IP	148	Sampath J;Sun D;Kidd VJ;Grenet J;Gandhi A;Shapiro LH;Wang Q;Zambetti GP;Schuetz JD;	Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1	2001	J Biol Chem	276	39359	11483599
2159	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (HLA-B7)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	161	Griffioen M;Steegenga WT;Ouwerkerk IJ;Peltenburg LT;Jochemsen AG;Schrier PI;	Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms	1998	Mol Immunol	35	829	9839551
2147	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	Mdm2 binding	TR (C-MYC)	NA	TA (C-MYC)	NA	37°C 	Human	Saos-2	WT control	CAT assay, co-IP	74	Brown DR;Deb D;Frum R;Hickes L;Munoz R;Deb S;Deb SP;	The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants	2001	Int J Oncol	18	449	11179471
1713	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (NFkB2-P2)	NA	TA (NFkB2-P2)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	99	Scian MJ;Stagliano KE;Anderson MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Tumor-derived p53 mutants induce NF-kappaB2 gene expression	2005	Mol Cell Biol	25	10097	16260623
1672	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	TA (EGFR) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay	89	Ludes-Meyers JH;Subler MA;Shivakumar CV;Munoz RM;Jiang P;Bigger JE;Brown DR;Deb SP;Deb S;	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53	1996	Mol Cell Biol	16	6009	8887630
1767	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (ANGPT1, EBAG-9, ITGA6, Cyclin B2, POLD2, E2F-5)	NA	TA (ANGPT1, EBAG-9, ITGA6, Cyclin B2, POLD2, E2F-5)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	111	Scian MJ;Stagliano KE;Ellis MA;Hassan S;Bowman M;Miles MF;Deb SP;Deb S;	Modulation of gene expression by tumor-derived p53 mutants	2004	Cancer Res	64	7447	15492269
3752	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TA (EGFR, MDR-1)	NA	37°C 	Human	Saos-2	no WT control	Luciferase or CAT assay	59	Deb D;Scian M;Roth KE;Li W;Keiger J;Chakraborti AS;Deb SP;Deb S;	Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants	2002	Oncogene	21	176	11803461
3758	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TA (PCNA)	NA	37°C 	Human	Saos-2	no WT control	CAT assay	86	Lanyi A;Deb D;Seymour RC;Ludes-Meyers JH;Subler MA;Deb S;	'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain	1998	Oncogene	16	3169	9671396
3759	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TA (MDR-1); CDDP resistance	NA	37°C 	Human	Saos-2	no WT control	CAT assay, cisplatin treatment	88	Atema A;Chene P;	The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers	2002	Cancer Lett	185	103	12142085
3895	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	R 	NA	NA	NA	No (p73 binding)	NA	37°C 	Human	Saos-2	no WT control	Co-IP	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3896	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	P 	NA	NA	NA	No (p73 binding)	NA	37°C 	Human	Saos-2	no WT control	Co-IP	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
4037	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	No (culture in soft agar); No (TUMOR+)	NA	37°C 	Human	Saos-2	no WT control	Culture in soft agar, tumorigenicity assay	14	Dittmer D;Pati S;Zambetti G;Chu S;Teresky AK;Moore M;Finlay C;Levine AJ;	Gain of function mutations in p53	1993	Nat Genet	4	42	8099841
4088	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	Daxx binding (moderate); culture in soft agar (moderate)	NA	37°C 	Human	Saos-2	WT control	Co-IP, culture in soft agar	284	Ohiro Y;Usheva A;Kobayashi S;Duffy SL;Nantz R;Gius D;Horikoshi N;	Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53	2003	Mol Cell Biol 	23	322	12482984
4228	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TR (MCM-3, MCM-7)	NA	TA (MCM-3, MCM-7)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	305	Scian MJ;Carchman EH;Mohanraj L;Stagliano KE;Anderson MA;Deb D;Crane BM;Kiyono T;Windle B;Deb SP;Deb S;	Wild-type p53 and p73 negatively regulate expression of proliferation related genes	2008	Oncogene	27	2583	17982488
4229	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TA (MCM-5)	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	305	Scian MJ;Carchman EH;Mohanraj L;Stagliano KE;Anderson MA;Deb D;Crane BM;Kiyono T;Windle B;Deb SP;Deb S;	Wild-type p53 and p73 negatively regulate expression of proliferation related genes	2008	Oncogene	27	2583	17982488
3503	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	NA	TR (ATF3)	NA	37°C 	Human	SK-OV-3	WT control	Luciferase assay	227	Buganim Y;Kalo E;Brosh R;Besserglick H;Nachmany I;Rais Y;Stambolsky P;Tang X;Milyavsky M;Shats I;Kalis M;Goldfinger N;Rotter V;	Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction	2006	Cancer Res 	66	10750	17108111
3151	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TRANSF- (partial)	NA	NA	NA	37°C 	Other	Rat-1	WT control	Transformation assay	208	Zhang W;Guo XY;Hu GY;Liu WB;Shay JW;Deisseroth AB;	A temperature-sensitive mutant of human p53	1994	EMBO J 	13	2535	8013454
2106	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	P 	NA	NA	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	Transformation assay	157	Hinds PW;Finlay CA;Quartin RS;Baker SJ;Fearon ER;Vogelstein B;Levine AJ;	Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes	1990	Cell Growth Differ	1	571	2288874
3237	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1431	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
800	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	P 	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
358	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
4613	p.D281G	D281G	281	Asp	Gly	006012	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (BAX, WAF1)]; No [TA (MDM2, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3760	[p.D281G;L344P]	D281G/L344P	281	Asp	NA		L1/S/H2	NA	NA	NA	NA	No [TA (MDR-1)]; no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	CAT assay, cisplatin treatment	88	Atema A;Chene P;	The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers	2002	Cancer Lett	185	103	12142085
1665	[p.D281G;L344P]	D281G/L344P	281	Asp	NA		L1/S/H2	NA	NA	TETR; DNAb (WAF1); TR (MDR-1)	No [TA (WAF1)]	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay	45	Chene P;Bechter E;	p53 mutants without a functional tetramerisation domain are not oncogenic	1999	J Mol Biol	286	1269	10064694
4211	p.D281H	D281H	281	Asp	His	006013	L1/S/H2	NA	TA (WAF1) supertrans; TA (PUMA); upregulation (p21waf1)	TA (MDM2) partial; TA (BAX, AIP1); APO; DOX, CDDP and 5-FU sensitivity	NA	DOX, CDDP and 5-FU resistance	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, FACS analysis, treatment with Doxorubicin, Cisplatin or 5-FU, western blot	298	Kawamata H;Omotehara F;Nakashiro K;Uchida D;Shinagawa Y;Tachibana M;Imai Y;Fujimori T;	Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage	2007	Int J Oncol 	30	1089	17390010
4212	p.D281H	D281H	281	Asp	His	006013	L1/S/H2	NA	GA	NA	NA	NA	NA	37°C 	Human	Saos-2	no WT control	FACS analysis	298	Kawamata H;Omotehara F;Nakashiro K;Uchida D;Shinagawa Y;Tachibana M;Imai Y;Fujimori T;	Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage	2007	Int J Oncol 	30	1089	17390010
2728	p.D281H	D281H	281	Asp	His	006013	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
730	p.D281N	D281N	281	Asp	Asn	047202	L1/S/H2	NA	NA	NA	Yes [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
689	p.D281N	D281N	281	Asp	Asn	047202	L1/S/H2	NA	NA	NA	Yes [TA (WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
307	p.D281N	D281N	281	Asp	Asn	047202	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
877	p.D281N	D281N	281	Asp	Asn	047202	L1/S/H2	NA	NA	TA (MDM2, WAF1 5')	Yes [TA (WAF1 5')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
3449	p.D281N	D281N	281	Asp	Asn	047202	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4614	p.D281V	D281V	281	Asp	Val	006014	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3124	p.D281V	D281V	281	Asp	Val	006014	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3246	p.D281Y	D281Y	281	Asp	Tyr	045383	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
779	p.D281Y	D281Y	281	Asp	Tyr	045383	L1/S/H2	NA	NA	TA (RGC)	Yes [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1439	p.D281Y	D281Y	281	Asp	Tyr	045383	L1/S/H2	P 	NA	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase)]	NA	No (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
359	p.D281Y	D281Y	281	Asp	Tyr	045383	L1/S/H2	NA	NA	NA	Yes [TA (p53CON)]	NA	NA	30°C 	Yeast	Yeast	WT control	Growth selection	33	Brachmann RK;Vidal M;Boeke JD;	Dominant-negative p53 mutations selected in yeast hit cancer hot spots	1996	Proc Natl Acad Sci U S A	93	4091	8633021
3450	p.D281Y	D281Y	281	Asp	Tyr	045383	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
200	p.R282A	R282A	282	Arg	Ala		L1/S/H2	NA	NA	TA (RGC, p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
3346	p.R282G	R282G	282	Arg	Gly	045384	L1/S/H2	NA	NA	Upregulation (p21waf1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot	230	Ferrone M;Perrone F;Tamborini E;Paneni MS;Fermeglia M;Suardi S;Pastore E;Delia D;Pierotti MA;Pricl S;Pilotti S;	Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y)	2006	Mol Cancer Ther 	5	1467	16818505
3454	p.R282G	R282G	282	Arg	Gly	045384	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4679	p.R282G	R282G	282	Arg	Gly	045384	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	Yes [TA (WAF1)]; No [TA (MDM2, BAX, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2766	p.R282G	R282G	282	Arg	Gly	045384	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
3499	p.R282H	R282H	282	Arg	His	045385	L1/S/H2	P 	NA	Upregulation (WAF1, GADD45); upregulation (p53R2) partial; downregulation (MDR-1); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT)	NA	TA (hTERT)	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
3500	p.R282H	R282H	282	Arg	His	045385	L1/S/H2	R 	NA	Upregulation (WAF1, GADD45, p53R2); TA (IGF-BP3, p53R2, GADD45, CyclinG); TR (hTERT) partial	NA	NA	NA	37°C 	Human	H1299	WT control	RT-PCR, luciferase assay	234	Vikhanskaya F;Lee MK;Mazzoletti M;Broggini M;Sabapathy K;	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53	2007	Nucleic Acids Res 	35	2093	17344317
4137	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	PC-3	WT control	Stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4149	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	NA	NA	NA	Growth advantage	NA	37°C 	Human	PC-3	no WT control	FACS analysis	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
4141	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	NA	NA	NA	Upregulation (IL-6) moderate; culture in soft agar	NA	37°C 	Human	Saos-2	no WT control	ELISA assay, culture in soft agar	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
34	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	TA (PCNA) supertrans	GS	NA	TA (MDR-1)	NA	37°C 	Human	Saos-2	WT control	CAT assay, stable transfection	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
331	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
259	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C	6	Shi XB;Nesslinger NJ;Deitch AD;Gumerlock PH;deVere White RW;	Complex functions of mutant p53 alleles from human prostate cancer	2002	Prostate	51	59	11920959
248	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
1268	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	P 	TA (RGC) supertrans	TA (WAF1 5', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2,MDM2-RE2, IGF-BP3, PA26, BAX, PUMA) partial; TA (WAF1 3', NOXA)	No [TA (GADD45, CD95-Fas, PCNA, MDM2, IGF-BP3, PUMA)]; Yes [TA (WAF1 3')] moderate	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3455	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	P 	NA	TA (RGC)	NA	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
3456	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4680	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	TA (PUMA, WAF1)	TA (MDM2, BAX) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4549	p.R282Q	R282Q	282	Arg	Gln	045387	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
3913	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	R 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3914	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	GS; CDDP sensitivity	NA	CDDP resistance; no (GEM, VIN, DOX and ETO resistance); p73 interference	NA	37°C 	Human	H1299	no WT control	Proliferation assay, drugs treatment, luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1459	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	TA (WAF1 5', NOXA)	Yes [TA (WAF1 5', KILLER/DR5, NOXA, PCNA)] moderate	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
1790	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
1791	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	R 	NA	TA (WAF1, AIP-1, BAX)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
4165	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TR (FAK); TA (WAF1)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	294	Golubovskaya VM;Finch R;Kweh F;Massoll NA;Campbell-Thompson M;Wallace MR;Cance WG;	p53 regulates FAK expression in human tumor cells	2008	Mol Carcinog 	47	373	17999388
4045	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	p14ARF binding	JNK and Mdm2 binding	NA	NA	NA	37°C 	Human	PC-3 (endo)	Endogenous Mutant	Co-IP	274	Buschmann T;Minamoto T;Wagle N;Fuchs SY;Adler V;Mai M;Ronai Z;	Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability	2000	J Mol Biol 	295	1009	10656807
4071	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	HR repression	NA	NA	NA	NA	37°C 	Human	Saos-2	no WT control	Ionizing irradiation + homologous recombination (HR) assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
4075	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	282	Lu X;Lozano G;Donehower LA;	Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system	2003	Mutat Res 	522	69	12517413
3919	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	R 	NA	NA	NA	p73 interference	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3920	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	NA	NA	p73 interference (moderate)	NA	37°C 	Human	Saos-2	no WT control	Luciferase assay	115	Vikhanskaya F;Siddique MM;Kei LM;Broggini M;Sabapathy K;	Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs	2005	Clin Cancer Res	11	4348	15958617
3893	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	R 	NA	NA	NA	p73 interference; CDDP resistance (moderate)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
3894	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	NA	NA	p73 interference (moderate); no (CDDP resistance)	NA	37°C 	Human	Saos-2	no WT control	FACS analysis, cisplatin treatment	83	Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis	2003	Cancer Cell	3	387	12726864
1680	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	Ag T binding	GS	NA	hsc70 binding (weak)	NA	37°C 	Human	Saos-2	WT control	CFA, IP	91	Frebourg T;Kassel J;Lam KT;Gryka MA;Barbier N;Andersen TI;Borresen AL;Friend SH;	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein	1992	Proc Natl Acad Sci U S A	89	6413	1631137
3159	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay	209	Frebourg T;Barbier N;Kassel J;Ng YS;Romero P;Friend SH;	A functional screen for germ line p53 mutations based on transcriptional activation	1992	Cancer Res 	52	6976	1458490
925	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	TR (SV40)	TA (WAF1, MDM2); TR (ASNS, hTERT); DNAb (WAF1, RGC)	NA	TA (ASNS, hTERT)	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, EMSA	61	Scian MJ;Stagliano KE;Deb D;Ellis MA;Carchman EH;Das A;Valerie K;Deb SP;Deb S;	Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	2004	Oncogene	23	4430	15077194
4000	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	NA	NA	TRANSF+ (moderate)	NA	37°C 	Other	REF	WT control	Transformation assay	261	Kikuchi-Yanoshita R;Tanaka K;Muraoka M;Konishi M;Kawashima I;Takamoto S;Hirai H;Miyaki M;	Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene	1995	Oncogene	11	1339	7478555
3453	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
4537	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4681	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (PUMA)]; No [TA (MDM2, BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1442	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	TA (CD95-Fas, GADD45, WAF1 5')	TA (CSR, Cyclin G, GML, KILLER/DR5, MDM2, WAF1 3', type IV collagenase, , 14-3-3s, B99, p53AIP1, RGC, S100A2)	Yes [TA (Cyclin G, MDM2, WAF1 3')]; No [TA (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5', type IV collagenase)]	NA	No (CSR, Cyclin G, GML, KILLER/DR5, MDM2, WAF1 3', type IV collagenase, , 14-3-3s, B99, p53AIP1, RGC, S100A2); Yes mut_H (CD95-Fas, GADD45, WAF1 5')	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
233	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
3180	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2771	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2850	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	186	Partridge M;Li SR;Pateromichelakis S;Francis R;Phillips E;Huang XH;Tesfa-Selase F;Langdon JD;	Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment	2000	Clin Cancer Res	6	2718	10914716
2809	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
2888	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2918	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	193	Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;	Influence of p53 mutations on prognosis of patients with glioblastoma	2002	Cancer	95	249	12124823
1865	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	101	Flaman JM;Frebourg T;Moreau V;Charbonnier F;Martin C;Chappuis P;Sappino AP;Limacher IM;Bron L;Benhattar J;Tada M;Van Meir EG;Estreicher A;Iggo R;	A simple p53 functional assay for screening cell lines, blood, and tumors	1995	Proc Natl Acad Sci U S A	92	3963	7732013
2672	p.R282W	R282W	282	Arg	Trp	006016	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	169	Waridel F;Estreicher A;Bron L;Flaman JM;Fontolliet C;Monnier P;Frebourg T;Iggo R;	Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract	1997	Oncogene	14	163	9010218
4682	p.R283C	R283C	283	Arg	Cys	006017	L1/S/H2	NA	NA	TA (MDM2); TA (BAX, PUMA, WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1463	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	P 	TA (WAF1 5', NOXA) supertrans	NA	NA	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
139	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	P 	NA	TA (WAF1 5')	Yes [TA (WAF1 5')] moderate	p63 and p73 binding (low affinity); p63 and p73 interference (weak); no (hsp70 binding)	NA	37°C 	Human	H1299	WT control	Co-IP, luciferase assay	20	Gaiddon C;Lokshin M;Ahn J;Zhang T;Prives C;	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain	2001	Mol Cell Biol	21	1874	11238924
99	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	APO	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1221	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	NA	TRANSF-	NA	TRANSF+ (moderate)	NA	NA   	Other	REF	WT control	transformation assay	12	Smith PD;Crossland S;Parker G;Osin P;Brooks L;Waller J;Philp E;Crompton MR;Gusterson BA;Allday MJ;Crook T;	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	1999	Oncogene	18	2451	10229196
1269	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	P 	TA (WAF1 5', P53R2, CD95-Fas, PCNA, MDM2-RE2, PA26, BAX)	TA (GADD45, 14-3-3s, AIP1, MDM2, WAF1 3', PUMA) partial; TA (RGC, IGF-BP3, NOXA)	No [TA (GADD45, PCNA, RGC)]; Yes [TA (WAF1 3', PUMA)] moderate	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1451	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	P 	TA (CD95-Fas, GADD45, WAF1 5')	TA (CSR, Cyclin G,  GML, KILLER/DR5, MDM2, WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	No [TA (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5', type IV collagenase)]; Yes [TA (Cyclin G, MDM2, WAF1 3')]	NA	No (Cyclin G, MDM2, WAF1 3', 14-3-3s, B99, p53AIP1, RGC, S100A2); Yes mut_L (CSR, CD95-Fas, GADD45, GML, KILLER/DR5, WAF1 5', type IV collagenase)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
823	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	R 	NA	TA (RGC) partial	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
873	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	TA (WAF1 5')	TA (MDM2) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	36	Epstein CB;Attiyeh EF;Hobson DA;Silver AL;Broach JR;Levine AJ;	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	1998	Oncogene	16	2115	9572492
387	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	TA (WAF1 5')	TA (BAX); TA (PIG3, RGC) partial	NA	NA	Yes mut_L (WAF1 5', BAX, PIG3, RGC)	33°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 30°C and 35°C	41	Maurici D;Monti P;Campomenosi P;North S;Frebourg T;Fronza G;Hainaut P;	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	2001	Oncogene	20	3533	11429700
429	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	TA (WAF1, P53CON, Cyclin G)	TA (RGC, BAX, IGF-BP3-boxA&B); TA (MDM2, GADD45) partial	NA	NA	No (p53CON, WAF1, MDM2, Cyclin G, GADD45, BAX, IGF-BP3-boxA&B)	30°C 	Yeast	Yeast	WT control	Growth selection	35	Di Como CJ;Prives C;	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	1998	Oncogene	16	2527	9627118
710	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	R 	NA	NA	Yes [TA (BAX)]; No [TA (WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
2824	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	TA (WAF1 5')	TA (BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
3245	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	P 	TA (NOXA)	TA (BAI1, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, PA26, PCNA, PIDD, PTGF-beta_FBS01); Yes Mut_L (NOXA)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3271	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	R 	TA (WAF1)	TA (RGC) partial; TA (BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
3134	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	DNAb (WAF1)	DNAb (BAX) partial	NA	NA	NA	NA   	Yeast	Yeast	WT control	EMSA	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
4683	p.R283H	R283H	283	Arg	His	006019	L1/S/H2	NA	TA (WAF1)	TA (MDM2, BAX, PUMA) partial	Yes [TA (PUMA)]; No [TA (MDM2, BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
636	p.R283P	R283P	283	Arg	Pro	006020	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45); No (P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
580	p.R283P	R283P	283	Arg	Pro	006020	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (GADD45, P53R2); No (WAF1, MDM2, BAX, 14-3-3s, AIP1, Noxa)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4597	p.R283P	R283P	283	Arg	Pro	006020	L1/S/H2	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4468	p.T284R	T284R	284	Thr	Arg		L1/S/H2	NA	GS	TA (p53CON) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4469	[p.T284R;A364_D393del]	T284R/A364_D393del	284	Thr	NA		L1/S/H2	NA	GS	TA (p53CON) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
637	p.E285D	E285D	285	Glu	Asp	045393	L1/S/H2	NA	NA	NA	NA	NA	No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
581	p.E285D	E285D	285	Glu	Asp	045393	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2); No (GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
639	p.E285G	E285G	285	Glu	Gly	045394	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (BAX); No (WAF1, MDM2, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
443	p.E285G	E285G	285	Glu	Gly	045394	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, AIP1, Noxa); No (BAX, GADD45, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3722	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	 DNAb (RGC, WAF1) partial	NA	NA	Mut_H (DNAb)	37°C 	Human	BT-474 (endo)	Endogenous Mutant	EMSA, temperature sensitive assay at 4 and 32°C	242	Brazda V;Muller P;Brozkova K;Vojtesek B;	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity	2006	Biochem Biophys Res Commun 	351	499	17070499
1460	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	P 	NA	TA (WAF1 5', NOXA)	Yes [TA (WAF1 5') moderate]	NA	NA	37°C 	Human	H1299	WT control	luciferase assay	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3387	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	GS	NA	NA	NA	37°C 	Human	HeLa	WT control	MTT assay	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
638	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
147	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (MDM2, WAF1); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay, CFA	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
448	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2, BAX); No (WAF1, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1452	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	P 	TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	NA	No [TA (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5')]; Yes [TA (WAF1 3', type IV collagenase)]	NA	Yes mut_H (CSR, Cyclin G, CD95-Fas, GADD45, GML, KILLER/DR5, MDM2, WAF1 5', WAF1 3', type IV collagenase, 14-3-3s, B99, p53AIP1, RGC, S100A2)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 37°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
3125	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
3269	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	P 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
3187	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	P 	NA	TA (BAI1, NOXA, PA26, PCNA, PIDD, PTGF-beta_FBS01)	NA	NA	No (BAI1, NOXA, PIDD); Yes mut_H (PA26, PCNA, PTGF-beta_FBS01)	37°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 25 and 30°C	79	Dearth LR;Qian H;Wang T;Baroni TE;Zeng J;Chen SW;Yi SY;Brachmann RK;	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers	2006	Carcinogenesis			16861262
2778	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	TA (RGC)	NA	NA	NA	Yes mut_H (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 35°C	183	Yamamoto S;Tada M;Lee CC;Masuda C;Wanibuchi H;Yoshimura R;Wada S;Yamamoto K;Kishimoto T;Fukushima S;	p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry	2000	Jpn J Cancer Res	91	181	10761705
2977	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2988	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
1774	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	112	Lomax ME;Barnes DM;Gilchrist R;Picksley SM;Varley JM;Camplejohn RS;	Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family	1997	Oncogene	14	1869	9150393
2731	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
2050	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	NA	TA (p53CON)	NA	NA	Yes mut_H (p53CON)	30°C 	Yeast	Yeast	WT control	Growth selection, temperature sensitive assay at 29 and 36°C	146	Scharer E;Iggo R;	Mammalian p53 can function as a transcription factor in yeast	1992	Nucleic Acids Res	20	1539	1579447
4188	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	TA (WAF1, RGC)	TA (BAX) partial	NA	NA	Yes mut_H (WAF1, BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
4598	p.E285K	E285K	285	Glu	Lys	006023	L1/S/H2	NA	TA (11 different p53-RE)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4618	p.E285Q	E285Q	285	Glu	Gln	006024	L1/S/H2	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4552	p.E285V	E285V	285	Glu	Val	006025	L1/S/H2	NA	NA	TA (p53CON); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, CFA	334	Russell-Swetek A;West AN;Mintern JE;Jenkins J;Rodriguez-Galindo C;Ribeiro R;Zambetti GP;	Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma	2008	J Med Genet	45	603	18762572
640	p.E285V	E285V	285	Glu	Val	006025	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
441	p.E285V	E285V	285	Glu	Val	006025	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (WAF1, MDM2, BAX, GADD45, AIP1, Noxa); No (14-3-3s, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3126	p.E286A	E286A	286	Glu	Ala	006026	L1/S/H2	NA	NA	TA (WAF1 5', BAX)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	206	Flaman JM;Robert V;Lenglet S;Moreau V;Iggo R;Frebourg T;	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	1998	Oncogene	16	1369	9546439
4619	p.E286A	E286A	286	Glu	Ala	006026	L1/S/H2	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (WAF1)]; No [TA (MDM2, BAX, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1942	p.E286G	E286G	286	Glu	Gly	006028	L1/S/H2	P 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
1855	p.E286G	E286G	286	Glu	Gly	006028	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	95	Campomenosi P;Fronza G;Ottaggio L;Roncella S;Inga A;Bogliolo M;Monti P;Assereto P;Moro F;Cutrona G;Bozzo S;Chiorazzi N;Abbondandolo A;Ferrarini M;	Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements	1997	Int J Cancer	73	816	9399658
691	p.E286G	E286G	286	Glu	Gly	006028	L1/S/H2	NA	NA	NA	Yes [TA (BAX)]; No [TA (RGC, WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
332	p.E286G	E286G	286	Glu	Gly	006028	L1/S/H2	NA	TA (WAF1)	TA (BAX, PIG3)	NA	NA	Yes mut_H (WAF1); No (BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
4373	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (KILLER/DR5, GML, WAF1)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4316	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (p53CON)	NA	NA	NA	30°C 	Yeast	Yeast	no WT control	Growth selection	321	Baroni TE;Wang T;Qian H;Dearth LR;Truong LN;Zeng J;Denes AE;Chen SW;Brachmann RK;	A global suppressor motif for p53 cancer mutants	2004	Proc Natl Acad Sci U S A	101	4930	15037740
4538	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
4189	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (WAF1, BAX, RGC)	NA	NA	Yes mut_H (WAF1, BAX)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
309	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1, BAX); No (PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
692	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	P 	NA	NA	Yes [TA (BAX)]; No [TA (WAF1 5’, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
731	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
824	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	P 	NA	TA (RGC)	NA	No (p73beta interference)	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
2679	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	171	Tada M;Matsumoto R;Iggo RD;Onimaru R;Shirato H;Sawamura Y;Shinohe Y;	Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations	1998	Cancer Res	58	1793	9581814
2981	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (RGC) partial	NA	NA	Yes mut_H (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	197	Pavlova S;Mayer J;Koukalova H;Smardova J;	High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast	2003	Int J Oncol	23	121	12792784
2996	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	199	M'kacher R;Bennaceur A;Farace F;Lauge A;Plassa LF;Wittmer E;Dossou J;Violot D;Deutsch E;Bourhis J;Stoppa-Lyonnet D;Ribrag V;Carde P;Parmentier C;Bernheim A;Turhan AG;	Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma	2003	Oncogene	22	5961	12970738
2908	p.E286K	E286K	286	Glu	Lys	006029	L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	191	Millon R;Muller D;Schultz I;Salvi R;Ghnassia JP;Frebourg T;Wasylyk B;Abecassis J;	Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance	2001	Oral Oncol	37	620	11590071
420	[p.E286K;E287D]	E286K/E287D	286	Glu	NA		L1/S/H2	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	Yes mut_H (WAF1, BAX); No (PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
392	p.E286Q	E286Q	286	Glu	Gln	006030	L1/S/H2	NA	GS	TA (WAF1, BAX); TA (MDM2) partial; DNAb (MDM2) partial	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, CFA, EMSA	42	Ko JL;Chiao MC;Chang SL;Lin P;Lin JC;Sheu GT;Lee H;	A novel p53 mutant retained functional activity in lung carcinomas	2002	DNA Repair (Amst )	1	755	12509279
641	p.E286Q	E286Q	286	Glu	Gln	006030	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
469	p.E286Q	E286Q	286	Glu	Gln	006030	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H ( BAX, 14-3-3s, GADD45, AIP1, Noxa); No (WAF1, MDM2, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
642	p.E286V	E286V	286	Glu	Val	045395	L1/S/H2	NA	NA	NA	NA	NA	Yes mut_H (WAF1, MDM2, 14-3-3s, GADD45, P53R2); No (BAX)	37°C 	Human	Saos-2	WT control	Luciferase assay, temperature sensitive assay at 32 and 37°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
467	p.E286V	E286V	286	Glu	Val	045395	L1/S/H2	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (AIP1, Noxa); No (WAF1, MDM2, BAX, 14-3-3s, GADD45, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
4190	p.E286V	E286V	286	Glu	Val	045395	L1/S/H2	NA	TA (WAF1)	TA (BAX, RGC) partial	NA	NA	Yes mut_H (WAF1, BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
3000	p.E286*	E286X	286	Glu	Stop		L1/S/H2	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	201	Schlichtholz B;Presler M;Matuszewski M;	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast	2004	Carcinogenesis	25	2319	15308588
2998	p.E286*	E286X	286	Glu	Stop		L1/S/H2	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	200	Mitsumoto Y;Nakajima T;Marutani M;Kashiwazaki H;Moriguchi M;Kimura H;Okanoue T;Kagawa K;Tada M;	Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry	2004	Hum Pathol	35	350	15017592
1270	p.N288D	N288D	288	Asn	Asp	045400	NDBL/beta-sheets	P 	NA	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, NOXA, PUMA, C-FOS, RGC)	Yes [TA (WAF1 5', P53R2, GADD45, CD95- Fas, PCNA, MDM2, RGC, IGF-BP3, BAX, NOXA, PUMA)] moderate; Yes [TA (WAF1 3')]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3279	p.N288K	N288K	288	Asn	Lys	045401	NDBL/beta-sheets	NA	SuperGS; superAPO; superGA; UV supersensitivity	gamma-irradiation resistance	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, FACS analysis, UV or gamma-irradiation treatment	216	Menendez D;Inga A;Resnick MA;	The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes	2006	Mol Cell Biol 	26	2297	16508005
1271	p.N288K	N288K	288	Asn	Lys	045401	NDBL/beta-sheets	P 	TA (WAF1 5', WAF1 3', P53R2, GADD45, CD95-Fas, 14-3-3s, PCNA, AIP1, MDM2, MDM2-RE2, RGC, IGF-BP3, PA26, BAX, NOXA, PUMA, C-FOS, RGC) supertrans	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
853	p.N288K	N288K	288	Asn	Lys	045401	NDBL/beta-sheets	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
838	p.N288K	N288K	288	Asn	Lys	045401	NDBL/beta-sheets	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1321	p.N288S	N288S	288	Asn	Ser	045402	NDBL/beta-sheets	P 	TA (RGC, WAF1 5')	NA	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
582	p.L289P	L289P	289	Leu	Pro	045407	NDBL/beta-sheets	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1322	p.R290C	R290C	290	Arg	Cys	045410	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1504	p.R290H	R290H	290	Arg	His	045411	NDBL/beta-sheets	NA	GS	Upregulation (p21waf1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Western blot, CFA	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
1498	p.R290H	R290H	290	Arg	His	045411	NDBL/beta-sheets	NA	TA (RGC)	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	82	Quesnel S;Verselis S;Portwine C;Garber J;White M;Feunteun J;Malkin D;Li FP;	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome	1999	Oncogene	18	3970	10435620
4684	p.R290H	R290H	290	Arg	His	045411	NDBL/beta-sheets	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
119	p.K291del	K291del	291	Lys	NA		NDBL/beta-sheets	NA	NA	TA (MDM2, PG13); TR (C-FOS) ; GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1225	p.K291del	K291del	291	Lys	NA		NDBL/beta-sheets	NA	NA	TRANSF-	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	transformation assay	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1323	p.K291M	K291M	291	Lys	Met	045414	NDBL/beta-sheets	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
3388	p.K291N	K291N	291	Lys	Asn	045415	NDBL/beta-sheets	NA	NA	GS	NA	NA	NA	37°C 	Human	HeLa	WT control	MTT assay	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
148	p.K291N	K291N	291	Lys	Asn	045415	NDBL/beta-sheets	NA	NA	TA (MDM2, WAF1); GS	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT assay, CFA	23	Oh SJ;Im MY;	The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity	2000	Mol Cells	10	386	10987134
4463	p.K291*	K291X	291	Lys	Stop		NDBL/beta-sheets	NA	NA	TR (BCL-2)	NA	TA (BCL-2) moderate	NA	37°C 	Human	MCF-7	no WT control	Luciferase assay	324	Pratt MA;White D;Kushwaha N;Tibbo E;Niu MY;	Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells	2007	Apoptosis 	12	657	17252199
4464	p.K291*	K291X	291	Lys	Stop		NDBL/beta-sheets	NA	NA	Bcl-2 binding	NA	NA	NA	37°C 	Human	MCF-7	WT control	IP	324	Pratt MA;White D;Kushwaha N;Tibbo E;Niu MY;	Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells	2007	Apoptosis 	12	657	17252199
4636	p.K292I	K292I	292	Lys	Ile	015819	NDBL/beta-sheets	NA	TA (WAF1)	TA (MDM2, BAX, PUMA) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4226	p.G293_E343del	G293_E343del	293	Gly	NA		C-term	NA	NA	Interference with Beta-catenin-dependent TCF signalling	No (interference with Beta-catenin-dependent TCF signalling)	NA	NA	37°C 	Human	PC-3	WT control	Luciferase assay	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
4628	p.G293W	G293W	293	Gly	Trp	045426	C-term	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1946	p.E294*	E294X	294	Glu	Stop		C-term	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
2763	p.E294*	E294X	294	Glu	Stop		C-term	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
2796	p.H296L	H296L	296	His	Leu	047207	C-term	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
1816	p.H296R	H296R	296	His	Arg	045439	C-term	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
52	p.P300_L308del	P300_L308del	300	Pro	NA		C-term	NA	TA (WAF1); upregulation (p21waf1); GS	TA (BAX); APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
53	p.P300_Y327del	P300_Y327del	300	Pro	NA		C-term	NA	TA (WAF1); upregulation (p21waf1); GS	TA (BAX); APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
54	p.P300S	P300S	300	Pro	Ser	045457	C-term	NA	TA (WAF1); upregulation (p21waf1); TA (BAX) supertrans; GS; APO	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
1324	p.T304S	T304S	304	Thr	Ser	047209	C-term	P 	NA	TA (RGC, WAF1 5')	NA	NA	Yes mut_L (WAF1 5')	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
399	p.K305M	K305M	305	Lys	Met	045471	C-term	NA	GS	TA (BAX)	Yes [TA (BAX)]; No [TA (WAF1)]; No (GS)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
3407	p.K305M	K305M	305	Lys	Met	045471	C-term	NA	NA	TA (BAX); APO partial	Yes [TA (BAX)]; No [TA (WAF1)]; No (APO)	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
4637	p.K305M	K305M	305	Lys	Met	045471	C-term	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (MDM2, PUMA)]; No [TA (BAX, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4599	p.K305M	K305M	305	Lys	Met	045471	C-term	NA	NA	TA (11 different p53-RE)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
757	p.K305M	K305M	305	Lys	Met	045471	C-term	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
780	p.K305N	K305N	305	Lys	Asn	045472	C-term	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
1799	p.K305Q	K305Q	305	Lys	Gln		C-term	R 	TA (PG13)	NA	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1325	p.K305R	K305R	305	Lys	Arg	045473	C-term	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
55	p.R306P	R306P	306	Arg	Pro	045475	C-term	NA	TA (WAF1); upregulation (p21waf1); GS	TA (BAX); APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
4685	p.R306P	R306P	306	Arg	Pro	045475	C-term	NA	NA	TA (MDM2, BAX, PUMA); TA (WAF1) partial	Yes [TA (BAX)]; No [TA (MDM2, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
2091	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TR (HSP70)	NA	No [TA (HSP70)]	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2103	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	156	Tsutsumi-Ishii Y;Tadokoro K;Hanaoka F;Tsuchida N;	Response of heat shock element within the human HSP70 promoter to mutated p53 genes	1995	Cell Growth Differ	6	1	7718482
2724	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
1736	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	103	Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;	Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer	2005	Int J Cancer	116	514	15825182
2886	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
2947	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
3058	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
3074	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	204	Fouquet C;Antoine M;Tisserand P;Favis R;Wislez M;Commo F;Rabbe N;Carette MF;Milleron B;Barany F;Cadranel J;Zalcman G;Soussi T;	Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study	2004	Clin Cancer Res	10	3479	15161705
193	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
250	p.R306*	R306X	306	Arg	Stop		C-term	NA	NA	NA	No [TA (RGC, WAF1 5’, BAX, PIG3)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
310	p.L308M	L308M	308	Leu	Met	045478	C-term	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
698	p.L308M	L308M	308	Leu	Met	045478	C-term	NA	NA	NA	No [TA (RGC)]	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	39	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Inga A;Abbondandolo A;Resnick MA;Fronza G;	Tumour p53 mutations exhibit promoter selective dominance over wild type p53	2002	Oncogene	21	1641	11896595
2755	p.L308M	L308M	308	Leu	Met	045478	C-term	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	182	Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;	Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx	2000	Int J Cancer	89	187	10754498
1326	p.L308P	L308P	308	Leu	Pro		C-term	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1327	p.L308Q	L308Q	308	Leu	Gln		C-term	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	yes mut_L (RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
825	p.S314F	S314F	314	Ser	Phe	045493	C-term	R 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
795	p.S314F	S314F	314	Ser	Phe	045493	C-term	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	48	Tada M;Furuuchi K;Kaneda M;Matsumoto J;Takahashi M;Hirai A;Mitsumoto Y;Iggo RD;Moriuchi T;	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants	2001	Carcinogenesis	22	515	11238194
831	p.S315A	S315A	315	Ser	Ala		C-term	NA	TA (MDM2, PIG3)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
120	p.S315A	S315A	315	Ser	Ala		C-term	NA	TA (MDM2, PG13); GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
2015	p.S315A	S315A	315	Ser	Ala		C-term	NA	TRANSF-	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
2168	p.S315D	S315D	315	Ser	Asp		C-term	NA	TRANSF-	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
1947	p.Q317*	Q317X	317	Gln	Stop		C-term/NLS	R 	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	131	Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo	2005	Clin Cancer Res	11	8372	16322298
3257	p.Q317*	Q317X	317	Gln	Stop		C-term/NLS	R 	NA	TA (RGC, BAX, WAF1)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	214	Dekairelle AF;Tombal B;Cosyns JP;Gala JL;	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder	2005	Clin Cancer Res 	11	4724	16000567
4551	p.Q317*	Q317X	317	Gln	Stop		C-term/NLS	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
1746	p.K320Q	K320Q	320	Lys	Gln		C-term/NLS	NA	TR (Cyclin B2) supertrans	TA (MDM2) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	105	Imbriano C;Gurtner A;Cocchiarella F;Di Agostino S;Basile V;Gostissa M;Dobbelstein M;Del Sal G;Piaggio G;Mantovani R;	Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters	2005	Mol Cell Biol	25	3737	15831478
4243	p.K320R	K320R	320	Lys	Arg		C-term/NLS	NA	Super-upregulation (p21waf1)	DNAb (WAF1) 5-aza-CdR induced; upregulation (p21waf1) 5-aza-CdR induced; GA 5-aza-CdR induced	NA	NA	NA	37°C 	Human	H1299	WT control	5-aza-2'-deoxycitidine treatment and ChIP assay, western blot, proliferation assay	311	Wang H;Zhao Y;Li L;McNutt MA;Wu L;Lu S;Yu Y;Zhou W;Feng J;Chai G;Yang Y;Zhu WG;	An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment	2008	J Biol Chem 	283	2564	17977830
1747	p.K320R	K320R	320	Lys	Arg		C-term/NLS	NA	TA (MDM2); TR (Cyclin B2)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	105	Imbriano C;Gurtner A;Cocchiarella F;Di Agostino S;Basile V;Gostissa M;Dobbelstein M;Del Sal G;Piaggio G;Mantovani R;	Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters	2005	Mol Cell Biol	25	3737	15831478
1328	p.K321E	K321E	321	Lys	Glu	045508	C-term/NLS	P 	TA (WAF1 5')	TA (RGC) partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
1101	p.P322A	P322A	322	Pro	Ala		C-term/NLS	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1102	p.P322L	P322L	322	Pro	Leu	045510	C-term/NLS	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1103	p.P322Q	P322Q	322	Pro	Gln		C-term/NLS	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1104	p.P322R	P322R	322	Pro	Arg	045511	C-term/NLS	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1105	p.P322S	P322S	322	Pro	Ser		C-term/NLS	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1062	p.L323M	L323M	323	Leu	Met	045512	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1063	p.L323P	L323P	323	Leu	Pro	045513	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
311	p.L323P	L323P	323	Leu	Pro	045513	C-term/tetramerisation	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
719	p.L323P	L323P	323	Leu	Pro	045513	C-term/tetramerisation	NA	NA	NA	No [TA (RGC)]	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	37	Inga A;Cresta S;Monti P;Aprile A;Scott G;Abbondandolo A;Iggo R;Fronza G;	Simple identification of dominant p53 mutants by a yeast functional assay	1997	Carcinogenesis	18	2019	9364015
1064	p.L323Q	L323Q	323	Leu	Gln		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1065	p.L323R	L323R	323	Leu	Arg	045514	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1066	p.L323V	L323V	323	Leu	Val	047211	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
56	p.D324_G325del	D324_G325del	324	Asp	NA		C-term/tetramerisation	NA	TA (WAF1, BAX) supertrans; upregulation (p21waf1); GS; APO	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
57	p.D324_I332del	D324_I332del	324	Asp	NA		C-term/tetramerisation	NA	NA	TA (WAF1, BAX); upregulation (p21waf1); GS; APO	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot, CFA, FACS analysis	8	Kong XT;Gao H;Stanbridge EJ;	Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	2001	J Biol Chem	276	32990	11395510
975	p.D324A	D324A	324	Asp	Ala		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
976	p.D324E	D324E	324	Asp	Glu	045515	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
977	p.D324G	D324G	324	Asp	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
978	p.D324H	D324H	324	Asp	His		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
979	p.D324N	D324N	324	Asp	Asn		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
980	p.D324V	D324V	324	Asp	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1040	p.G325A	G325A	325	Gly	Ala	045517	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1041	p.G325E	G325E	325	Gly	Glu	045518	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1042	p.G325R	G325R	325	Gly	Arg		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
400	p.G325V	G325V	325	Gly	Val	006039	C-term/tetramerisation	NA	GS	TA (BAX)	Yes [TA (BAX)]; No [TA (WAF1)]; No (GS)	NA	NA	37°C 	Human	Calu-6	WT control	Luciferase assay, CFA	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
3408	p.G325V	G325V	325	Gly	Val	006039	C-term/tetramerisation	NA	NA	TA (BAX); APO partial	Yes [TA (BAX)]; No [TA (WAF1)]; No (APO)	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, TUNEL assay	43	Aurelio ON;Kong XT;Gupta S;Stanbridge EJ;	p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines	2000	Mol Cell Biol	20	770	10629033
4629	p.G325V	G325V	325	Gly	Val	006039	C-term/tetramerisation	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1043	p.G325V	G325V	325	Gly	Val	006039	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
407	p.E326A	E326A	326	Glu	Ala		C-term/tetramerisation	NA	TA (WAF1, BAX); TR (MDR-1); GS; TETR	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
987	p.E326A	E326A	326	Glu	Ala		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
988	p.E326D	E326D	326	Glu	Asp		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
989	p.E326G	E326G	326	Glu	Gly	045519	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
990	p.E326K	E326K	326	Glu	Lys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
991	p.E326Q	E326Q	326	Glu	Gln		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
992	p.E326V	E326V	326	Glu	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
408	p.Y327A	Y327A	327	Tyr	Ala		C-term/tetramerisation	NA	TA (BAX); TR (MDR-1); GS; TETR	TA (WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1140	p.Y327C	Y327C	327	Tyr	Cys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1141	p.Y327D	Y327D	327	Tyr	Asp		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1142	p.Y327F	Y327F	327	Tyr	Phe		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1143	p.Y327H	Y327H	327	Tyr	His	045520	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1144	p.Y327N	Y327N	327	Tyr	Asn		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1145	p.Y327S	Y327S	327	Tyr	Ser	045521	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
317	p.Y327*	Y327X	327	Tyr	Stop		C-term/tetramerisation	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
409	p.F328A	F328A	328	Phe	Ala		C-term/tetramerisation	NA	TR (MDR-1)	TA (WAF1); TA (BAX) partial ; GS partial; TETR	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1022	p.F328C	F328C	328	Phe	Cys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1023	p.F328I	F328I	328	Phe	Ile		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1024	p.F328L	F328L	328	Phe	Leu	045522	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1025	p.F328S	F328S	328	Phe	Ser	045523	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1026	p.F328V	F328V	328	Phe	Val	045524	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1027	p.F328Y	F328Y	328	Phe	Tyr		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
410	p.T329A	T329A	329	Thr	Ala		C-term/tetramerisation	NA	TA (WAF1, BAX); GS; TR (MDR-1); TETR	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1136	p.T329A	T329A	329	Thr	Ala		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1137	p.T329N	T329N	329	Thr	Asn		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1138	p.T329P	T329P	329	Thr	Pro		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1139	p.T329S	T329S	329	Thr	Ser	045526	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
411	p.L330A	L330A	330	Leu	Ala		C-term/tetramerisation	NA	NA	TA (WAF1, BAX); GS; TR (MDR-1); TETR	NA	No [TA (MDR-1)]	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1067	p.L330F	L330F	330	Leu	Phe		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
58	p.L330H	L330H	330	Leu	His	045527	C-term/tetramerisation	NA	NA	DNAb (WAF1); TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
1068	p.L330H	L330H	330	Leu	His	045527	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1069	p.L330I	L330I	330	Leu	Ile		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1070	p.L330P	L330P	330	Leu	Pro	047212	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1071	p.L330R	L330R	330	Leu	Arg	045528	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
2885	p.L330R	L330R	330	Leu	Arg	045528	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	189	Duddy PM;Hanby AM;Barnes DM;Camplejohn RS;	Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay	2000	J Mol Diagn	2	139	21121188
1072	p.L330V	L330V	330	Leu	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
3350	p.I331fs	I331fs	331	Gln	NA		C-term/tetramerisation	NA	NA	TA (MDM2); upregulation (p21waf1, mdm2)	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay, western blot	232	Feuerborn A;Moritz C;Von Bonin F;Dobbelstein M;Trumper L;Sturzenhofecker B;Kube D;	Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma	2006	Leuk Lymphoma	47	1932	17065008
412	p.Q331A	Q331A	331	Gln	Ala		C-term/tetramerisation	NA	TA (WAF1, BAX); GS; TR (MDR-1); TETR	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1106	p.Q331E	Q331E	331	Gln	Glu		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1107	p.Q331H	Q331H	331	Gln	His	045529	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1108	p.Q331K	Q331K	331	Gln	Lys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1109	p.Q331L	Q331L	331	Gln	Leu		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1110	p.Q331R	Q331R	331	Gln	Arg	045531	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
758	p.Q331*	Q331X	331	Gln	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
318	p.Q331*	Q331X	331	Gln	Stop		C-term/tetramerisation	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
2883	p.Q331*	Q331X	331	Gln	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
3063	p.Q331*	Q331X	331	Gln	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
3334	p.I332A	I332A	332	Ile	Ala		C-term/tetramerisation	NA	NA	Downregulation (Vrk1)	NA	NA	NA	37°C 	Human	H1299	WT control	Western blot	226	Valbuena A;Vega FM;Blanco S;Lazo PA;	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop	2006	Mol Cell Biol 	26	4782	16782868
413	p.I332A	I332A	332	Ile	Ala		C-term/tetramerisation	NA	NA	TA (WAF1, BAX); GS; TR (MDR-1); TETR	NA	No [TA (MDR-1)]	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1049	p.I332F	I332F	332	Ile	Phe		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1050	p.I332L	I332L	332	Ile	Leu		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1051	p.I332M	I332M	332	Ile	Met		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1052	p.I332N	I332N	332	Ile	Asn		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1053	p.I332S	I332S	332	Ile	Ser		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1054	p.I332T	I332T	332	Ile	Thr		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1055	p.I332V	I332V	332	Ile	Val	045532	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
414	p.R333A	R333A	333	Arg	Ala		C-term/tetramerisation	NA	GS; TR (MDR-1); TETR	TA (WAF1, BAX) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay, CFA	44	Chene P;Bechter E;	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties	1999	J Mol Biol	288	891	10329187
1116	p.R333C	R333C	333	Arg	Cys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1117	p.R333G	R333G	333	Arg	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1118	p.R333H	R333H	333	Arg	His		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1119	p.R333L	R333L	333	Arg	Leu		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1120	p.R333P	R333P	333	Arg	Pro		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1121	p.R333S	R333S	333	Arg	Ser		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1044	p.G334A	G334A	334	Gly	Ala		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1045	p.G334E	G334E	334	Gly	Glu		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1046	p.G334R	G334R	334	Gly	Arg		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1047	p.G334V	G334V	334	Gly	Val	006040	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1048	p.G334W	G334W	334	Gly	Trp	045533	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1122	p.R335C	R335C	335	Arg	Cys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1123	p.R335G	R335G	335	Arg	Gly	045534	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1124	p.R335H	R335H	335	Arg	His	045535	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1125	p.R335L	R335L	335	Arg	Leu	045536	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1126	p.R335P	R335P	335	Arg	Pro		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1127	p.R335S	R335S	335	Arg	Ser		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
993	p.E336A	E336A	336	Glu	Ala		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
994	p.E336D	E336D	336	Glu	Asp		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
995	p.E336G	E336G	336	Glu	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
996	p.E336K	E336K	336	Glu	Lys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
997	p.E336Q	E336Q	336	Glu	Gln		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
998	p.E336V	E336V	336	Glu	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
3325	p.E336*	E336X	336	Glu	Stop		C-term/tetramerisation	NA	NA	Dynein binding	NA	NA	NA	37°C 	Human	PC3	WT control	Co-IP	225	Trostel SY;Sackett DL;Fojo T;	Oligomerization of p53 precedes its association with dynein and nuclear accumulation	2006	Cell Cycle	5	2253	16969106
934	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	TETR	TA (BAX) partial; GS partial; APO partial; mdm2 binding	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis, luciferase assay, CFA, IP	62	Lomax ME;Barnes DM;Hupp TR;Picksley SM;Camplejohn RS;	Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	1998	Oncogene	17	643	9704930
59	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	DNAb (WAF1); TA (WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
1128	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1329	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	P 	TA (WAF1 5', p53CON, P53R2, CD95-Fas, MDM2, BAX)	TA (RGC, GADD45, PCNA, PUMA, AIP1, NOXA, WAF1 3') partial	NA	NA	No (RGC)	30°C 	Yeast	Yeast	WT control	Color selection + luciferase measurement, temperature sensitive assay at 34°C	77	Resnick MA;Inga A;	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity	2003	Proc Natl Acad Sci U S A	100	9934	12909720
2854	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (RGC) partial	NA	NA	No (RGC)	35°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 30°C and 42°C	187	Smardova J;Nemajerova A;Trbusek M;Vagunda V;Kovarik J;	Rare somatic p53 mutation identified in breast cancer: a case report	2001	Tumour Biol	22	59	11125276
2870	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2826	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
1771	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (RGC) partial	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	112	Lomax ME;Barnes DM;Gilchrist R;Picksley SM;Varley JM;Camplejohn RS;	Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family	1997	Oncogene	14	1869	9150393
3470	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (RGC) partial	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	62	Lomax ME;Barnes DM;Hupp TR;Picksley SM;Camplejohn RS;	Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	1998	Oncogene	17	643	9704930
4191	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (WAF1, BAX, RGC) partial	NA	NA	No (RGC); Yes mut_L (BAX) low; Yes (WAF1) low	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
4686	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (MDM2, BAX); TA (PUMA, WAF1) partial	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4600	p.R337C	R337C	337	Arg	Cys	006041	C-term/tetramerisation	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
1129	p.R337G	R337G	337	Arg	Gly		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
312	p.R337G	R337G	337	Arg	Gly		C-term/tetramerisation	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
3468	p.R337H	R337H	337	Arg	His	035016	C-term/tetramerisation	NA	TA (BAX)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	62	Lomax ME;Barnes DM;Hupp TR;Picksley SM;Camplejohn RS;	Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	1998	Oncogene	17	643	9704930
4601	p.R337H	R337H	337	Arg	His	035016	C-term/tetramerisation	NA	NA	TA (11 different p53-RE) partial	NA	NA	NA	30°C 	Yeast	Yeast	WT control	color and Luciferase assay	335	Jordan JJ;Inga A;Conway K;Edmiston S;Carey LA;Wu L;Resnick MA;	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation	2010	Mol.Cancer Res	8	701	20407015
4687	p.R337H	R337H	337	Arg	His	035016	C-term/tetramerisation	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
1130	p.R337H	R337H	337	Arg	His	035016	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
60	p.R337L	R337L	337	Arg	Leu	045537	C-term/tetramerisation	NA	NA	DNAb (WAF1); TA (WAF1) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
1131	p.R337L	R337L	337	Arg	Leu	045537	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
2734	p.R337L	R337L	337	Arg	Leu	045537	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
759	p.R337P	R337P	337	Arg	Pro	045538	C-term/tetramerisation	R 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
781	p.R337S	R337S	337	Arg	Ser		C-term/tetramerisation	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
826	p.R337S	R337S	337	Arg	Ser		C-term/tetramerisation	P 	NA	TA (RGC)	No [TA (RGC)]	p73beta interference	NA	30°C 	Yeast	Yeast	WT control	Color selection	49	Monti P;Campomenosi P;Ciribilli Y;Iannone R;Aprile A;Inga A;Tada M;Menichini P;Abbondandolo A;Fronza G;	Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	2003	Oncogene	22	5252	12917626
1132	p.R337S	R337S	337	Arg	Ser		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1028	p.F338C	F338C	338	Phe	Cys		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1029	p.F338I	F338I	338	Phe	Ile	045539	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1030	p.F338L	F338L	338	Phe	Leu	045540	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
839	p.F338L	F338L	338	Phe	Leu	045540	C-term/tetramerisation	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1031	p.F338S	F338S	338	Phe	Ser		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
453	p.F338S	F338S	338	Phe	Ser		C-term/tetramerisation	NA	NA	TA (WAF1, MDM2, BAX, 14-3-3s, GADD45, AIP1, NOXA, P53R2)	NA	NA	Yes mut_H (MDM2, BAX); No (WAF1, 14-3-3s, GADD45, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1032	p.F338V	F338V	338	Phe	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1033	p.F338Y	F338Y	338	Phe	Tyr		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
999	p.E339A	E339A	339	Glu	Ala		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1000	p.E339D	E339D	339	Glu	Asp		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1001	p.E339G	E339G	339	Glu	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1002	p.E339K	E339K	339	Glu	Lys	022316	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1003	p.E339Q	E339Q	339	Glu	Gln	045541	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1004	p.E339V	E339V	339	Glu	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1088	p.M340I	M340I	340	Met	Ile		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1089	p.M340K	M340K	340	Met	Lys		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1090	p.M340L	M340L	340	Met	Leu		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1091	p.M340R	M340R	340	Met	Arg		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1092	p.M340T	M340T	340	Met	Thr		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1093	p.M340V	M340V	340	Met	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1034	p.F341C	F341C	341	Phe	Cys	045542	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1035	p.F341I	F341I	341	Phe	Ile		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1036	p.F341L	F341L	341	Phe	Leu		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1037	p.F341S	F341S	341	Phe	Ser		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1038	p.F341V	F341V	341	Phe	Val		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1039	p.F341Y	F341Y	341	Phe	Tyr		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1133	p.R342G	R342G	342	Arg	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1134	p.R342L	R342L	342	Arg	Leu	045543	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
417	p.R342P	R342P	342	Arg	Pro	045544	C-term/tetramerisation	NA	NA	TETR; TR (MDR-1)	No [TA (WAF1)]	No [TA (MDR-1)]	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay	45	Chene P;Bechter E;	p53 mutants without a functional tetramerisation domain are not oncogenic	1999	J Mol Biol	286	1269	10064694
61	p.R342P	R342P	342	Arg	Pro	045544	C-term/tetramerisation	NA	NA	DNAb (WAF1); TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
1135	p.R342P	R342P	342	Arg	Pro	045544	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
62	p.R342Q	R342Q	342	Arg	Gln	047213	C-term/tetramerisation	NA	DNAb (WAF1); TA (WAF1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
3326	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	(dynein binding) partial	NA	NA	NA	37°C 	Human	PC3	WT control	Co-IP	225	Trostel SY;Sackett DL;Fojo T;	Oligomerization of p53 precedes its association with dynein and nuclear accumulation	2006	Cell Cycle	5	2253	16969106
2861	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2958	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	195	Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;	Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma	2003	Oral Oncol	39	163	12509970
2989	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	198	Concin N;Zeillinger C;Tong D;Stimpfl M;Konig M;Printz D;Stonek F;Schneeberger C;Hefler L;Kainz C;Leodolter S;Haas OA;Zeillinger R;	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines	2003	Breast Cancer Res Treat	79	37	12779080
2665	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
760	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
4539	p.R342*	R342X	342	Arg	Stop		C-term/tetramerisation	NA	NA	NA	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	333	Hassan NM;Tada M;Hamada JI;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;	Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer	2008	Cancer Lett	270	108	18555592
1005	p.E343A	E343A	343	Glu	Ala		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1006	p.E343D	E343D	343	Glu	Asp		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1007	p.E343G	E343G	343	Glu	Gly	045545	C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
583	p.E343G	E343G	343	Glu	Gly	045545	C-term/tetramerisation	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1008	p.E343K	E343K	343	Glu	Lys		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1009	p.E343Q	E343Q	343	Glu	Gln		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1010	p.E343V	E343V	343	Glu	Val		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
2797	p.E343*	E343X	343	Glu	Stop		C-term/tetramerisation	NA	NA	TA (RGC, WAF1 5', BAX, PIG3)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	184	Robert V;Michel P;Flaman JM;Chiron A;Martin C;Charbonnier F;Paillot B;Frebourg T;	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis	2000	Carcinogenesis	21	563	10753186
1073	p.L344M	L344M	344	Leu	Met		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
935	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	TETR (monomer); TA (BAX); GS; APO; mdm2 binding (partial)	NA	NA	NA	37°C 	Human	Saos-2	WT control	FACS analysis, luciferase assay, CFA, IP	62	Lomax ME;Barnes DM;Hupp TR;Picksley SM;Camplejohn RS;	Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	1998	Oncogene	17	643	9704930
956	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	GS partial; TETR (monomer)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, cross-link of proteins with glutaraldehyde + SDS/PAGE	70	Ishioka C;Shimodaira H;Englert C;Shimada A;Osada M;Jia LQ;Suzuki T;Gamo M;Kanamaru R;	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells	1997	Biochem Biophys Res Commun	232	54	9125151
418	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	TETR; TR (MDR-1)	No [TA (WAF1)]	No [TA (MDR-1)]	NA	37°C 	Human	Saos-2	WT control	Luciferase or CAT assay	45	Chene P;Bechter E;	p53 mutants without a functional tetramerisation domain are not oncogenic	1999	J Mol Biol	286	1269	10064694
63	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	DNAb (WAF1); TA (WAF1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
2032	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	TA (RGC); GA; GS partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, FACS analysis, CFA	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
2028	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
1074	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
4640	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	TA (MDM2, BAX, PUMA, WAF1)	Yes [TA (WAF1)]; No [TA (MDM2, BAX, PUMA)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
3469	p.L344P	L344P	344	Leu	Pro	045546	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	62	Lomax ME;Barnes DM;Hupp TR;Picksley SM;Camplejohn RS;	Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	1998	Oncogene	17	643	9704930
1075	p.L344Q	L344Q	344	Leu	Gln		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1076	p.L344R	L344R	344	Leu	Arg	045547	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
4192	p.L344R	L344R	344	Leu	Arg	045547	C-term/tetramerisation	NA	TA (WAF1)	TA (BAX, RGC) partial	NA	NA	No (WAF1); Yes mut_L (BAX, RGC)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 25°C, 30°C and 35°C	295	Grochova D;Vankova J;Damborsky J;Ravcukova B;Smarda J;Vojtesek B;Smardova J;	Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	2008	Oncogene	27	1243	17724467
1094	p.N345D	N345D	345	Asn	Asp		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1095	p.N345H	N345H	345	Asn	His		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1096	p.N345I	N345I	345	Asn	Ile		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1097	p.N345K	N345K	345	Asn	Lys		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1098	p.N345S	N345S	345	Asn	Ser		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
855	p.N345S	N345S	345	Asn	Ser		C-term/tetramerisation	NA	TA (RGC) supertrans	NA	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	51	Inga A;Monti P;Fronza G;Darden T;Resnick MA;	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	2001	Oncogene	20	501	11313981
1099	p.N345T	N345T	345	Asn	Thr		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1100	p.N345Y	N345Y	345	Asn	Tyr		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1011	p.E346A	E346A	346	Glu	Ala	045548	C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1012	p.E346D	E346D	346	Glu	Asp		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1013	p.E346G	E346G	346	Glu	Gly		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1014	p.E346K	E346K	346	Glu	Lys		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1015	p.E346Q	E346Q	346	Glu	Gln		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1016	p.E346V	E346V	346	Glu	Val		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
963	p.A347D	A347D	347	Ala	Asp		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
964	p.A347G	A347G	347	Ala	Gly	045549	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
761	p.A347G	A347G	347	Ala	Gly	045549	C-term/tetramerisation	P 	NA	TA (RGC)	No [TA (RGC)]	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	38	Marutani M;Tonoki H;Tada M;Takahashi M;Kashiwazaki H;Hida Y;Hamada J;Asaka M;Moriuchi T;	Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme	1999	Cancer Res	59	4765	10519380
2667	p.A347G	A347G	347	Ala	Gly	045549	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	168	Tada M;Iggo RD;Waridel F;Nozaki M;Matsumoto R;Sawamura Y;Shinohe Y;Ikeda J;Abe H;	Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses	1997	Mol Carcinog	18	171	9115587
965	p.A347P	A347P	347	Ala	Pro		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
966	p.A347S	A347S	347	Ala	Ser		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
967	p.A347T	A347T	347	Ala	Thr	045550	C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
3060	p.A347T	A347T	347	Ala	Thr	045550	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	203	Deissler H;Kafka A;Schuster E;Sauer G;Kreienberg R;Zeillinger R;	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response	2004	Oncol Rep	11	1281	15138567
968	p.A347V	A347V	347	Ala	Val		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1077	p.L348F	L348F	348	Leu	Phe	045551	C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1078	p.L348M	L348M	348	Leu	Met		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1079	p.L348S	L348S	348	Leu	Ser	045552	C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1080	p.L348V	L348V	348	Leu	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1081	p.L348W	L348W	348	Leu	Trp		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
3327	p.L348*	L348X	348	Leu	Stop		C-term/tetramerisation	NA	NA	(dynein binding) partial	NA	NA	NA	37°C 	Human	PC3	WT control	Co-IP	225	Trostel SY;Sackett DL;Fojo T;	Oligomerization of p53 precedes its association with dynein and nuclear accumulation	2006	Cell Cycle	5	2253	16969106
2884	p.L348*	L348X	348	Leu	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	Color selection	188	Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;	Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group	2001	Clin Cancer Res	7	600	21190917
2825	p.L348*	L348X	348	Leu	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Growth selection	185	Kato H;Kato S;Kumabe T;Sonoda Y;Yoshimoto T;Kato S;Han SY;Suzuki T;Shibata H;Kanamaru R;Ishioka C;	Functional evaluation of p53 and PTEN gene mutations in gliomas	2000	Clin Cancer Res	6	3937	11051241
64	p.E349D	E349D	349	Glu	Asp	045553	C-term/tetramerisation	NA	DNAb (WAF1); TA (WAF1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
1017	p.E349D	E349D	349	Glu	Asp	045553	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1018	p.E349G	E349G	349	Glu	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1019	p.E349K	E349K	349	Glu	Lys		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1020	p.E349Q	E349Q	349	Glu	Gln		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1021	p.E349V	E349V	349	Glu	Val		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
2723	p.E349*	E349X	349	Glu	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	NA   	Yeast	Yeast	WT control	Color selection	178	Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;	Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay	1999	Int J Cancer	84	587	10567903
1082	p.L350F	L350F	350	Leu	Phe		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1083	p.L350H	L350H	350	Leu	His		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
584	p.L350H	L350H	350	Leu	His		C-term/tetramerisation	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
1084	p.L350I	L350I	350	Leu	Ile		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1792	p.L350P	L350P	350	Leu	Pro		C-term/tetramerisation	R 	TA (PG13)	AP2alpha binding (partial)	NA	NA	NA	37°C 	Human	HCT-116 (p53-null)	WT control	Co-IP, luciferase assay	116	Stabach PR;Thiyagarajan MM;Woodfield GW;Weigel RJ;	AP2alpha alters the transcriptional activity and stability of p53	2005	Oncogene			16288208
1085	p.L350P	L350P	350	Leu	Pro		C-term/tetramerisation	P 	NA	TETR (monomer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1086	p.L350R	L350R	350	Leu	Arg		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1087	p.L350V	L350V	350	Leu	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
955	p.K351E	K351E	351	Lys	Glu		C-term/tetramerisation	NA	NA	GS partial; TETR (dimer)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, cross-link of proteins with glutaraldehyde + SDS/PAGE	70	Ishioka C;Shimodaira H;Englert C;Shimada A;Osada M;Jia LQ;Suzuki T;Gamo M;Kanamaru R;	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells	1997	Biochem Biophys Res Commun	232	54	9125151
2033	p.K351E	K351E	351	Lys	Glu		C-term/tetramerisation	NA	NA	TA (RGC) partial; GA partial; GS partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, FACS analysis, CFA	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
2027	p.K351E	K351E	351	Lys	Glu		C-term/tetramerisation	NA	NA	TA (RGC) partial	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
1056	p.K351E	K351E	351	Lys	Glu		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1057	p.K351M	K351M	351	Lys	Met		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1058	p.K351N	K351N	351	Lys	Asn		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1059	p.K351Q	K351Q	351	Lys	Gln		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1060	p.K351R	K351R	351	Lys	Arg		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1061	p.K351T	K351T	351	Lys	Thr		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
958	p.K351*	K351X	351	Lys	Stop		C-term/tetramerisation	NA	TETR; superGS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, cross-link of proteins with glutaraldehyde + SDS/PAGE	70	Ishioka C;Shimodaira H;Englert C;Shimada A;Osada M;Jia LQ;Suzuki T;Gamo M;Kanamaru R;	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells	1997	Biochem Biophys Res Commun	232	54	9125151
2034	p.K351*	K351X	351	Lys	Stop		C-term/tetramerisation	NA	SuperGS	TA (RGC) partial; GA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, FACS analysis, CFA	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
2029	p.K351*	K351X	351	Lys	Stop		C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
981	p.D352A	D352A	352	Asp	Ala		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
982	p.D352G	D352G	352	Asp	Gly		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
983	p.D352H	D352H	352	Asp	His	045554	C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
984	p.D352N	D352N	352	Asp	Asn		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
585	p.D352N	D352N	352	Asp	Asn		C-term/tetramerisation	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
586	p.D352V	D352V	352	Asp	Val		C-term/tetramerisation	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
985	p.D352V	D352V	352	Asp	Val		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
986	p.D352Y	D352Y	352	Asp	Tyr		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
969	p.A353D	A353D	353	Ala	Asp		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
970	p.A353G	A353G	353	Ala	Gly		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
971	p.A353P	A353P	353	Ala	Pro		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
587	p.A353P	A353P	353	Ala	Pro		C-term/tetramerisation	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
972	p.A353S	A353S	353	Ala	Ser		C-term/tetramerisation	P 	NA	TETR (dimer)	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
973	p.A353T	A353T	353	Ala	Thr	045555	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
974	p.A353V	A353V	353	Ala	Val		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1111	p.Q354E	Q354E	354	Gln	Glu	045556	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
313	p.Q354E	Q354E	354	Gln	Glu	045556	C-term/tetramerisation	NA	NA	TA (WAF1, BAX, PIG3)	NA	NA	No (WAF1, BAX, PIG3)	30°C 	Yeast	Yeast	WT control	Color selection, temperature sensitive assay at 24°C and 37°C	34	Campomenosi P;Monti P;Aprile A;Abbondandolo A;Frebourg T;Gold B;Crook T;Inga A;Resnick MA;Iggo R;Fronza G;	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	2001	Oncogene	20	3573	11429705
1694	p.Q354E	Q354E	354	Gln	Glu	045556	C-term/tetramerisation	NA	NA	TA (RGC)	NA	NA	NA	35°C 	Yeast	Yeast	WT control	Color selection	95	Campomenosi P;Fronza G;Ottaggio L;Roncella S;Inga A;Bogliolo M;Monti P;Assereto P;Moro F;Cutrona G;Bozzo S;Chiorazzi N;Abbondandolo A;Ferrarini M;	Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements	1997	Int J Cancer	73	816	9399658
1112	p.Q354H	Q354H	354	Gln	His		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1113	p.Q354K	Q354K	354	Gln	Lys	045557	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
1114	p.Q354P	Q354P	354	Gln	Pro		C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
65	p.Q354R	Q354R	354	Gln	Arg	047214	C-term/tetramerisation	NA	DNAb (WAF1); TA (WAF1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	EMSA, luciferase assay	9	Rollenhagen C;Chene P;	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain	1998	Int J Cancer	78	372	9766574
1115	p.Q354R	Q354R	354	Gln	Arg	047214	C-term/tetramerisation	P 	TETR	NA	NA	NA	NA	30°C 	Yeast	Yeast	WT control	cross-link of proteins with glutaraldehydeSDS/PAGE	71	Kawaguchi T;Kato S;Otsuka K;Watanabe G;Kumabe T;Tominaga T;Yoshimoto T;Ishioka C;	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	2005	Oncogene	24	6976	16007150
3328	p.Q354*	Q354X	354	Gln	Stop		C-term/tetramerisation	NA	NA	(dynein binding) partial	NA	NA	NA	37°C 	Human	PC3	WT control	Co-IP	225	Trostel SY;Sackett DL;Fojo T;	Oligomerization of p53 precedes its association with dynein and nuclear accumulation	2006	Cell Cycle	5	2253	16969106
2035	p.Q354*	Q354X	354	Gln	Stop		C-term/tetramerisation	NA	TA (RGC) supertrans; GA; GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Beta-gal assay, FACS analysis, CFA	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
957	p.Q354*	Q354X	354	Gln	Stop		C-term/tetramerisation	NA	GS	TETR (dimer)	NA	NA	NA	37°C 	Human	Saos-2	WT control	CFA, cross-link of proteins with glutaraldehyde + SDS/PAGE	70	Ishioka C;Shimodaira H;Englert C;Shimada A;Osada M;Jia LQ;Suzuki T;Gamo M;Kanamaru R;	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells	1997	Biochem Biophys Res Commun	232	54	9125151
2030	p.Q354*	Q354X	354	Gln	Stop		C-term/tetramerisation	NA	TA (RGC)	NA	NA	NA	NA	37°C 	Yeast	Yeast	WT control	Growth selection	144	Ishioka C;Englert C;Winge P;Yan YX;Engelstein M;Friend SH;	Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo	1995	Oncogene	10	1485	7731702
4467	p.A364_D393del	A364_D393del	364	Ala	NA		C-term	NA	GS	TA (p53CON) partial	NA	NA	NA	37°C 	Human	Saos-2	WT control	Gene reporter assay, CFA	326	Wieczorek AM;Waterman JL;Waterman MJ;Halazonetis TD;	Structure-based rescue of common tumor-derived p53 mutants	1996	Nat Med 	2	1143	8837616
4632	p.H365Y	H365Y	365	His	Tyr	045568	C-term	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
4692	p.S366A	S366A	366	Ser	Ala	022317	C-term	NA	TA (MDM2, BAX, PUMA, WAF1)	NA	No [TA (MDM2, BAX, PUMA, WAF1)]	NA	NA	30°C 	Yeast	Yeast	WT control	Luciferase assay	336	Monti P;Perfumo C;Bisio A;Ciribilli Y;Menichini P;Russo D;Umbach DM;Resnick MA;Inga A;Fronza G;	Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes	2011	Mol Cancer Res	9	271	21343334
121	p.K370del	K370del	370	Lys	NA		C-term	NA	TA (MDM2, PG13); TR (C-FOS); GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1226	p.K370del	K370del	370	Lys	NA		C-term	NA	NA	TRANSF- (partial)	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	transformation assay	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
3462	p.K370R	K370R	370	Lys	Arg		C-term	NA	TA (PG13)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	55	Rodriguez MS;Desterro JM;Lain S;Lane DP;Hay RT;	Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation	2000	Mol Cell Biol	20	8458	11046142
4244	[p.K373R;K382R]	K373R/K382R	373	Lys	NA		C-term	NA	NA	DNAb (WAF1) 5-aza-CdR induced; upregulation (p21waf1) 5-aza-CdR induced; GA 5-aza-CdR induced	NA	NA	NA	37°C 	Human	H1299	WT control	5-aza-2'-deoxycitidine treatment and ChIP assay, western blot, proliferation assay	311	Wang H;Zhao Y;Li L;McNutt MA;Wu L;Lu S;Yu Y;Zhou W;Feng J;Chai G;Yang Y;Zhu WG;	An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment	2008	J Biol Chem 	283	2564	17977830
832	p.S376A	S376A	376	Ser	Ala	045570	C-term	NA	TA (MDM2, PIG3)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
3381	p.S376A	S376A	376	Ser	Ala	045570	C-term	NA	TA (WAF1)	Upregulation (p21waf1)	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot	21	Stavridi ES;Chehab NH;Malikzay A;Halazonetis TD;	Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest	2001	Cancer Res	61	7030	11585729
140	p.S376A	S376A	376	Ser	Ala	045570	C-term	NA	DNAb (p53CON)	14-3-3 binding; GA	NA	NA	NA	37°C 	Human	U2OS	WT control	Co-IP, EMSA, FACS analysis	21	Stavridi ES;Chehab NH;Malikzay A;Halazonetis TD;	Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest	2001	Cancer Res	61	7030	11585729
588	p.S376T	S376T	376	Ser	Thr	045571	C-term	NA	NA	NA	NA	NA	Yes mut_H (WAF1); No (MDM2, GADD45, BAX, 14-3-3s, AIP1, Noxa, P53R2)	37°C 	Yeast	Yeast	WT control	Fluorescence intensity, temperature sensitive assay at 30°C	46	Shiraishi K;Kato S;Han SY;Liu W;Otsuka K;Sakayori M;Ishida T;Takeda M;Kanamaru R;Ohuchi N;Ishioka C;	Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	2004	J Biol Chem	279	348	14559903
3383	p.T377A	T377A	377	Thr	Ala		C-term	NA	TA (WAF1) supertrans; upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot	21	Stavridi ES;Chehab NH;Malikzay A;Halazonetis TD;	Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest	2001	Cancer Res	61	7030	11585729
829	p.T377A	T377A	377	Thr	Ala		C-term	NA	DNAb (p53CON); 14-3-3 binding; GA	NA	NA	NA	NA	37°C 	Human	U2OS	WT control	Co-IP, EMSA, FACS analysis	21	Stavridi ES;Chehab NH;Malikzay A;Halazonetis TD;	Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest	2001	Cancer Res	61	7030	11585729
3382	p.S378A	S378A	378	Ser	Ala		C-term	NA	TA (WAF1); upregulation (p21waf1)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay, western blot	21	Stavridi ES;Chehab NH;Malikzay A;Halazonetis TD;	Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest	2001	Cancer Res	61	7030	11585729
141	p.S378A	S378A	378	Ser	Ala		C-term	NA	DNAb (p53CON)	14-3-3 binding (partial); GA	NA	NA	NA	37°C 	Human	U2OS	WT control	Co-IP, EMSA, FACS analysis	21	Stavridi ES;Chehab NH;Malikzay A;Halazonetis TD;	Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest	2001	Cancer Res	61	7030	11585729
904	p.K386R	K386R	386	Lys	Arg		C-term	NA	TA (PG13) supertrans	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	55	Rodriguez MS;Desterro JM;Lain S;Lane DP;Hay RT;	Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation	2000	Mol Cell Biol	20	8458	11046142
1748	p.K386R	K386R	386	Lys	Arg		C-term	NA	TA (MDM2); TR (Cyclin B2)	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	Luciferase assay	105	Imbriano C;Gurtner A;Cocchiarella F;Di Agostino S;Basile V;Gostissa M;Dobbelstein M;Del Sal G;Piaggio G;Mantovani R;	Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters	2005	Mol Cell Biol	25	3737	15831478
833	p.S392A	S392A	392	Ser	Ala		C-term	NA	TA (MDM2, PIG3)	NA	NA	NA	NA	37°C 	Human	H1299	WT control	Luciferase assay	22	Roth J;Koch P;Contente A;Dobbelstein M;	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	2000	Oncogene	19	1834	10777217
4227	p.S392A	S392A	392	Ser	Ala		C-term	NA	NA	Interference with Beta-catenin-dependent TCF signalling	NA	NA	NA	37°C 	Human	PC-3, 22Rv1	WT control	Luciferase assay	304	Prowald A;Cronauer MV;von KC;Eilers T;Rinnab L;Herrmann T;Spindler KD;Montenarh M;Jonas U;Burchardt M;	Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53	2007	Prostate	67	1751	17929268
122	p.S392A	S392A	392	Ser	Ala		C-term	NA	TA (MDM2, PG13); GS	NA	NA	NA	NA	37°C 	Human	Saos-2	WT control	CAT (PG13) or  luciferase (MDM2) assay, CFA	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
1227	p.S392A	S392A	392	Ser	Ala		C-term	NA	NA	TRANSF- (partial)	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	transformation assay	16	Crook T;Marston NJ;Sara EA;Vousden KH;	Transcriptional activation by p53 correlates with suppression of growth but not transformation	1994	Cell	79	817	8001119
2011	p.S392A	S392A	392	Ser	Ala		C-term	NA	NA	NA	NA	No (TRANSF+)	NA	NA   	Other	REF	WT control	Transformation assay	142	Slingerland JM;Jenkins JR;Benchimol S;	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation	1993	EMBO J	12	1029	8458321
